Conceptus and Uterine Factors Contributing to the Establishment of Pregnancy in Pigs by Ross, Jason Wayne
CONCEPTUS AND UTERINE FACTORS CONTRIBUTING
TO THE ESTABLISHMENT OF PREGNANCY IN PIGS
By
JASON WAYNE ROSS
Bachelor of Science in Animal Science
Iowa State University
Ames, Iowa
2000
Master of Science in Animal Science
Oklahoma State University
Stillwater, Oklahoma
2003
Submitted to the Faculty of the
Graduate College of the
Oklahoma State University
in partial fulfillment of
the requirements for
the Degree of
DOCTOR OF PHILOSOPHY
December, 2006
ii
CONCEPTUS AND UTERINE FACTORS CONTRIBUTING
TO THE ESTABLISHMENT OF PREGNANCY IN PIGS
Dissertation Approved:
Rodney D. Geisert
Dissertation Adviser
Jerry R. Malayer
Patricia J. Ayoubi
Udaya E. DeSilva
A. Gordon Emslie
Dean of the Graduate College
iii
ACKNOWLEDGEMENTS
The most important people in my life are those who have sacrificed the most for me to be
able to complete this degree. To Rose Mary, you have been so patient and supportive during
graduate school. You are the most important person to me. I could not have done it without you,
thank you for being such a loving and caring wife and mother. Abbey, Jake and Gracie, I am
more proud to be your Dad than anything else in the world. Thank you for loving me so
unconditionally and bringing so much joy to my life. Thank you also to the rest of my family for
encouragement and support and for believing in me.
Dr. Geisert, thank you for the opportunity to pursue this degree under your guidance and
leadership. The freedom that you have allowed Morgan and myself to think independently and
pursue questions in the lab over the past 5 years is not common practice but has been a key
component to developing the abilities to be creative in research which will have significant
impact on my future success. You have many qualities that I also want to exemplify throughout
my career. Thank you for leadership by example. It has not always been just about science, as
life is more than just people, it is also relationships. Thank you for your mentoring and friendship
over the past six years.
Dr. Ayoubi, Dr. DeSilva, Dr. Malayer and Dr. Ritchey. Thank you all for your service on
my PhD committee. You all have excellent qualities that I admire and think have contributed
greatly to your successes. My interaction with you during my education at Oklahoma State
University has been valuable at both a personal and scientific level. I have enjoyed the time that I
have got to spend with you in both scientific and nonscientific settings. Thank you all for your
service.
Morgan and Dan, you guys have made going to graduate school much more enjoyable
than it could have ever been otherwise. Many of my memories of this era in my life will involve
the three of us. Your friendships are far more valuable than the degree.
I would also like to express my gratefulness to God, who is above all. The past
five years, through coursework and research, have given me the ability to recognize the
intricacies of life that can never be fully comprehended have solidified my faith as a
Christian. While I am far from perfect, I am forgiven, and that is the most important gift
in life.
iv
TABLE OF CONTENTS
Chapter Page
I. INTRODUCTION …….….…………….……………………………………...…………..……1
II. LITERATURE REVIEW ......……………...…………………………………………….……3
Porcine Estrous Cycle …………………………………………...………………………….. 3
Factors Affecting Litter Size in Pigs …….…...………………………………………...…….5
Early Embryonic Mortality ....................................................................................…..5
Uterine Capacity ………………………...……………………………….…….…….8
Porcine Embryonic Development …………………….……………………………...….....10
Early Conceptus Development (first 30 days of gestation)………………..………..10
Conceptus Trophoblastic Elongation…………………………………………....….12
Conceptus Apposition and Attachment to the Uterine Luminal Epithelium ..............15
Porcine Conceptus Gene Expression ………………………………….……............18
Role of Estrogen During Early Pregnancy in the Pig ….………….………………….…....31
Estrogen as the Maternal Recognition of Pregnancy Signal ……………………….31
Control of Luteolysis ……………………………………………….……………….34
Endocrine Disruption of Pregnancy ………………………….………………….…............37
The Opening of the Implantation Window …………………………….…………………..39
Statement of the Problem ……………………………………….………………………….43
Approach ………………………………………………………….………………..………45
III. ANALYSIS AND CHARACTERIZATION OF DIFFERENTIAL GENE
EXPRESSION DURING PORCINE CONCEPTUS RAPID
TROPHOBLASTIC ELONGATION AND ATTACHMENT TO THE
UTERINE LUMENAL EPITHELIUM …..……………..……………...............…….....47
INTRODUCTION ……………………………...………...………………...…..……………..47
MATERIALS AND METHODS ………………...…………...………...…………………….50
Conceptus Collection ………………………..…………………...…………………..…….50
RNA Isolation ………………………………..……………………………...……………..51
Microarray Analysis ……………………………..………………………………..……….51
Affymetrix Porcine Chip ………………………………………………...……….....…51
Normalization and Standardization …………………………….…………...………..52
Log Transformation and Statistical Analysis ………………………………...….……52
GeneChip® Porcine Genome Array Re-annotation ...…………………...………..….…….52
Clustering Analysis …………………………..……………………………………..….….53
Database for Annotation, Visualization and Integrated Discovery ………………...…...…53
Quantitative Two-Step RT-PCR ……...………………………...…………………….........54
Quantitation and Statistical Analysis ……………..…………………….………...…..56
RESULTS …………………..……………...….…………………………………………..…...58
Affymetrix Analysis …………………………………………………...…………………..58
GeneChip® Porcine Genome Array Re-annotation ………………………………...….…..58
Database for Annotation, Visualization and Integrated Discovery …………………….….61
Clustering Analysis ……………………………………………..……………..…………..64
vQuantitative One-Step RT-PCR ……………………………..………..……………..…….69
Interferon- ……………………………………………………………………...…….69
Heat Shock Protein 27 kDa ……………………………………….…………...……...72
Angiomotin ……………………………………………………....................................72
Epidermal Growth Factor Receptor ………………………………………..………...72
Actinin 4 …………………………………………………….………...……………..72
B-cell Linker …………………………………………………………………...……...73
Chemokine Ligand 14 ………………………………………..………………...……...73
Parathyroid Hormone Like Hormone …………………………...................................73
Maspin …………………………………………………………...................................74
DISCUSSION ………...……………………...………………………………………………79
IV. IDENTIFICATION AND ANALYSIS OF MOLECULAR MARKERS
FOLLOWING ENDOCRINE DISRUPTION OF PREGNANCY IN
THE PIG ……………………………………………………….……………………..…….……89
INTRODUCTION …………………………..………………………………………….……..89
MATERIALS AND METHODS……..………..............................................................……...91
Animals ………………..…………………………………………………...………...…….91
Tissue Collection ……………...……………...………………………………………..…..91
RNA Isolation ………………...……...……………………………………….………...….92
Microarray Analysis ……...……………………...………………………………………...92
cDNA Synthesis and Hybridization ………………………………………………...…92
Imaging and Microarray Data Acquisition …………………….………………….….94
Analysis Using GenePix Auto Processor………………………………………...……94
Analysis by the Database for Annotation, Visualization and Integrated Discovery .…94
Validation through Quantitative One-Step RT-PCR .……………..…..…..……..….….….95
In Situ Hybridization Analysis …………...……………………………………...…….98
Photomicrography …………………………...………………………….………...…..98
Statistical Analysis ………….……………………………………………..............…...….99
RESULTS …………………...…………………..……………………………………………..99
Conceptus Growth and Development ……………………..…...…………..………………99
Microarray Analysis ………..…………………………………………..………….………99
Database for Analysis, Visualization and Integrated Discovery ………………………....100
Quantitative RT-PCT …….……………..……………………..……………………….....107
In Situ Hybridization ………….……..……………………………….………………..…110
DISCUSSION ...………………………...……………………..…………………………..….121
V. ACTIVATION OF THE TRANSCRIPTION FACTOR, NUCLEAR FACTOR
KAPPA B, DURING THE ESTROUS CYCLE AND EARLY PREGNANCY
IN THE PIG ...……………………………..……………………………………………….…..129
INTRODUCTION ……………………………………………..…………………………….129
MATERIALS AND METHODS ……………………………………..……………………..131
Animals …………………………………………………………………………...………131
Tissue Collection …………………………………………………………...…………….132
RNA Isolation ……………………………………………………………...……………..133
Protein Extraction …………………………………………………………...…………....133
NFB Activity ……………………………………………………………...…………….134
Electrophoretic Mobility Shift Assay ………………………………...………………134
NFB RelA ELISA ……………………………………………………...……………135
In Situ Hybridization ……………...……………………………………………..……….136
Hybridization ………………………………………………………...………………136
Photomicrography …………………………………………...………………………136
Quantitative One-Step RT-PCR ………………...………..……………………………....137
vi
Statistical Analysis ………………………………..……………………………………...139
RESULTS ……………………………………………………………………………….....…140
Activation of NFB ………………………………………………………...…………….140
Electrophoretic Mobility Shift Assay …………………………...……………………140
NFB RelA ELISA ………………………………………………………...…………140
In Situ Hybridization ………………………………………………….…………………140
Estrogen Receptor  ………………………………………...……………………..…145 
Progesterone Receptor ………………………………………………………...….....145
Receptor Activator of NFB …………………………………………...…………….148
Quantitative RT-PCR ………………………………………………..………………...…148
NFB Mediating Receptors ……………………………………………………….....153
NFB Subunits: p50 and RelA ……………………………………………...……….153
Inhibitors of NFB …………………………………………………...…………...…158
DISCUSSION …………………………………………………..…………………………….161
VI. SUMMARY AND CONCLUSION ....………………………...………...……………....168
LITERATURE CITED……………..…………...…………………………………………………176
APPENDIX I
Additional Tables Characterizing Conceptus Gene Expression Data during Trophoblastic
Elongation and the Establishment of Pregnancy in the Pig……………………………………..….198
APPENDIX II
Methodology for In Situ Hybridization ………………………………………...…………………..296
vii
LIST OF TABLES
Table Page
3.1. Primer and probe sequence information for the quantitative amplification of each
target gene ………………………………………………….……………..………57
3.2. Intensities, percent present, and outliers for each AffyChip utilized during
microarray analysis …………………………………………………………..…...59
3.3. Numbers of statistically different mRNA abundance for genes identified between
morphological comparisons …………………………………..…..………………60
3.4. Functional annotation clusters of biological terms representing processes affected
during the conceptus transition from spherical to D12F ….……………..………..62
3.5. Functional annotation clusters of biological terms representing processes affected
during the conceptus transition from D12F to D14F ……………………………..63
3.6. Results from quantitative RT-PCR in comparison with Affymetrix Results ….....70
4.1. Primer and probe sequences used for quantitative RT-PCR analysis ……....…….97
4.2. Differentially expressed genes in uterine endometrium on Day 10 following
exogenous EC on Day 9 of gestation ……………….…………………………...101
4.3. Differentially expressed genes in uterine endometrium on Day 13 following
exogenous EC on Days 9 and 10 of gestation …...……………...……………….102
4.4. Differentially expressed genes in uterine endometrium on Day 15 following
exogenous EC on Days 9 and 10 of gestation ………………………...………....105
4.5. Functional annotation clusters of Gene Ontology terms representing biological
processes affected by exogenous EC treatment on Days 9 and 10 of gestation …106
5.1. Primer and probe sequences used for quantitative RT-PCR analysis ………...…138
A.1. Differentially expressed genes during the transition from Spherical to Day 12
filamentous conceptuses……………………………………………………….....199
A.2. Differentially expressed genes during the transition from Day 12 to Day 14
filamentous conceptuses ...……………………………………………………….233
viii
A.3. Differentially expressed genes during the transition from Day 12 to Day 14
filamentous conceptuses …………………………………………………………250
ix
LIST OF FIGURES
Figure Page
3.1 Twenty-five clusters were generated using the k-means clustering algorithm to
associate genes with similar expression patterns from the transition from spherical to
D14F. The 1473 genes determined to be both significantly and biologically different
between at least one of the comparisons of morphological stage of development
produced an average cluster size of 59 genes and a median cluster of 19 genes. Note
that five clusters indicate genes whose peak or nadir expression occurs during the
D12F morphological stage of development (clusters 4, 7, 14, 21 and 24). The number
of genes associated with each cluster is indicated in the title of each chart ..……....65
3.2 A significant morphological effect on relative mRNA units (mean ± SEM) was
detected for IFN (A, P < 0.001), HSP27 (B, P = 0.002), angiomotin (C, P < 0.001),
EGFR (D, P = 0.026), ACTN4 (E, P = 0.045), BLNK (F, P = 0.002), CXCL14 (G, P
< 0.001), PTHrP (H, P < 0.001), and maspin (I, P < 0.004) during the porcine
conceptus trophoblastic elongation and trophectoderm attachment to the uterine
luminal epithelium. Abundance of mRNA was calculated from the real-time PCR
analysis as described in Materials and Methods. Relative mRNA abundance is
presented as mean ± SEM. Bars with without a common superscript represent a
statistical difference between morphological stages of development (P < 0.05) .….75
4.1 Fold differences of mRNA abundance for endometrial AR (A; day x treatment, P <
0.03), CD24 (B; day effect, P = 0.02), SPP1 (C; day x treatment, P < 0.14) and
NMB (D; day x treatment, P < 0.001) in response to EC (yellow bar) and CO (blue
bar). Relative abundance of mRNA was calculated from the quantitative RT-PCR
analysis as described in Materials and Methods. Bars without common lowercase
superscripts represent a statistical difference (P < 0.05) between day/treatment
combinations whereas differences in uppercase superscripts represent statistical
differences between days of gestation.…………………………………………….108
4.2 In Situ hybridization analysis of AR mRNA expression in porcine endometrium
during early gestation in response to estradiol cypionate (EC) or corn oil (CO) given
i.m. on Days 9 and 10 of gestation. Protected transcripts in endometrium from Days
10, 12, 13, 15 and 17 of each treatment were visualized by liquid emulsion
autoradiography and imaged under bright-field and dark-field illumination. Note
during normal gestation (CO) on Days 12 and 13 of gestation, the expression is
abundant, but limited to the luminal epithelium (LE) and lacking in the stromal (ST)
and glandular epithelium (GE). Following EC treatment, mRNA abundance was
dramatically and prematurely reduced in the LE. A representative Day 13 EC
section was hybridized with radiolabeled sense cRNA probe (sense) to serve as a
xnegative control. All other images are representative from four biological
replications. 4X Objective and 10X eyepiece for original magnification 40X ….111
4.3 In Situ hybridization analysis of SPP1 mRNA expression in porcine endometrium
during early gestation in response to estradiol cypionate (EC) or corn oil (CO) given
i.m. on Days 9 and 10 of gestation. Protected transcripts in endometrium from Days
10, 12, 13, 15 and 17 of each treatment were visualized by liquid emulsion
autoradiography for 5 days and imaged under bright-field and dark-field
illumination. During normal gestation (CO), expression increases in the luminal
epithelium (LE) on Days 15 and 17 while expression is lacking in the stromal (ST)
and glandular epithelium (GE). EC treatment, however, visually increased mRNA
abundance in the LE on Days 12, 13, 15 and 17 in the LE when compared to the EC.
A representative section on Day 15 EC hybridized with radiolabeled sense cRNA
probe (sense) served as a negative control. All other images are representative of
four biological replications. 4X Objective and 10X eyepiece for original
magnification 40X.
……………………………………………………………………………….113
4.4 In Situ hybridization analysis of CD24 mRNA expression in porcine endometrium
during early gestation in response to estradiol cypionate (EC) or corn oil (CO) given
i.m. on Days 9 and 10 of gestation. Protected transcripts in endometrium from Days
10, 12, 13, 15 and 17 of each treatment were visualized by liquid emulsion
autoradiography for 8 wks and imaged under bright-field and dark-field illumination.
CD24 expression seems to occur predominately in the LE although some expression
appears present in ST cells on Days 10, 12, and 13 of both CO and EC gilts.
Expression is greatest in the LE of endometrium from gilts on Days 13, 15 and 17 in
both CO and EC gilts. A representative section on Day 13 CO hybridized with
radiolabeled sense cRNA probe (sense) to serve as a negative control. All other
images are representative of four biological replications. 4X Objective and 10X
eyepiece for original magnification 40X ……………………………………….…115
4.5 In Situ hybridization analysis of CD24 mRNA expression in porcine endometrium on
Day 12 of gestation in the presence and absence of a conceptus. Protected transcripts
in endometrium was visualized by liquid emulsion autoradiography for 8 wks and
imaged under bright-field and dark-field illumination. Note the lack of expression in
the LE of endometrium distant from the conceptus (upper half of the panel) and the
amplified expression of CD24 in adjacent to the conceptus trophectoderm (lower half
of the panel). CD24 expression is expressed abundantly by the trophectoderm
conceptus. 4X Objective and 10X eyepiece for original magnification 40X …….117
4.6 In situ hybridization analysis of NMB mRNA expression in porcine endometrium
during early gestation in response to estradiol cypionate (EC) or corn oil (CO) given
i.m. on Days 9 and 10 of gestation. Protected transcripts in endometrium from Days
10, 12, 13, 15 and 17 of each treatment were visualized by liquid emulsion
autoradiography and imaged under bright-field and dark-field illumination. Note the
expression is very specifically limited to the LE. Expression is greatest on Days 12
xi
and 13 of CO gilts while expression appeared prematurely elevated on Day 10 and
reduced on Day 13 in LE of EC gilts. A representative section on Day 13 CO
hybridized with radiolabeled sense cRNA probe (sense) to serve as a negative
control. All other images are representative of four biological replications. 4X
Objective and 10X eyepiece for original magnification 40X ……………………119
5.1 Electrophoretic mobility shift assay was conducted using a commercially available
EMSA as described in the Materials and Methods. Nuclear and cytoplasmic protein
fractions extracted from gilts on Days 5, 10, and 13 of the estrous cycle and Days 10
and 13 of pregnancy were exposed to an oligo containing an NFB consensus
sequence followed by electrophoresis through a polyacrylamide gel and transferred
to a positively charged membrane. Labeled oligo was detected through
chemiluminescence. Unbound, labeled oligo migrates the most rapidly and is
indicated with an arrow (A), while bound oligo, migrating slower is shifted towards
the upper end of the gel (indicated by the B and C arrows). Note the lack of a shifted
labeled oligo for the negative control in which 100 fold excess unlabeled probe was
added to the hybridization reaction. The cytoplasmic fraction represented a single
shift while two shifts, indicative of multiple NFB dimers, was indicated by the
nuclear fraction. Each lane is equally represented by protein extracted from
endometrium of four gilts ……………………………………………………..…141
5.2 Transcription factor assay to determine relative amounts of activated NFB RelA in
the nuclear (day effect, P = 0.005) and cytoplasmic (day effect, P = 0.006; status
effect, P < 0.001) protein fractions of endometrium collected from gilts on Days 5,
10 and 13 of the estrous cycle and Days 10 and 13 of pregnancy (n = 4/day/status).
Relative optical density for each sample was corrected for total protein concentration
in the sample. Data is presented as relative O.D. mean ± SEM ……………..…...143
5.3 In Situ hybridization analysis of ER mRNA expression in porcine endometrium
during the estrous cycle and early pregnancy. Protected transcripts in endometrium
from Days 0, 5, 7.5, 10, 12, 13, 15 and 17 of the estrous cycle and Days 10, 12, 13,
15 and 17 of pregnancy were visualized by liquid emulsion autoradiography and
imaged under bright-field and dark-field illumination. Note the greatest expression
is prior to (17), during (Day 0) and after estrus (Day 5). ER expression is abundant
in the luminal epithelium (LE) and glandular epithelium (GE) during Days 0 and 5
while only in the LE on Day 17 of the estrous cycle. A representative Day 5 section
was hybridized with radiolabeled sense cRNA probe to serve as a negative control.
All other images are representative from four biological replications. 4X Objective
and 10X eyepiece for original magnification 40X …………………...……………146
5.4 In Situ hybridization analysis of progesterone receptor (PR) mRNA expression in
porcine endometrium during the estrous cycle and early pregnancy. Protected
transcripts in endometrium from Days 0, 5, 7.5, 10, 12, 13, 15 and 17 of the estrous
cycle and Days 10, 12, 13, 15 and 17 of pregnancy were visualized by liquid
emulsion autoradiography and imaged under bright-field and dark-field illumination.
Note the greatest expression is during (Day 0) and after estrus (Day 5) abundant in
xii
the luminal epithelium (LE) and glandular epithelium (GE) and stromal (ST)
fractions. PR expression is devoid in the LE and GE by Day 10 of the estrous cycle
and pregnancy. A representative Day 5 section was hybridized with radiolabeled
sense cRNA probe (sense) to serve as a negative control. All other images are
representative from four biological replications. 4X Objective and 10X eyepiece for
original magnification 40X ………………………………………………………..149
5.5 In Situ hybridization analysis of receptor activator of NFB (RANK) mRNA
expression in porcine endometrium during the estrous cycle and early pregnancy.
Protected transcripts in endometrium from Days 0, 5, 7.5, 10, 12, 13, 15 and 17 of
the estrous cycle and Days 10, 12, 13, 15 and 17 of pregnancy were visualized by
liquid emulsion autoradiography and imaged under bright-field and dark-field
illumination. While expression was low in all tissues evaluated, evidence of RANK
expression is detected in the LE on Day 12 of the estrous cycle and pregnancy. A
representative Day 12 pregnant section was hybridized with radiolabeled sense
cRNA probe (sense) to serve as a negative control. All other images are
representative from four biological replications. 4X Objective and 10X eyepiece for
original magnification 40X …………….………………………………………….151
5.6 Relative mRNA abundance for receptor mediators of NFB activation. Expression
differences for endometrial RANK (Top panel; effect of day, P < 0.93; effect of
status, P = 0.34) and TLR-4 (Lower panel; day x status effect, P = 0.017), in cyclic
(orange bar) and pregnant (yellow bar) gilts. Relative abundance of mRNA was
calculated from the quantitative RT-PCR analysis as described in Materials and
Methods. Bars without common lowercase superscripts represent a statistical
difference (P < 0.05) between day/status combinations. Superscripts are not included
in the upper panel as no main or interacting effects were detected. Relative mRNA
units are presented as mean ± SEM ……………………………………………….154
5.7 Relative mRNA abundance for NFB subunits, p50 and RelA. Expression
differences for endometrial p50 (Top panel; day x status interaction, P < 0.01) and
RelA (Lower panel; day x status effect, P = 0.017), in cyclic (orange bar) and
pregnant (yellow bar) gilts. Relative abundance of mRNA was calculated from the
quantitative RT-PCR analysis as described in Materials and Methods. Bars without
common lowercase superscripts represent a statistical difference (P < 0.05) between
day/status combinations. Relative mRNA units are presented as mean ± SEM ….156
5.8 Relative mRNA abundance for endometrial IB (Top panel; effect of day, P <
0.001) and IB (Lower panel; day x status effect, P = 0.079), in cyclic (orange bar)
and pregnant (yellow bar) gilts. Relative abundance of mRNA was calculated from
the quantitative RT-PCR analysis as described in Materials and Methods. Bars
without common lowercase superscripts represent a statistical difference (P < 0.05)
between day/status combinations whereas differences in uppercase superscripts
represent statistical differences between days of gestation. Relative mRNA units are
presented as mean ± SEM …………………………………………………………159
xiii
NOMENCLATURE
ACTN4 Actinin 4
AR Aldose Reductase
ATP Adenosine Triphosphate
BLAST Basic Local Alignment Search Tool
CD24a CD24 Antigen
cDNA Complimentary Deoxyribonucleic Acid
CL Corpora Lutea
CSF-1  Colony Stimulating Factor-1 
CO Corn Oil
CT Cycle Threshold
CXCL14 Chemokine Ligand 14
D12F Day 12 Filamentous
D14F Day 14 Filamentous
DAVID Database for Annotation, Visualization and Integrated Discovery
dChip DNA-Chip Analyzer
ddPCR Differential Display Polymerase Chain Reaction
DNA Deoxyribonucleic Acid
DTT Dithiothreitol
EC Estradiol Cypionate
ECM Extracellular Matrix
EGF Epidermal Growth Factor
EGFR Epidermal Growth Factor Receptor
ELISA Enzyme-Linked Immunosorbent Assay
EMSA Electrophoretic Mobility Shift Assay
EPC Ectoplacental Cone
ER Estrogen Receptor 
ER Estrogen Receptor 
ERKO Estrogen Receptor Knock Out
EST Expressed Sequence Tag
EV Estradiol Valerate
F-actin Filamentous Actin
FDR False Discovery Rate
FSH Follicle Stimulating Hormone
GCOS GeneChip Operating Software
GE Glandular Epithelium
GnRH Gonadotropin Releasing Hormone
GO Gene Ontology
GPAP3.0 GenePix Auto Processor 3.0
xiv
HA Hyaluronic Acid
HSP27 Heat Shock Protein 27
ICM Inner Cell Mass
IFN- Interferon-
IGF Insulin-like Growth Factor
IGFBP Insulin-like Growth Factor Binding Proteins
IL-1RAP Interleukin-1 Receptor Accessory Protein
IL-1RT1 Interleukin-1 Receptor Type 1
IL-1 Interleukin-1
IL-6  Interleukin-6 
ITI Inter--trypsin Inhibitor
IBs Inhibitors of Nuclear Factor B
IB Inhibitor of B
JAK-STAT Janus Kinase- Signal Transducer and Activator of Transcription
LE Luminal Epithelium
LH Luteinizing Hormone
LIF Leukaemia Inhibitory Factor
LPS Lipopolysaccharide
MBEI Model-Based Expression Indices
mRNA Messenger Ribonucleic Acid
NADPH Nicotinamide Adenine Dinucleotide Phosphate
NBA Number Born Alive
NFB Nuclear Factor B
NK Natural-Killer
NMB Neuromedin B
NMB-R Neuromedin B Receptor
OD Optical Density
P45017 P45017-hydroxylase
P450arom Aromatase
PCOS Polycystic Ovarian Syndrome
PCR Polymerase Chain Reaction
PG Prostaglandin
PGE Prostaglandin E
PGF Prostaglandin F
PGF2 Prostaglandin F2
PLA2 Phospholipase A2
PLAZ Phospholipase AZ
PM Perfect-Match
PR Progesterone Receptor
PTGS1 Prostaglandin Synthetase-1 (also referred to as cyclooxygenase-1)
PTGS2 Prostaglandin Synthetase-2 (also referred to as cyclooxygenase-2)
PTHrP Parathyroid Hormone Like Hormone
QT-RT-PCR Quantitative Reverse-Transcriptase Polymerase Chain Reaction
RANK Receptor Activator of NFB
RANKL Receptor Activator of NFB Ligand
RAR Retinoic Acid Receptors
xv
RBP Retinol Binding Protein
RNA Ribonucleic Acid
rRNA Ribosomal Ribonucleic Acid
RT-PCR Reverse Transcriptase Polymerase Chain Reaction
SAGE Serial Analysis of Gene Expression
SPP1 Secreted Phosphoprotein 1
sqPCR Semi-quantitative Polymerase Chain Reaction
ST Stromal Cells
STAR Steroidogenic Acute Regulatory Protein
STAT Signal Transducer and Activator of Transcription
TGC Trophoblast Giant Cells
TGF Transforming Growth Factor-Alpha
TGF Transforming Growth Factor-Beta
TH T-Helper
TLR-4  Toll-like Receptor-4 
TNF- Tumor Necrosis Factor 
TSG6 Tumor Necrosis Factor Stimulated Gene 6
UG Uterine Glycocalyx
1Chapter I
Introduction
The average pig ovulates 16-18 oocytes per estrus, of which the majority are
fertilized and initiate development. However, reproductive efficacy in the swine industry
is limited by a prenatal mortality rate ranging from 20-46% [Pope et al., 1990].
According to the National Agriculture Statistics Service (http://www.nass.usda.gov/) the
current breeding inventory in the United States is 6.06 million sows, suggesting that even
a slight increase in survivability during in utero development would make a dramatic
impact on the production capability of the swine industry in the United States.
It is not uncommon to have females that can consistently give birth to above
average litter sizes and provide ample milk production to wean litters significantly larger
than other sows. Unfortunately, the genetic parameters that regulate this unique ability of
only a few females is not known. It is likely that numerous factors, both genetic and
environmental, impact the variability between the reproductive prolificacy of female pigs
making the objective of obtaining a predictable, substantial increase in littersize difficult
to obtain. Biologically speaking, multiple mammalian species contain the propensity to
regulate their reproductive success with consistent progeny per pregnancy despite other
reproductive limitations or superfluities. For example, following fertilization and the
formation of a single blastocyst, and an approximate 14-week arrest in development, the
nine-banded armadillo (Dasypus novemcinctus) consistently gives birth to genetically
2identical quadruplets [Enders, 2002]. This occurs by the ability of the inner cell mass
within the blastocoele to divide into four separate areas, each giving rise to a single
individual while all four utilizing the same placenta [Enders, 2002]. By contrast,
different species of elephant shrews exhibit a distinct ability to regulate the quantity of
embryos developing in utero despite differences in ovulation rate. While some species
(E. rozeti) consistently ovulate on average 1.2 follicles per ovary and others (E. edwardi
and E. myurus) ovulate 44 – 49 oocyte per ovary, all three of these species appear to limit
extended development to an average of only two embryos [Tripp, 1971]. Littersize
among female pigs that are of similar lines of selection is still variable. However, the
larger litter consistency of some females suggest that some endogenous mechanisms do
exist that allow the control of producing consistently large litters.
The following review of literature will focus on the areas of early gestation which
represent a significant amount of embryonic mortality, the potential mechanisms
involved in those areas, and how disruptions within those mechanisms may lead to
reduced littersize in production swine in the United States.
3Chapter II
LITERATURE REVIEW
Porcine Estrous Cycle
Once the female pig attains puberty, typically 5-7 months of age, the estrous cycle
remains unaffected by season and is halted by anestrous only during pregnancy or
postpartum piglet suckling. The porcine estrous cycle is 21 days in length and consists of
four distinct phases (proestrous, estrus, metestrus and diestrus) which are under precise
regulation of the steroid hormones estrogen and progesterone. Proestrus (Days 17-20) is
a result of corpora lutea (CL) regression concomitant with the selection and growth of a
cohort of tertiary follicles. Together, the loss of the CL results in rapidly reduced plasma
progesterone while estradiol-17 increases steadily as the growing follicles reach
maturity and become Graafian follicles. Increasing plasma concentrations of estradiol-
17 occur around Day 18 of the estrous cycle and the reduced negative feedback effect of
estrogen on the basal medial nuclei of the hypothalamus allows the chronic release of
gonadotropin releasing hormone (GnRH) into the hypophyseal portal system causing the
pulsitile release of follicle stimulating hormone (FSH). Estrus is the result of mature
Graafian follicles producing peak plasma concentrations (~ 45 pg/mL) of estradiol-17.
These elevated levels of circulating estrogen result in the behavior modification of the
gilt or sow causing her to be receptive to the boar. This behavior is directly associated
with estrus, which typically lasts from 48 to 72 hours in the pig with ovulation occurring
4about 36 hours after the onset of estrus. Peak estadiol-17 levels result in positive
feedback regulation on the pre-optic nuclei of the hypothalamus resulting in the surge
release of luteinizing hormone (LH). The LH surge causes the luteinization of the theca
interna and granulosa cells resulting in the degradation of the junctional complexes
holding the granulosa cells together as well as the oocyte’s resumption of meiosis and the
expulsion of a polar body. Continued proteasomal degradation of the theca interna
outward near the apex of the follicle results in the formation of a hole and the expulsion
of the oocyte. The ovulation of 16-18 oocytes are representative of a follicular pool of as
many as 85 tertiary follicles present on the surface of the ovary during the mid-luteal
phase of the estrous cycle [Guthrie et al., 1995]. Metestrus lasts only a few days in pig
and is characterized by declining plasma estrogen concentrations with the initiation of
progesterone production by the conversion of the corpora hemorrhagica to corpora lutea
(CL). Diestrus (Days 5-16) is the longest phase of the estrous cycle in the pig. High
plasma progesterone concentrations maintain myometrial quiescence and induce
endometrial glandular secretions (histotroph) providing an environment for initial
conceptus development in the event that fertilization has occurred. The absence of viable
conceptuses allows the uterine synthesis and endocrine release of prostaglandin F2
(PGF2) resulting in CL regression and reduction of plasma progesterone by Day 16 of
the estrous cycle allowing the recruitment and maturation of the next group of developing
tertiary follicles.
5Factors Affecting Litter Size in Pigs
Prior to parturition there are four different factors that can affect litter size in pigs;
1) ovulation rate, 2) fertilization rate, 3) early embryonic survival, and 4) uterine
capacity. Fertilization rate in the pig is extremely efficient, estimated to be at least 95%
[Polge, 1978], suggesting that it is unlikely to be the limiting factor with respect to
number of piglets born alive (NBA) at term. However, multiple attempts to increase litter
size through superovulation have been unsuccessful (Longenecker and Day, 1968; Dziuk,
1968). While superovulation of gilts increases the number of CL, and thereby the
number of viable conceptuses initiating development, the number of conceptuses
developing past Day 40 of gestation was not different between superovulated gilts and
non-superovulated gilts serviced naturally by a boar [Longenecker and Day, 1968]. The
inability of superovulation to significantly impact litter size indicates the importance of
early embryonic survival and uterine capacity on litter size at term in the pig. In 1923,
Corner established that the number of corpora lutea present on the ovaries is an accurate
estimate of ovulation rate and could be utilized to estimate embryonic mortality.
Utilizing this method, embryonic mortality has been determined throughout multiple
stages of gestation and several assessments of mortality during pregnancy in the pig
suggest that the overall embryonic mortality rate is between 20 and 46% [Pope, 1994].
The occurrence of embryonic mortality can be broadly broken into two phases; the peri-
implantation stage of development, Days 10-18 of gestation; and post-implantation
development, between Day 18 and 114 of gestation.
6Early Embryonic Mortality
Not only is early embryonic development critical for the establishment of
subsequent placental size but this peri-implantation period (Days 10-18) is also vital for a
variety of developmental landmarks that are indicative of conceptus viability and
establishment of conceptus uterine cross-talk resulting in the adhesion of the conceptus
trophectoderm to the uterine glycocalyx and the initial formation of a diffuse
epitheliochorial placenta. Anderson et al. [1978] estimated that 17% of conceptuses are
lost during Days 9-18 of gestation, the peri-implantation stage of development.
Numerous factors contribute to the significant loss of viable conceptuses during this stage
of development. Specifically, conceptus rapid trophoblastic elongation and successful
implantation are the two major components of this developmental stage in the pig which
represent processes where conceptus loss is recognized.
Incompatibility between the developing conceptus and the rapidly changing
uterine environment can result is a major constraint to conceptus survival. Asynchrony
greater than 24 h between potentially viable conceptuses and the uterine environment has
been established to cause conceptus death as early as Day 8 of gestation [Polge, 1982;
Geisert et al., 1991]. Conceptus-uterine asynchrony is less tolerant when the uterine
environment is further advanced than conceptus development. Pope et al. [1990]
demonstrated this when gestation Day 6 conceptuses transferred to a gestation Day 7
uteri exhibited greater mortality than Day 7 conceptuses transferred to a Day 6 uteri.
Moreover, while both Day 5 and 7 conceptuses exhibit viability to at least day 60 when
transferred to a gestation Day 6 uteri (24 h asynchrony), the older conceptuses exhibit
greater viability when they are both transferred to the same uteri [Pope et al., 1990].
7In addition to the developmental limitations caused by conceptus-uterine
asynchrony, asynchrony between littermates may represent a significant amount of
conceptus mortality realized during the peri-implantation period. Duration of ovulation
in the pig requires an average of 1.8 h and ranges from 0.75 to 3.6 hs [Soede et al., 1992],
although the authors found no correlation between embryonic diversity with respect to
duration of ovulation. Contrary to this finding, Pope et al. [1988a] determined that
destroying Day-1 non-ovulated follicles via cauterization resulted in a significant
reduction in morphological diversity among pig conceptuses on Day 11 of gestation, with
the difference being primarily a reduction of small spherical conceptuses (1-5 mm
diameter). Because multiple assessments suggest the timing of ovulation occurs
approximately 35-48 h after the onset of estrus behavior [Soede and Kemp, 1997], it
seems plausible that insemination and capacitation would not be the limiting factor
regarding variation in fertilization and initiation of development but rather would be more
directly associated with the variation in ovulation, supporting the data provided by Pope
et al. [1988a].
Variation in the duration of ovulation and the subsequent diversity associated with
the embryonic morphology could be paramount with respect to the microenvironment
asynchrony within the uterus as described by Pope [1988b]. Because of differences in
the timing for initiation of trophoblastic elongation and the rapid rate of elongation (less
than 2 hours) during the transition from spherical to filamentous morphology, variation in
the duration of ovulation may be a very valid cause of multiple morphologies observed
between conceptuses within a litter [Anderson et al., 1979]. Primarily, the variation
within littermates with respect to the onset of elongation may be related to the lack of
8uniform placental size which results in the lesser developed conceptuses acquiring
insufficient uterine space for placentation. A secondary consequence of variable onset of
trophoblast elongation within a litter may be the endometrial changes stimulated by
estrogen release from the advanced conceptuses resulting in endometrial modifications
that are difficult for less developed conceptuses to overcome. Administration of
exogenous estradiol following progesterone priming results in specific alteration of
uterine secretions [Basha et al., 1980; Geisert et al., 1982a]. Moreover, both conceptus
aromatase expression and estrogen synthesis and release is directly related to
morphological stage of development [Yelich et al., 1997a; Wilde and Pope, 1987]. This
would suggest that while conceptuses equidistantly space themselves from one another
prior to elongation, endometrial secretions induced by elongating, estradiol-17 secreting
conceptuses may generate a uterine environment unsuitable for conceptuses lagging in
development, or the additional uterine space acquired by the more advanced conceptuses
limits available surface endometrium for placentation by conceptuses tardy in their
initiation of conceptus elongation.
Uterine Capacity
Uterine capacity is defined as the maximum number of piglets carried to term
when potentially viable conceptuses are not limiting [Christenson et al., 1987]. By
applying ligatures to the uterine horn varying lengths (5 cm for each CL) from the
uterotubal-junction, Wu et al., (1989) were able to show that a dramatic loss of viable
conceptuses occurs between Days 20 and 50 of gestation when uterine space is limited,
suggesting that pig conceptuses are vulnerable during uterine crowding. To more
9specifically determine the effects of uterine crowding, Vallet and Christenson [1993]
double ligated uterine horns ipsilateral to the ovary with the most CL midway between
the uterine bifurcation and the utero-tubal junction producing both a crowded and roomy
environment for the developing conceptuses. On both Days 25 and 35 of gestation, there
was a significant affect of uterine space reducing both placental weight and fetal weight
of the conceptuses developing in the crowded uterine environment compared to those
developing in the roomy uterine environment. Agreeably, methods to reduce uterine
space; unilateral hysterectomy and uterine ligature, and methods to increase embryo
numbers; ovulation rate selection, superovulation, and embryo transfer all tend to indicate
the capacity of the uterus becomes limiting around Day 40 of gestation [Vallet, 2000].
The Meishan breed of swine originating from China is well known for their
reproductive prolificacy. While having similar uterine space and ovulation rate, the
Chinese breed consistently produces over 3 pigs per litter more than the less prolific
European swine breeds [Ford, 1997]. Ford speculated that this is due to the Meishan
conceptuses ability to develop a smaller, more vascular placenta, enabling adequate
downstream nutrient exchange while requiring less uterine space. This thought process
resulted in the hypothesis that placental efficiency, used as a selection tool may have an
impact on litter size in the European breeds. Placental efficiency (fetal weight/placental
weight) is highly variable between littermates; however, after one generation of selection
of individual littermates in a small research study, Wilson et al. [1999] reported a
significant increase in litter size. In a larger study, utilizing swine from a commercial
herd, Vonnahme et al. [2002] identified a positive correlation between ovulation rate and
the number of viable conceptuses at Day 25 of gestation, however, this correlation was
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not present at Days 36 or 44 of gestation. Alternatively, a significant correlation did exist
between uterine length and the number of viable conceptuses at Days 36 and 44 but not at
Day 25 suggesting that uterine capacity is defined between Days 25 and 36 of gestation.
Additionally, placental efficiency was found to be significantly positively correlated to
the number of viable conceptuses on Days 25, 36 and 44 [Vonnahme et al., 2002]. While
these data support the work done by Wilson et al. [2001] up to Day 44 of gestation, an
additional study on using in a much larger population suggested that placental efficiency
has a negative correlation to littersize in pigs [Mesa et al., 2003]. It should not be
overlooked however, that if placental efficiency truly contributes to increased litter size,
these data further indicate the underlying importance of the initial establishment of
placenta size which occurs on Day 12 of gestation during trophoblastic elongation.
Porcine Embryonic Development
Early Conceptus Development (first 30 days of gestation)
In 1929, after collecting porcine reproductive tracts from an abattoir, Heuser and
Streeter described many of the morphological changes that occur during early porcine
embryonic development. Following fertilization and the fusion of the male and female
pronuclei to produce a single cell zygote, holoblastic cleavage occurs shortly after
nuclear division. Because the holoblastic cleavage plane spans completely through the
zygote; thus enabling cytokinesis, the process of equally dividing; each cleavage division
results in a reduction of cell size. The initial two divisions occur early, allowing the
porcine embryo to reach the 4-cell stage within 24 h following fertilization. Divisions
occur less frequently after the 4-cell stage albeit still occurring approximately 24-26 h
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until the embryos reach the 8-16 cell stage. Blastomeres from 4-cell stage porcine
embryos readily take-up radiolabeled uridine and incorporate it into synthesized RNA
suggesting the depletion of the maternal mRNA stored in the oocyte and the activation of
the embryonic genome [Tomanek et al., 1989]. Morulation and subsequent blastulation
occur by Day 6 following fertilization and the embryos, now migrating into the uterine
horns, are defined by having a distinct outside trophectodermal cell layer and a rapidly
growing inner cell mass within the blastocoele. Hatching from the zona pellucida on Day
7 to 8 of gestation allows the embryo to expand in diameter concurrent with trophoblast
expansion and differentiation of the inner cell mass. By Day 10 of gestation, the
conceptus reaches a spherical diameter of 2-3 mm. During their collection of porcine
conceptuses, Heuser and Streeter [1929] reported distinct variation in conceptus
morphologies present between Days 11 to 12 of gestation, and presented photographs of
spherical, tubular and filamentous conceptuses. The morphological transition is followed
by the initial attachment of the elongated trophectoderm to the uterine epithelium on Day
13 of gestation [Perry et al., 1981; Dantzer, 1985]. Formation of the extraembryonic
membranes occurs after elongation as the allantois is formed, from the expanding
embryonic hindgut by Day 14 of gestation and is as long as the expanded trophoblast
chorion by Day 17 [Friess et al., 1980]. Allantois expansion continues reaching nearly
full contact with the meter long chorion by Day 19 of gestation. By Day 30, allantoic
blood vessels completely vascularize the chorion [Wislocky and Dempsy, 1946].
Essentially, Day 12 to 30 of gestation is a critical developmental period in which the
conceptuses expand throughout the uterus and establish a nutrient exchange interface
with the dam. The extent to which each individual conceptus placenta attains uterine
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space for downstream nutrient exchange is directly regulated by the extent at which
conceptus trophectoderm is allowed to elongate initially on Day 12 of gestation. In
general, conceptuses with the most extensive trophoblastic elongation develop the largest
placenta and acquire the greatest uterine surface contact resulting in the highest chance of
survival to term; indicating the critical importance of gestational Days 10 to 12, when
trophoblastic elongation is initiated.
Conceptus Trophoblastic Elongation
On approximately Day 10 of gestation, 2-3 mm spherical porcine conceptuses will
grow in diameter at a rate of 1 mm/4 h through cellular hyperplasia [Geisert et al.,
1982b]. The conceptuses continue to expand until they reach an approximate 9-10 mm
diameter within 24-36 h [Geisert et al., 1982b; Pusateri et al., 1990]. Upon reaching 9-10
mm in diameter, the spherical conceptus initiates the process of rapid trophoblastic
elongation usually between Days 11 to 12 of gestation [Geisert et al., 1982b]. This rapid
trophoblastic elongation occurs at the rate of approximately 45 mm / h [Ross, Ashworth
and Geisert; unpublished data] throughout the uterine lumen concomitantly with the
synthesis and release of the conceptus maternal recognition signal, estrogen [Geisert et
al., 1982b; Bazer et al., 1986] and the proinflammatory cytokine, interleukin-1 (IL-1)
[Ross et al., 2003a]. Trophoblastic elongation in the pig is characterized by a series of
unique events and the transformation through transient morphological stages. Initially, a
10 mm spherical conceptus transforms into a transient ovoid shape (10-14 mm length),
quickly becomes tubular (15-25 mm length), and then rapidly elongating until the
conceptus becomes a thin filamentous thread that is 150-200 mm in length within 2 to 4
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h. The transformation of the spherical to the elongating conceptus is not the result of
cellular hyperplasia, but is rather a process of cellular migration causing trophectodermal
migration [Geisert et al., 1982c; Mattson et al., 1990; Pusateri et al., 1990].
Trophoblastic elongation is likely to be very dependent on the uterine three dimensional
architecture surrounding the conceptus as these unique morphological transformation
events to date has not been accomplished in vitro. Perry [1981] likens the process of
trophoblastic elongation to rolling a ball a plasticene between two hands, forcing the
expansion of the ends while reducing the diameter of the trophectoderm. Mattson et al.
[1990] later suggested that the rapid and ephemeral trophectoderm changes were a result
of cytoskeletal rearrangements of filamentous actin (f-actin).
The process of trophoblastic elongation serves several fundamental roles. The
primary role is that conceptus expansion within the length of the uterine horns allows
individual porcine littermates the ability to garner sufficient uterine space for placentation
to ensure adequate nutrient exchange throughout gestation [Stroband and Van der Lende,
1990; Geisert and Yelich, 1997]. Another essential role that trophoblastic elongation
serves is the delivery of the maternal recognition signal, estrogen, throughout the uterine
lumen resulting in the prevention of luteolysis. Evidence for the necessity of this
mechanism to deliver the conceptus derived signaling molecules throughout the uterus
relies on the demonstration that at least two viable conceptuses are required in each horn
to sufficiently prevent luteolysis during the establishment of pregnancy [Polge et al.,
1966; Dziuk, 1968].
How the induction of trophoblastic elongation is regulated is not well defined
although it has been hypothesized to be either conceptus self regulation or regulated
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through maternal signaling. Administration of exogenous progesterone in pregnant gilts
on Days 2 and 3 of gestation resulted in an increase in both endometrial protein
secretions and an increase in conceptus synthesis and secretion of estrogen on Day 11 of
gestation [Vallet et al., 1998]. While this suggests that conceptus development rate can
be affected by steroid hormones, the synchrony within littermates seems unaffected.
Even though the synthesis and secretion of estrogen occurs simultaneous with
trophoblastic elongation, it is unlikely that estrogen is involved with the induction of the
morphological transformation. Morgan et al. [1987a] demonstrated that small spherical
conceptuses in uteri stimulated with exogenous estrogen fail to commence trophoblastic
elongation until they reach at least 10 mm in diameter, the size when normal induction
occurs. Furthermore, it seems conceivable that if elongation is under the regulation of
maternal sources, it would be synchronous between conceptuses. However, it is not
uncommon for littermates that are spherical, tubular and filamentous to exist
simultaneously within the same uteri [Anderson et al., 1978; Geisert et al., 1982b]. The
presence of multiple morphologies within littermates suggests the maternal system is
unable to stimulate uniformity during trophoblastic elongation and that this is rather a
process regulated by the conceptuses themselves.
Interleukin-1 receptor type 1 (IL-1RT1) and IL-1 receptor accessory protein are
both required for IL-1 signaling to occur. The expression of both receptors in the
conceptus while IL-1 levels are elevated suggests that the secretion of IL-1 may have
an autocrine effect on the conceptuses themselves [Ross et al., 2003a]. Ross et al.
[2003a] also hypothesized that due to the potential autocrine signaling, conceptus
synthesis and release of IL-1 may be a potential contributor to trophoblastic elongation.
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Interleukin-1 is known to induce gene expression for both phospholipase A2 (PLA2)
[Kol et al., 2002] and prostaglandin synthase-2 (PTGS2) [Huang et al., 1998] in
reproductive tissues of various species. Activity of phospholipase A2 [Davis et al., 1983]
and PTGS2 [Wilson et al., 2002] both increase in the Day 12 filamentous porcine
conceptus initiating the subsequent increase of prostaglandin E in the uterine lumen.
Phospholipase A2 enzyme activity is responsible for the cleavage and release of free
arachidonic acid used in the synthesis of prostaglandins through prostaglandin synthase
activity. The release of arachidonic acid from the phospholipid bilayer may contribute to
the increased cell membrane fluidity necessary for trophectoderm remodeling [Davis and
Blair, 1993; Geisert and Yelich, 1997].
Conceptus Apposition and Attachment to the Uterine Luminal Epithelium
Following trophoblastic elongation and secretion of the maternal recognition of
pregnancy signal, estrogen, placental attachment to the uterine luminal epithelium occurs
between Days 13 and 18 of gestation [Perry et al., 1981; Dantzer, 1985]. Underlying the
importance of trophoblastic elongation as a means to acquire uterine space for
placentation is that porcine conceptuses are very non-invasive in vivo and develop an
epitheliochorial type of placenta [King et al., 1982; Keys and King, 1990], an inefficient
transporter of nutrients compared to alternative placental types in other mammals. The
pig is unique in that the formation of the diffuse, epitheliochorial placenta preserves the
life of the uterine luminal epithelial cells and are not destroyed during placental invasion
as in other species, but contribute to the apposition and attachment of the trophectoderm
[Burghardt et al., 1997].
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The attachment of the conceptus trophectoderm to the extracellular matrix in the
uterus involves factors regulating tissue cohesion, cell migration and cell-cell
communication. Similar to the formation of a cumulus oocyte complex, extracellular
matrix formation and its stabilization is a result of the interactions between hyaluronic
acid (HA), the members of the inter--trypsin inhibitor (ITI) protein family, CD44, and
tumor necrosis factor stimulated gene 6 (TSG6) [Richards et al., 2002; Bost et al., 1998].
The detection of bikunin, the light chain of the ITI protein family, as well as ITI heavy
chain 4 are expressed in uterine endometrium during the establishment of pregnancy
[Hettinger et al., 2001; Geisert et al., 1998]. Collectively, ITI family members,
hyaluronic acid, bikunin, CD44 and TSG6 can function to form an adhesion matrix on the
surface of the uterine luminal epithelium as proposed by Ashworth [2005].
Other specific alterations in the uterine epithelium are required for the
reorganization and remodeling of the extracellular matrix (ECM), expressing specific
ligands and receptors necessary for uterine receptivity and conceptus attachment.
Integrins are a family of cell transmembrane glycoproteins that are known to contribute
to cell-cell communications and linkage [Hynes, 1992; Lessey, 1995] and are well
established in their roles regulating conceptus attachment in the pig [see reviews Jaeger et
al., 2001; Burghart et al., 1997]. Integrins consist of numerous  and  subunits, and
when forming an  heterodimer, results in the formation of a membrane bound receptor
whose ligand specificity is dependant on the subunits comprising the heterodimer. In the
pig, at least five  (1, 2, 3, 4, v) and three  (1, 3, 5) subunits exist in the uterine
epithelium while three  (1, 4, 5) and 2  (1, 3) have been detected in the conceptus
[Bowen et al., 1996]. During conceptus estrogen secretion and initial trophectoderm
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attachment, the expression of 4, 5, and 1 is elevated in the uterine endometrium,
whereas the expression of v and 3 are constitutive and 1 and 3 remain low [Bowen et
al., 1996]. Bowen et al. [1996, 1997] further demonstrated that the elevation of 4, 5,
and 1 is regulated through progesterone. The potential integrin heterodimers capable of
forming in either the pig conceptus, uterine epithelium, or both, include; 41, 51, v1
and v3, all of which are members of the fibronectin/vitronectin family of receptors
[Bowen and Hunt, 2000]. Vitronectin has been demonstrated to be expressed by both the
trophectoderm and the uterine luminal epithelium [Bowen et al., 1996] while fibronectin
has been identified in the trophectoderm of conceptuses collected from Day 12 to 15 of
gestation [Tou and Bazer, 1996a]. Other potential integrin heterodimer ligands include
the transforming growth factor  latency-associated peptide and osteopontin [review,
Jaeger et al., 2001]. Osteopontin, also referred to as secreted phosphoprotein 1 (SPP1), is
expressed in the uterine luminal epithelium as early as Day 15 of gestation, with
expression being much greater by Day 25 of gestation [Garlow et al., 2002]. White et al.,
[2005] have more recently demonstrated that luminal epithelial expression during early
pregnancy is regulated by conceptus estrogen and the prolonged expression throughout
late gestation in the uterine glandular epithelium is driven by progesterone.
While the ligand-receptor interaction between the conceptus trophectoderm and
the uterine luminal epithelium are critical for attachment to occur, other factors, such as
cell surface mucins can also impact trophectoderm adhesion to the luminal epithelium in
the pig. The cell surface mucin, MUC-1 has been reported to be a likely regulator of
uterine receptivity through its ability to prevent integrin binding between the
trophectoderm and uterine epithelium [Surveyor et al., 1995]. With respect to expression
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during the estrous cycle, MUC-1 has a similar expression pattern in the mouse [Braga
and Gendler, 1993] and pig [Bowen et al., 1996]. Ovarian hormones are likely the key
regulators of MUC-1 expression in the pig as expression is greatest following high
estrogen and low progesterone plasma concentrations on Days 0 to 4 of the estrous cycle
but is nearly undetectable in the by Day 10 in both cyclic and pregnant gilts, when
progesterone levels are elevated [Bowen et al., 1996]. The loss of progesterone
stimulation is a possible mechanism for MUC-1 depletion in the pig as progesterone
receptor is dramatically reduced in the luminal epithelium on Day 10 of gestation after
being the greatest on Day 0 [Geisert el al., 1994].
The expression of another cell surface mucin, MUC-4, is also reduced in the
uterine epithelium during implantation in rodents [McNeer et al., 1998; Carraway and
Idris, 2001]. Interestingly, Ferrel et al. [2003] demonstrated an increased expression of
MUC-4 protein expression during placental attachment in the pig. While placentation in
the pig is non-invasive, porcine conceptuses themselves are highly invasive ex utero
[Samuel and Perry, 1972]. Perhaps the coordinated expression of mucins such as MUC-1
and MUC-4 is required to be both permissive for attachment yet regulatory of conceptus
proteolytic activity. In rodents, however, the down-regulation of both MUC-1 and MUC-
4 may be necessary for a more invasive placentation.
Porcine Conceptus Gene Expression
Because of the substantial impact the events during early porcine conceptus development
have on subsequent placental expansion, a significant amount of research has been
targeted to identify gene expression changes during early development that may be linked
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to critical events. Niemann and Wrenzycki [2000] made the general estimation that
following the activation of the embryonic genome, the appropriate expression of
approximately 10, 000 genes are involved in successful embryogenesis. Gene expression
in the pig following fertilization is predominately under maternal regulation until the
activation of the porcine embryonic genome occurs, specifically during the 4 to 8-cell
stage of development [Tomanek et al., 1989]. Numerous genes and factors contribute to
the transition from maternal to embryonic control, pre-zona pellucida hatching
development, and nucleoulus development [see review, Maddox-Hytell et al., 2001].
Why these early developmental events are biologically necessary for subsequent
development, most research efforts have focused on the factors regulating conceptus
trophoblastic elongation due to the impact this developmental phenomena has on
placental expansion, uterine capacity, and ultimate survivability of littermates.
Therefore, the remainder of this section will focus on the genes and factors described to
be involved with conceptus development on Days 10 to 13 of gestation, when the
initiation of both trophoblastic elongation [Geisert et al., 1982b] and conceptus
attachment to the uterine epithelium occur [Perry et al., 1981; Dantzer, 1985].
Multiple approaches have been utilized to identify differentially expressed genes
during trophoblastic elongation. Numerous strategies have been utilized to identify major
regulators of trophoblastic elongation and attachment to the uterine luminal epithelium
through utilization of semi-quantitative polymerase chain reaction (sqPCR) [Green et al.,
1995; Yelich et al., 1997a; Yelich et al., 1997b; Kowalski et al., 2002], differential
display PCR (ddPCR) [Wilson et al, 2000; Wilson et al., 2002], suppression subtractive
hybridization (SSH) [Ross et al., 2003b], expressed sequence tag (EST) library
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construction and analysis [Smith et al., 2001], utilization of embryonic based cDNA array
[Lee et al., 2005] and serial analysis of gene expression (SAGE) [Blomberg et al., 2005].
Activation of conceptus estrogen synthesis during the first signs of mesodermal
differentiation in 5 mm spherical conceptuses suggests that the programming for
trophoblastic elongation may occur up to 24 h in advance [Geisert and Yelich, 1997]. In
mice, mesodermal outgrowth is dependent on the temporally correct expression of the
transcription factor, brachyury [Herrman et al., 1990]. Porcine conceptus brachyury gene
expression occurs concomitantly with mesodermal outgrowth of 5 mm spherical
conceptuses and is temporally associated with P450arom expression [Yelich et al., 1997a].
Cytochromes P450 17-hydroxylase (P45017) and aromatase (P450arom) are two required
enzymes for estrogen synthesis. Three distinct isoforms have been identified in the pig
for P450arom, each encoded by a unique gene [Graddy et al., 2000]. The isoforms,
P450arom type I, II and III are expressed specific to the ovary, late gestation placental
tissue [Corbin et al., 1995] and conceptus [Choi et al., 1996], respectively. Gene
expression for both P45017 and P450arom increase during Day 11 to 12 of gestation
concurrent with the initiation of trophoblastic elongation and the formation of
filamentous conceptuses [Yelich et al., 1997a]. Another critical enzyme regulating
estrogen synthesis is steroidogenic acute regulatory protein (STAR), which is involved
with the cleavage of cholesterol resulting in the accumulation of substrates necessary for
steroid hormone biosynthesis. The differential expression of STAR during rapid
trophoblastic elongation was identified through SAGE [Blomberg et al., 2005].
Interestingly, while the gene expression for STAR increases during the morphological
transition from spherical to filamentous; protein expression, as revealed by western
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blotting, is significantly less in filamentous conceptuses [Blomberg and Zuelke, 2005].
This translational control of enzyme activity during trophoblastic elongation is indicative
of the tight regulation of estrogen biosynthesis and alludes to the mechanism by which
estrogen secretion by the pig conceptus remains transient. Increasing amounts of
estrogen in uterine luminal flushings has largely been associated with trophoblastic
elongation of pig conceptuses [Geisert et al., 1982b; Fischer et al., 1985]. Wilde and
Pope [1987] demonstrated that the morphological stage of pig conceptus development
directly affects their ability to produce estrogen in vitro during a 6 h incubation.
Essentially, while detectable amounts of estrogen are synthesized by spherical
conceptuses, filamentous conceptuses from the same litter produce significantly more. In
Meishan conceptuses, increased estrogen production is associated with the days in which
elongating conceptuses are present; however, the proportion of spherical conceptuses
capable of producing estrogen on Day 12 of gestation is much greater than the proportion
of spherical conceptuses capable of producing estrogen on Day 11 [Pickard et al., 2003].
This suggests the mechanisms regulating estrogen secretion in Meishan conceptuses is
regulated through a time dependent mechanism separate from conceptus morphology.
As production of progesterone from the corpora lutea is greatly elevated it seems
plausible that progesterone may also affect conceptus development. Plasma
concentration of progesterone peaks by Day 10 of gestation or the estrous cycle.
Conflicting evidence exists on the expression progesterone receptor (PR) mRNA by pig
conceptuses. Ying et al. [2000] were not able to identify PR protein in Day 6
conceptuses whereas two abstracts presented at annual research symposiums reported
RT-PCR revealed PR gene expression in filamentous conceptuses [Dekaney et al., 1998;
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Kowalski et al., 2000]. However, Yelich et al. [1997a] were unable to amplify PR
mRNA through RT-PCR in Day 11 to 12 conceptuses ranging from 2 mm spheres to
filamentous morphology. The occurrence of PR mRNA expression by the pig conceptus
would suggest that maternal progesterone may induce responses by developing
conceptuses resulting in the establishment of a communication pathway.
The possibility of the synthesis and release of conceptus estrogen to function in an
autocrine/paracrine fashion has been suggested due to estrogen receptor  (ER)
expression in elongating conceptuses [Kowalski et al., 2002] while estrogen receptor 
(ER) was not detected in elongating conceptuses using RT-PCR [Yelich et al., 1997a].
However, ER has been immunohistochemically detected in the uterine endometrium of
gilts from Days 0 to 12 of the estrous cycle and pregnancy [Geisert et al., 1993].
Collectively, this would suggest the mechanisms of conceptus estrogen secretion could be
two-fold, operating through each receptor isoform within the conceptus and uterus.
Prostaglandin (PG) production by the developing conceptus is also temporally
associated with trophoblastic elongation and conceptus production of estrogen. Both
PGF2 and PGE2 in uterine flushings significantly increase during Days 11 to 12 of
gestation [Geisert et al., 1982b]. Prostaglandin production is dependant on the
availability of arachidonic acid and the enzymatic activity of both phospholipase A2
(PLA2) and cyclooxygenases-1 (PTGS1) and -2 (PTGS2). Phospholipase A2 functions
to enzymatically free arachidonic acid from the phospholipid bilayer which is then
utilized as a substrate for prostaglandin synthesis. Guthrie and Lewis [1986] indicated
that during elongation, porcine conceptuses increase the synthesis and release of
prostaglandins. As expected, the activity of PLA2 and expression of PTGS2 both
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increase in filamentous conceptuses [Davis et al., 1983; Wilson et al., 2002]. The
relationship between prostaglandin release and trophoblastic elongation is not known
other than the temporal and spatial association between the two. However, prostaglandin
production may be related to the remodeling of the trophoblast through the release of
arachidonic acid, which permits membrane fluidity in the cell membrane phosholipid
bilayer necessary for remodeling of the trophectoderm [Davis and Blair, 1993; Geisert
and Yelich, 1997]. The induction of prostaglandin synthesis may be related to the
conceptus synthesis and production of interleukin-1 (IL-1) which is transiently
expressed during rapid trophoblastic elongation [Tou et al., 1996b; Ross et al., 2003a].
Interleukin-1 is capable of inducing phospholipase A2 gene expression [Kol et al.,
2002] and cycoloxygenase-2 gene expression [Huang et al., 1998] in reproductive tissues
of various species. The presence of both receptors required for IL-1 signaling in the
elongating pig conceptuses [Ross et al., 2003a] suggest that this may be a valid role of
conceptus synthesized and released IL-1. However, the transient, pregnancy specific
up-regulation of both receptors in the uterine endometrium suggests a role for the
cytokine with respect to induction of a uterine response as well.
Insulin-like growth factors (IGFs), particularly IGF-I and IGF-II, which may have
significant impact on the growth and development of the pig conceptus, have been well
characterized throughout early gestation in the pig. Endometrial secretion of IGF-I is
elevated during the time of trophoblastic elongation and declines shortly thereafter
[Simmen et al., 1992] while conceptus gene expression for IGF-I increases steadily
during pre-elongation stages peaking at Day 12 of gestation [Letcher et al., 1989]. IGF-I
receptor gene expression is present throughout peri-implantation conceptus development;
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however there is no variation in expression throughout early development [Green et al.,
1995]. The enhanced release of IGF-I by the endometrium is correlated with an increase
in conceptus P450arom gene expression [Ko et al., 1994; Green et al., 1995] and has been
suggested to regulate conceptus ability to produce estrogen [Hofig et al., 1991]. Uterine
IGF-I secretion, which is significantly greater in the uterine lumen of pregnant gilts on
Day 12 of gestation compared to Day 12 of the estrous cycle, may act in an
autocrine/paracrine fashion to regulate uterine changes [Geisert et al., 2001]. Uterine
receptivity to IGF-I occurs through the IGF-1 receptor that is copiously expressed in the
uterine endometrium [Simmen et al., 1992]. Pig conceptuses also express IGF-II receptor
[Chastant et al., 1994] and its stimulation is likely associated with growth and
development before and during the time of conceptus elongation. Endometrial release of
IGF-II into the uterine lumen significantly increases from Day 10 to 12 of gestation and
is much greater on Day 12 of pregnancy compared to the equivalent day of the estrous
cycle [Geisert et al., 2001]. Both IGF-I and -II can stimulate conceptus growth and
development by acting through the IGF- II receptor in the conceptus [Czech, 1986]. IGF
binding proteins (IGFBP) function to bind IGF thereby regulating the degree to which
IGF is capable of biologically stimulating a target cell [Rechler, 1993]. Lee et al. [1998]
demonstrated that IGFBPs were present in the pig uterine lumen before Day 11 of
gestation and became absent in the lumen after Day 11 of gestation. The loss of IGFBP-2
and -3 was not caused by a decrease in endometrial gene expression but rather through
cleavage of IGFBP-2 and -3. Since the loss of IGFBPs correlated with the time of
trophoblastic elongation, Lee et al [1998] suggested conceptus regulation of IGFBP
cleavage. However, Geisert et al. [2001] have indicated that the cleavage of IGFBP-2
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and -3 in the uterine lumen on Day 12 occurs in both pregnant and cyclic gilts likely
through the protease activity of kallikrein and/or matrix metalloproteinases. Cleavage of
IGFBP-2 and -3 increases the bioavailability of IGF-I and -II at a time period when
conceptus growth and steroid production is peaking.
Epidermal growth factor (EGF) and transforming growth factor-alpha (TGF) are
additional growth factors that can affect conceptus development. Interestingly, EGF and
TGF serve as ligands for the same receptor, EGF receptor (EGF-R) [Burgress, 1989].
Porcine conceptus TGF gene expression is detected briefly during peri-implantation
development from Days 8 through 12 of gestation with maximal expression occurring on
Day 10. In contrast, conceptus EGF gene expression commences on Day 15 of gestation
and continues to increase into early organogenesis [Vaughan et al., 1992]. EGF-R is
constitutively expressed in the conceptus from Day 7 until at least Day 22 of gestation
[Vaughan et al., 1992]. While the gene expression profiles of TGF and EGF differ
drastically, it is likely that they both act via EGF-R and serve unique stimulatory roles
affecting early conceptus development in the pig. In mouse conceptus development,
TGF stimulates fluid uptake thereby regulating blastocoele expansion [Dardik and
Schultz, 1991]. Blastocyst formation in the pig occurs on Day 8 of gestation and may be
under the partial regulation of TGF as the receptor is expressed as early as Day 7. It is
also highly possible that TGF could illicit similar effects in porcine conceptuses
regulating membrane fluidity, which is necessary for commencement of trophoblastic
elongation [Geisert and Yelich, 1997]. However, EGF probably contributes most to
early organ and placental development occurring from Day 14 to 22 of gestation as
indicated by its temporally associated gene expression.
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Another family of growth factors that have been extensively investigated during
conceptus-maternal interfacing that occurs between Days 10 and 14 of gestation are the
three transforming growth factor  isoforms (TGF-1, -2 and -3). In situ hybridization
analysis indicated gene expression for all three TGF isoforms tends to increase in the
porcine conceptus trophectoderm and endoderm from Days 10 to 14 of gestation while
only TGF-2 increased in the embryonic ectoderm and mesoderm during Days 12 to 14
[Gupta et al., 1998]. Gene expression for all three TGF isoforms increases in uterine
luminal epithelium on Days 10 to 14 of gestation [Gupta et al., 1998], which coincides
with increasing estrogen synthesis and release into the uterine lumen during conceptus
elongation [Geisert et al., 1982b]. Yelich et al. [1997b] evaluated conceptus TGF-2 and
-3 gene expression during trophoblastic elongation and reported that TGF-2 was not
detectable through RT-PCR. However, Yelich and coworkers [1997b] confirmed that
TGF-3 gene expression increased during the period of rapid morphological change in
conceptus development during Days 10 to 12 of gestation. Immunostaining for
TGF receptors revealed both TGF receptor type I and II are expressed in the peri-
implantation pig conceptus during Days 10-14 of gestation [Gupta et al., 1996]. Presence
of the TGF receptors indicates the ability of the conceptus to respond to TGF
stimulation from conceptus or endometrial origin.
Throughout the last decade retinol, the common form of vitamin A, has received
thorough investigation regarding the effects it may have on conceptus development in
pigs, particularly during Days 10-18 of gestation. Retinol likely plays integral roles
orchestrating cell division, organogenesis and placental growth in all mammals [Roberts
et al., 1993], however, when excessive, retinol can be embryotoxic [Thompson et al.,
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1964]. Retinol, retinal, and retinoic acid, collectively termed retinoids, induce biological
actions via retinoic acid receptors (RAR) , , and . Yelich et al. [1997b] revealed that
all three RAR isoforms are expressed before, during and after rapid trophoblastic
elongation. Both RAR and RAR continue to be expressed in Day 15 porcine
conceptuses [Harney et al., 1994]. Roberts et al. [1993] reviewed the changes in uterine
retinol and indicated its concentration in uterine flushings containing filamentous
conceptuses during Days 10-13 of gestation is 10-50 fold greater than uterine flushings
during the same time frame only containing spherical conceptuses. Flushings containing
spherical conceptuses had a concentration of retinol that was similar to that of uterine
flushings from non-pregnant animals on Day 11 to 12 of the estrous cycle. Vallet et al.
[1996] published similar data indicating significantly higher retinol binding protein
(RBP) in the uterine lumen on Day 13 compared to Day 10 of gestation. Retinol
transport from the uterine lumen to the conceptus is primarily under the regulation of
RBP. RBP is a secretory product of the pig conceptus [Harney et al., 1990] whose gene
expression increases steadily as conceptuses develop from 4 mm spheres into more
advanced filamentous conceptuses [Yelich et al., 1997b]. Furthermore, gene expression
of RBP by the uterine endometrium of Day 12 pregnant gilts is highly dependent on
morphological stage of conceptus development [Trout et al., 1992]. Endometrium from
gilts bearing Day 12 filamentous conceptuses had dramatically greater RBP gene
expression than Day 12 endometrium in the presence of spherical conceptuses.
Synchronization and timing of the gene expression for both RAR’s and RBP in the
conceptus and endometrium suggests a significant dependency of conceptus development
on retinol availability. Geisert and Yelich [1997] proposed that conceptus secreted
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estrogen stimulates the endometrial release of RBP resulting in the transport of retinol to
the conceptus cytoplasm where it is converted to retinoic acid (RA). Available RA
stimulates conceptus RAR’s inducing extracellular matrix (ECM) remodeling, needed for
trophoblastic elongation to occur, both directly, and indirectly through downstream
stimulation of morphogens such as TGF’s.
During the past decade, cytokines are proving to be intimately involved with the
regulation of conceptus development and the establishment of pregnancy in many
species. Mathialagan et al. [1992] evaluated interleukin-6 (IL-6) gene expression in pig
conceptuses and indicated that greatest expression occurred during the period of
attachment and early placentation. A later study by Modric et al. [2000] reported that IL-
6 gene expression in the preimplantation conceptus peaked in Day 12 filamentous
conceptuses but gene expression was not detectable in Day 14 conceptuses. The ability
of IL-6 to induce an acute phase pro-inflammatory response is imitated, albeit to a lesser
degree, by interleukin-1 (IL-1) [Mantovani et al., 1998]. Using northern blotting, Tou et
al. [1996b] demonstrated that IL-1 is transiently expressed by porcine conceptuses
between 11 and 13 days of gestation. Ross et al. [2003a] further demonstrated the
increased mRNA abundance associated with trophoblastic elongation is temporally
associated with significant increased IL-1 concentrations in uterine lumen flushings.
Both receptors for IL-1, IL-1RT1 and IL-1RAP, increase in gene expression in the
uterine endometrium and conceptus while IL-1 protein levels are elevated in the uterine
flushings on days 12-15 of gestation [Ross et al., 2003a]. Peri-implantation IL-1 gene
expression has also been documented to increase prior to initiation of blastocyst
implantation in the mouse [Takacs and Kauma, 1996; Kruessel et al., 1997] and has been
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suggested as the initiator of conceptus-uterine cross-talk during early pregnancy in the
human [Lindhard et al., 2002]. The importance of a conceptus induced acute phase
inflammatory response in the pig uterus is not well understood although its occurrence
has been described by Geisert and Yelich [1997]. Inflammation is generally associated
with the recruitment of immune cells. During pregnancy in the pig, stromal leukocyte
populations are significantly greater at attachment sites opposed to between attachment
sites [Engelhardt et al., 2002]. The majority of these leukocytes morphologically
resembled lymphocytes suggesting they were predominately T, B and/or natural killer
(NK) cells. This initial contact, coupled with embryonic signals, invokes an acute phase
inflammatory response by the uterus and likely results in the differentiation of
undifferentiated T-helper (Th0) cells to either type 1 (Th1) or type 2 (Th2) cells. Th1
mediated immunity is referred to as cell-mediated immunity and is generally associated
with pregnancy failure [Raghupathy, 1997] while humoral immunity mediated by Th2 is
thought to be required for the successful establishment of pregnancy [Wegmann et al.,
1993]. However, the TH1/TH2 paradigm is challenged in that numerous factors such as
IL-1 [Ross et al., 2003a] and interferon  (IFN-) [Lefevre et al., 1990]; which are
generally considered to be stimulators of TH1 immunity, are both expressed by the
conceptus during the early attachment phase. Immunological stimulation of the uterine
milieu is unavoidable; however, the induced inflammation is necessary and not
necessarily devastating to the conceptus as it stimulates counter regulatory responses
limiting induced damage while encouraging shifts in the maternal T cell repertoire more
suitable for a successful pregnancy [Mellor and Munn, 2000].
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Colony stimulating factor-1 (CSF-1) is an additional factor produced by the
conceptus that is suspected to accentuate growth and differentiation. CSF-1 gene
expression is present in conceptuses as early as Days 10 to 12 of gestation. However,
CSF-1 expression peaks at Day 30 and continues to be expressed in fetal tissues
throughout gestation [Tuo et al., 1995]. CSF-1 is thought to be responsible for the
recruitment of macrophages to the site of implantation and involved in regulating
placental development [Wood et al., 1997]. Osteopetrotic (op/op) mice lack the CSF-1
gene [Wiktor-Jedrzejczak et al., 1990], which is required for successful female fertility.
Pollard and coworkers [1991] demonstrated that while op/op x op/op crosses resulted in
consistent infertility, pregnancies created by crossing heterozygous males (+/op) with
op/op females were partially salvaged. This indicates that the necessity for conceptus
produced CSF-1 to either compensate or attenuate the CSF-1 production in the uterine
endometrium.
Leukaemia inhibitory factor (LIF) is a cytokine that has been proposed to regulate
conceptus growth and development. Anegon et al. [1994] indicated that LIF is present in
porcine uterine luminal flushings on Days 7-13 of the estrous cycle and peaks on Day 12
of gestation. LIF likely has direct effects on the conceptus as both pre- and post-
elongation conceptuses express LIF receptor  [Modric et al., 2000]. Pregnancy specific
endometrial gene expression of LIF is detected in pregnant animals during the
approximate time rapid trophoblastic elongation is initiated and could serve as a pathway
for possible conceptus-uterine communication [Anegon et al., 1994]. LIF receptor is also
expressed in the mouse uterus on Day 4, the time of blastocyst implantation [Ni et al.,
2002]. Interestingly, LIF receptor was not expressed in the uterus following progesterone
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priming although it was greatly increased following estrogen-mediated termination of
delayed implantation [Ni et al., 2002]. Estrogen likely mediates similar effects in pigs as
the transient increase in expression of LIF in the uterus occurs concurrently with
increased conceptus estrogen production and LIF receptor expression.
While the information presented in this section provides valuable information
regarding gene expression during early porcine conceptus development. Genes
controlling trophoblastic elongation remain largely unknown.
Role of Estrogen During Early Pregnancy in the Pig
Estrogen as the Maternal Recognition of Pregnancy Signal
In 1969, Short coined the term “maternal recognition of pregnancy” when
describing the process resulting in the extension of the CL life beyond that which occurs
during a normal estrous cycle. Maternal recognition of pregnancy is the process by
which the developing conceptus(es) synthesize and release a chemical signal, that
modifies a molecular cascade of events prolonging the lifespan of the CL beyond the
length of a normal estrous cycle [Geisert et al., 1990]. Protection of the CL promotes
continued progesterone production thereby allowing maintenance of myometrial
quiescence and endometrial histotroph production. In pigs, progesterone production by
the CL is required throughout pregnancy as ovariectomy at any stage of pregnancy results
in abortion [Nara et al., 1981]. Perry et al. [1973, 1976] demonstrated that porcine
conceptuses possess the metabolic ability to convert steroid precursor molecules into
estrogens. Later, Bazer et al. [1982] established that the conceptus synthesis and
secretion of estrogen did in fact serve as the maternal recognition signal. Conceptus
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synthesis and release of estrogen during early pregnancy in the pig is biphasic; first
transiently peaking on Day 11 to 12 during trophoblastic elongation trailed by a more
sustained period of secretion initiated on Day 15-16 of gestation [Geisert et al., 1990]. A
variety of studies have coordinately established that estrogen alone is capable of
functioning as a luteotrophin. While responses were highly variable, injections of
estradiol valerate on Days 11 to 15 of the estrous cycle induced psuedopregnancy in gilts
for an average of 146 days [Frank et al., 1977]. Even single injections of exogenous
estrogen given to gilts after Day 9 of the estrous cycle extended the corpora lutea lifespan
[Kidder et al., 1955]. In 1963, Gardner et al. demonstrated the ability to lengthen the
interestrous interval by administration of exogenous estrogen on Day 11-12 of the estrous
cycle. Similarly, Geisert et al. [1987] demonstrated a 7 day extension to the CL lifespan
in response to exogenous estrogen administered on Day 12 of the estrous cycle. These
data are further supported by estradiol valerate extending CL survival following infusions
directly into the uterine lumen between Days 11-15 of the estrous cycle [Ford et al.,
1982a]. King and Rajamahendran [1988] also demonstrated the ability of estrogen
impregnated sialastic beads implanted into the uterine lumen on Day 10 of the estrous
cycle induced psuedopregnancy. In an effort to mimic the physiological release of
estrogen by the conceptus as described by Geisert et al. [1982b], an initial injection of
estrogen on Day 11 to 12 followed by an additional 2nd dose of estrogen on Days 14-16
of the estrous cycle prolonged the life of the corpora lutea greater than 60 days [Geisert et
al., 1987]. The impersonation of the biphasic estrogen synthesis and release establishing
a prolonged psuedopregnancy indicates the critical temporal nature of conceptus estrogen
secretions as injections mimicking conceptus estrogen release at either phase only did not
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induce psuedopregnancy beyond 35 days [Geisert et al., 1987]. Clearly, the extensive,
confirming reports of exogenous estrogen, when given at time points temporally
associated with the endogenous conceptus synthesis and release of estrogen, having the
ability to induce psuedopregnancy has resulted in its acceptance as the maternal
recognition of pregnancy signal in the pig.
Temporally associated with increased uterine lumen estrogen concentrations
during early pregnancy is the augmentation of uterine blood flow [Ford and Christenson,
1979; Ford et al., 1982b] as well as the production and secretion of PGE2 into the uterine
lumen [Geisert et al., 1982b]. The association of PGE2 production was later determined
to be a result of conceptus phospholipase A2 activity and prostaglandin production
between Days 7 and 14 of gestation [Davis et al., 1983]. PGE2 has been shown to
enhance CL performance through increased weight and progesterone production [Ford
and Christenson, 1991] and is considered a luteotrophic agent during pregnancy in the pig
[Ziecik, 2002]. Production of prostaglandins is critical for the establishment of
pregnancy in pigs as inhibition results in pregnancy failure during early gestation
[Kraeling et al., 1985]. Interestingly, gene and protein expression of both prostaglandin
synthase-1 (PTGS1) and -2 (PTGS2) have been detected in the uterine endometrium
during the estrous cycle and early pregnancy [Ashworth et al., 2006; Blitek et al., 2006].
Both PTGS1 and -2 are principal enzymes that convert arachidonic acid to prostaglandin
H2 (PGH2). While PTGS1 appears to be constitutively expressed, PTGS2 may have a
more prominent role with respect to prostaglandin production as its gene and protein
expression increases during the luteal phase of the estrous cycle and early pregnancy in
the pig [Ashworth et al., 2006; Blitek et al., 2006]. Subsequently, two terminal enzymes,
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PGE synthase and PGF synthase catalyze the conversion of PGH2 to PGE2 and PGF2,
respectively [Smith and Dewitt, 1996]. Both PGE2 and PGF2 are intricately involved in
the establishment of pregnancy in the pig. PGE2 is a vasodilator that, in addition to
estrogen, dramatically increases in concentration in the uterine flushings during the time
of trophoblastic elongation and maternal recognition of pregnancy in the pig [Geisert et
al., 1982b], while PGF2 is a vasoconstrictor synthesized and released by the uterine
endometrium that is responsible for corpora lutea death around Day 15 of the estrous
cycle in the pig [Moeljono et al., 1976].
Control of Luteolysis
Luteolysis in pigs is dependant on the uterine endometrial secretion of the
luteolysin, PGF2, into the vasculature through an endocrine mechanism resulting in the
delivery to and subsequent lysis of the CL. The response of the CL in the pig to the
luteolysin varies dramatically during the estrous cycle and early pregnancy and is a
tightly regulated process. Gadsby et al. [1990] demonstrated that the CL refractory
period to luteolysis is most likely in response to the low abundance of luteal receptors for
PGF2 prior to Day 12 of the estrous cycle or early pregnancy. On Day 13, there is a
dramatic increase in luteal PGF2 receptor expression that remains elevated on Day 14 to
17 resulting in the susceptibility of the CL to PGF2. A more comprehensive review
outlining the involvement of other factors such as endothelin-1, tumor necrosis factor-
and insulin like growth factor-1 during the acquisition of luteolytic sensitivity and
luteolysis is available [Gadsby et al., 2006]. While specific mechanisms regulating
endometrial prostaglandin production are not well elucidated, McCracken et al. [1999]
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have hypothesized that the hypothalamic production of oxytocin subsequently binding to
its receptor in the uterine endometrium as an initiator and/or potentiator of endometrial
production of prostaglandins in the ewe. It also seems plausible that activation of the
transcription factor, nuclear factor  B (NFB), may occur as the PTGS2 gene contains
the B site [Ali and Mann, 2004]; and that PTGS2 expression increases are specific to the
luminal epithelium and temporally associated with PGF2 production [Ashworth et al.,
2006].
Because prostaglandin synthesis and secretion is required for pregnancy
establishment and PGF2 is also the luteolysin in the pigs, the mechanisms by which
PGF2 is capable of communicating with the CL is tightly regulated. Frank et al. [1977]
demonstrated that i.m. delivery of 5 mg of estradiol valerate on Days 11 to 15 of the
estrous cycle reduced PGF2 concentrations in the utero-ovarian vein. This mechanism
of action was further confirmed when infusion of 375 ng of estradiol-17 into the uterine
lumen of gilts every 6 h on Days 11 to 15 of the estrous cycle also had lower PGF2
concentrations in the utero-ovarian vein compared to control gilts [Ford et al., 1982a].
The conceptuses are the main instigators preventing luteolysis during early
pregnancy in the pig. Dziuk [1968] demonstrated that prior to Day 18 of gestation, at
least two conceptuses must be present in each uterine horn to prevent luteolysis and
establish pregnancy in the pig. This is largely due to the expansive nature of the pig
uterine endometrium that is capable of producing prostaglandins and the necessity of
local communication of conceptuses with the maternal endometrium during pregnancy
establishment. As the synthesis and secretion of PGF2 from endometrium of both cyclic
and pregnant gilts occurs, specific mechanisms are required to prevent luteolysis in
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pregnant gilts while allowing it to occur in cyclic gilts. The most accepted theory
describing the mechanisms by which pregnant gilts overcome luteolysis is described by
the endocrine/exocrine theory of maternal recognition [Bazer and Thatcher, 1977].
During the estrous cycle and normal CL regression, the uterine endometrium functions as
an endocrine tissue capable of releasing PGF2. Bazer and Thatcher suggested that the
conceptus estrogen secretion redirects movement of endometrial PGF2 release toward
the uterine lumen (exocrine) rather than being directed through the underlying
endometrial stroma and secreted into uterine vasculature network (endocrine). This is
supported in that both pregnant and estrogen induced psuedopregnant gilts have elevated
PGF2 in their uterine flushings [Zavy et al., 1982]. Failure to redirect endometrial
PGF2 can result in release of PGF2 directly into the utero-ovarian portal vessels
allowing the transportation of the luteolysin directly to the CL. Also, because the pig
lungs are capable of reducing only 18% of the systemic PGF2 to its metabolite, 15 keto-
13,14 dihydro-prostaglandin F2, through one circulatory passage, systemic as well as
local delivery of PGF2 from the uterus is capable of initiating luteolysis [Davis et al.,
1979]. While increased PGF2 concentrations have been detected in the utero-ovarian
vein just prior to and during luteolysis [Bazer et al., 1982], systemic delivery also appears
to contribute to corpora lutea death as Dhindsa and Dziuk [1968] demonstrated that
conceptuses were required in both uterine horns to prevent luteolysis and extend gestation
past 30 days. Once the CL becomes sensitive to the luteolysin, endometrial PGF2
induces intra-luteal production of PGF2 through the activation of PTGS2 in the CL [Diaz
et al., 2002]. Ultimately, maternal recognition of pregnancy in the pig requires a
sufficient number of embryos equidistantly spaced to deliver the maternal recognition of
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pregnancy signal, estrogen. Adequate and synchronized trophoblastic elongation
throughout the uterine lumen during estrogen secretion redirects endometrial PGF2
production from systemic venous drainage to exocrine secretion thereby protecting the
integrity of the corpora lutea and enabling the establishment of pregnancy.
Endocrine Disruption of Pregnancy
In general, a thickening of the uterine glycocalyx (UG) occurs between Days 13
and 18 of gestation in the pig [Perry et al., 1981; Dantzer, 1985; Geisert et al., 1991] and
ultimately provides an essential adhesion matrix necessary for the attachment of the
conceptus trophectoderm to the uterine epithelium. Premature administration of estrogen
(Days 9 and 10) impairs the thickening of the UG, actually causing it to completely
slough off by Day 16 of gestation preventing the necessary cell-cell interactions for
conceptus attachment resulting in conceptus mortality and loss of pregnancy [Morgan et
al., 1987a; Blair et al., 1991; Geisert et al., 1991]. This disruption of the UG formation is
closely associated with embryonic mortality on Days 15 to 18 of gestation in gilts [Blair
et al., 1991]. While adverse timing of estrogen exposure via i.m. administration of
estrogen to the dam on Days 9 and 10 of gestation results in a total pregnancy loss, the
same dosage given on Days 11 and 12, in sync with conceptus synthesis and release of
estrogen, has no adverse affect on pregnancy establishment [Pope et al., 1994]. Ill-timed
ingestion of naturally occurring estrogenic alfatoxins, such as zearalenone, found in
moldy corn, also results in total litter loss [Long and Diekman, 1984]. The effects of
early estrogen exposure do not affect the ability for the conceptuses to elongate or
equidistantly space themselves, but is rather a result of endometrial modification.
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The negative effects estrogen bears on early pregnancy establishment appears to
be paralogous. Estrogen stimulation, albeit of ovarian origin, appears necessary for
pregnancy in mice as estrogen receptor alpha null (ERKO) mice are infertile [Couse and
Kourach, 1999]. The infertility in ERKO mice is thought to occur in part to
dysfunctional ovarian events; however, uterine hormone insensitivity is thought to
contribute as well. Indeed, transferred embryos into uteri of ERKO mice failed to
implant successfully, however, decidualization associated markers were still expressed
[Hewitt et al., 2002]. Estrogen may also affect implantation in humans as recurrence of
spontaneous miscarriage in individuals with polycystic ovarian syndrome (PCOS) may be
related to the greater amounts of serum estrogen and increased endometrial estrogen
receptor alpha (ER). While the estrogen source varies between mice and pigs (ovarian
in mice, conceptus in pigs), the timing and dosage of estrogen stimulation has been
shown to dramatically affect the ability of the conceptus to attach to the uterine
epithelium and initiate implantation in both species.
Critical parameters exist with regards to the specific timing and amount of
estrogen released during this stage of pregnancy in the pig. Insufficient estrogen
production, as seen in litters with less than two piglets per uterine horn at the time of
implantation, results in the failure to prevent luteolysis and subsequent pregnancy loss
[Polge et al., 1966; Dziuk, 1968]. While estrogen is required as a maternal recognition of
pregnancy signal and thought to be involved with the opening of the “implantation
window” in the pig, timing and extent of estrogen exposure can have dramatic effects on
conceptus development and survival. While estrogen exposure to the uterine
endometrium has a huge impact with regard to endometrial function and the ability to
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regulate the outcome of pregnancy, little is known considering the mechanisms of
estrogen during the establishment of pregnancy in the pig. Moreover, this underlines the
physiological importance of conceptus trophoblastic elongation to deliver estrogen
throughout the uterine lumen and also the synchrony by which it happens between
conceptuses. As it is evident that estrogen modification of the uterine microenvironment
can be destructive to conceptuses still in early spherical development; the production and
secretion of estrogen by developmentally advanced conceptuses may alter the micro-
environment surrounding conceptuses that are lagging in development and ensure their
demise.
The Opening of the Implantation Window
The opening of the implantation window is the initiating point of the period
during gestation at which specific endometrial alterations occur to allow the attachment
of the conceptus trophectoderm and subsequent development. It is this period of
development that requires the formation of a communication network between the
developing conceptus and the maternal endometrium; dysfunction on the part of either
the conceptus or the uterine endometrium will result in the inability to establish
pregnancy. Steroid hormones, progesterone and estrogen, no doubt serve a fundamental
responsibility in the pattern of endometrial secretions and the induction of uterine
receptivity. While progesterone serves more of a conceptus nurturing role through
regulating myometrial quiescence and endometrial histotroph secretion, estrogen
stimulation is critical for uterine receptivity through its protective mechanisms regarding
the corpora lutea and endometrial alterations necessary for conceptus attachment.
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Progesterone and progesterone receptor expression are thought to play a dramatic
role in regulating uterine receptivity in many species, including the pig. Corpora lutea
production of progesterone during early pregnancy is chiefly responsible for regulating
the production of uterine histotroph and prevention of myometrial contractions.
Recently, Geisert et al. [2006] described the potential role of progesterone and
progesterone receptor as regulators of the estrous cycle through its potential to interact
with the transcription factor, NFB, during the opening of the implantation window.
Progesterone supplementation to sheep and cattle prior to endogenous production via the
corpora lutea results in shortened estrous cycle [Ottobre et al., 1980; Garrett et al., 1988].
Mifepristone, a progesterone receptor antagonist, administered to sheep during days 3-5
of the estrous cycle results in a delay of luteolysis [Morgan et al., 1993]. Collectively,
these data suggest that the duration of progesterone exposure is directly related to
endometrial events necessary for luteolysis. Progesterone signaling requires the
expression of progesterone receptor. The down-regulation of progesterone receptor in the
uterine luminal epithelium is generally associated with the opening of the implantation
window in the human [Lessey et al., 1988, 1996], baboon [Fazleabas et al., 1999], sheep
[Spencer and Bazer, 1995], cattle [Meikle et al., 2001], pigs [Geisert et al., 1994] and
horses [Hartt et al., 2005]. While the down-regulation of progesterone receptor in the
luminal epithelium limits progesterone signaling, it is not obsolete as expression persists
in the underlying stroma during the time of implantation in the pig [Geisert et al., 1994].
Recently, data has provided insight into progesterone receptor regulation of
transcription of genes through its interactions with the transcription factor, NFB
[Kalkoven et al., 1996]. The data suggest that the p65 sub-unit of NFB and
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progesterone receptor are mutually repressive of each other and the authors hypothesize
that this is through interaction with the transcription factors themselves or binding to
genomic DNA in regions preventing transcriptional machinery necessary for gene
transcription to occur [Kalkoven et al., 1996]. Thus the down-regulation of progesterone
receptor just prior to the opening of the implantation window may be associated with
endometrial transcriptional changes necessary for uterine receptivity leading to
implantation. In mice, NFB activity has been assessed via electrophoretic mobility shift
assay and increased activity is associated with the period of implantation [Nakamura et
al., 2004a]. Viral delivery of inhibitor of NFB  (IB) into the uterus in mice delays
implantation by suppressing NFB activity and subsequent leukemia inhibitory factor
expression [Nakmura et al., 2004b]. Interestingly, the authors were capable of partially
restoring uterine receptivity when LIF was administered with the in vivo delivery of
IB.
The pig also expresses numerous NFB regulated genes in the uterine epithelium
such as interleukin-6, LIF, and others [see review; Geisert and Yelich, 1997].
Prostaglandin synthase-2, also an NFB regulated gene increases expression in the
uterine luminal epithelium in both cyclic and pregnant gilts coordinately with
progesterone receptor down-regulation and uterine receptivity and associated with the
significant production of PGF2 secreted into the uterine lumen [Ashworth et al., 2006].
Interestingly, the administration of indomethacin during the period of uterine receptivity
in pigs dramatically reduced prostaglandin production in the uterine lumen and resulted
in a total pregnancy loss [Kraeling et al., 1985]. Notably, indomethacin is an inhibitor of
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IB kinase activity which thereby functions to prevent IB degradation and the
freeing of the nuclear localization signal on the NFB dimers.
What regulates this activation of NFB, or the down-regulation of progesterone
receptor in the uterine endometrium remains unclear. One potential regulator of NFB
activation is receptor activator of nuclear factor B (RANK) and its ligand (RANKL)
which are both involved in bone remodeling and mammary gland development [Jones et
al., 2002; Cao and Karin, 2003]. Because expression of RANKL can be stimulated by
progesterone [Srivastava et al., 2003] may suggest the potential of RANK mediated
NFB activation in the pig endometrium if RANKL is capable of signaling through
endometrial stromal cells which still express progesterone receptor during the
implantation window in the pig [Geisert et al., 1994].
Another critical component of NFB activation during implantation in the pig
during the period of conceptus elongation and secretion of both estrogen and IL-1
secretion is the potentiation and/or regulation of NFB activation in the uterine
endometrium provided by the conceptus. While both receptors for IL-1, an inducer of
NFB activity, are expressed in the uterine endometrium [Ross et al., 2003a], the
production and secretion of conceptus estrogen may also regulate activity of NFB.
Ghilsetti et al. [2005] demonstrated the in vitro ability of estrogen, signaling through
ER and not ER, of preventing activated NFB in the cytoplasm from being
translocated into the nucleus of the cell and inducing transcription. The progesterone
receptor down-regulation in the luminal epithelium concurrent with conceptus secretion
of both IL-1 and estrogen, all potential modulators of NFB activity suggests the
molecular mechanisms by which uterine receptivity, and subsequent attachment and
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implantation in the pig, remain unclear. Perhaps the down-regulation of the luminal
epithelial progesterone receptor just prior to implantation is merely a default mechanism
by the uterine endometrium during cyclicity following progesterone “priming”. By
omission, the uterine endometrium is “putting the ball in the conceptus’ court”, allowing
the default activation of NFB by progesterone driven progesterone receptor withdrawal.
Then requiring progressive stimulation by the conceptuses to prevent or redirect
endometrial PGF2 secretion as well as provoke the appropriate endometrial response
necessary for conceptus-endometrial cross-talk. Nonetheless, the biological
understanding of this process is critical due to the implications regarding agricultural
farm animal production and the reproductive health of humans.
Statement of the Problem
There are numerous conceptus and endometrial factors that contribute to the
establishment of a successful pregnancy yielding large litter size in pigs. Unfortunately,
pig production from a reproductive standpoint in the United States is far from optimal.
Of the 20 to 46 % conceptus mortality rate realized throughout gestation in the pig, a
majority is directly related to the events during the peri-implantation stage of
development. Three extremely critical events occur during this time period: 1) the rapid
elongation of the conceptus trophoblast and delivery of the maternal recognition signal,
estrogen; 2) the uterine response to conceptus secreted estrogen, and 3) the down-
regulation of the luminal epithelial progesterone receptor and the uterine receptivity
associated with it. Temporally, these three biological processes all occur coordinately
within a very narrow time frame (Days 10 to 13 of gestation). As important as they are
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regarding the establishment of pregnancy in the pig, little biological information is
available delineating the mechanisms that regulate these events.
Ford [1997] attributes the larger litter size of the Meishan sows to the ability of
the conceptuses to regulate the uniformity and the extent to which they expand their
trophoblast. Geisert and Schmitt [2000] suggested that the ability to regulate the
simultaneous initiation of trophoblastic elongation would result in more consistent
placental size and uterine space among littermates potentially increasing litter size.
While multiple attempts to identify mechanisms critical for this stage of development
have provided much data, there remains a void as to what exactly regulates rapid
trophoblastic elongation in the pig.
Estrogen, while a required component of pregnancy establishment in the pig also
plays integral roles during pregnancy establishment. Copious amounts of estrogen
delivered by the conceptus during Days 11 to 12 of gestation appear to be required as too
few conceptuses are incapable of establishing pregnancy. While amount of estrogen
stimulation appears to have a requirement, the timing of the estrogen stimulation is also
critical as ill-timed administration or ingestion of estrogen has been shown to cause a
total loss of pregnancy in the pig. While certain events such as the redirecting of
endometrial PGF2 secretion are attributed to conceptus estrogen stimulation, very little is
known regarding the endometrial molecular mechanisms and events following estrogen
exposure. A deeper understanding the regulatory roles that estrogen serves during
pregnancy establishment in the pig will lend insight to steroidogenic factors affecting
pregnancy outcome in pigs. Also the biological understanding of estrogen’s impact on
endometrial function may also be applicable to women who suffer from polycystic
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ovarian syndrome that is associated with elevated estrogen circulation and early recurrent
spontaneous miscarriage.
Finally, the critical molecular events associated with the opening of the
implantation window and the period of uterine receptivity is vaguely described in any
species. While the down-regulation of the progesterone receptor in the luminal
epithelium is associated with uterine receptivity in most species, the biological forces
driving that phenomenon are not well described. Certainly, the regulation of specific
transcription factors and the downstream activation of their regulated genes contribute to
the establishment of pregnancy in the pig. Determining if a relationship between the
activation of the transcription factor, NFB, and progesterone receptor down-regulation
during exists during the period at which endocrine release of endometrial PGF2 is
redirected in the pig will be prudent biological information necessary for understanding
the events of pregnancy establishment for many species.
Approach
While biotechnological advancements have been rapid over the past few years,
bioinformatics resources have made exceptional progress recently. The ability to link
microarray data acquisition platforms to bioinformatics tools has dramatically changed
the capability to identify differentially expressed genes in a biological system and then
accurately annotate the biological themes associated with the alterations in the system
evaluated. Recently, a porcine 15K cDNA microarray representing genes from
conceptus, brain, ovarian and uterine tissues has been developed [Whitworth et al., 2005].
Also, the significant amount of expressed sequence tags from the pig deposited into
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GenBank has prompted the development of the GeneChip® Porcine Genome Array by
Affymetrix®. The 23, 937 probe set interrogates 23, 256 transcripts representing 20, 201
porcine genes. Utilization of these array platforms and modern bioinformatics
approaches will help identify the biological processes that are associated with both
endometrial response to estrogen stimulation as well as the factors that are involved with
rapid trophoblastic elongation during early porcine conceptus development.
Identification and characterization of the changes in gene expression that are related to
trophoblastic elongation, endometrial estrogen stimulation and uterine receptivity as a
result of transcription factor activation will provide a better understanding of the
biological events necessary for embryonic survival, implantation and a successful
pregnancy in the pig.
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Chapter III
ANALYSIS AND CHARACTERIZATION OF DIFFERENTIAL GENE
EXPRESSION DURING PORCINE CONCEPTUS RAPID TROPHOBLASTIC
ELONGATION AND ATTACHMENT TO THE UTERINE LUMENAL
EPITHELIUM
Introduction
As in any mammalian species, successful establishment of pregnancy and
embryonic development in the pig follows a specific pattern of temporal and spatial gene
expression. It is estimated that successful pre-implantation and early fetal development
involves the expression of approximately 10,000 genes [Niemann and Wrenzycki, 2000].
During early pregnancy in the pig, the peri-implantation period is one of the most critical
stages of conceptus development. After ovulation and fertilization, prenatal mortality in
the pig ranges from 20% to 46% by term [Pope, 1994] with the majority of the loss
occurring during the peri-implantation stage of development between Days 12 to 18 of
gestation [Stroband and Van der Lende, 1990]. This significant period of elevated
conceptus mortality during the peri-implantation stage of development coincides with
conceptus rapid trophoblastic elongation [Geisert et al., 1982b], neurulation of the inner
cell mass, the transient synthesis and release of the maternal recognition of pregnancy
signal, estrogen [Geisert et al., 1982b]; and finally, trophectoderm differentiation
followed by adhesion and attachment to the uterine surface epithelium [Burghardt et el.,
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1997]. The disruption of any of these critical biological processes can result in conceptus
mortality and a reduction in litter size.
Conceptus trophoblastic elongation, which occurs between Days 11 to 12 of
gestation, is characterized by transition through four distinct morphological stages
(spherical, ovoid, tubular and filamentous). The cellular remodeling and migration of the
trophectoderm is initiated when a conceptus reaches a 9-10 mm spherical morphology,
rapidly transforming from a ovoid shape into a tubular morphology which rapidly
expands into a long filamentous thread greater than 150 mm in length within 2-3 h
[Geisert et al., 1982b]. Secretion of the conceptus produced maternal recognition signal,
estrogen [Geisert et al., 1990, Bazer and Thatcher, 1977], and IL-1 [Ross et al., 2003a]
occurs concomitantly with elongation of the trophoblastic membrane. Trophoblastic
elongation and expansion through the uterine horns provides the biological function of
maximizing nutrient exchange throughout gestation through increased placental-uterine
contact during the formation of a diffuse epitheliochorial type of placenta [Stroband and
Van der Lende, 1990]. The associated release of estrogen induces alterations in the
endometrium, shifting the uterine environment, which may be unfavorable for less
developed littermates [Pope, 1994; Geisert and Yelich, 1997]. Litter variation in
conceptus morphological stage of development around Day 12 of gestation is not
uncommon [Anderson et al., 1978]. Given that the amount of estrogen production by
individual conceptuses is directly proportional to the morphological stage of development
[Pope et al., 1988], it is plausible to conclude that variation within the onset of
trophoblastic elongation and estrogen production between littermates can reduce
survivability of the lesser developed conceptuses as the uterine microenvironment is
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altered. While conceptus trophoblastic elongation is a required phenomenon for the
establishment of pregnancy in the pig, the subsequent adhesion of the trophectoderm to
the uterine surface epithelium is also critical for continued conceptus development.
Numerous conceptus products have been hypothesized to be important in porcine
conceptus development following detection of its mRNA expression in the various
conceptus morphological stages using techniques such as semi-quantitative RT-PCR
[Green et al., 1995; Yelich et al., 1997a; Yelich et al., 1997b; Kowalski et al., 2002],
differential display RT-PCR [Wilson et al, 2000], suppression subtractive hybridization
(SSH) [Ross et al., 2003b], expressed sequence tag (EST) library construction and
analysis [Smith et al., 2001], utilization of embryonic based cDNA array [Lee et al.,
2005] and serial analysis of gene expression (SAGE) [Blomberg et al., 2005]. While
these techniques have compiled complementary data representing potential regulators of
trophoblastic elongation, most studies have only compared the expression of Day 12
filamentous conceptuses to those of earlier morphological stages of development and not
post-elongated conceptuses which are initiating attachment to the uterine epithelial
surface. At present, little information is available regarding the large number of genes
that may be responsible for initiating rapid trophoblastic elongation as well as those
involved with the initial attachment to the uterine lumenal epithelium. The objective of
the present investigation was to utilize the GeneChip® Porcine Genome Array from
Affymetrix representing 20, 201 genes to identify differentially expressed genes during
rapid trophoblastic elongation and attachment to the uterine surface in the pig.
Identification and characterization of conceptus gene expression patterns during rapid
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trophoblastic elongation and attachment in the pig will provide a better understanding of
the events required for successful implantation and embryonic survival.
Materials and Methods
Conceptus Collection
Research was conducted in accordance with and approved by the Oklahoma State
Institutional Animal Care and Use Committee. Twenty crossbred, cyclic gilts were
checked for expression of estrus twice daily in the presence of an intact boar and
naturally mated at the onset of the second estrus and again 24 h later. Gilts were
hysterectomized between Days 11 and 12 of gestation to collect spherical and tubular
conceptuses while filamentous conceptuses were collected on Days 12 and 14 of
gestation. Hysterectomies were conducted as previously described for our laboratory
[Gries et al., 1989]. After removal of the uterine horns, conceptuses from each uterine
horn were flushed into a sterile petri dish with 20 mL of physiological saline. Due to the
limited time frame when conceptuses are in tubular transitional development (2-3 h) and
difficulty in determining when tubular conceptuses are in the uterus following mating,
one uterine horn was removed on Day 11.5 of gestation in a subset of gilts. Conceptuses
were evaluated to determine an appropriate time-delayed removal of the second horn
corresponding to a predicted time conceptuses would be in a tubular morphology per the
rate of development described by Geisert et al. [1982c]. Following collection from the
uterine horns, conceptuses of identical morphologies were transferred to cryogenic vials,
snap-frozen in liquid nitrogen, and stored at -80oC until RNA was extracted.
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RNA Isolation
Total RNA was isolated from conceptus pools, each representing multiple
individuals (4-8) of identical morphologies. Total RNA was isolated using RNAwiz
(Ambion, Austin, TX) according to the manufacturer’s recommendations. The RNA
pellet was dried at 22-25oC and re-suspended in 30 µl of nuclease-free H2O. RNA
concentrations were calculated based on absorbance at the 260 nm wavelength. Purity
and integrity of the RNA was determined from the 260:280 ratio and agarose gel
electrophoresis.
Microarray Analysis
Affymetrix Porcine Chip
The GeneChip® Porcine Genome Array (Affymetrix, Santa Clara, CA) contains
23, 937 probe sets interrogating 23, 256 transcripts, representing 20, 201 genes. Four
chips were used for each morphological stage of development (spherical, tubular, Day 12
filamentous (D12F) and Day 14 filamentous (D14F)). RNA utilized for each chip
represented a unique pool of conceptus total RNA for the respective morphological stage
of development. Prior to target labeling, RNA was further purified (RNeasy MinElute
Cleanup, Qiagen, Valencia, CA). Target labeling, GeneChip® hybridization, scanning
and quantitation were conducted by The University of Tulsa Microarray Core Facility.
Affymetrix GeneChip Operating Software (GCOS version 1.1.1, Affymetrix, Santa Clara,
CA) was used to quantitate each GeneChip®. The summary intensities for each probe
were loaded into DNA-Chip Analyzer (dChip), version 1.3 for normalization,
standardization, and analysis.
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Normalization and Standardization
For normalization, dChip’s method of invariant set normalization in which the
chip with the median intensity value was used as the baseline against which the
brightness of the remaining chips were adjusted in order to be of a comparable level. To
reduce variance of expression level estimates by accounting for probe differences,
standardization was conducted by calculating model-based expression indices (MBEI)
using dChip’s Perfect-Match (PM)-only model.
Log Transformation and Statistical Analysis
The MBEI were log base 2 transformed to approximate a normal distribution for
each gene and provide measures by which to conduct the statistical analysis. Unpaired t-
tests were calculated using dChip to evaluate differences between two groups. Analysis
of gene expression was done to compare expression changes between all morphological
stages of development utilized in the study. The false discovery rate (FDR) utilized to
restrict the list of candidate genes was a P value less than 0.001 as determined by the
unpaired t-test and a numerical change in expression of at least 2-fold for each
morphological comparison evaluated.
GeneChip® Porcine Genome Array Re-annotation
The annotation was updated by utilizing the provided sequence from Affymetrix
that was utilized in probe development. Through the utilization of BLAST [Altschul et
al., 1990], a human accession number, based on homology, was assigned to each
Affymetrix ID already correlated to each probe on the chip. The assignment of a human
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accession number allowed a more elaborate analysis of the biological processes being
regulated during this transition, by enabling the more effective use of software such as
the Database for Annotation, Visualization and Integrated Discovery (DAVID).
Clustering Analysis
All genes determined to be significantly different based on the FDR indicated for
at least one comparison between morphological stages of development (n = 1473) were
utilized for analysis in Cluster 3.0 [Eisen et al., 1998]. We chose to sort the 1473 genes
that were both statistically (P< 0.001) and numerically (± 2-fold change) different into
25 clusters. The 25 clusters were identified using the k-means learning algorithm
following 1000 replications.
Database for Annotation, Visualization and Integrated Discovery
Database for Annotation, Visualization and Integrated Discovery (DAVID)
version 2.0 (http://david.niaid.nih.gov/david/version2/index.htm) is a program that
enables the utilization of microarray gene lists to generate specific functional annotations
of the biological processes affected by the treatment as determined through microarray
experiments [Glynn et al., 2003]. DAVID was utilized to annotate biological themes
occurring during the two major developmental transitions during pig conceptus
development; spherical to D12F and D12F to D14F. These two transitional stages are
characteristic of trophoblastic elongation induction and initial conceptus-uterine
attachment. All genes identified to be both significantly different (P < 0.001) and
biologically different (± 2-fold change) for the spherical vs. D12F and D12F vs. D14F
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comparisons, and also successfully assigned a human accession number, were used in the
analysis via DAVID. Utilizing gene ontology (GO) terms as identified through
biological process, cellular component and molecular function; as well as protein domain,
and biochemical pathway membership; biological themes were generated by grouping
like terms thereby creating annotation clusters associated with each developmental
transition.
Quantitative One-Step RT-PCR
Quantitative RT-PCR analysis of transcripts of interest was conducted as previously
described by our laboratory [Ashworth et al., 2006]. RNA from the same conceptus
pools utilized for affymetrix analysis was aliquoted to be used for PCR analysis.
Genomic DNA removal and the synthesis of cDNA to be used for quantitative analysis
were done using the QuantiTect Reverse Transcription kit according to manufacturer’s
recommendations (Qiagen, Valencia, CA). Briefly, 0.8 µg of each embryo pool (n = 4
pools for each conceptus developmental stage) was added to a genomic DNA wipeout
buffer for 5 min at 37oC, followed by a 2 min incubation on ice, then proceeding to the
addition of reverse transcription buffer, RT primer mix and reverse transcriptase; and
incubated at 42oC for 30 min. Individual and small pools of conceptuses were evaluated
at the four morphologically distinct stages (spherical, tubular, D12F and D14F). The
PCR amplification was conducted using the ABI PRISM 7700 Sequence Detection
System (PE Applied Biosystems). The real-time detection during each amplification
cycle was done by using either a sequence specific dual-labeled fluorescent probe
designed to have a 5’ reporter dye (6-FAM) and a 3’ quenching dye (TAMRA) nested
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between the forward and reverse sequence specific primers or the intercalating dye,
SYBR green. All primers and probes utilized for quantitative analysis for each target
gene are presented in Table 3.1. One hundred nanograms of synthesized cDNA were
assayed for each sample in duplicate. Thermal cycling conditions using the dual labeled
probe were 50oC for 30 min, 95oC for 15 min, followed by 40 repetitive cycles of 95oC
for 15 sec and a combined annealing/extension stage, 59oC for 1 min. Fluorescent data
acquisition was done during the annealing/extension phase when using the dual-labeled
probes. Cycling conditions for SYBR green detection were 50oC for 30 min and 95oC for
15 min, followed by 40 repetitive cycles of 95 for 15oC sec and variable annealing
temperature for 30 sec, 72oC for 33 sec and a variable temperature during fluorescent
detection for 33 sec. Fluorescence detection temperature was determined by evaluating
melting curve analysis for the samples and the no template control amplification plot.
Detection temperatures were set at a temperature when the intended target was the only
contributing factor to fluorescence. 18S ribosomal RNA was assayed as a normalization
control to correct for loading discrepancies. Following RT-PCR, quantitation of gene
amplification was made by determining the cycle threshold (CT) based on the
fluorescence detected within the geometric region of the semilog view of the
amplification plot. Relative quantitation of target gene expression was evaluated using
the comparative CT method as previously described [Hettinger et al. 2001; Ashworth et
al., 2006]. The CT value was determined by subtracting the target CT of each sample
from its respective ribosomal 18S CT value. Calculation of CT involves using the
single greatest sample CT value (the sample with the lowest expression) as an arbitrary
constant to subtract from all other sample CT values. Relative mRNA units for each
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sample were calculated assuming an amplification efficiency of 2 during the geometric
region of amplification, and applying the equation, 2Ct. Relative units in figures 3.2A-
3.2J are presented as mean ± SEM. To compare the expression patterns determined
through QT-RT-PCR with that determined using microarray analysis, the mean relative
mRNA units for tubular, D12F and D14F, as determined for each gene, were divided by
the mean relative mRNA units for the spherical morphology to produce fold differences
presented in Table 3.6.
Quantitation and Statistical Analysis
Normalized QT-RT-PCR CT values were analyzed using the PROC MIXED of
the Statistical Analysis System. The statistical model used in the analysis tested the fixed
effect of morphology (spherical, tubular, D12F and D14F). Significance (P < 0.05) was
determined by probability differences of least squares means between morphological
stages of development on normalized gene expression.
Table 3.1. Primer and probe sequence information for the quantitative amplification of each target gene.
aThe Affymetrix ID refers to the ID given by Affymetrix for which the probe set was designed.
bThe target gene name was determined through manual annotation of the EST sequence used by Affymetrix during the generation of
the probe set.
cForward and reverse primers for each target gene. The forward primer sequence is above the reverse for each target gene. Forward
and reverse do not necessarily indicate the in vivo direction of transctiption.
dEither a dual-labeled probe (FAM-TAMRA) or the intercalating dye, SYBR Green was used to measure amount of amplified target
during each cycle of quantitative RT-PCR.
eAmplicon size refers to the product size of the amplified PCR product.
Affymetrix IDa Targetb Primers (Forward/Reverse)c Fluorescent Reporterd AmpliconSizee
GGTAGCTCTGGGAAACTGAATGACTTCG
Ssc.4093.1.A1_at IFN TGCTCTCTGGCCTTGGAACATAGT
TCTGCAGATCCAGCGCAAAGCCATCAGTGA 174 bp
AAAGAGCACAGAGAGTTGGCAGGT
Ssc.11197.1.S1_at
HSP27
GGCTTCATTTCCCGGTGTTTCACT
AGCAGCAGGGCGAAGGCCTTTACTTGGTT 304 bp
TTCCAGATCACACAGCACAGCGTT
Ssc.13805.1.S1_at Angiomotin ACCCTGGACAAACTATGCAAGCCA AGCGACATGGCCCAGGGCACATGCATTT 159 bp
ACACTTGATTCCACTGGCTCTGCT
Ssc.55.1.S1_at
Epidermal Growth
Factor Receptor TGGCTTATCCTCTTGCACCTGACA
TGTCCCAGGCAGGCCCGATTGGTACTCTGT 132 bp
CCCTCACACATACACACACAA
Ssc.27214.2.S1_at Actinin 4 GGGCAAATCAGCTATGTCTTCA
ACATATCTCTGCCGCCTCTTGCTCCCGT 196 bp
CCTGCGCAGAAACCAATCCATCAA
Ssc.8594.1.A1_at
B-Cell Linker
ATACAGCCTCTTCAGCTGACTTCCGA
SYBR Green 190 bp
TCATCACCACCAAGAGCATGTCCA
Ssc.4984.1.S1_at
Chemokine Ligand
14 TCCAGGCGTTGTACCACTTGATGA
SYBR Green 102 bp
TGGCTGAACTGCAGCATGGSsc.9991.1.S1_at Parathyroid HormoneLike Hormone ATACGTCCTCTGAAGGTCTCTGCT SYBR Green 200 bp
TCCTTGGGTAGCAGGATGAGCATA
Ssc.26693.1.S1_at Maspin ACCAAAGAATGCCCTTTCAGGGTC SYBR Green 127 bp
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Results
Affymetrix Analysis
Chips with more than 5% of probe sets flagged as array outliers are of suspect quality.
dChip did not flag any of the arrays as an outlier (when fitted expression for the entire
probe set has a standard error greater than 3 standard deviations from the mean when
compared to the other chips). Accordingly, no tissue was re-hybridized to a new array
nor was any array dropped from analysis. Single outliers are lone probes of unusual
intensity within a chip. In this set of samples, outlier percentages ranged from 0.02% to
0.13%. Single outliers were treated as missing values in subsequent analyses. The
percentage of genes called “present” by the GCOS software ranged from 65.49% to
70.37%. Table 3.2 lists the intensities, presence call percentages, and outlier percentages
for each gene chip as produced by dChip. When the results from the six comparisons
were combined, there were 3850 significantly altered probe sets of which 3759 remained
after deleting those with an “absent” detection call across all chips in both comparison
groups. When the results were restricted to unique GenBank Accession numbers, 3736
were found to differ significantly in their expression in one or more of the six
comparisons. The number of statistically, as well as statistically and biologically
different for each comparison between morphologies is present in Table 3.3.
GeneChip® Porcine Genome Array Re-annotation
Two comparisons, spherical vs. D12F and D12F vs. D14F were further analyzed
due to their biological importance with respect to this stage of pregnancy. For the
specific biological comparisons of interest, spherical vs. D12F and D12F vs. D14F, 280
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Table 3.2. Intensities, percent present, and outliers for each AffyChip utilized during
microarray analysis.
Arraya
Median Intensity
(unnormalized)b
“Present”
Detection Call %c Single Outlier %d
Spherical, Chip 1 129 66.64 0.02
Spherical, Chip 2 94 65.96 0.06
Spherical, Chip 3 95 65.83 0.04
Spherical, Chip 4 97 66.51 0.05
Tubular, Chip 5 100 67.48 0.04
Tubular, Chip 6 118 68.38 0.04
Tubular, Chip 7 114 65.49 0.06
Tubular, Chip 8 118 65.75 0.04
Day 12, Chip 9 99 68.45 0.03
Day 12, Chip 10 126 67.93 0.02
Day 12, Chip 11 127 66.10 0.10
Day 12, Chip 12 114 66.93 0.05
Day 14, Chip 13 98 69.14 0.13
Day 14, Chip 14 94 68.08 0.13
Day 14, Chip 15 93 67.20 0.08
Day 14, Chip 16 113 70.37 0.05
aEach morphological stage of development was hybridized to four chips.
bUnnormalized median target intensity for each chip. Prior to analysis in dChip, intensity
for each chip was normalized by adjusting the brightness of each chip to be comparable
to the median intensity; Day 14, Chip 16.
cDetection call percentage refers to the percentage of targets that were identified present
for each chip.
dThis column represents the percentage of individual outliers for each chip. Five percent
or greater of individual probe set outliers would indicate an array of poor quality.
Table 3.3. Numbers of statistically different mRNA abundance for genes identified between
morphological comparisons
aRepresents the morphological comparison for each row.
bThe number of genes with a unique identity based on the accession number utilized for the creation
cThe number of unique genes that have at least a 2-fold difference in mRNA abundance between the
two morphologies.
dThe number of genes increasing or decreasing in mRNA abundance for a given comparison.
Comparisona N unique
Genesb
N unique,  2-
Fold Differencec
N unique,   2-
Fold Differenced
N unique,   2-
Fold Differenced
Spherical v Tubular 12 0 0 0
Spherical v Day 12 1367 482 177 305
Spherical v Day 14 1522 915 465 450
Tubular v Day 12 1048 433 127 306
Tubular v Day 14 1565 997 420 577
Day 12 v Day 14 708 232 152 80
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of 482 and 157 of 232 genes were successfully assigned a GenBank accession number for
a homologous human gene, respectively. The human accession numbers assigned to each
Affy ID representing a gene with statistical and biological differences are presented in the
Appendix, Tables 7.1 and 7.2.
Database for Annotation, Visualization and Integrated Discovery
Analysis through Database for Annotation, Visualization and Integrated
Discovery was conducted to allow detection of biological processes affected during the
two major transitions; spherical vs. D12F and D12F vs. D14F. Several processes were
consistent throughout this overall period of development but distinct differences were
also notable. During the transition from spherical to D12F morphology, genes associated
with lipid metabolism, phospholipid metabolism, localization/transport, locomotion/cell
motility, ATP activity and binding, regulation of cell growth, amino acid
utilization/metabolism, metal ion binding, and regulation of apoptosis were detected
(Table 3.4). Transition of D12F to D14F morphology revealed that several biological
themes were still persistent from the spherical to D12F transition. The regulation of
apoptosis was the most prominent biological theme during the transition for D12F to
D14F as three annotation clusters represented terms associated with apoptosis. Other
critical processes appear to be those involved with protein kinase activity, regulation of
cell cycle progression and other cell physiological processes, and chromosome
organization (Table 3.5). The processes that appeared to be involved in both
developmental transitions did differ in their significance ranking as determined through
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Table 3.4. Functional annotation clusters of biological terms representing processes
affected during the conceptus transition from spherical to D12F.
Annotation
Clustera
Enrichment
Scoreb Biological Termsc
1 2.81 phospholipid dephosphorylation(4), inositol or phosphatidylinositol
phosphatase activity (5), lipid modification (4)
2 2.68 metal ion binding (68), ion binding (68), cation binding (63)
3 2.10 localization (9), establishment of localization (9), transport (9)
4 1.88 membrane lipid biosynthesis (6), phospholipid biosynthesis (5),
phospholipid metabolism (5), membrane lipid metabolism (6)
5 1.68 locomotion (9), cell motility (9), localization of cell (9)
6 1.59 positive regulation of cellular process (16), positive regulation of cellular
physiological process (13), positive regulation of biological process (16),
positive regulation of physiological process (13)
7 1.50 adenyl nucleotide binding ( 29), ATP binding (28), purine nucleotide
binding (34), nucleotide binding (36)
8 1.45 ATPase activity, coupled to movement of substances (8), ATPase activity,
coupled to transmembrane movement of substances (8), hydrolase
activity, acting on acid anhydrides, catalyzing transmembrane movement
of substances (8), ATPase activity, coupled (10), ATPase activity (10),
pyrophosphatase activity(12), hydrolase activity, acting on acid
anhydrides, in phosphorus-containing anhydrides (12), hydrolase activity,
acting on acid anhydrides (12), nucleoside-triphosphatase activity (10)
9 1.38 growth (8), regulation of cell growth (6), regulation of growth (6), cell
growth (6), regulation of cell size (6)
10 1.32 amino acid transport (5), amine transport (5), carboxylic acid transport
(5), organic acid transport (5), amino acid transporter activity (4), amine
transporter activity (4), carboxylic acid transporter activity (4), organic
acid transporter activity (4), polyamine transporter activity (3)
11 1.28 amino acid and derivative metabolism (10), amino acid metabolism (9),
amine metabolism (10), nitrogen compound metabolism (10)
12 1.23 acyltransferase activity (6), transferase activity, transferring groups other
than amino-acyl groups (6), transferase activity, transferring acyl groups
(6)
13 1.11 calcium ion transporter activity (3), di-, tri-valent inorganic cation
transporter activity (3), metal ion transporter activity (4)
14 1.06 channel or pore class transporter activity (11), alpha-type channel activity
(10), ion channel activity (9)
15 0.86 regulation of apoptosis (10), regulation of programmed cell death (10),
apoptosis (12), programmed cell death (12), cell death (12), death (12)
aThe fifteen most significant annotation clusters identified based on the gene list
submitted for analysis through DAVID.
bThe enrichment score is determined through DAVID and ranks the significance of each
annotation cluster based on the relatedness of the terms and the genes associated with
them.
cThis column represents terms in the annotation clusters. The gene ontology (GO) terms
were gathered based on the known annotation of the submitted genes with respect to
biological process, cellular component, and molecular function; as well as biological
pathway membership and protein domains.
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Table 3.5. Functional annotation clusters of biological terms representing processes
affected during the conceptus transition from D12F to D14F.
Annotation
Clustera
Enrichment
Scoreb Biological Termsc
1 2.79 apoptosis (12), programmed cell death (12), cell death (12), death (12)
2 1.75 regulation of cellular process (36), regulation of cellular physiological
process (33), regulation of biological process (36), regulation of
physiological process (33)
3 1.62 negative regulation of biological process (12), negative regulation of
cellular process (11), negative regulation of cellular physiological process
(10), negative regulation of physiological process (10)
4 1.60 positive regulation of cellular process (10), positive regulation of
biological process (10), positive regulation of cellular physiological
process (8), positive regulation of physiological process (8)
5 1.43 protein kinase inhibitor activity (3), kinase inhibitor activity (3), protein
kinase regulator activity (3), kinase regulator activity (3)
6 1.37 regulation of progression through cell cycle (8), regulation of cell cycle
(8), cell cycle (10)
7 1.07 cellular physiological process (85), physiological process (91), cellular
process (91)
8 1.07 induction of apoptosis (4), induction of programmed cell death (4),
positive regulation of apoptosis (4), positive regulation of programmed
cell death (4)
9 0.99 negative regulation of apoptosis (4), negative regulation of programmed
cell death (4), anti-apoptosis (3)
10 0.77 intracellular membrane-bound organelle (52), membrane-bound organelle
(52), intracellular organelle (59), organelle (59), intracellular (69)
11 0.73 heparin binding (3), glycosaminoglycan binding (3), polysaccharide
binding (3), pattern binding (3), carbohydrate binding (3)
12 0.72 chromosome organization and biogenesis (sensu Eukaryota) (5),
establishment and/or maintenance of chromatin architecture (4), DNA
packaging (4)
13 0.66 locomotion (4), cell motility (4), localization of cell (4)
14 0.64 metal ion binding (30), ion binding (30), cation binding (28)
15 0.63 regulation of kinase activity (3), regulation of protein kinase activity (3),
regulation of transferase activity (3), regulation of enzyme activity (4)
aThe fifteen most significant annotation clusters identified based on the gene list
submitted for analysis through DAVID.
bThe enrichment score is determined through DAVID and ranks the significance of each
annotation cluster based on the relatedness of the terms and the genes associated with
them.
cThis column represents terms in the annotation clusters. The gene ontology (GO) terms
were gathered based on the known annotation of the submitted genes with respect to
biological process, cellular component, and molecular function; as well as biological
pathway membership and protein domains.
64
DAVID. While cell motility/locomotion ranked high and apoptosis regulation ranked
low during the spherical to D12F transition, apoptosis was of the most prominent
themes during the D12F to D14F transition while cell motility/locomotion was much less
distinguished (Tables 3.4 and 3.5).
Clustering Analysis
The 25 clusters generated utilizing the K-means clustering algorithm were
distinguishable by their expression patterns and represented the 1473 genes that were
determined to meet the FDR threshold for one or more of the comparisons between the
morphological stages of development. The smallest cluster contained 3 genes while the
largest contained 364 genes. The mean cluster size was nearly 59 genes; however, the
median cluster size was 19 genes suggesting that most of the clusters represented unique
expression patterns and a few larger clusters represented general trends (Figure 3.1).
Expression patterns that displayed a transient shift in expression during the spherical to
D12F transition are represented by clusters 4, 7, 14, 21, 24. Clusters 4, 14, 21, and 24
represent 17, 10, 3 and 76 genes, respectively, whose expression was greatest in the
elongating D12F conceptuses; while cluster 7 represented 88 genes whose expression
was at a transient nadir in D12F conceptuses. The affymetrix ID, associated human
GenBank accession number, putative identity for each gene and expression profile is
listed for each gene that was significantly (P < 0.001) and biologically different (> 2-fold
change) between any two developmental stages are listed in association with their k-
means cluster in the Appendix, Table 7.3.
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Figure 3.1. Twenty-five clusters were generated using the k-means clustering algorithm
to associate genes with similar expression patterns from the transition from spherical to
D14F. The 1473 genes determined to be both significantly and biologically different
between at least one of the comparisons of morphological stage of development produced
an average cluster size of 59 genes and a median cluster of 19 genes. Note that five
clusters indicate genes whose peak or nadir expression occurs during the D12F
morphological stage of development (clusters 4, 7, 14, 21 and 24). The number of genes
associated with each cluster is indicated in the title of each chart.
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Quantitative Two-Step RT-PCR
Based on the evaluation through DAVID and k-means clustering, differences in
mRNA abundances between the four conceptus developmental stages were further
quantified using the two-step method for QT-RT-PCR. Messenger RNA’s that were
evaluated using this method are listed in association with the primer/probe sequences
used for detection (Table 3.1). Quantitative gene expression was done to analyze
expression of interferon- (IFN), heat shock protein 27 kDa (HSP27), angiomotin,
epidermal growth factor receptor (EGFR), and actinin 4 (ACTN4), B-cell linker
(BLNK), chemokine ligand 14 (CXCL14), parathyroid hormone like hormone (PTHrP)
and maspin. The expression patterns for IFN, HSP27, and angiomotin, BLNK,
CXCL14, PTHrP and maspin mRNA, as determined by quantitative RT-PCR, were
similar to that determined by microarray analysis while expression patterns for EGFR and
ACTN4 differed slightly between the two techniques (Table 3.6).
Interferon-
An effect of morphology (P < 0.001) was observed regarding IFN mRNA
abundance during early conceptus development. The expression was not different
between spherical and tubular morphologies. However, there was an approximate 150-
and 570-fold increase in gene expression in D12F and D14F conceptuses, respectively,
when compared to spherical development (Figure 3.2A).
Table 3.6. Results from quantitative RT-PCR in comparison with Affymetrix Results.
¶Primer and probe sets were designed to specifically assay each of the targets using fluorescent probes.
#The method for which the data was generated to determine fold differences in gene expression.
§Fold differences were determined by using dChip for Affymetrix analysis while the comparative CT method was utilized
for determining fold differences from the QT-RT-PCR. Fold differences within a row without a common superscript differ
significantly (P < 0.05).
*Statistical analysis was performed in dChip for Affymetrix analysis and LS Means of PROC MIXED in SAS for
quantitative RT-PCR as described in the Materials and Methods
Fold Change§
Target¶ Method# Spherical Tubular
D 12
Filamentous
D 14
Filamentous
P
Value*
QT-RT-PCR 1.0a 2.6a 143.2b 566.8b < 0.001IFN AffyChip 1.0a 1.0ab 4.3b 4.8b < 0.001
QT-RT-PCR 1.0a 8.4b 30.8c 31.2c < 0.002HSP27 AffyChip 1.0a 1.2a 4.1b 4.8b < 0.002
QT-RT-PCR 1.0a 4.1b 15.8c 23.6c < 0.001Angiomotin AffyChip 1.0a 1.1a 4.4b 4.7b < 0.001
QT-RT-PCR 1.0a 3.5b 1.5ab 3.3b 0.026Epidermal Growth Factor Receptor AffyChip 1.0a 1.1a -2.2b 1.1a < 0.001
QT-RT-PCR 1.0a 3.4ab 2.5ab 6.6b 0.045Actinin 4 AffyChip 1.0a -1.2ab -2.0b -1.3ab < 0.001
QT-RT-PCR 1.0a 1.4a -9.8b -2.8b 0.002B-Cell Linker
AffyChip 1.0a -2.0a -28.8b -17.3b < 0.001
QT-RT-PCR 1.0a 4.2ab 27.4b 1285.1c < 0.001Chemokine Ligand 14 AffyChip 1.0a -1.0a 1.9a 36.7b < 0.001
QT-RT-PCR 1.0a 3.4a 54.6b 140.4b < 0.001Parathyroid Hormone Like Hormone AffyChip 1.0a 1.2ab 16.9bc 20.3c < 0.001
QT-RT-PCR 1.0a 3.6b -1.7ac -2.3c 0.004Maspin (Serpin Peptidase Inhibitor) AffyChip 1.0a -1.1a -5.2b -5.9b < 0.001
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Heat Shock Protein 27 kDa
HSP27 mRNA abundance was affected by morphological stage of development
(P < 0.002). Expression increased about 8-fold in tubular conceptuses compared to those
in spherical morphology (Table 3.6, Figure 3.2B). Messenger RNA abundance continued
to increase with concetpus development as expression was approximately 5-fold greater
in D12F and D14F compared to tubular conceptuses (Figure 3.2B)
Angiomotin
The expression of angiomotin was affected by morphological stage of
development (P < 0.001). Messenger RNA abundance increased steadily with a 3.8-,
15.8-, and 28.0-fold greater expression in tubular, D12F and D14F compared to spherical
stage of development (Table 3.6, Figure 3.2C).
Epidermal Growth Factor Receptor
Gene expression of EGFR was affected by morphological stage of development
(P < 0.026). Conceptus EGFR expression was greatest in tubular and D14F conceptuses,
with a 3.5- and 3.3-fold greater mRNA abundance compared to spherical conceptuses.
However, expression in D12F conceptuses was not different from any other
morphological stage of development (Table 3.6, Figure 3.2D).
Actinin 4
The ACTN4 gene expression profile was inversed compared to the expression
profile generated by microarray hybridizations (Table 3.6). While a significant
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morphological effect (P < 0.045) was detected, there were no differences between
spherical, tubular and D12F conceptuses while D14F was significantly (5.9-fold) greater
in D14F conceptuses compared to spherical (Figure 3.2E).
B-cell Linker
Expression of BLNK was affected by morphological stage of development (P <
0.002). While mRNA abundance was not different between spherical and tubular
conceptuses, there as a significant 9.8 and 2.8-fold reduction in D12F and D14F
conceptuses in comparison to those spherical in morphology (Table 3.6, Figure 3.2F).
Chemokine Ligand 14
There was a morphological affect (P < 0.001) on CXCL14 mRNA abundance
during trophoblastic elongation and attachment to the uterine LE. Expression was not
different between spherical and tubular conceptuses. However, mRNA expression
increased 27- and 1285-fold in D12F and D14F conceptuses in comparison to those
morphologically spherical, respectively (Table 3.6, Figure 3.2G).
Parathyroid Hormone Like Hormone
PTHrP was significantly different between morphological stages of development
(P < 0.001). While expression was not different between spherical and tubular
morphologies or D12F and D14F conceptuses, there was an approximate 16-fold increase
during the tubular to D12F transition (P < 0.003) and remaining elevated in the D14F
conceptuses (Table 3.6, Figure 3.2H).
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Maspin
Maspin mRNA abundance was affected by morphology (P < 0.004). While the
expression pattern was consistent with the microarray data in that mRNA abundance was
lower (P < 0.05) in D14F conceptuses compared to their spherical counterparts, QT-RT-
PCR demonstrated that tubular conceptuses had the greatest maspin expression (P <
0.04), being at least 3.6-fold greater compared to all other morphological stages of
development (Table 3.6, Figure 3.2I).
Discussion
Conceptus and endometrial changes during the peri-implantation development in
the pig are critical for successfully establishing pregnancy and minimizing prenatal
mortality throughout the gestation period [Pope et al., 1994]. Trophoblastic elongation is
among the most critical events during early gestation in the pig. Conceptus expansion
throughout the extensive uterine horns of the pig is essential for delivery of the maternal
recognition signal, estrogen, which stages the uterine surface area that each individual
conceptus is allowed to attach and develop within throughout gestation. The extent of
initial trophoblastic elongation establishes whether adequate downstream nutrient flow
between the dam and the conceptuses can occur throughout gestation, impacting
conceptus survivability [Stroband and Van der Lende, 1990].
Utilization of the Affymetrix GeneChip® Porcine Genome Array allowed the
identification of numerous factors that are differentially expressed during the transition
through the multiple developmental stages during early pregnancy in the pig.
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Figure 3.2 A significant morphological effect on relative mRNA units (mean ± SEM)
was detected for IFN (A, P < 0.001), HSP27 (B, P = 0.002), angiomotin (C, P < 0.001),
EGFR (D, P = 0.026), ACTN4 (E, P = 0.045), BLNK (F, P = 0.002), CXCL14 (G, P <
0.001), PTHrP (H, P < 0.001), and maspin (I, P < 0.004) during the porcine conceptus
trophoblastic elongation and trophectoderm attachment to the uterine luminal epithelium.
Abundance of mRNA was calculated from the real-time PCR analysis as described in
Materials and Methods. Relative mRNA abundance is presented as mean ± SEM. Bars
with without a common superscript represent a statistical difference between
morphological stages of development (P < 0.05).
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Interestingly, as determined through the statistical analysis using dChip, there were no
genes detected during the transition from spherical to tubular morphology (Table 3.3) that
met the FDR criteria, whereas targets for 482 probes had different abundance levels
between spherical and D12F morphologies. The lack of significant gene expression
changes detected during the spherical to tubular transition while a large transcriptional
change is present between D12F versus spherical conceptuses suggests the initial
trophectodermal remodeling is not dependant on large transcriptional changes. Also,
transcriptional differences between conceptuses being 8, 9 and 10 mm in diameter were
not detected as these morphologies were pooled to collectively represent the spherical
morphoblogical stage of development. It is possible that changes in gene expression in
between 8 mm to 10 mm spherical conceptuses could contribute to the initiation of
trophoblastic elongation. It is alsp possible that the initiation of trophoblastic remodeling
may be the result of an in place mechanism requiring instigation once specific
developmental landmarks are achieved. Perhaps very subtle changes in expression of
select genes may be capable of initiating trophectoderm remodeling. While D14F
conceptuses are still elongating to some degree, it is not as rapid as the initial several
hundred millimeters of the spherical to D12F transition. However, the D14F conceptuses
represent the stage of conceptus development which trophoblast attachment to the uterine
lumenal epithelia occurs. During this initial attachment to the uterine endometrium, 232
genes had at least a 2-fold change in mRNA abundance. These genes likely represent
factors associated with ending elongation, placental differentiation and conceptus-uterine
crosstalk.
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As no differences between spherical and tubular were detected, the transitions
from spherical to D12F and D12F to D14F were the two developmentally critical
comparisons whose gene lists were utilized for biological annotation in DAVID. Based
on the enrichment score, the most significant processes affected from spherical to D12F
were related to lipid and membrane metabolism/biosynthesis as well as cell motility and
locomotion. This seems plausible in that visually, conceptuses collected that are in early
stages of elongation appear more fluid, with filipodia extending from trophectodermal
cells within an elongation zone of the conceptus trophectoderm aiding in the elongation
process [Geisert et al., 1982c]. The alterations in genes during the period also suggest the
involvement of significant ATP utilization, cell growth factors, amino acid transport and
the regulation of apoptosis, (Table 3.4). It is logical that the dramatic increase in
conceptus mass from spherical to D12F is a result of energy catabolism and several cell
growth factors contribute the morphological change. Interestingly, as DAVID ranks the
significance of each cluster, apoptosis related genes were ranked low in the spherical vs.
D12F transition but apoptosis represented clusters 1, 8 and 9 in the D12F to D14F
transition suggesting the critical nature apoptosis may play regarding conceptus
development during attachment to the uterine epithelium. However, it is difficult to
ascertain whether gene expression changes are specific to the trophectoderm or inner cell
mass or both. Overall, the processes identified in the transition of D12F to D14F
compared to spherical to D12F involved more complicated processes, which is expected
as conceptus complexity is greatly increased during these two days of development; such
as the attachment to the uterine epithelium, neurulation of the inner cell mass, as well as
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cell lineage branching in preparation for early organ development of the ICM and the
differentiation of placental layers from the single trophectoderm.
Clustering analysis is critical in the ability to identify expression patterns for
specific genes allowing the identification of associations between genes that may be
regulated by a similar mechanism. This transient expression pattern associated with the
rapid stage of trophectoderm remodeling (clusters 4, 7, 14, 21 and 24) would indicate
those genes that could be considered as putative markers of trophoblastic elongation.
Thus, these markers of trophoblastic elongation are targets for exploration regarding
biological function during this stage of conceptus development to determine their effect
during the establishment of pregnancy.
Quantitative RT-PCR was utilized to evaluate gene expression differences and
confirm the expression patterns of multiple genes associated with DAVID annotation
clusters of interests, k-means clusters suggestive of particular biological importance and
genes that are of interest based on their potential roles in early porcine conceptus
development according to literature. To name a few; PTGS2 [Wilson et al., 2002],
steroidogenic acute regulatory factor [Blomberg et al., 2005], transforming growth factor
 [Gupta et al., 1996], epidermal growth factor receptor [Vaughn et al., 1992], interferon-
 [La Bonnardiere et al., 2002], and retinol binding protein [Yelich et al., 1997a] are
among the many genes previously identified to be differentially regulated during early
peri-implantation conceptus development in the pig that have also been identified as
differentially expressed during or after trophoblastic elongation in this communication.
However, this approach to the analysis of gene expression during trophoblastic
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elongation has allowed a tremendous amount of new information regarding this
developmental phenomenon.
PDZ-LIM binding proteins are capable of linking LIM binding proteins to the
cytoskeleton. Numerous genes identified in this communication possess intact PDZ-LIM
domains (Appendix, Table A.3). Intact PDZ and LIM domains allow colocalization with
1-integrins and -actinin, and attachment to collagen and fibrinogen; all components of
the uterine epithelium extracellular matrix [Burghardt et al., 1997; Jaeger et al., 2001],
potentially regulating epithelial cell motility [Loughran et al., 2005]. Collectively, the
association of so many genes that are differentially regulated during the transition of
spherical to D12F that are related to and have the ability to interact with F-actin through
PDZ-LIM domains is suggestive to their contribution to trophoblastic cellular
remodeling.
Prostaglandin synthase-2 (PTGS-2) gene expression has been previously reported
to increase in pig conceptuses once reaching the D12F morphology [Wilson et al., 2002]
and is temporally associated with increased prostaglandin F2 and E2 concentrations in
the uterine lumen [Geisert et al. 1982b], which is required for pregnancy establishment in
the pig [Kraeling et al., 1985]. While prostaglandins have predominately been linked to
uterine angiogenesis and luteolysis, these data suggest prostaglandin signaling may also
affect conceptus development as prostaglandin F receptor is much greater (14-fold) in
D14F conceptuses compared to the earlier three morphologies evaluated using the array
(Table A.3, cluster 23).
Interferon- is a significant component of pregnancy in many species and is
generally known for its immune related function in non-pregnancy related biology. In
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certain B-cell lymphoma cell lines, IFN is capable of reducing cell growth through
apoptosis sensitivity [Niitsu et al., 2002]. Generally, IFN largely elicits its effects
through the activation of either signal transducer and activator of transcription (STAT) -1
or -3 JAK-STAT activation pathways, that lead to transcription through the activation of
interferon regulatory factors [Darnell, 1997]. The data presented herein demonstrate a
temporal down-regulation of interferon regulatory factor 6 (IRF6; Table A.3, Cluster 6)
and an up-regulation of STAT-3 (Table A.3, cluster 11) suggesting that STAT3 activation
by IFN is likely during conceptus development although it is difficult to assess what
activation occurs downstream as a result.
By definition, heat shock proteins generally serve protective roles and are
involved in protein folding and chaperoning. Using yeast two-hybrid screening, HSP27
has been shown to strongly associate with ER, but not ER, suggesting a role in
estrogen modulated signaling [Miller et al., 2005]. Interestingly, the pig conceptuses also
express ER during trophoblastic elongation [Kowalski et al., 2002] whereas ER is not
[Yelich et al., 1997a]. It is possible that HSP27 may also regulate the ability of
conceptus secreted estrogen to function in an autocrine fashion. HSP27 has also been
shown to closely associate with F-actin, which may contribute to the maintenance of cell
architecture during ATP depletion, as in renal epithelial cells [Van Why et al., 2003]. It
is clear that actin stabilization/remodeling is tightly regulated based on the data presented
within this manuscript that many of the genes that are differentially expressed during
trophoblastic elongation have the ability to attach to actin, particularly those with PDZ-
LIM domains. The protective role of HSP27 during ATP deletion may also be critical as
the transition from spherical to D12F is associated with 8-12 genes related to ATPase
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activity/utilization. Genes related functionally to ATP binding and utilization represented
the 7th and 8th most significant biological annotation clusters characterizing the transition
from spherical to D12F as determined through DAVID (Table 3.4).
Angiomotin was originally identified through its ability to bind and block the
inhibitory effects of angiostatin thereby promoting angiogenesis through endothelial cell
migration [Troyanovsky et al., 2001]. While deletion of the C-terminal PDZ binding
motif of angiomotin in mouse endothelial cells blocked chemotactic capacity of those
cells, the mutant protein was still localized to the lamellipodia of cells, as in migrating
cells that contain PDZ intact angiomotin [Levchenko et al., 2003]. More recently, the
report of two alternative splice isoforms of angiomotin working coordinately suggest that
an 80 kDa (p80-angiomotin) form is primarily responsible for cell migration and a 130
kDa isoform (p130-angiomotin) colocalizes with F-actin regulating cell shape. While
both isoforms are expressed in mouse placental tissue the predominant form is p80-
angiomotin, which is the exclusive form expressed it the mouse embryo [Ernkvist et al.,
2006]. Because the angiomotin sequence information available for the pig is not
complete; the region in which the primers for quantitative RT-PCR were developed are
homologous to the mouse sequence that codes the C-terminal of angiomotin, present in
both the p80 and p130 isoforms of angiomotin, making it difficult to ascertain which
isoform is differentially expressed during trophoblastic elongation in the pig. It still
seems quite plausible that either angiomotin isoform could be involved with conceptus
elongation, due to its ability to localize to the lamellipodia, suggesting it is involved with
cellular homing as well as its ability to interact with F-actin, which the rearrangement of
has been previously suggested to be involved with rapid trophectoderm changes in the
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pig [Mattson et al., 1990]. Interestingly, electron microscopy of elongating tubular
conceptuses identifies the extension of filipodia extending from the trophectodermal cells
[Geisert et al., 1982c] suggesting that angiomotin may indeed be associated with the
cellular remodeling of the trophectoderm cells as it is in endothelial cells during
angiogenesis. It may also be suggested that angiomotin is a key component of
angiongenic development of the porcine placenta as expression increases 4-fold from
spherical to D12F is persistent at D14F (Figure 3.2C).
B-cell linker is a required component of B cell development as progenitor B cells
in BLNK -/- mice fail transition into precursor B cells [Pappu et al., 1999]. BLNK may
also regulate B cell function through B cell receptor mediated signaling inhibition during
conceptus attachment in the pig as conceptus BLNK expression is so dramatically down-
regulated (28- and 17-fold in D12F and D14F, respectively, relative to spherical
conceptuses; Table 3.6) during adhesion of the trophectoderm to the uterine
endometrium. In pregnant mice, maternal B lymphocytes capable of responding to
paternal MHC antigens are partially deleted [Ait-Azzouzene et al., 1998], suggesting the
importance of B cell regulation during pregnancy. Because BLNK is critical for B cell
function, it is likely that the significant reduction in BLNK expression during pig
conceptus development involves the regulation of the maternal immune response to the
developing conceptus.
In contrast to BLNK, CXCL14 is significantly upregulated (over 27-fold, Table
3.6, Figure 3.2G) following trophoblastic elongation by D14F conceptuses, during the
period of trophoblastic elongation. The receptor for CXCL14, CCR1, is abundantly
expressed in endometrium at the maternal–fetal interface during implantation; and
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CXCL14 promotes the migration of human cytotrophoblast cells [Hannan et al., 2006].
Furthermore, CCR1 is also expressed in human extravillous trophoblast cells but not in
cytotrophoblast cells [Sato et al., 2003] suggesting a role in trophoblast differentiation
and invasion into the decidua. The significant upregulation of CXCL14 in D14F pig
conceptuses may also be part of trophoblast differentiation as placental layers begin to
differentiate during the adhesion to the uterine endometrium [Friess et al., 1980].
Parathryroid hormone (PTH) and PTHrP are both involved in the calcium
mobilization and homeostatis [Potts, 2005]. Calcium concentrations change significantly
in the uterine lumen during this period of pregnancy in the pig [Geisert et al., 1982b].
The temporal increase in conceptus PTHrP production may be associated with the
changes in uterine lumenal calcium concentrations. The dramatic upregulation of PTHrP
associated with trophoblastic elongation is also suggestive of a regulatory role in
trophectoderm remodeling and conceptus growth. Indeed, in mice trophoblast giant cells
(TGC), PTHrP has been shown to be involved with the rearrangement and cytoskeleton
organization near the ectoplacental cone (EPC) [El-Hashash and Kimber, 2006]. Human
cytotrophoblast express PTHrP mRNA while lacking protein expression whereas
syncytiotrophoblast and avascular amnion cells express both gene and protein expression
for PTHrP suggesting a role regulating migration and differentiation of trophectoderm
cells [Dunne et al., 1994]. During pregnancy in the rat, the expression of PTHrP and its
receptor are spatially and temporally associated with the differentiation of uterine stromal
cells into decidual cells during implantation [Tucci and Beck, 1998]. While the roles of
PTHrP during conceptus elongation could be multifaceted, it is important to note that the
morphological changes induced by the PTHrP in TGCs of mice near the EPC [El-
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Hashash and Kimber, 2006] are similar in nature to those described to occur in
trophoblast cells near the elongation zone in pig conceptuses during rapid trophoblastic
elongation [Geisert et al., 1982c].
Maspin has been shown in numerous scenarios to function as a suppressor of
tumor growth and metastasis [Chen and Yates, 2006]. Its expression during pig
conceptus development is significantly down-regulated in D12F and D14F conceptuses
compared to those spherical in morphology. Interestingly, the downregulation of maspin
also occurs during the transition of non-invasive to invasive prostate carcinomas [Pierson
et al., 2002]. While placentation in the pig results in the formation of a non-invasive
placenta, pig conceptuses exhibit a highly invasive phenotype ex utero [Samuel and
Perry, 1972], which could be associated with the loss of maspin expression during the
period of conceptus attachment.
The use of the Affymetrix GeneChip® Porcine Genome Array effectively
identified hundreds of porcine genes that are differentially expressed during the
developmental period consisting of trophoblastic elongation and the initial attachment of
the conceptus trophectoderm to the maternal uterine endometrium. While, based on
literature, mechanisms of action for the reported lists of genes can be hypothesized; it is
also critical to determine what interactions do exist between these proteins and others
during pig conceptus elongation and the exact regulatory functions these genes may
elicit. Enhanced understanding of this process will allow a more comprehensive
approach to select for effective conceptus development resulting in optimal degrees of
placentation among conceptuses; promoting similar development between littermates and
increased litter size in pigs.
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Chapter IV
IDENTIFICATION AND ANALYSIS OF MOLECULAR MARKERS
FOLLOWING ENDOCRINE DISRUPTION OF PREGNANCY IN THE PIG
Introduction
Porcine conceptuses initiate attachment to the uterine lumenal surface on Day 13
of pregnancy following a rapid morphological elongation of their trophoblast throughout
the uterine lumen [Geisert et al., 1982b]. This dramatic transformation in structural
morphology coincides with the elevated conceptus estrogen synthesis and release [Geisert
et al., 1982b] which is required for the establishment of pregnancy in the pig.
Critical parameters exist with regards to the specific spatiotemporal release of
estrogen during this stage of pregnancy in the pig. Insufficient estrogen production, as
seen in litters with less than two piglets per uterine horn at the time of trophoblast
elongation, results in the failure to prevent luteolysis and subsequent termination of
pregnancy [Polge et al., 1966; Dziuk, 1968]. On the contrary, adverse timing of estrogen
exposure to the dam on Days 9 and 10 of gestation results conceptus degeneration during
the period of placental attachment to the uterine surface. However, the same dosage of
estrogen given on Days 11 and 12, in synchrony with conceptus synthesis and release of
estrogen, has no adverse affect on conceptus development and pregnancy establishment
[Pope et al., 1987; Pope et al., 1986]. In the commercial swine industry, it is well known
that ill-timed ingestion of naturally occurring estrogenic alfatoxins, such as zearalenone,
found in moldy corn, also causes total litter loss [Long and Diekman, 1984].
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While estrogen is required as a maternal recognition of pregnancy signal and
thought to be involved with the opening of the “implantation window” in the pig, timing
and extent of estrogen exposure can have dramatic effects on conceptus development and
survival as described. In general, the diffuse type of porcine placental attachment occurs
between Days 13 and 18 of gestation and is associated with a thickening of the uterine
glycocalyx (UG) [Perry et al., 1981; Dantzer, 1985; Geisert et al., 1991]. Disruption of
the UG is closely associated with embryonic mortality that occurs in gilts treated with
estrogen on Days 9 and 10 of gestation [Morgan et al., 1987a; Blair et al., 1991; Geisert
et al., 1991]. The ability for estrogen to regulate implantation success or failure also
occurs in mice, where high concentrations of endogenous estrogen shortens the
implantation window and alters the gene expression profile in the uterine endometrium
around the time of blastocyst attachment [Ma et al., 2003]. We propose that the cascade
of molecular events induced by normal endogenous conceptus release of estrogen into the
uterine lumen is initiated prematurely by exogenous estrogen administered on Days 9 and
10 of gestation.
Identification of endometrial changes in gene expression in response to premature
exposure to exogenous estrogen will aid in determining those factors which may also be
regulated by conceptus estrogen stimulation that are critically expressed during the initial
stages of attachment during pregnancy in the pig.
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Materials and Methods
Animals
Research was conducted in accordance with the Guide for Care and Use of
Animals promoted by The Endocrine Society and approved by the Oklahoma State
Institutional Animal Care and Use Committee. Cyclic, crossbred gilts of similar age (8-
10 mo) and weight (100-130 kg) were checked for estrous behavior twice daily in the
presence of an intact boar. Onset of estrus was designated Day 0 of the estrous cycle.
Gilts were naturally mated with fertile boars at the onset of their second estrus (Day 0 of
estrous cycle) and again 24 h later.
Tissue Collection
Pregnant gilts (4 animals/treatment/day) were randomly assigned to one of the
following treatment groups: (a) Control (CO), i.m. injection of corn oil (2.5 mL) on Days
9 and 10 of gestation or (b) Estrogen (EC), 5 mg i.m. injection of estradiol cypionate
(A.J. Legere, Scottsdale, AZ) on Days 9 and 10 of gestation. Gilts were hysterectomized
(n=4 gilts/treatment/day) through midventral laporatomy as previously described by
Gries et al. [1989] on either Days 10, 12, 13, 15 and 17 of gestation. Following induction
of anesthesia with 1.8 mL of i.m. administration of a cocktail consisting of 2.5 mL
(Xylazine: 100 mg/mL: Miles Inc., Shawnee Mission, KS) and 2.5 mL Vetamine
(Ketamine HCl 100 mg/mL Molli Krodt Veterinary, Mundelein, IL) in 500 mg of Telazol
(Tiletamine HCl and Zolazepum HCl: Fort Dodge, Syracuse, NE), anesthesia was
maintained with a closed circuit system of halothane (5%) and oxygen (1.5 liters/min).
Immediately following removal, each uterine horn was flushed with 20 mL of a
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physiological saline and conceptuses were removed. Uterine flushings were transferred
to a 50 mL conical tube and centrifuged at 1000 rpm for 1 min to remove cell debris.
Uterine flushings were stored at -80oC until utilized. Following conceptus removal, one
uterine horn was cut along its anti-mesometrial border, and endometrium (5-10 g) was
removed with sterile scissors. Endometrium was snap-frozen in liquid nitrogen and
stored at -80oC until analyzed.
RNA Isolation
Total RNA was extracted from uterine endometrium tissue using the RNAwiz
reagent (Ambion, Inc., Austin, TX) according to manufacturer’s recommendations.
Approximately 500 mg of endometrium was homogenized in 5 mL RNAwiz reagent
using a Virtishear homogenizer (Virtis Company Inc., Gardiner, NY). RNA pellets were
rehydrated in nuclease-free H2O and stored at -80oC. RNA content was estimated
spectrophotmetrically and purity determined by the 260:280 ratio. RNA quality was
assessed through gel electrophoresis.
Microarray Analysis
Microarray analysis was conducted utilizing a spotted cDNA array which
represents mRNA transcripts from pig brain, uterine endometrium, early pregnancy
conceptuses and ovarian tissues. The array, developed at the University of Missouri,
contains 19 968 features, representing 14 970 PCR amplified cDNA transcripts of which
4108 lack useful annotation, meaning approximately 10 800 genes with known identity
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can be interrogated. Specific procedures utlizied in the development of the array have
been described [Whitworth et al., 2005].
cDNA Synthesis and Hybridization
Total RNA (20 µg) from endometrial tissue collected on Days 10, 13 and 15 of
pregnancy representing each day x treatment combination was utilized for reverse
transcribed cDNA labeling using the 3DNA Array 50 Expression Array Detection Kit
(Genisphere Inc, Hatfield, PA). This method employs the use of a dendrimer ridden with
fluor molecules which hybridizes to a “capture” sequence specific to an oligonucleotide
utilized in the reverse transcription reaction during cDNA synthesis. Hybridizations were
conducted per the manufacturer’s recommendations. Four hybridizations were conducted
for each day to compare mRNA abundance differences between CO and EC treated gilts
on Days 10, 13 and 15. Day 12 tissue samples were not included in the microarray
analyses due to morphological variation of conceptus development between the litters
and Day 17 was not included in the analysis as conceptus mortality and degradation was
conclusive. For each technical replication (n = 4), the total volume from the cDNA
synthesis reaction was combined with the cDNA created for the opposite treatment to
compare differences using dual-channel analysis. After combining the cDNA synthesis
reactions for each treatment (260 µl), the cDNA was concentrated to 3-10 µl volume
using Microcon YM-30 centrifugal devices (Millipore, Billerica, MA). Nuclease free
water was added to bring the total volume of the concentrated cDNA to 10 µl.
Hybridizations were performed according to the manufacturer’s recommendations. For
the primary hybridization, the hybridization solution (10 µl concentrated cDNA, 25 µl 2X
formamide hybridization buffer, 2 µl LNA dT blocker, and 13 µl of nuclease free water)
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was denatured at 80oC for 10 min, applied to the array slide utilizing a 22 x 40 mm
LifterSlip (Erie Scientific Co., Portsmouth, NH) then incubated at 53oC for 16 h in a
humidified hybridization cassette. Following hybridization, coverslips were washed off in
2X SSC, 0.2% SDS at R.T. followed by a series of washes (2X SSC, 0.2% SDS, 65oC, 15
min; 2X SSC, R.T., 15 min; 0.2X SSC, R.T., 15 min). Slides were rinsed in 95% EtOH
for 2 min at R.T. to fix cDNA molecules then dried on a slide centrifuge. Secondary
hybridizations, the attachment of the fluorescent dendrimer ridden capture sequence to
probes bound during the primary hybridization, were conducted at 50oC for 3 h in a
humidified hybridization cassette. Post secondary hybridization washes were carried out
as followed the primary hybridization. Slides were dried on a slide centrifuge and stored
in a light protected box.
Imaging and Microarray Data Acquisition
Each microarray slide was scanned with both the Cy3 and Cy5 channels using the
ScanArray Express (Perkin-Elmer, Wellesly, MA). Laser power and PMT gain were
adjusted for each slide to minimize variation between wavelengths.
Analysis Using GenePix Auto Processor (GPAP3.0)
GenePix Auto Processor 3.0 software (GPAP3.0;
http://darwin.biochem.okstate.edu/gpap3, Weng and Ayoubi, in preparation) was used for
data pre-processing, background correction, and Local Loess pin by pin intensity
normalization, and microarray statistical analysis. Genes that were determined to change
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at least 1.8-fold in response to EC with a P value less than 0.1 were included in further
analysis using the Database for Annotation, Visualization and Integrated Discovery.
Analysis by the Database for Annotation, Visualization and Integrated Discovery
The Database for Annotation, Visualization and Integrated Discovery (DAVID
2.1; http://niaid.abcc.ncifcrf.gov/) is a program that enables the utilization of microarray
gene lists to generate specific functional annotations of the biological processes affected
by the treatment as determined through microarray experiments [Glynn et al., 2003]. A
gene list containing the GenBank accession numbers for all genes affected by the
treatment for all days was compiled to determine the underlying biological themes that
were altered due to EC treatment. Accession numbers utilized were those assigned to
each gene during annotation as previously described [Whitworth et al., 2005]. Based on
the gene ontology (GO) assessment of the biological process, molecular function, and
cellular component of each gene altered by the treatment; clusters of functional
annotation terms were generated. Not all differentially expressed genes were utilized in
the functional annotation as a number of genes differentially expressed were unique or
lacked sufficient biological annotation to be useful for functional annotation.
Validation through Quantitative One-Step RT-PCR
Quantitative analysis of secreted phosphoprotein 1 (SPP1), aldose reductase (AR),
neuromedin B (NMB), and CD24 antigen (CD24) mRNA were assayed using
quantitative real-time RT-PCR and a fluorescent reporter as previously described
[Hettinger et al., 2001]. The PCR amplification was conducted using the ABI PRISM
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7500 Sequence Detection System (PE Applied Biosystems, Foster City, CA). The
samples were evaluated for SPP1 expression differences using a dual-labeled probe
designed to have a 5' reporter dye (6-FAM) and a 3' quenching dye (TAMRA) and to
anneal between the forward and reverse primers. Thermal cycling conditions were 50oC
for 30 min and 95oC for 15 min, followed by 40 repetitive cycles of 95 for 15oC sec and
60oC for 1 min. Amplification differences for AR, CD24, and NMB mRNA were
detected using the intercalating dye, SYBR green. Primer and probe sequences are
presented in Table 4.1. Cycling conditions for SYBR green detection were 50oC for 30
min and 95oC for 15 min, followed by 40 repetitive cycles of 95 for 15oC sec and variable
annealing temperature for 30 sec, 72oC for 33 sec and a variable temperature during
fluorescent detection for 33 sec. Fluorescence detection temperature was determined by
evaluating melting curve analysis for the samples and the no template control
amplification plot. Detection temperatures were set at a temperature when the intended
target was the only contributing factor to fluorescence. One hundred nanograms of total
RNA were assayed for each sample in duplicate for each target template. 18S ribosomal
RNA was assayed as a normalization control to correct for loading discrepancies for all
samples assayed. Template amplification was quantified by determining the threshold
cycle (CT) based on the fluorescence detected within the geometric region of the semilog
plot. Theoretically, in the geometric region, one cycle is equivalent to the doubling of the
PCR target template. A dilution series was made for each assay to determine the
dynamic range of amplification for each gene target. To confirm genomic DNA
contamination was not contributing to the amplification, pooled samples were assayed in
the presence and absence of reverse transcriptase to insure only synthesized cDNA
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contributed to the amplification of the target. Relative mRNA abundance was
determined using a previously established method [Ashworth et al., 2006]. The CT
value was determined by subtracting the target CT of each sample from its respective
ribosomal 18S CT value. Target mRNA expression differences were calculated by
arbitrarily setting the highest sample CT (the sample with the least expression) as the
standard to subtract all other sample CT to produce the CT. Relative mRNA
expression units between sample means was calculated by assuming an amplification
efficiency of 2 and applying the equation 2Ct for each sample mean CT.
In Situ Hybridization Analysis
SPP1, AR, CD24, NMB mRNA were localized in porcine uterine cross-sections
by in situ hybridization using methods previously described [Johnson et al., 1999].
Paraffin embedded cross-sections (~5 µm) were deparaffinized, rehydrated, and
deproteinated then hybridized with radiolabeled antisense or sense porcine cRNA probes
(5.0 X 106 counts per minute/slide) synthesized by in vitro transcription with [-35S]
uridine 5-triphosphate (MP Biomedicals, Irvine, CA). For in vitro transcription,
appropriate RNA polymerases (T3, T7, SP6) were utilized with the linearized plasmid
carrying the transcript printed on the array [Whitworth et al., 2005]. Following
hybridization washes, and RNase A digestion, hybridized slides were exposed to Biomax
maximum resolution film (Eastman Kodak, New Haven, CT) overnight to determine
signal strength. Autoradiography was performed using NTB liquid photographic
emulsion (Eastman Kodak). Slides were dipped in emulsion and exposed at 4°C for a
period of time relative to signal strength, developed in Kodak D-19 developer,
Table 4.1 Primer and probe sequences used for quantitative RT-PCR analysis.
Targeta Forward/Reverse Primers (5'3')b Fluorescent Reporterc
Length of
Amplicond
GenBank
Accession #e
TTGGACAGCCAAGAGAAGGACAGTSPP1
GCTCATTGCTCCCATCATAGGTCTTG
5'-TGGAAACCCGCAGCCAGGAGCAGTCCAAA-3' 121 bp NM_214023
AAGGAGCACAGTTCCAAGCAGTCAAR
CCCGAAGAGCACTACCTGTAGATT
SYBR Green 166 bp CO994619
AGAGATGTACAGCATTCAGGTATGAAACCD24
TCTTTAGAAACCTACACTGGAACAGCC
SYBR Green 105 bp AJ952935
CCTGGCAACTCAACCAGAAATCACNMB
AGACTCCACAACATGGCTTAGGCT
SYBR Green 136 bp CO993274
aThe amplification target. SPP1, Secreted phosphoprotein 1; AR, Aldose Reductase; CD24, CD24 antigen; and NMB, Neuromedin B.
bThe forward and reverse DNA oligos used in the amplification of the target. Forward and reverse do not necessarily indicate the in
vivo direction of transctiption.
cEither a dual-labeled probe (FAM-TAMRA; SPP1) or the intercalating dye, SYBR Green (AR, CD24, NMB) was used to measure
amount of amplified target during each cycle of quantitative RT-PCR.
dThe length of the amplicon created during PCR.
eThe accession number to the porcine sequence that was utilized during primer and probe design.
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counterstained with Harris modified hematoxylin (Fisher Scientific, Fairlawn, NJ),
dehydrated, and protected with cover slips.
Photomicrography
Digital photomicrographs of in situ hybridization, bright-field and dark-field
images of liquid emulsion autoradiography, were collected using a Nikon Eclipse E6000
microscope interfaced with the CoolSNAPcf digital camera equipped with a cooled
charge-coupled device (Photometrics, Tucson, AZ) and imaging software (MetaVue,
Molecular Devices, Downington, PA). Photographic plates were assembled using Adobe
Photoshop (version 6.0, Adobe Systems Inc., San Jose, CA).
Statistical Analysis
Quantitative RT-PCR CT values were analyzed using PROC MIXED of the
Statistical Analysis System. Analysis of endometrial gene expression tested for the effect
of treatment, day and day x treatment interaction. Significance (P < 0.05) was
determined by probability differences of least squares means. Figures representing fold
differences in gene expression have superscripts above bars depicting significant
differences as determined by the CT values (P < 0.05).
Results
Conceptus Growth and Development
The physiological response regarding conceptus development and viability
following premature exposure of pregnant gilts to estrogen has been previously reported
[Ashworth et al., 2006]. Briefly, conceptuses recovered on Days 10 and 12 of pregnancy
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were phenotypically normal. Normal, viable appearing peri-attachment conceptuses were
recovered in both CO and EC treated gilts on Day 13 of pregnancy, however, conceptuses
from EC treated gilts harvested on Days 15 and 17 of pregnancy were severly fragmented
into small pieces. The deterioration of the conceptus trophectoderm indicated the
viabliblity of the conceptuses was completely compromised by Day 17.
Microarray Analysis
Microarray hybridizations were conducted to identify differential gene expression
between EC and CO treated pigs on Days 10, 13 and 15 of gestation. The specific days
for microarray analyses represent three critical periods in the establishment of pregnancy;
pre-conceptus estrogen release, post-conceptus estrogen release and initiation of
implantation. Following hybridization, scanning and raw data acquisition through
GenePix4000, data for each day was processed and analyzed using GenePix Auto
Processor 3.0. Following pin-by-pin intensity dependant normalization, 8, 32 and 5
endometrial genes were identified up-regulated at least 1.8-fold (P < 0.1) in the EC gilts
on Days 10, 13 and 15, respectively. A total of 1, 39, 16 endometrial genes expressed in
EC were down-regulated at least 1.8-fold (P < 0.1) on Days 10, 13 and 15, respectively
(Tables 4.2, 4.3, and 4.4). Twenty-one of the total 77 differentially expressed genes
represented unique sequences. The remaining 56 differentially expressed genes assigned
a putative annotation based on their associated GenBank accession number representing
factors involved with attachment, immunology, transcription regulation, protein
regulation and metabolism.
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Database for Analysis, Visualization and Integrated Discovery
Utilization of DAVID resulted in identification of 10 functional annotation
clusters representing biological systems that were affected by exogenous EC treatment on
Days 9 and 10 of gestation (Table 4.5). Collectively, regulation of cellular/physiological
processes, biosynthesis, immune response, multiple aspects of metabolism, apoptosis,
transport, calcium and metal ion binding are among the general functional themes
affected. Not all genes presented in Tables 4.2-4.4 were included in all the functional
annotation clusters. Other functional processes identified by DAVID that may also be
involved based on the expression differences that were not included in a cluster include
response to chemical stimuli, cytoskeleton protein binding, and signal transduction.
Table 4.2. Differentially expressed genes in uterine endometrium on Day 10 following exogenous EC on Day 9 of gestation.
aAccession numbers of genes with strong homology to porcine microarray probes identified during annotation of the porcine EST
library.
bThe clone ID assigned during the creation of the microarray.
cPutative identity of probe determined during annotation.
dFold difference in gene expression following processing and normalization using GPAP 3.0 as described in materials and methods.
eP Values determined via GPAP regarding the significance of the detected differences.
fAnnotation clusters identified through DAVID, presented in Table 4.5, which the probe associates with.
GenBank
Accession
Number
Clone ID Putative Annotation
E2/CO
Fold
Change
P
Value
Functional
Annotation
Cluster
Association
NM_006744 Pd12-14end 01-04-P15 Retinol Binding Protein 4 8.25 0.028 8
NM_002970 Pd12-14end 05-08-G21 Spermidine/spermine N1-acetyltransferase 6.82 0.028 2,
NM_002213 Pd12-14end 01-04-A20 Similar to integrin, beta 5 (Human) 4.59 0.031
UNIQUE pfubo 45-48-N23 UNIQUE pd6end1-009-H10 3.13 0.100
UNIQUE pfubo 49-52-C05 UNIQUE pd6end2-001-e06 2.92 0.100
NM_003187 pfubo 41-44-P03 TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated
factor, 32kDa
2.87 0.031 2, 5, 7, 10
XM_379200 pfu14 57,58,09,10-D12 Similar to Homo sapiens LOC401078 (LOC401078) 2.30 0.031
XM_370781 puof 21-24-F16 Similarity to Ig alpha-2 chain C region (Human) 1.91 0.028
CB424794 pfu14 57,58,09,10-N05 Strong similarity to Metastasis-associated protein MTA1 (Human) -2.18 0.098100
Table 4.3. Differentially expressed genes in uterine endometrium on Day 13 following exogenous EC on Days 9 and 10 of gestation.
GenBank
Accession
Numbera
Clone IDb Putative Identityc
E2/CO
Fold
Changed
P
Valuee
Functional
Annotation
Cluster
Associationf
UNIQUE pfubo 53-56-A18 UNIQUE peov3-001-H05 9.65 0.005
CB169174 pfu14 57,58,09,10-E01 Transcribed sequences 7.18 0.002
AK095434 pfubo 53-56-B01 Similar to Chromosome 14 open reading frame 43 (Human) 5.98 0.063 5, 10
NM_006135 Pd12-14end 01-04-H08 Capping protein (actin filament) muscle Z-line, alpha 1 (CAPZA1) 4.91 0.010 1, 3, 5, 7, 10
NM_009846 puof 69-72-C19 CD24a antigen 4.55 0.001 3
NM_018955 Pd12-14end 05-08-N12 Ubiquitin B (UBB) 4.43 0.001 7,
BC047028 pfubo 05-08-O23 Fanconi anemia, complementation group F 3.83 0.003 7, 10
NM_000582 pfu14 57,58,09,10-M11 Secreted phosphoprotein 1 (osteopontin) 3.42 0.008 1, 3, 5, 6, 10
BP444412 pfubo 21-24-J13 Weak similarity to hypothetical protein LOC51316 (Human) 3.26 0.015
NM_199161 pfu14 57,58,09,10-K03 Serum amyloid A1 2.92 0.005
BF712745 pfubo 09-12-G18 Transcribed sequence 2.88 0.046
NM_003167 predoch 01-04-H20 Sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA) -
preferring, member 1
2.85 0.083 4
NM_000067 pfu14 57,58,09,10-I03 Carbonic anhydrase II 2.67 0.033 9
XM_072554 pfu14 57,58,09,10-F02 Similar to RIKEN cDNA 4833436C18 gene (LOC138729), mRNA 2.62 0.062
NM_006021 puof 33-36-M10 Deleted in lymphocytic leukemia, 2 2.50 0.025
BQ605000 pfubo 49-52-D15 Strong similarity to phosphoserine aminotransferase, isoform 1 (Human) 2.29 0.007
NM_016015 peuo 17-20-C20 Leucine carboxyl methyltransferase 1 2.26 0.062
NM_012332 pfubo 37-40-B01 Likely ortholog of mouse acyl-Coenzyme A thioesterase 2, mitochondrial 2.21 0.065
AK033438 puof 33-36-I11 Similar to unknown EST (Human) 2.12 0.041
NM_005627 pfubo 41-44-F20 Serum/glucocorticoid regulated kinase 2.01 0.023 6, 7, 8
NM_145740 puof 33-36-F22 Glutathione S-transferase A1 1.98 0.019
NM_001614 Pd12-14end 01-04-O20 Actin, gamma 1 (ACTG1) 1.97 0.019 1, 7
BF704319 puof 73-76-I18 Transcribed sequences 1.96 0.056
NM_020676 pfubo 21-24-H22 Abhydrolase domain containing 6 1.94 0.083
NM_005827 pfubo 17-20-F12 UGTREL1; UDP-galactose transporter 1.93 0.009 8
BM659101 pfubo 49-52-L23 Transcribed sequences 1.93 0.032
NM_014579 pfubo 21-24-B18 Solute carrier family 39 (zinc transporter), member 2 1.91 0.008 9
101
NM_002970 Pd12-14end 01-04-L04 Spermidine/spermine N1-acetyltransferase 1.90 0.021
NM_014160 pfu14 57,58,09,10-H02 Similar to Makorin (Human) 1.90 0.059 9
NM_005952 pfubo 49-52-D20 Metallothionein 1X 1.87 0.019 8, 9
BF702843 pfubo 09-12-O08 Moderate similarity to AKAP-associated sperm protein (Human) 1.83 0.084
NM_173630 pfubo 33-36-O07 Rotatin 1.80 0.072
UNIQUE pfu14 57,58,09,10-L04 UNIQUE peov3-014-D12 -1.81 0.015
NM_024911 peuo 17-20-D17 Putative NFkB activating protein 373 -1.81 0.065 5, 10
NM_006623 pfubo 29-32-H20 Phosphoglycerate dehydrogenase -1.82 0.016 2, 8
BF711640 pfubo 05-08-E24 Transcribed sequences -1.83 0.068
NM_014328 pfubo 05-08-H24 RUN and SH3 domain containing 1 -1.83 0.089
NM_144583 pfu14 57,58,09,10-J15 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C isoform 2 -1.85 0.056 2, 7, 8, 10
UNIQUE pfubo 17-20-O17 UNIQUE pd10en3-013-E11 -1.92 0.017
BQ605109 pfubo 17-20-B18 Transcribed sequences -1.93 0.053
UNIQUE Pd12-14end 01-04-J05 UNIQUE pd12-14end-002-E05 -1.93 0.065
UNIQUE pfubo 29-32-L14 UNIQUE pd3end2-003-C10 -1.98 0.041
NM_004665 pfubo 53-56-K04 Vanin 2 -1.99 0.018 1, 2,
BI402645 pfubo 17-20-B23 Moderate similarity to Neuromedin U-25 precursor (Human) -2.05 0.100
NM_001153 Pd12-14end 01-04-N14 Annexin A4 -2.06 0.015 1, 3, 5, 6, 9,
10
BG894507 Pd12-14end 05-08-O10 Transcribed sequences -2.13 0.014
UNIQUE pfubo 37-40-E15 UNIQUE pd3ov2-001-A03 -2.16 0.016
UNIQUE peuo 17-20-O11 UNIQUE pblivv4-016-d08 -2.17 0.013
NM_000245 pfubo 13-16-F21 Hepatocyte growth factor receptor -2.25 0.006 3, 7
UNIQUE Pd12-14end 01-04-P23 UNIQUE pd12-14end-004-H11 -2.29 0.005
UNIQUE pfubo 49-52-C05 UNIQUE pd6end2-001-e06 -2.34 0.096
XM_372261 pfubo 17-20-M18 Similar to DKFZP586L0724 protein (Human; LOC389900) -2.34 0.010
BF712656 pfubo 09-12-C20 Moderate similarity to alanine-glyoxylate aminotransferase 2-like 1
(Human)
-2.35 0.008
NM_001623 pfubo 05-08-L09 Allograft inflammatory factor 1 -2.37 0.100 1, 3, 5, 9, 10
NM_001903 Pd12-14end 05-08-M23 Catenin (cadherin-associated protein), alpha 1, 102kDa -2.48 0.016 7,
BC040077 pfubo 01-04-I06 Mitogen-activated protein kinase kinase kinase kinase 4 -2.51 0.003 7,
NM_002004 puof 13-16-H10 Farnesyl diphosphate synthase -2.66 0.013 4,
NM_006681 Pd12-14end 05-08-E10 Neuromedin U -2.69 0.004
XM_084530 Pd12-14end 05-08-L06 Similarity to mRNA for KIAA0033 protein (Human) -2.74 0.004
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BQ604324 puof 73-76-E19 Moderate similarity to N-acetylated alpha-linked acidic dipeptidase 2
(Human)
-2.80 0.088
UNIQUE pfubo 45-48-N23 UNIQUE pd6end1-009-H10 -2.95 0.015
NM_174142 Pd12-14end 05-08-O09 Phytanoyl-CoA hydroxylase -2.95 0.015
UNIQUE Pd12-14end 05-08-K21 UNIQUE pd12-14end-007-F09 -3.16 0.056
BC054832 pfubo 05-08-A14 Zinc finger protein 191 -3.22 0.004
NM_024315 puof 89-92-N14 Similar to Chromosome 7 open reading frame 23 (Human) -3.45 0.015
BQ601110 Pd12-14end 01-04-F13 Transcribed sequences -3.49 0.030
NM_021077 predoch 05-08-N17 Neuromedin B -3.72 0.001
BM069527 puof 77-80-L13 Programmed cell death 1 ligand 1 -4.07 0.013 3
L20826 puof 85-88-P11 Plastin 1 (I isoform) -4.40 0.004 9
NM_005563 pfubo 05-08-A23 Stathmin 1 -4.53 0.003 7
NM_001628 Pd12-14end 05-08-K01 Aldose reductase -13.93 0.001 7
aAccession numbers of genes with strong homology to porcine microarray probes identified during annotation of the porcine EST
library.
bThe clone ID assigned during the creation of the microarray.
cPutative identity of probe determined during annotation.
dFold difference in gene expression following processing and normalization using GPAP 3.0 as described in materials and methods.
eP Values determined via GPAP regarding the significance of the detected differences.
fAnnotation clusters identified through DAVID, presented in Table 4.5, which the probe associates with.
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Table 4.4. Differentially expressed genes in uterine endometrium on Day 15 following exogenous EC on Days 9 and 10 of gestation.
GenBank
Accession
Numbera
Clone IDb Putative Identityc
E2/CO
Fold
Changed
P
Valuee
Functional
Annotation
Cluster
Associationf
BF711640 pfubo 05-08-E24 Transcribed sequences 4.29 0.065
UNIQUE pfubo 45-48-N23 UNIQUE pd6end1-009-H10 3.01 0.058
UNIQUE pfubo 49-52-P15 UNIQUE peov1-004-A10 2.82 0.073
UNIQUE pfubo 49-52-C05 UNIQUE pd6end2-001-e06 2.26 0.099
UNIQUE pd12-14end 05-08-P20 UNIQUE pd12-14end-008-H08 1.90 0.065
BI345641 puof 89-92-C02 Transcribed sequences -1.81 0.076
BF711276 puof 73-76-C23 Transcribed sequence -1.82 0.064
NM_013758 puof 85-88-G21 Adducin 3 (gamma) -1.84 0.073
CB477767 pfubo 33-36-P16 Beta 2-microglobulin -1.86 0.064
NM_000582 pfu14 57,58,09,10-M11 Secreted phosphoprotein-1 (osteopontin) -1.88 0.062 1, 3, 5, 6, 10
AK092773 pfubo 05-08-K21 aarF domain containing kinase 5 -1.88 0.073
NM_138799 pfubo 33-36-D06 Similar to hypothetical protein BC016005 (Human; LOC129642) -1.89 0.073
BF713356 puof 73-76-C06 Signal transducer and activator of transcription 1 -2.07 0.064
NM_199161 pfu14 57,58,09,10-K03 Serum amyloid A1 -2.07 0.056 1, 3, 5
BC040643 pfubo 49-52-D11 Sortilin-related receptor, L(DLR class) A repeats-containing -2.15 0.056 4, 8
UNIQUE pfubo 53-56-K24 UNIQUE peov3-003-H04 -2.17 0.056
UNIQUE pfubo 53-56-A18 UNIQUE peov3-001-H05 -2.29 0.062
AB033044 pfubo 41-44-D02 Similar to mRNA for KIAA1218 protein (Human) -2.29 0.072
AF152103 puof 73-76-O08 Interferon stimulated gene 17 -2.29 0.056
CB169174 pfu14 57,58,09,10-E01 Transcribed sequences -2.37 0.056
NM_013285 pfubo 53-56-I17 Nucleolar GTPase -2.80 0.056 7,
aAccession numbers of genes with strong homology to porcine microarray probes identified during annotation of the porcine EST
library.
bThe clone ID assigned during the creation of the microarray.
cPutative identity of probe determined during annotation.
dFold difference in gene expression following processing and normalization using GPAP 3.0 as described in materials and methods.
eP Values determined via GPAP regarding the significance of the detected differences.
fAnnotation clusters identified through DAVID, presented in Table 4.5, which the probe associates with.
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Table 4.5. Functional annotation clusters of Gene Ontology terms representing
biological processes affected by exogenous EC treatment on Days 9 and 10 of
gestation.
Annotation
Cluster #a
Functional Annotations Based on GO Biological Process, Cellular Component,
and Molecular Functionb
1 localization of cell, cell motility, negative regulation of physiological process
2
amine biosynthesis, nitrogen compound biosynthesis, nitrogen compound
metabolism, amino acid and derivative metabolism, amine metabolism, cellular
biosynthesis
3
negative regulation of physiological process, inflammatory response, cell
proliferation, response to pest, pathogen or parasite, response to other organism,
response to wounding, immune response, defense response
4 steroid metabolism, cellular lipid metabolism, lipid metabolism
5
negative regulation of physiological process, negative regulation of cellular
physiological process, negative regulation of cellular process, regulation of cellular
physiological process
6 apoptosis, programmed cell death, cell death
7
purine nucleotide binding, ATP binding, adenyl nucleotide binding,
phosphorylation, phosphate metabolism, phosphorus metabolism, protein amino
acid phosphorylation, protein modification, biopolymer modification, protein
metabolism, cellular protein metabolism, macromolecule metabolism, cellular
macromolecule metabolism, biopolymer metabolism
8 cation transport, transport, ion transport
9 calcium ion binding, cation binding, metal ion binding, zinc ion binding, transition
metal ion binding
10
regulation of cellular physiological process, regulation of metabolism, regulation of
transcription; regulation of nucleobase, nucleoside, nucleotide and nucleic acid
metabolism; nucleobase, nucleoside, nucleotide and nucleic acid metabolism;
transcription, regulation of cellular metabolism
aThe ten most significant annotation clusters identified based on the gene list
submitted for analysis through DAVID.
bThis column represents terms in the annotation clusters. The gene ontology
(GO) terms were gathered based on the known annotation of the submitted genes
with respect to biological process, cellular component, and molecular function.
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Quantitative RT-PCR
Quantitative RT-PCR was utilized to validate differential expression of candidate
genes identified through microarray analysis using all the endometrial tissue samples
collected in the study (Days 10, 12, 13, 15, and 17).
A day x treatment interaction (P < 0.03) was detected for endometrial AR gene
expression. In CO gilts, AR mRNA expression was relatively low on Days 10, 15 and 17
in contrast to a 25- and 45-fold greater expression that occurred on Days 12 and 13,
respectively (Figure 4.1A). Although no significant difference in AR mRNA abundance
was detected between CO and EC treatments on Days 10, 12, 15, or 17; EC treatment
caused a 40-fold reduction in AR expression (P < 0.001) on Day 13 (Figure 4.1A).
Expression of CD24 antigen mRNA was affected by a day x treatment interaction
(P < 0.02). Endometrial CD24 mRNA expression was lowest on Day 10 in both CO and
EC treated gilts (Figure 4.1B). In comparison to Day 10, endometrial CD24 expression
increased 8, 53, 276 and 353-fold in CO gilts on Days 12, 13, 15 and 17, respectively.
EC treatment increased CD24 mRNA abundance on Days 12 (6.7-fold) and 13 (6.5-fold)
while expression was similar to CO gilts on Days 10, 15 and 17 (Figure 4.1B).
Quantitative analysis of SPP1 mRNA abundance was affected by day (P < 0.001).
Gene expression increased from Days 10 to 17 with Day 15 and 17 endometrial SPP1
expression 61 and 115 fold greater, respectively, compared to Day 10 (Figure 4.1C).
While not statistically significant, SPP1 expression was numerically greater (7-fold) in
EC treated gilts compared to CO treated gilts on Day 13 of pregnancy (Figure 4.1C). No
day x treatment interaction was detected (P = 0.19).
107
Figure 4.1. Fold differences of mRNA abundance for endometrial AR (A; day x
treatment, P < 0.03), CD24 (B; day effect, P = 0.02), SPP1 (C; day x treatment, P <
0.14) and NMB (D; day x treatment, P < 0.001) in response to EC (yellow bar) and CO
(blue bar). Relative abundance of mRNA was calculated from the quantitative RT-PCR
analysis as described in Materials and Methods. Bars without common lowercase
superscripts represent a statistical difference (P < 0.05) between day/treatment
combinations whereas differences in uppercase superscripts represent statistical
differences between days of gestation.
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A significant day x treatment interaction (P < 0.001) was detected for endometrial
NMB mRNA expression (Figure 4.1D). In comparison to CO gilts, expression of NMB
mRNA was greater in the EC treated gilts on Days 10 (P < 0.002) and 12 (P < 0.04) by
6.7- and 2.8-fold, respectively. Alternately, expression tended to be reduced (2.7 fold) in
EC treated gilts on Day 13 (P < 0.07) and significantly reduced 4.4 fold on Day 15 (P <
0.01) when compared to CO gilts.
In Situ Hybridization
Endometrial expression of AR was localized only to the uterine luminal
epithelium (LE) of both CO and EC gilts. Expression of AR was detectable in the LE on
Days 12 and 13 in CO treated gilts and on Day 12 EC treated gilts (Figure 4.2).
Administration of estrogen on Days 9 and 10 of pregnancy completely suppressed the
expression of AR in the LE of gilts on Day 13 of pregnancy. Expression of AR mRNA
in the LE was low by Days 15 and 17 of gestation in both CO and EC gilts.
Similar to AR mRNA expression, SPP1 was not clearly localized to the LE until
Day 15 of pregnancy in CO gilts. Intensity of the signal increased from Days 15 to 17
(Figure 4.3). Expression of SPP1 mRNA was apparent in the LE on Days 12 and 13 of
EC treated gilts with a strong signal detectable in the uterine LE on Day 15 (Figure 4.3).
Expression of CD24 was present in the LE of both CO and EC gilts. Uterine LE
CD24 expression increased steadily from Days 12 through 17 (Figure 4.4). Slight CD24
expression was detected in the glandular epithelium (GE) on Days 13 through 17 in both
CO and EC gilts. Interestingly, the GE CD24 expression appeared to be elevated on Day
10 in EC compared to Day 10 CO gilts.
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Figure 4.2. In Situ hybridization analysis of AR mRNA expression in porcine
endometrium during early gestation in response to estradiol cypionate (EC) or corn oil
(CO) given i.m. on Days 9 and 10 of gestation. Protected transcripts in endometrium
from Days 10, 12, 13, 15 and 17 of each treatment were visualized by liquid emulsion
autoradiography and imaged under bright-field and dark-field illumination. Note
during normal gestation (CO) on Days 12 and 13 of gestation, the expression is
abundant, but limited to the luminal epithelium (LE) and lacking in the stromal (ST)
and glandular epithelium (GE). Following EC treatment, mRNA abundance was
dramatically and prematurely reduced in the LE. A representative Day 13 EC section
was hybridized with radiolabeled sense cRNA probe (sense) to serve as a negative
control. All other images are representative from four biological replications. 4X
Objective and 10X eyepiece for original magnification 40X.
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Figure 4.3. In Situ hybridization analysis of SPP1 mRNA expression in porcine
endometrium during early gestation in response to estradiol cypionate (EC) or corn oil (CO)
given i.m. on Days 9 and 10 of gestation. Protected transcripts in endometrium from Days
10, 12, 13, 15 and 17 of each treatment were visualized by liquid emulsion autoradiography
for 5 days and imaged under bright-field and dark-field illumination. During normal
gestation (CO), expression increases in the luminal epithelium (LE) on Days 15 and 17 while
expression is lacking in the stromal (ST) and glandular epithelium (GE). EC treatment,
however, visually increased mRNA abundance in the LE on Days 12, 13, 15 and 17 in the LE
when compared to the EC. A representative section on Day 15 EC hybridized with
radiolabeled sense cRNA probe (sense) served as a negative control. All other images are
representative of four biological replications. 4X Objective and 10X eyepiece for original
magnification 40X.
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Figure 4.4. In Situ hybridization analysis of CD24 mRNA expression in porcine
endometrium during early gestation in response to estradiol cypionate (EC) or corn oil
(CO) given i.m. on Days 9 and 10 of gestation. Protected transcripts in endometrium
from Days 10, 12, 13, 15 and 17 of each treatment were visualized by liquid emulsion
autoradiography for 8 wks and imaged under bright-field and dark-field illumination.
CD24 expression seems to occur predominately in the LE although some expression
appears present in ST cells on Days 10, 12, and 13 of both CO and EC gilts.
Expression is greatest in the LE of endometrium from gilts on Days 13, 15 and 17 in
both CO and EC gilts. A representative section on Day 13 CO hybridized with
radiolabeled sense cRNA probe (sense) to serve as a negative control. All other images
are representative of four biological replications. 4X Objective and 10X eyepiece for
original magnification 40X.
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Figure 4.5. In Situ hybridization analysis of CD24 mRNA expression in porcine
endometrium on Day 12 of gestation in the presence and absence of a conceptus.
Protected transcripts in endometrium was visualized by liquid emulsion autoradiography
for 8 wks and imaged under bright-field and dark-field illumination. Note the lack of
expression in the LE of endometrium distant from the conceptus (upper half of the panel)
and the amplified expression of CD24 in adjacent to the conceptus trophectoderm (lower
half of the panel). CD24 expression is expressed abundantly by the trophectoderm
conceptus. 4X Objective and 10X eyepiece for original magnification 40X.
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Figure 4.6. In situ hybridization analysis of NMB mRNA expression in porcine
endometrium during early gestation in response to estradiol cypionate (EC) or corn oil
(CO) given i.m. on Days 9 and 10 of gestation. Protected transcripts in endometrium
from Days 10, 12, 13, 15 and 17 of each treatment were visualized by liquid emulsion
autoradiography and imaged under bright-field and dark-field illumination. Note the
expression is very specifically limited to the LE. Expression is greatest on Days 12 and
13 of CO gilts while expression appeared prematurely elevated on Day 10 and reduced on
Day 13 in LE of EC gilts. A representative section on Day 13 CO hybridized with
radiolabeled sense cRNA probe (sense) to serve as a negative control. All other images
are representative of four biological replications. 4X Objective and 10X eyepiece for
original magnification 40X.
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Expression of CD24 is also present in the conceptus during the peri-implantation stage of
development and appears to be expressed at much greater levels in the LE adjoining to a
conceptus as compared to LE distal form the conceptus within the same cross-section
(Figure 4.5).
Neuromedin B mRNA expression was localized to the uterine LE (Figure 4.6).
Expression of NMB increased in the LE of EC gilts on Days 10 and 12 of pregnancy
while increased expression was not increased until Days 13 and 15 of pregnancy in CO
gilts. Intensity of NMB expression on Day 17 was similar between treatments.
Discussion
Conceptus synthesis and release of estrogen is an essential component to the
establishment of pregnancy in the pig [Bazer and Thatcher, 1977]. While estrogen is a
critical constituent of early pregnancy recognition in swine, endometrial exposure to
estrogen prior to the normal conceptus secretion results in total pregnancy loss [Blair et
al., 1991]. Exogenous exposure of pregnant pigs to estrogen before Day 10 of gestation
causes conceptus degeneration between Days 15 and 18 of gestation [Pope et al., 1986,
Blair et al., 1991; Ashworth et al., 2006]. Our laboratory has utilized the treatment of
pregnant gilts with estrogen on Days 9 and 10 as an endocrine disruptor model to
evaluate factors involve with implantation in the pig. Based on our microarray analysis,
the greatest number of genes altered from the EC treatment occurred on Day 13 of
gestation, five days following the initial estrogen injection. It may be possible that the
disruptive response is a result of the confounding interaction between the EC treatment
and the developmental events that occur between the elongating conceptus and uterine
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endometrium. Not only does the elongating conceptus produce estrogen that alters
uterine secretion during normal pregnancy [Geisert et al., 1982b], but there is elevated
conceptus production of interleukin-1 (IL-1) and a concomitant increase in
endometrial expression of IL-1 receptors [Tuo et al., 1996b; Ross et al., 2003b].
Interestingly, the EC injection on Days 9 and 10 of gestation in gilts does not alter the
pattern of IL-1 secretion by the conceptus [Ashworth et al., 2006], collectively
suggesting that a cohesive function existing between simultaneous conceptus secretion of
estrogen and IL-1 may be abrogated by the premature estrogen exposure to the uterine
endometrium. This may lead to the alteration or inhibition of the initial attachment of the
trophectoderm to the uterine endometrium which occurs on Day 13 of gestation [Perry et
al., 1981; Dantzer, 1985].
Based on evaluation through the DAVID, several common biological themes
affected by EC treatment were clustered to represent the most likely affected biological
processes (Table 4.5). It is not surprising that the alterations in gene expression represent
processes such as immune, inflammatory, wound, and defense response (annotation
cluster 3, Table 4.5) and apoptosis related events (annotation cluster 6) as the phenotypic
outcome is pregnancy loss, resulting from conceptus degeneration (Ashworth et al., 2006)
and sloughing of the extracellular matrix (Blair et al., 1991). Disruption of cation
(calcium or zinc) ion binding (annotation cluster 9) has previously been shown to be
disrupted due to exogenous estrogen administration on Days 9 and 10 of gestation
(Geisert et al., 1982). Because of their relevant biological effects in protein
modification/metabolism, immune/inflammatory response and Ca2+ transport that are
critical to conceptus development and ECM formation on the LE during peri-
122
implantation, we investigated endometrial expression of AR, NMB, SPP1, and CD24
through quantitative RT-PCR.
Many of the genes affected by the EC treatment are known to be differentially
regulated in the porcine endometrium during peri-implantation, such as retinol binding
protein 4 (Vallet et al., 1996; Groothius et al., 2002), spermidine/spermine N1-
acetyltransferase (Green et al., 1996; 1998) and SPP1 (Garlow et al., 2002; Johnson et al.,
2003). However, several genes, such as CD24, NMB, AR and allograft inflammatory
factor 1, have little literature regarding their association with the uterine endometrium
during implantation in the pig. Numerous sequences represented on the array that lacked
a quality annotation that appeared to be estrogen regulated were also identified during the
period of endometrial receptivity and conceptus attachment during pregnancy (Tables
4.2-4.4).
Aldose reductase is the rate-limiting enzyme of the polyol pathway responsible
for the reduction of glucose to sorbitol while consuming an NADPH, and is also involved
in the reduction on toxic aldehydes, created by reactive oxygen species, to inactive
alcohols [see review, Brownlee, 2001]. Following the conversion of glucose to sorbitol
via AR, sorbitol can be utilized to produce fructose. During normal pregnancy in the pig,
the expression of AR mRNA is transient and localized to the endometrial LE (Figures
4.1A and 4.3). Peri-implantation expression of AR in sheep appears to be regulated by
the trophectoderm, for which expression is elevated between Days 12 and 17 of gestation
[Lee et al., 1998]. In human endometrial ST cells, IL-1 significantly up-regulates the
expression of AR [Rossi et al., 2005]. The induction of AR gene expression in the pig
may be regulated through conceptus IL-1 as the peak AR expression is concurrent to
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previously reported peak IL-1 gene and protein production [Ross et al., 2003b]. The
critical nature of AR expression in the LE during implantation may be associated with
both glucose and toxic aldheyde reduction. It is likely that AR plays a critical role in
production of sorbitol from glucose to be utilized in fructose production. Pregnant gilts
have higher levels of glucose and fructose [Zavy et al., 1982] following conceptus
estrogen stimulation. While glucose itself is a vital energy substrate, conversion of
glucose to fructose may also provide a critical carbon source for DNA and RNA
synthesis while conceptuses undergo the dramatic increase in transcriptional activity and
cellular mitosis following the initiation of trophoblastic elongation, occurring
concomitant with LE AR expression. Indirectly, the alteration in AR expression leading
to the potential shift in available fructose in the uterine lumen may affect the fructation,
and subsequently, the activity and biological function of specific proteins during
periimplantation development in the pig.
Secreted phosphoprotein 1, also referred to as osteopontin, has been previously
shown to be expressed in the uterine LE and GE of pigs during early pregnancy and is
sustained through at least to Day 85 of gestation [Garlow et al., 2002]. Estrogen, when
given on Days 11-15 of the estrous cycle induces the expression of SPP1 in the LE but
not in GE on Day 15 [White et al. 2005]. Our data indicates that estrogen stimulates LE
expression of SPP1 in a progesterone primed uterus. In the CO pregnant gilts, conceptus
estrogen synthesis and release stimulated SPP1 expression on Day 15 while early
administration of estrogen in EC gilts prematurely induced LE expression.
SPP1 has a superfluity of potential functions in the uterus during the
establishment of pregnancy in species forming an epitheliochorial type of placentation,
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such as the pig [Johnson et al., 2003]. These include contributions to extracellular matrix
formation, migration of immune cells, alterations in intracellular calcium levels, and
activation of phosphotidylinositol 3’-kinase activity; and has also been hypothesized to
form as a bridging ligand between the uterine LE and the conceptus trophectoderm [see
review; Johnson et al. 2003]. The induction of SPP1 following EC treatment may be
related to several of these aspects. Blair et al., [1991] documented the sloughing off of
the extracellular matrix of gilts by Day 15 of gestation following injections of estradiol
valerate (EV) on Days 9 and 10, also resulting in total conceptus mortality. A single
estradiol injection of EV on Day 11 of the estrous cycle results in an approximate 4.5-
fold increase in calcium concentrations in uterine flushings 12 and 24 h post injection
(Geisert et al. 1982a). However, there is no increase in uterine luminal calcium content
24 h after treatment of gilts with EV on Day 9 which also dramatically (> 12-fold)
reduces the surge release of calcium in uterine flushing of pregnant gilts on Day 12
[Gries et al., 1989]. While impossible to directly link EC alteration of SPP1 expression
in the LE of gilts during early pregnancy based on these data, the associations regarding
disrupted ECM formation and endometrial calcium secretion resemble the pattern of
disruption that estrogen causes in SPP1 mRNA expression.
Similar to SPP1, the expression of CD24 was also localized to the uterine LE
and prematurely elevated in EC treated gilts. CD24 is a membrane bound molecule
whose structure lacks a cytoplasmic fraction and has specific binding ability for P-
selectin, phenotypically suggesting CD24 may serve as a mucin-like adhesion molecule
[review; Kristiansen et al., 2004]. However, the interaction of P-selectin and CD24 may
also induce excessive TH1 lymphocyte trafficking as over-expression of P-selectin is
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associated with increased TH1 lymphocytes in human patients suffering from
spontaneous miscarriage [Zenclussen et al., 2001]. Interestingly, treatment of abortion
prone mice (CBA/J x DBA/2J) with anti-P-selectin monoclonal antibody prior to
implantation significantly reduced the occurrence of abortion and the production of IFN-
and TNF- production by decidual lymphocytes [Bertoja et al., 2005]. Because of the
multiple roles CD24 has with immune response, the contribution CD24 over-expression
in EC treated gilts may elicit an elevated immune response disrupting conceptus
attachment to the uterine surface. While P-selectin expression is not well characterized in
the pig, an mRNA sequence has been isolated from uterine endometrium during early
pregnancy, sequenced, and annotated as P-selectin (GenBank accession number:
DQ097865); suggesting that CD24 may serve as a bridging ligand during the attachment
and adhesion of the conceptus trophectoderm to the uterine endometrium. It is clear that
as early as Day 12 of gestation both the conceptus and the endometrium are producing
copious amounts of CD24 in a spatiotemporal manner (Figure 4.5). If expression of P-
selectin by the endometrium is required for CD24 bridging during attachment, it is
possible that increased expression by the uterine endometrium in response to the EC
treatment resulted in excessive P-selectin/CD24 binding prior to the conceptus ability to
express CD24 and bind P-selectin on the LE resulting in attachment failure.
Neuromedin B is a bombesin-like peptide first discovered in porcine spinal cord
[Minamino et al., 1988]. Immunologically, NMB has been shown to be expressed by
multiple cancer cell lines and, like other bombesin-like peptides, can negatively influence
IL-12 production and the maturation, antigen presentation, and endocytotic capability of
dendritic cells [Makarenkova et al., 2003]. Interestingly, the greatest endometrial NMB
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gene expression occurred in CO animals on Day 13 of gestation. Treatment of pregnant
gilts with estrogen caused a significant increase or advancement in NMB expression on
Day 12 on the LE (Figure 4.1D and 4.6). There is a void in the literature regarding the
role of endometrial NMB expression in establishment of pregnancy in the pig as well as
its role in other species. NMB has been demonstrated to stimulate smooth muscle
contractions in a variety of tissues including the uterus [see review; Ohki-Hamazaki et
al., 2000]. While the expression of NMB and its receptor, NMB-R, has been shown to
affect maternal and emotional behavior [Yamada et al., 2002a; 2002b]; NMB has also
been shown to increase the release of arachidonic acid and promote cell growth [Moody
et al., 1995] and elevate cellular Ca2+ concentrations [Wang et al., 1992] in C6 glioma
cancer cells through bombesin receptors. The promoted cell growth is consistent with
NMB and its receptor, NMB-R, functioning as mitogens in epithelial cells lining the
colon while elevated NMB-R was associated with those epithelial cells that had
differentiated into tumor cells [Matusiak et al., 2005]. The expression of bombesin-like
peptides does appear to be a significant factor during pregnancy as neuromedin U was
also shown to be differentially expressed in response to EC on Day 13 of gestation (Table
4.3). Bombesin-like peptide receptors, specifically, gastrin-releasing peptide receptor
and NMB-R are expressed in the developing mouse embryo throughout gestation [Battey
et al., 1994]. Because of the ability for bombesin-like peptides to function as mitogens
affecting cell growth it is requisite to determine the expression patterns of NMB-R in
both the elongating conceptus and uterine endometrium during the establishment of
pregnancy in the pig.
Premature estrogen exposure affects multiple factors in the uterine endometrium
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that are common in that their abnormal expression, whether increased or decreased, is
advanced approximately 48 h compared to normal expression. These alterations in
gene expression may cause an asynchrony between the endometrium and conceptus
similar to that described by Polge (1982) where embryos transferred greater than 48 h
out of synchrony with the uterine endometrium fail to establish pregnancy. Geisert et
al. (1991) demonstrated that gestation Day 6 embryos transferred into a more advanced
uterine environment (48 h) are degenerate within 36 hours following transfer.
Uniquely, conceptus loss as a result of estrogen exposure on Day 9 and 10 does not
occur before Day 12, as conceptuses continue to elongate and don’t become degenerate
until approximately Day 15 of gestation. These data suggest that exogenous estrogen
administration causes significant alterations in endometrial gene expression on Days 12
and 13 of gestation and may prevent attachment and promote immunological rejection
of the conceptus resulting in its deterioration by Day 15 of gestation.
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Chapter V
ACTIVATION OF THE TRANSCRIPTION FACTOR, NUCLEAR FACTOR
KAPPA B, DURING THE ESTROUS CYCLE AND EARLY PREGNANCY IN
THE PIG
Introduction
The diversion from cyclicity to establishment of pregnancy in any spontaneously
ovulating species requires distinct alterations in uterine molecular events that allow for
attachment and implantation of a developing conceptus. Given the uterine
proinflammatory response during early conceptus development, it is possible that the
transcription factor, nuclear factor B (NFB), is intricately involved in the regulation of
the cascade of events regulating early pregnancy establishment in pigs. NFB consists of
multiple subunits that have a common Rel homology domain [Ghosh et al., 1998].
Inactive NFB is sequestered in the cytoplasm through binding to inhibitors of NFB
(IBs) until activation of IB kinases, which results in the release and ubiquitination of
IB and the subsequent translocation of NFB dimers into the nucleus regulating
transcription of NFB responsive genes [Ghosh et al., 1998; Ali and Mann, 2004]. NFB
activation can be the result of numerous stimuli such as bacterial endotoxin
lipopolysaccharide, reactive oxygen species, and cytokines such as tumor necrosis factor
 (TNF) and interleukin-1 (IL-1). It is likely that the pregnancy specific increase of
IL-1 in the uterine lumen during conceptus elongation and attachment in pigs [Ross et
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al., 2003b] may regulate the activation of NFB and transcription of regulated genes,
such as prostaglandin synthase-2 (PTGS2). Interestingly, PTGS2 expression is not
pregnancy specific as the gene and enzyme is significantly upregulated in the luminal
epithelium (LE) of gilts beginning on Days 10-12 of the estrous cycle and early
pregnancy [Ashworth et al., 2006]. Indomethacin, a non-steroidal anti-inflammatory
drug that inhibits prostaglandin synthesis through NFB [Takada et al., 2004], results in
the loss of embryos when given on Days 11 to 16 of pregnancy in the pig [Kraeling et al.,
1985]. While elevated PTGS2 mediated prostaglandin production by the uterine
endometrium of cyclic and pregnant gilts could be mediated by mechanisms independent
of NFB, results suggest a relationship between the NFB and elevated PTGS2 in the
uterine endometrium.
While NFB transcription regulation in the endometrium is likely, the
mechanisms by which it is regulated in the uterus is elusive. We hypothesize NFB
activation of PTGS2 transcription in the uterine endometrium is progesterone driven as
conceptus production of IL-1 [Ross et al., 2003a] and estradiol-17 [Geisert et al.,
1982b] does not affect PTGS2 expression in the uterine LE. Plasma concentrations of
progesterone are high during diestrus inducing a LE specific downregulation of
progesterone receptor protein in pigs on Days 10 to 12 of the estrous cycle and pregnancy
[Geisert et al., 1994]. Progesterone receptor regulation of transcription is cell specific as
protein expression persists in the underlying stroma during the time of attachment in the
pig [Geisert et al., 1994]. The downregulation of progesterone receptor in the pig uterine
LE prior to and during the opening of the implantation window is associated with
endometrial transcriptional changes leading to either uterine receptivity for conceptus
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development and attachment to the uterine surface during pregnancy or pathways
releasing prostaglandin F2 to regress the corpora lutea and initiate a return to estrus
[Geisert et al., 2006]. In fact the association of progesterone receptor downregulation
temporal to the opening of the implantation window and conceptus attachment is not
limited to the pig. Progesterone receptor downregulation in the uterine LE is generally
associated with the opening of the implantation window in the human [Lessey et al.,
1988, 1996], baboon [Fazleabas et al., 1999], sheep [Spencer and Bazer, 1995], cattle
[Meikle et al., 2001] and horses [Hartt et al., 2005].
Although the specific downregulation of progesterone receptor in the LE has been
well established, the pathway for this important biological event is not known.
Progesterone receptor is capable of regulating transcription of genes through its
interactions with NFB as RelA and progesterone receptor are mutually repressive of
each other [Kalkoven et al., 1996]. Thus we propose that regulation of progesterone
receptor expression in the uterine LE involves an interaction with NFB. The objective
of this study was to characterize the contributing factors NFB p50/RelA activation
during the estrous cycle and early pregnancy in pig uterine endometrium.
Materials and Methods
Animals
Research was conducted in accordance with the Guiding Principles for Care and
Use of Animals promoted by the Society for the Study of Reproduction and approved by
the Oklahoma State Institutional Animal Care and Use Committee. Cyclic, crossbred
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gilts of similar age (8-10 mo) and weight (100-130 kg) were checked for estrous behavior
twice daily in the presence of an intact boar. Onset of estrus was designated Day 0 of the
estrous cycle. Gilts were naturally mated with fertile boars at the onset of their second
estrus (Day 0 of estrous cycle) and again 24 h later.
Tissue Collection
During the observation of estrus, gilts were randomly assigned to be either
pregnant or cyclic. Gilts destined for pregnancy were mated by natural service from
intact boars at the onset of estrus and again 24 h later. Uteri were collected from cyclic
gilts on Days 0, 5, 7.5, 10, 12, 13, 15 and 17 of the estrous cycle while uteri were
collected from pregnant gilts on Days 10, 12, 13, 15 and 17. Gilts were hysterectomized
(n = 4 gilts/status/day) through midventral laporatomy as previously described by Gries
et al. [1989]. Following induction of anesthesia with 1.8 mL of i.m. administration of a
cocktail consisting of 2.5 mL (Xylazine; 100 mg/mL, Miles Inc., Shawnee Mission, KS)
and 2.5 mL Vetamine (Ketamine HCL; 100 mg/mL, Molli Krodt Veterinary, Mundelein,
IL) in 500 mg of Telazol (Tiletamine HCl and Zolazepum HCl; Fort Dodge, Syracuse,
NE), anesthesia was maintained with a closed circuit system of halothane (5%) and
oxygen (1.5 liters/min). Immediately following removal, each uterine horn was flushed
with 20 mL of a physiological saline and conceptuses were removed. Uterine flushings
were transferred to a 50 mL conical tube and centrifuged at 1000 rpm for 1 min to
remove cell debris. Uterine flushings were stored at -80oC until utilized. Following
conceptus removal, one uterine horn was cut along its anti-mesometrial border, and
endometrium (5-10 g) was removed with sterile scissors and snap-frozen in liquid
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nitrogen and stored at -80oC until analyzed. Cross sections of uteri were also fixed in 4
% paraformaldehyde and dehydrated in 70% ethanol to use for in situ hybridization.
RNA Isolation
Total RNA was extracted from uterine endometrium tissue using the RNAwiz
reagent (Ambion, Inc., Austin, TX) according to manufacturer’s recommendations.
Approximately 500 mg of endometrium was homogenized in 5 mL RNAwiz reagent
using a Virtishear homogenizer (Virtis Company Inc., Gardiner, NY). RNA pellets were
rehydrated in nuclease-free H2O and stored at -80oC. RNA content was estimated
spectrophotmetrically and purity determined by the 260:280 ratio. RNA quality and
integrity was assessed through gel electrophoresis.
Protein Extraction
Cytoplasmic and nuclear protein fractions were prepared using a previously established
method [Deryckere and Gannon, 1994; Nakamura et al., 2004a]. Briefly, 5.0 mg of
uterine endometrium from cyclic (Days 5, 10 and 13) and pregnant (Days 10 and 13) gilts
(n = 4/day/status) was pulverized in liquid nitrogen. Pulverized tissue was re-suspended
in lysis buffer [150 m NaCl, 10 m Hepes-KOH (pH 7.9), 1 m
ethylenediaminetetraacetic acid (EDTA), 0.6% NP-40 and 1X Protease inhibitor cocktail
(Pierce Biotechnology, Rockford, IL)] and homogenized with a loosely fitted pestle in a
Dounce homogenizer (Wheaton, Millville, NJ). Homogenate was centrifuged at 1000 x g
for 1 min at 4oC then supernatant was transferred to a new tube, incubated in ice for 5
min followed by additional centrifugation at 3300 x g, for 5 min at 4oC. The supernatant,
133
containing the cytoplasmic protein fraction was transferred and stored at -80oC while the
pelleted nuclei were resuspended in 200 µl of nuclear extraction buffer [25% glycerol, 20
mM Hepes KOH (pH 7.9), 420 mM NaCl, 1.2 mM MgCl2, 0.2 mM EDTA, 0.5 mM DL-
Dithiothreitol (DTT) and 1X protease inhibitor cocktail]. Resuspended nuclei were
incubated on ice for 30 min, vigorously vortexing intermittently. The nuclear suspension
was centrifuged at 12 000 x g for 5 min at 4oC. Following centrifugation, the supernatant
containing the nuclear protein extract was transferred to a new tube and stored at -80oC.
Total protein concentrations were determined using the method of Bradford [1976]
through the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA).
NFB Activity
Activity of NFB in cytoplasmic and nuclear protein fractions from uterine
endometrium of pregnant and cyclic gilts was determined through an electrophoretic
mobility shift assay and a transcription factor ELISA specific for NFB p65 activity.
Electrophoretic Mobility Shift Assay
The electrophoretic mobility shift assay (EMSA) was conducted using a
commercially available kit that specifically interrogates activated NFB (Panomics,
Fremont, CA). A total of 20 µg (representing a pool of 5 µg from 4 biological
replications) was utilized in the EMSA. Pools assayed represented cytoplasmic and
nuclear protein fractions isolated from uterine endometrium of cyclic gilts on Days 5, 10
and 13 and from endometrium from pregnant gilts on Days 10 and 13. Briefly, following
hybridization of the protein sample with labeled probe, the hybridization mixture was
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electrophoresed through a 6% polyacrylamide gel, transferred to a positively charged
nylon membrane and crosslinked using ultra violet rays. Chemiluminescence detection
was conducted according to manufacture’s protocol. Membranes were exposed to
Biomax MR film and developed. Positive control was the hybridization of control
protein, included in the kit, with labeled probe. Negative controls included the
hybridization of endometrial sample (Day 13 pregnant, cytoplasmic fraction) with labeled
probe, but in the presence of 100-fold excess cold probe. Positive control probe and
nuclear extract were included in the kit.
NFB RelA ELISA
The presence of the NFB RelA in nuclear and cytoplasmic protein extractions
was determined using the TransAM NFB RelA transcription factor assay kit (Active
Motif, Carlsbad, CA). The assay utilizes a 96-well format for which each well contains
immobilized oligonucleotide containing the NFB consensus sequence. NFB RelA was
assayed in both nuclear and cytoplasmic protein fractions collected from endometrium of
gilts on Days 5, 10 and 13 of the estrous cycle and Days 10 and 13 of pregnancy (n = 4
gilts per status/day). All samples, positive control nuclear extract and blank (using
nuclear extraction buffer) were assayed in duplicate according to the manufacturer’s
recommendations. Positive control nuclear extract was included in the kit and excess
wild-type and mutated NFB consensus sequence oligo was added in excess to other
control wells to determine specificity. Following protein/DNA binding and washing of
the wells, anti-RelA primary and HRP-conjugated secondary antibodies, including with
the assay kit, were utilized to determined relative amounts of bound RelA. Following
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secondary antibody binding, the wells were developed colorimetrically and absorbance at
450 nm was determined. The optical density (OD) for each sample was first corrected by
subtraction of the Blank OD and subsequently corrected for total protein in the sample.
In Situ Hybridization
Hybridization
Progesterone receptor (PR), estrogen receptor  (ER), and receptor activator of
NFB (RANK), mRNA were localized in porcine uterine cross-sections by in situ
hybridization using methods previously described [Johnson et al., 1999]. Paraffin
embedded cross-sections (~5 µm) were deparaffinized, rehydrated, and deproteinated;
then hybridized with radiolabeled antisense or sense porcine cRNA probes (5.0 X 106
counts per minute/slide) synthesized through in vitro transcription with [-35S] uridine 5-
triphosphate (MP Biomedicals, Irvine, CA) using a linearized plasmid template.
Following hybridization washes, and RNase A digestion, hybridized slides were exposed
to Biomax maximum resolution film (Eastman Kodak, New Haven, CT) overnight to
determine signal strength. Autoradiography was performed using NTB liquid
photographic emulsion (Eastman Kodak). Slides were dipped in emulsion and exposed at
4°C for a period of time relative to signal strength, developed in Kodak D-19 developer,
counterstained with Harris modified hematoxylin (Fisher Scientific, Fairlawn, NJ),
dehydrated, and protected with cover slips.
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Photomicrography
Digital photomicrographs of in situ hybridization, bright-field and dark-field
images of liquid emulsion autoradiography, were collected using a Nikon Eclipse E6000
microscope interfaced with the CoolSNAPcf digital camera equipped with a cooled
charge-coupled device (Photometrics, Tucson, AZ) and imaging software (MetaVue,
Molecular Devices, Downington, PA).
Quantitative One-Step RT-PCR
Quantitative analysis of NFB RelA, NFB p50, RANK, Toll-like receptor-4
(TLR-4), and inhibitors of B (IB and IB) and were assayed using quantitative real-
time RT-PCR and a fluorescent reporter as previously described [Ashworth et al., 2006].
The PCR amplification was conducted using the ABI PRISM 7500 Sequence Detection
System (PE Applied Biosystems, Foster City, CA). The real-time detection during each
amplification cycle was done by using a sequence specific dual-labeled fluorescent probe
designed to have a 5’ reporter dye (6-FAM) and a 3’ quenching dye (TAMRA) nested
between the forward and reverse sequence specific primers. All primers and probes
utilized for quantitative analysis for each target gene are presented in Table 5.1. One
hundred nanograms of synthesized cDNA were assayed for each sample in duplicate.
Thermal cycling conditions using the dual labeled probe were 50oC for 30 min, 95oC for
15 min, followed by 40 repetitive cycles of 95oC for 15 sec and a combined
annealing/extension stage, 59oC for 1 min. Fluorescent data acquisition was done during
the annealing/extension phase. 18S ribosomal RNA was assayed as a normalization
control to correct for loading discrepancies. Following RT-PCR, quantitation of gene
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Table 5.1 Primer and probe sequences used for quantitative RT-PCR analysis.
Targeta Forward/Reverse Primers (5'3')b Fluorescent Reporterc
Length of
Amplicond
GenBank
Accession #e
GCTGACTCTGGAAGAGAAGGTGTTRANK
GCCCTGTCCACATATTCGTCTTCTGT
ATGTGCTGTCCAGACGGTGGTGGTGCCTGT
192 bp CB475057
ATGGCCTTTCTCTCCTGCCTGATLR-4
AGGTCCAGTATCTTGACTGATGTGGG
ATCTGAGAGCTGGGACCCTTGCGTGCAGGT
139 bp AB188301
CCCATGTAGACAGCACCACCTATGATNFB p50
ACAGAGGCTCAAAGTTCTCCACCA
ACCAGGCTGGCAGCTCTCCTCAAAGCAGCA
132 bp NM_001048232
ACATGGACTTCTCAGCCCTTCTGANFB RelA
CCGAAGACATCACCCAAAGATGCT
ACACCTGCTCTGCCCAGAGCACTGGGTT
168 bp CN155798
TGTGATCCTGAGCTCCGAGACTTT
B
TTGTAGTTGGTGGCCTGCAGAATG
TCTACACCTTGCCTGTGAGCAGGGCTGCCT
143 bp NM_001005150
TCATTCTGCAGGTCCAGGTACTCA
B
CACTTGGCGGTGATTCATCAGCAT
TGGATTTCCTCCTGGGCTTTGCTGCTGGCA
89 bp AK231853
aThe amplification target: RANK, Receptor activator of NFB; TLR-4, Toll-like receptor 4; NFB p50, Nuclear factor B p50
subunit; NFB RelA, Nuclear factor B RelA subunit, IB and IB, Inhibitors of B  and , respectively.
bThe forward and reverse DNA oligos used in the amplification of the target. Forward and reverse do not necessarily indicate the in
vivo direction of transctiption.
cThe DNA oligo sequence of the dual-labeled probe (possessing the FAM reporting dye on the 5’ end and the TAMRA quenching dye
on the 3’ end) used to measure amount of amplified target during each cycle of quantitative RT-PCR.
dThe length of the amplicon created during PCR.
eThe accession number to the porcine sequence that was utilized during primer and probe design.
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amplification was made by determining the cycle threshold (CT) based on the
fluorescence detected within the geometric region of the semilog view of the
amplification plot. Relative quantitative analysis of target gene expression was
evaluated using the comparative CT method as previously described [Hettinger et al.
2001; Ashworth et al., 2006]. The CT value was determined by subtracting the target CT
of each sample from its respective ribosomal 18S CT value. Calculation of CT
involves using the single greatest sample CT value (the sample with the lowest
expression) as an arbitrary constant to subtract from all other sample CT values.
Relative mRNA units for each sample were calculated assuming an amplification
efficiency of 2 during the geometric region of amplification, and applying the equation,
2Ct. Relative mRNA units in figures 5.6-5.8 are presented as mean ± SEM.
Statistical Analysis
Statistical analysis was conducted to determine differences for both the TransAM
NFB RelA assay and the quantitative RT-PCR results. Analysis was conducted using
the corrected OD values through PROC MIXED of the Statistical Analysis System. The
effects of day, pregnancy status, and protein fraction; as well as all possible interacting
effects. Data are presented as mean OD ± SEM.
Quantitative RT-PCR CT values; representing the raw, normalized data, were
used for analyses, also through PROC MIXED. Analysis of endometrial gene expression
tested for the effect of day, status and day x status interaction. Significance between
means of specific effects (P < 0.05) was determined by probability differences of least
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squares means. Figures representing relative mRNA units have superscripts above bars
depicting significant differences as determined by the CT values (P < 0.05).
Results
Activation of NFB
Electrophoretic Mobility Shift Assay
The EMSA effectively identified shifted probe containing the NFB consensus
sequence when hybridized with both nuclear and cytoplasmic protein extract of
endometrium from cyclic and pregnant gilts (Figure 5.1). The probe hybridized with the
positive control (Figure 5.1, far right lane) while hybridization of the probe with
cytoplasmic extract from Day 13 pregnant endometrium fail to bind in the presence of
100-fold excess cold probe (second lane from the right). There were two shifted regions
identified for all days evaluated. Interestingly, while both of the shifted regions (Figure
5.1, B and C arrows) were present in the nuclear protein fraction, only one of the regions
was present in the cytoplasmic fraction (Figure 5.1, B arrow). Based on visual
assessment, no differences in the amount of bound oligo are apparent between any of the
days which the cytoplasmic protein fractions were evaluated. Alternatively, the amount
of bound oligo in the hybridization containing the nuclear fraction from Day 5, cyclic
endometrium was less than that of the nuclear fraction evaluated during mid-luteal phase
(Days 10 and 13) of both cyclic and pregnant endometrium (Figure 5.1).
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Figure 5.1. Electrophoretic mobility shift assay was conducted using a commercially
available EMSA as described in the Materials and Methods. Nuclear and cytoplasmic
protein fractions extracted from gilts on Days 5, 10, and 13 of the estrous cycle and Days
10 and 13 of pregnancy were exposed to an oligo containing an NFB consensus
sequence followed by electrophoresis through a polyacrylamide gel and transferred to a
positively charged membrane. Labeled oligo was detected through chemiluminescence.
Unbound, labeled oligo migrates the most rapidly and is indicated with an arrow (A),
while bound oligo, migrating slower is shifted towards the upper end of the gel (indicated
by the B and C arrows). Note the lack of a shifted labeled oligo for the negative control
in which 100 fold excess unlabeled probe was added to the hybridization reaction. The
cytoplasmic fraction represented a single shift while two shifts, indicative of multiple
NFB dimers, was indicated by the nuclear fraction. Each lane is equally represented by
protein extracted from endometrium of four gilts.
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NFB RelA ELISA
There was a day x status (P = 0.05) and status x protein fraction (P = 0.001)
interaction for the detected amount of NFB RelA. Differences in the amount of RelA in
the nuclear fraction were insignificant between the days of the estrous cycle and
pregnancy evaluated (Figure 5.2). In contrast, the amount of RelA in the cytoplasmic
compartment was greater during the mid-luteal phase (Day 13) compared to Day 5.
Furthermore, the amount of RelA in the cytoplasmic fraction was greater than the amount
in the nuclear fraction on Days 10 and 13 in comparison to Day 5, for which there was no
detectable difference in RelA between the cytoplasmic and nuclear protein fractions.
While this difference in cellular compartment was present in both cyclic and pregnant
gilts, the difference appeared to be greater in the pregnant gilts (Figure 5.2).
In Situ Hybridization
Estrogen Receptor 
Endometrial expression of ER was localized to the uterine luminal epithelium
(LE), glandular epithelium (GE) and stromal cells (ST) during estrus (Day 0) when
expression was greatest (Figure 5.3). By Day 5, expression was still apparent in all cell
types of the endometrium albeit at a reduced abundance. Decline in ER expression
continued in all cell types being nearly devoid by Day 7.5 of the estrous cycle and Day 10
of both the estrous cycle and pregnancy. On Day 12 and 13 of pregnancy, ER
expression was elevated in the LE. Expression during Day 12 of the estrous cycle was
modest compared to Day 13 cyclic endometrium exhibiting elevated ER mRNA in the
GE. GE expression of ER was transient as expression in cyclic gilts steadily increased
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Figure 5.2. Transcription factor assay to determine relative amounts of activated NFB
RelA in the nuclear (day effect, P = 0.005) and cytoplasmic (day effect, P = 0.006; status
effect, P < 0.001) protein fractions of endometrium collected from gilts on Days 5, 10
and 13 of the estrous cycle and Days 10 and 13 of pregnancy (n = 4/day/status). Relative
optical density for each sample was corrected for total protein concentration in the
sample. Data is presented as relative O.D. mean ± SEM.
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Figure 5.3. In Situ hybridization analysis of ER mRNA expression in porcine
endometrium during the estrous cycle and early pregnancy. Protected transcripts in
endometrium from Days 0, 5, 7.5, 10, 12, 13, 15 and 17 of the estrous cycle and Days
10, 12, 13, 15 and 17 of pregnancy were visualized by liquid emulsion autoradiography
and imaged under bright-field and dark-field illumination. Note the greatest expression
is prior to (Day 17), during (Day 0) and after estrus (Day 5). ER expression is
abundant in the luminal epithelium (LE) and glandular epithelium (GE) during Days 0
and 5 while only in the LE on Day 17 of the estrous cycle. A representative Day 5
section was hybridized with radiolabeled sense cRNA probe to serve as a negative
control. All other images are representative from four biological replications. 4X
Objective and 10X eyepiece for original magnification 40X
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in the LE on Days 15 and 17 of the estrous cycle. While ER expression on Day 15 of
was similar between cyclic and pregnant gilts, by Day 17 LE expression was much less
during pregnancy (Figure 5.3).
Progesterone Receptor
Similar to ER mRNA expression, PR was localized to the LE, GE and ST on
estrus (Day 0) and began to dramatically decline as plasma content of circulating
follicular estrogen decreased (Figure 5.4). PR gene expression on Day 7.5 and 10 of the
estrous cycle was detectable, although greatly reduced, while it was near devoid by Day
12 of the estrous cycle and early pregnancy except for expression persisting in the ST
cells. PR expression remained at the lowest level throughout the remainder of the estrous
cycle and pregnancy until its expression began to increase in the LE of cyclic gilts
following luteolysis while remaining suppressed in the LE at Days 15 and 17 in pregnant
gilts (Figure 5.4).
Receptor Activator of NFB
RANK expression in the uterus was undetectable for many of the days of the
estrous cycle and pregnancy although the greatest expression appeared to occur in LE on
Day 0 during estrus. The expression was visible, although modestly, in the LE and ST
during the mid-luteal phase, Days 10 to 13 of both cyclic and pregnant gilts (Figure 5.5).
While LE expression of RANK was low on Days 15 and 17 of the estrous cycle, LE
expression in pregnant gilts was devoid on the same Days (Figure 5.5)
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Figure 5.4. In Situ hybridization analysis of progesterone receptor (PR) mRNA
expression in porcine endometrium during the estrous cycle and early pregnancy.
Protected transcripts in endometrium from Days 0, 5, 7.5, 10, 12, 13, 15 and 17 of the
estrous cycle and Days 10, 12, 13, 15 and 17 of pregnancy were visualized by liquid
emulsion autoradiography and imaged under bright-field and dark-field illumination.
Note the greatest expression is during (Day 0) and after estrus (Day 5) abundant in the
luminal epithelium (LE) and glandular epithelium (GE) and stromal (ST) cell types.
PR expression is greatly reduced in the LE and GE by Day 10 and nearly devoid on
Day 12 of the estrous cycle and pregnancy, although still present in ST cells. A
representative Day 5 section was hybridized with radiolabeled sense cRNA probe
(sense) to serve as a negative control. All other images are representative from four
biological replications. 4X Objective and 10X eyepiece for original magnification 40X.
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Figure 5.5. In Situ hybridization analysis of receptor activator of NFB (RANK)
mRNA expression in porcine endometrium during the estrous cycle and early
pregnancy. Protected transcripts in endometrium from Days 0, 5, 7.5, 10, 12, 13, 15
and 17 of the estrous cycle and Days 10, 12, 13, 15 and 17 of pregnancy were
visualized by liquid emulsion autoradiography and imaged under bright-field and dark-
field illumination. While expression was low in all tissues evaluated, evidence of
RANK expression is detected in the LE on Day 12 of the estrous cycle and pregnancy.
A representative Day 12 pregnant section was hybridized with radiolabeled sense
cRNA probe (sense) to serve as a negative control. All other images are representative
from four biological replications. 4X objective and 10X eyepiece for original
magnification 40X.
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Quantitative RT-PCR
The mRNA abundance for two receptors which possess the capability of inducing
NFB activity, RANK and TLR-4; in addition to two NFB regulated genes, NFB RelA
and p50 subunits, were assayed using quantitative RT-PCR.
NFB Mediating Receptors
There was no significant day (P = 0.92) or status (P = 0.34) effect detected for the
expression of RANK. Messenger RNA levels were not different in uterine endometrium
throughout the days of the estrous cycle and early pregnancy in pigs (Figure 5.6).
There was a day x status interaction (P = 0.017) on the mRNA abundance for
TLR-4 (Figure 5.6). Expression was least on Day 5 of the estrous cycle and greatest on
Day 13 of pregnancy. While expression on Days 10 through 17 of the estrous cycle were
greater than Days 5 and 7.5 (P < 0.05), endometrium of pregnant gilts expressed
significantly more TLR-4 mRNA transcript than cyclic gilts on Days 10, 12, 13, 15 and
17 (P < 0.05).
NFB Subunits: p50 and RelA
A significant day x pregnancy status interaction was detected for NFB p50 gene
expression (P < 0.01). Messenger RNA abundance for NFB p50 was greatest during
estrus and least on Day 5 (Figure 5.7). NFB p50 expression increased steadily during
diestrus being 2 to 3-fold greater in endometrium collected from Days 12, 13, 15 and 17
compared to Day 5 (P < 0.05). On Day 13 of gestation, expression was about 2-fold
greater when compared to Day 13 of the estrous cycle (P < 0.05) while the inverse was
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Figure 5.6. Relative mRNA abundance for receptor mediators of NFB activation.
Expression differences for endometrial RANK (Top panel; effect of day, P < 0.93;
effect of status, P = 0.34) and TLR-4 (Lower panel; day x status effect, P = 0.017), in
cyclic (orange bar) and pregnant (yellow bar) gilts. Relative abundance of mRNA was
calculated from the quantitative RT-PCR analysis as described in Materials and
Methods. Bars without common lowercase superscripts represent a statistical
difference (P < 0.05) between day/status combinations. Superscripts are not included
in the upper panel as no main or interacting effects were detected. Relative mRNA
units are presented as mean ± SEM.
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Figure 5.7. Relative mRNA abundance for NFB subunits, p50 and RelA. Expression
differences for endometrial p50 (Top panel; day x status interaction, P < 0.01) and
RelA (Lower panel; day x status effect, P = 0.017), in cyclic (orange bar) and pregnant
(yellow bar) gilts. Relative abundance of mRNA was calculated from the quantitative
RT-PCR analysis as described in Materials and Methods. Bars without common
lowercase superscripts represent a statistical difference (P < 0.05) between day/status
combinations. Relative mRNA units are presented as mean ± SEM.
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true when comparing Day 17 of the estrous cycle and pregnancy. Although endometrium
from cyclic gilts expressed more p50 transcript than pregnant gilts, the difference across
days was not significant (P < 0.05, Figure 5.7).
Similar to NFB p50, a day x status interaction (P < 0.013) affected the mRNA
abundance of RelA in the endometrium from cycle and pregnant gilts. Like the p50
subunit, RelA expression was greatest in endometrium collected during estrus, about 4-
fold greater that Day 5 of the estrous cycle which was the lowest expression of RelA
mRNA. After Day 5 of the estrous cycle, expression increased in both cyclic and
pregnant gilts on Days 10, 12, 13, and 15 (P < 0.05; Figure 5.7). While expression
remained elevated on Day 17 of the estrous cycle, expression returned to basal levels on
Day 17 of gestation, representing about a 2.3-fold difference in gene expression (P <
0.05).
Inhibitors of NFB
Gene expression for IB was affected by day (P = 0.001) but not status (P =
0.15). Status did not affect the expression of IB (P = 0.23). IB mRNA abundance
was greatest during estrus, being at least 7-fold greater in comparison to all other days
assayed (P < 0.05). There were no differences in gene expression between all other Days
as mRNA abundance remained at a consistent level from Day 5 through Day 17 (Figure
5.8).
There was a tendency for a day x status (P = 0.08), day (P = 0.07) and status (P =
0.09). The greatest expression differences existed during estrus and Day 17 of estrous
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Figure 5.8. Relative mRNA abundance for endometrial IB (Top panel; effect of
day, P < 0.001) and IB (Lower panel; day x status effect, P = 0.079), in cyclic
(orange bar) and pregnant (yellow bar) gilts. Relative abundance of mRNA was
calculated from the quantitative RT-PCR analysis as described in Materials and
Methods. Bars without common lowercase superscripts represent a statistical
difference (P < 0.05) between day/status combinations whereas differences in
uppercase superscripts represent statistical differences between days of gestation.
Relative mRNA units are presented as mean ± SEM.
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cycle. IB mRNA abundance was greater (P < 0.05) in endometrium of Day 17 cyclic
gilts with expression levels similar to Day 0 but was about 2-fold greater compared to all
other days during diestrus and early pregnancy (Days 5 to 15). No differences were
detected between Days 5 to 15 of the estrous cycle or pregnancy (Figure 5.8).
Discussion
The establishment of pregnancy requires diversion from the pathway of cyclicity
and return estrus following the opening of the implantation window and uterine
receptivity in pigs. Progesterone driven transcriptional regulation of specific endometrial
factors during the mid-luteal phase critically contributes to both induction of luteolysis
resulting in return to estrus in cyclic animals and conceptus growth and expansion to
establish pregnancy in bred females. We have suggested a relationship between PR
expression and the activation of NFB in the endometrial LE regulates the transcription
of specific genes, such as PTGS2 [Ashworth et al., 2006; Geisert et al., 2006].
Establishment of pregnancy in mice has been shown to involve the NFB system.
Not only does the activation of NFB during the implantation window in mice occur
[Nakamura et al., 2004a]; it has also been shown to be required for uterine receptivity
through its affects on leukaemia inhibitory factor (LIF) expression, as LIF administration
restores normal implantation during pregnancy when NFB function is compromised
[Nakmura et al., 2004b]. Interestingly, peak LIF secretion by the pig uterus occurs on
Day 12 of the estrous cycle [Anegon et al., 1994], as well as upregulation of uterine
PTGS2 [Ashworth et al., 2006], an NF B regulated gene [Kniss et al., 2001; Takada et
al., 2004], and we now demonstrate an increased p50 and RelA gene expression (Figure
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5.7), both of which can be induced through NFB [McNulty et al., 2001]. These NFB
regulated factors are all in congruence with the opening of the implantation window in
the pig. Based on the expression patterns of these genes in conjunction with the EMSA
(Figure 5.1) and RelA ELISA (Figure 5.2) it appears that transcriptional control of
uterine endometrium during the initiation of implantation is regulated by NFB
possessing the RelA subunit.
Steroid hormones, as well as their receptors, have in many studies been shown to
affect NFB activity in a variety of tissues. Kalkoven et al. [1996] demonstrated the
ability of both PR and NFB RelA to be mutually repressive of each other, which
suggests that the loss of PR during the opening of the implantation window may be
related to elevated expression of NFB regulated genes in the uterine endometrium
during the estrous cycle and early pregnancy. Downregulation of PR expression in the
uterine LE is temporally associated with uterine receptivity in the pig and other numerous
mammalian species [Lessey et al., 1988, 1996; Fazleabas et al., 1999; Spencer and Bazer,
1995; Meikle et al., 2001; Hartt et al., 2005]. The ability for PR downregulation to affect
the timing of uterine receptivity appears to carry over into the timing of the overall length
of estrous cycle. Progesterone itself functions as a regulator of PR gene expression;
confirmed by the present data where PR gene expression in uterine LE declined after
prolonged (7 to 8 days) stimulation by progesterone, increasing following regression of
the corpora lutea and return to estrus. In human myometrial cells, ablation of PR allows
increased IL-1 induced PTGS2 expression [Hardy et al., 2006]. These authors also
demonstrated the ability of progesterone to reduce IL-1 induced PTGS2 expression,
likely through progesterone’s ability to induce the expression of the inhibitor of NFB,
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IB. During the estrous cycle and pregnancy in the pig, IB and IB were both
expressed at the greatest levels during estrus (Figure 5.8) when PR expression was also
greatest (Figure 5.4). However, while PR is elevated at estrus, progesterone production is
minimal, suggesting that if IB regulation in the pig uterus does occur through PR, it is
either a ligand independent mechanism or that elevated progesterone concentrations drive
down IkB expression contrary to the observation described by Hardy et al. [2006].
The hypothesis, that progesterone driven downregulation of PR regulates uterine
receptivity and the estrous cycle, is supported by the demonstration of shortened estrous
cycles in sheep and cattle given progesterone supplementation shortly after estrus, prior
to normal endogenous progesterone secretion by the corpora lutea [Ottobre et al., 1980;
Garrett et al., 1988]. Additionally, administration of the PR antagonist, mifepristone, on
Days 3-5 of the ovine estrous cycle results in a delay of luteolysis [Morgan et al., 1993].
Collectively, these studies suggest that PR is involved in the regulation of PG production.
Indomethacin, an inhibitor of NFB induced PTGS2 expression [Takada et al., 2004],
when given to pigs during early gestation ablates PG production [Kraeling et al., 1985],
suggesting that uterine PG production during diestrus in the pig is NFB regulated.
Demonstrating that altering either PR expression levels or NFB activation, these studies
independently suggest the ability of both PR and NFB to regulate PG production during
the period of luteolysis.
The temporal affiliation between the gene expression patterns of TLR-4 and
RANK (Figure 5.1B) and NFB inducible genes, NFB p50 (Figure 5.2A), NFB RelA
(Figure 5.2B), PTGS2 (Ashworth et al., 2006) and LIF (Anegon et al., 1994) in the
uterine LE is suggestive of the involvement of TLR-4 and/or RANK during the activation
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of NFB during the initiation of uterine receptivity during the estrous cycle and early
pregnancy in pigs. Because a mutual repression between RelA and PR exists [Kalkoven
et al., 1996], what regulates this activation of NFB and potentially, the subsequent
down-regulation of PR in the uterine endometrium remains unclear. The expression of
RANK and its ligand (RANKL), both involved in bone remodeling and mammary gland
development [Jones et al., 2002; Cao and Karin, 2003], provide one such potential
mechanism. Expression of RANKL can be stimulated by progesterone [Srivastava et al.,
2003] suggesting the potential of RANK mediated NFB activation in the pig
endometrium if RANKL is capable of signaling through endometrial stromal cells which
still express PR during the implantation window in the pig [Geisert et al., 1994]. This
novel hypothesis has been presented [Geisert et al., 2006] and is supported by the
expression of RANK in the uterine endometrium (Figure 5.5); however no
communications to our knowledge have indicated the presence of RANKL or RANK in
the uterus of other mammalian species.
TLR-4 provides a more likely mechanism of NFB activation in the pig as its
expression pattern is temporally associated with that of the NFB regulated genes,
PTGS2 [Ashworth et al., 2006], LIF [Anegon et al., 1994], and the NFB subunits, p50
and RelA (Figure 5.7) in the pig uterine endometrium. TLR-4 expression has been
demonstrated in endometrial LE of a variety of species. In addition to the pig, TLR-4
has also been shown to be expressed in the uterine LE and ST of mice [Soboll et al.,
2006], women [Schaefer et al., 2004, Fazeli et al., 2005] and cattle [Herath et al., 2006].
While TLR-4 was originally described for its ability to respond to the gram-negative cell
wall component, lipopolysaccharide (LPS; Poltorak et al., 1998) recent data suggests a
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variety of endogenous ligands, such as heat shock proteins (HSPs) 60 and 70, fibrinogen,
fibronectin, heparan sulfate, certain -defensins, and high mobility group box 1 protein
also possess the ability to stimulate TLR-4 signaling [Tsan and Gao, 2004]. While the
suggestion that TLR-4 expression in the uterus allows the ability to respond to foreign
bacterial pathogens is valid, its roles in uterine biology in conjunction with endogenous
ligand expression should not be overlooked. In women, heat shock proteins increase
during the late proliferative and early secretory phase of the menstrual cycle [Tabibzadeh
et al., 1996] suggesting steroid hormone involvement in HSP regulation in the uterus. Of
the other mentioned endogenous ligands, fibronectin and heparin sulfate have both been
suggested to be involved in the attachment of the pig conceptus to the uterine LE
[Burghardt et al., 1997], occurring temporal and spatially to TLR-4 increased expression
in the uterine endometrium (Figure 5.6).
Based on these data and the literature presented hitherto, it appears that NFB
activation is a critical component to the opening of the implantation window. However,
stringent regulation of NFB activation is necessary to prevent an all-out inflammatory
response, which could otherwise potentially compromise pregnancy. It is possible that
the conceptus could augment the activation of NFB through at least two mechanisms.
The first possible mechanism is the spatiotemporal peak in conceptus secretion of IL-1
with uterine expression of IL-1 receptors on Day 12 of gestation [Ross et al., 2003a].
The second possible mechanism for augmented NFB activation is through conceptus
expression of TLR-4 endogenous ligands; fibronectin and fibrinogen [Tsan and Gao,
2004], both of which are upregulated during Days 11 to 14 of gestation 8.9 and 12.8 fold,
respectively (Table A.3, Cluster 1 and Cluster 13, respectively). Both of these
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mechanisms seem plausible as the amount of cytoplasmic RelA sequestered in the
cytoplasm was greatest on Day 13 of pregnant gilts compared to cyclic gilts and
conceptus absence (Figure 5.2). Bovine endometrial explants respond to LPS, the
bacterial TLR-4 ligand, by increasing PG production, with a notable increased PGE to
PGF ratio, while in vitro stimulation of LE or ST cells with LPS resulting in PTGS2 gene
expression could be ablated with an LPS antagonist [Herath et al., 2006]. Prostaglandin
production peaks during the mid-luteal phase for both PGE and PGF during both the
estrous cycle and pregnancy in the pig; however, a marked increase in the PGE:PGF ratio
is detected in pregnant gilts compared to cyclic gilts [Christenson et al., 1994], further
suggesting a relationship between pregnancy PG production ratios and TLR-4 conceptus
stimulation.
While total endometrial RelA detected was greatest in pregnant gilts supports
conceptus augmented NFB activation, being limited to the cytoplasm is indicative of in
place regulatory mechanisms preventing overwhelming inflammatory response. The
concomitant estrogen secretion by the conceptus [Geisert el al., 1982b] temporal to
conceptus production of both IL-1 and endogenous TLR-4 ligands may be one way
NFB transcriptional activity is regulated. Ghilsetti et al. [2005] demonstrated the in
vitro ability of estrogen, signaling through ER and not ER, of preventing activated
NFB in the cytoplasm from being translocated into the nucleus of the cell and inducing
transcription. Interestingly, the upregulation of ER on Days 12 and 13 of gestation in
the uterine LE (Figure 5.3) is temporally associated with the elevated uterine luminal
estradiol-17 [Geisert et al., 1982b] and the pregnancy associated elevation of activated
NFB p65 in the cytoplasmic protein fractions (Figure 5.1 and 5.2). Typically, the
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degradation of IB’s result not only in the ability for the activated NFB dimer to bind
DNA, but also exposes the nuclear localization signal necessary for expedited transport to
the nucleus of the cell [Ali and Mann, 2004]. These data suggest that while the p50/RelA
is capable of binding DNA, the heterodimer remains primarily in the cytoplasm of the
cell. The temporal relationship of endometrial ER expression and conceptus estradiol
secretion provides a potential mechanism by which this occurs. If this mechanism does
occur during pregnancy in the pig, it is likely that other mechanisms are also in place as
cytoplasmic RelA also increases in uterine endometrium from gilts during the estrous
cycle.
The opening of the implantation window is the initiating point of the period
during gestation at which specific endometrial alterations occur to allow the attachment
of the conceptus trophectoderm. It is this period of development that requires the
formation of a communication network between the developing conceptus and the
maternal endometrium with dysfunction on the part of resulting in the inability to
establish pregnancy. Steroid hormones, progesterone and estrogen, no doubt serve a
fundamental responsibility in the pattern of endometrial secretions and the induction of
uterine receptivity. The steroid hormone receptors ER and PR, through their ability to
affect the transcriptional activity of NFB, are likely a critical component to inducing and
regulating the degree of transcription necessary in the uterine endometrium for the
establishment of pregnancy in the pig.
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Chapter VI
SUMMARY AND CONCLUSION
The establishment of pregnancy in any mammalian species requires smoothly
orchestrated molecular events at the conceptus uterine interface during Days 11 to 14 of
gestation. It is during this period that the conceptuses produce both IL-1 and estadiol-
17 concomitant with the rapid elongation of the conceptus trophectoderm. Sufficient
secretory capacity of the pig conceptus [Polge et al., 1966; Dziuk, 1968] and an adequate
extent of trophoblastic elongation [Stroband and Van der Lende, 1990] are requirements
for the establishment of pregnancy and conceptus survival in the pig. Acquiring these
major conceptus developmental landmarks requires the temporal and spatial expression
of the appropriate mRNA transcripts to generate a phenotype suitable for continued
growth and development. However, little information has been isolated specifically
identifying a large number of conceptus transcripts that are critical for this stage of
development.
Not only is appropriate conceptus development critical for the establishment of
pregnancy in the pig, uterine endometrial function regulating uterine receptivity and
conceptus attachment are necessary components for pregnancy establishment. Two
major factors regulating endometrial function during the period of conceptus attachment
and implantation are conceptus synthesis and release of estradiol-17 and the endometrial
downregulation of the progesterone receptor.
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Collectively, the studies presented in this thesis use three separate approaches to
better understand the biology of pregnancy establishment in pigs with respect to
development during Days 11 to 14 of gestation. This short period of development
relative to the overall length of gestation is critical due to the numeruous physiological
events occurring in both the conceptus and the endometrium required for pregnancy
establishment in the pig. Conceptus trophoblastic elongation is simultaneous with
endometrial programming that allows uterine receptivity, and uterine receptivity can be
modified in response to conceptus secretory factors, such as estradiol-17 [Geisert et al.,
1982b] and IL-1 [Ross et al., 2003b].
The use of the Affymetrix GeneChip® Porcine Genome Array effectively
identified hundreds of porcine genes that are differentially expressed during the
developmental period consisting of trophoblastic elongation and the initial attachment of
the conceptus trophectoderm to the maternal uterine endometrium. Surprisingly, the
morphological transition from spherical to tubular represented differential expression of
very few genes, suggesting the possibility that spherical conceptuses possess the capacity
for rapid trophoblastic elongation but lack the stimulatory mechanism which induces it.
In contrast, Day 12 filamentous conceptuses, whose morphological difference from that
of tubular conceptuses is a matter of a few hours of development, differentially express
over 450 genes in comparison to spherical or tubular morphologies. This rapid
modification in the mRNA population is continued in Day 14 conceptuses. The hundreds
of genes that are differentially expressed during this period of development represent an
array of biological processes occurring during this stage of conceptus development.
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Many of the genes that were differentially expressed represented core biological
processes such as cell motility, energy catabolism, amino acid transport, apoptosis
regulation, cell growth, transcriptional regulation, and ATP utilization. The use of
clustering analysis allowed the characterization of genes by their expression patterns in
the conceptus during this stage of development and also allowed the association of genes
whose expression patterns were similar. We have identified the transient expression of
over 150 genes (Table A3, k-means clusters 4, 7, 14, 21 and 24) that could be considered
molecular markers of rapid trophoblastic elongation while the genes associated with
expression increasing in Day 14 conceptuses mark those factors whose expression is
temporal to placental layer differentiation during the attachment to the uterine
endometrium [Friess et al., 1980].
The data presented herein were also complementary of previously identified
factors which are differentially expressed, such as PTGS2 [Wilson et al., 2002],
steroidogenic acute regulatory factor [Blomberg et al., 2005], transforming growth factor
 [Gupta et al., 1996], epidermal growth factor receptor [Vaughn et al., 1992], interferon-
 [La Bonnardiere et al., 2002], and retinol binding protein [Yelich et al., 1997a]. We
have also identified numerous factors, which up unto this point were not associated with
conceptus development in any species such as B-cell linker and angiomotin.
Alternatively, the identification of genes whose expression during pig development is
novel, which have been documented to be expressed during embryonic development in
other species, such as chemokine14 ligand and parathyroid hormone like related
hormone, now have a better biological function assessment due to their associations with
the developmental processes occurring in pig conceptuses temporal to their expression.
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The identification of genes whose spatiotemporal expression patterns, such as
angiomotin, being associated with not only cell migration [Troyanovsky et al., 2001], but
the localization to the lamellipodia of migrating cells [Levchenko et al., 2003]. The
identified factors differentially expressed during pig conceptus development that are also
in cells phenotypically resembling trophectodermal cells in the pig conceptus during
elongation [Geisert et al., 1982c] provide numerous factors for which future studies can
be designed.
Estrogen is a critical component for the establishment of pregnancy in the pig
[Bazer and Thatcher, 1977] but can also be detrimental if uterine endometrial exposure to
estrogen occurs at an abnormal time during early gestation [Pope et al., 1986, Blair et al.,
1991; Ashworth et al., 2006]. The critical relationship between the temporally acceptable
point of endometrial exposure to estrogen during pregnancy and its affect on conceptus
survivability suggests that spatiotemporal regulation of key factors affecting pregnancy
outcome occur through estrogen. Also, while it is widely accepted that estrogen is the
maternal recognition of pregnancy signal, the molecular mechanisms behind estrogen
stimulation are not well described. Our approach has allowed the identification of
endometrial genes affected by estrogen stimulation in the presence of other conceptus
secreted factors.
Interestingly, the majority of transcriptional differences were detected on Day 13
of gestation following exogenous estrogen exposure on Days 9 and 10, after conceptus
estrogen is also secreted into the uterine lumen. Of the genes identified to be regulated
by exogenous estrogen we specifically evaluated the spatiotemporal expression patterns
of four through in situ hybridization and quantitative RT-PCR.
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Aldose reductase and neuromedin B were significantly downregulated in the
uterine luminal epithelium on Day 13 in response to exogenous estrogen on Days 9 and
10 while secreted phosphoprotein-1 and CD24 antigen were upregulated in the luminal
epithelium by estrogen on Day 13. Aldose reductase is a critical component in the
formation of fructose from glucose, both of which markedly increase during peri-
implantation development in the pig [Zavy et al., 1982], suggesting potential role
providing energy during conceptus growth and trophoblastic elongation. Alternatively,
neuromedin B, secreted phosphoprotein 1, and CD24 have all been shown in a variety of
tissues to regulate immunity [Makarenkova et al., 2003; Johnson et al., 2003; Zenclussen
et al., 2001; Bertoja et al., 2005]. Also as previously mentioned, CD24 [Kristiansen et
al., 2004] and secreted phosphoprotein 1 [Johnson et al., 2003] have been associated with
ligand bridging between cells suggesting potential roles in conceptus attachment to the
luminal epithelium. If indeed the function of these estrogen regulated genes is to regulate
conceptus trophectoderm attachment to the uterine luminal epithelium, the premature and
overexpression of these factors could alter the uterine extracellular matrix to an extent not
favorable for conceptus attachment, resulting in the delayed conceptus mortality that was
described.
These alterations in gene expression demonstrated in the uterine endometrium are
similar to the asynchrony between the endometrium and conceptus described by Polge
(1982) where embryos transferred greater than 48 h out of synchrony with the uterine
endometrium fail to establish pregnancy. These data suggest that exogenous estrogen
administration causes significant alterations in endometrial gene expression on Days 12
and 13 of gestation and may prevent attachment and promote immunological rejection of
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the conceptus resulting in its deterioration by Day 15 of gestation. However, the
underlying implication is that during normal gestation, conceptus induced changes
through endogenous estradiol-17 secretion occur synchronously to the dramatic
expression and phenotypic changes that enable the conceptus to survive in an uterine
environment following estrogen stimulation.
The opening of the implantation window is a critical process which occurs during
peak progesterone production by the corpora lutea, is characterized by uterine receptivity
to conceptus attachment, and occurs in all reproductively capable gilts, regardless if
mating, fertilization and early conceptus development have transpired. Endometrial
phenotype during uterine receptivity is poised to secrete prostaglandins in an endocrine
fashion, resulting in luteolysis and a return to estrus or release prostaglandins in and
exocrine fashion, sustaining the corpora lutea; and establish a communication network
with the developing conceptus, thereby commencing gestation. The downregulation of
progesterone receptor [Lessey et al., 1988, 1996; Fazleabas et al., 1999; Spencer and
Bazer, 1995; Meikle et al., 2001; Hartt et al., 2005] and the activation of NFB
[Nakamura et al., 2004a] during pregnancy establishment is not unique to the pig. We
were interested in the molecular factors that contribute to this endometrial phenotype.
This study evaluated potential mechanisms by which endometrial modifications
can occur through the interplay between RelA and progesterone receptor. The utilization
of an EMSA and NFB RelA ELISA confirmed the presence and likely activation of
NFB in the uterine endometrium around the time of progesterone receptor
downregulation in the uterine luminal epithelium. The temporal expression of NFB
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regulated genes, NFB p50 and RelA; as well as LIF [Anegon et al., 1994] and PTGS2
[Ashworth et al., 2006] also confirm NFB activation.
Two potential mechanisms of NFB activation were evaluated, one through
receptor activator of NFB (RANK) and the other being toll-like receptor 4 (TLR-4),
which is also capable of inducing the cascade of events resulting in activated NFB.
While both of these receptors were identified in the pig uterine endometrium, RANK
appeared to be constitutively expressed while TLR-4 expression was temporally
associated with the expression patterns for the NFB activated genes in the uterus such as
PGTS2, p50 and RelA. TLR-4 expression also provides the potential for regulation
through the stimulation by the developing conceptuses, which significantly increase
mRNA production for fibronectin and fibrinogen, both TLR-4 endogenous ligands,
during the implantation window.
The involvement of steroid hormones, as well as their receptors, has in many
studies been shown to affect NFB activity in a variety of tissues. Estrogen,
progesterone, and their receptors have been shown in multiple tissue types to regulate
NFB activity [Kalkoven et al., 1996; Ghilsetti et al., 2005, Hardy et al., 2006] and as
described, these mechanisms associate well with the steroid hormone regulation of the
estrous cycle and early pregnancy in the pig.
While these three individual studies were designed separately, each investigating
specific biological areas during diestrus of the estrous cyclic and peri-implantation
development during pregnancy; collectively they contribute to a better overall
understanding of pregnancy establishment not only in the pig, but in all mammalian
species. Collectively, these three studies bring novel insight to the understanding of the
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estrogenic affects on uterine receptivity, regulation of the opening of the implantation
window, and the identification of factors affecting conceptus ability to reach the
developmental landmarks required to hit the “window”.
These data have supplied a wealth of information that could be used for the
generation of many hypothesis’ to describe the specific functions of genes that regulate
conceptus trophoblastic elongation, estrogen’s molecular role as the maternal recognition
of pregnancy signal and NFB activation and function as it relates to the
endocrine/exocrine theory of prostaglandin production during pregnancy establishment in
the pig.
Current technologies, such as RNA interference, delivery of antisense
morpholinos, and transgenic swine embryo development have reached an efficacy that
can be applied for agricultural and biological gain. Through gene knock-down, knock-out
and knock-in methods, the specific genes that regulate trophoblastic elongation and
subsequent placental function can be identified, providing specific targets through which
modifications can be determined to improve pig reproductive efficiency.
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Table A.1. Differentially expressed genes during the transition from Spherical to Day 12 filamentous conceptuses.
Probe Set IDa
GenBank
Accesion
Numberb
P
Valuec
Fold
Changed
Putative Identity Following
Annotation Based on Homology
to Known GenBank Identitiese
Gene Title Assigned By Affymetrix
Annotationf
Gene
Symbolg
Ssc.4142.1.S1_at NM_181644 0.00046 59.22 hypothetical protein
DKFZp761N1114
Transcribed locus, strongly similar to
NP_857595.2 hypothetical protein
DKFZp761N1114 [Homo sapiens]
Ssc.4193.1.S1_at #N/A 0.00000 52.43 #N/A Transcribed locus
Ssc.22563.1.S1_at NM_006581 0.00005 27.76 fucosyltransferase 9 Transcribed locus, strongly similar to
NP_001005380.1 alpha-1,3-
fucosyltransferase 9 [Canis familiaris]
Ssc.7106.1.S1_at NM_001801 0.00009 25.39 cysteine dioxygenase; type I Clone Clu_1053.scr.msk.p1.Contig1,
mRNA sequence
Ssc.942.1.S1_at NM_000165 0.00094 24.64 gap junction protein; alpha 1;
43kDa
Transcribed locus, strongly similar to
NP_000156.1 connexin 43;
oculodentodigital dysplasia (syndactyly
type III) [Homo sapiens]
Ssc.9288.1.A1_at NM_020799 0.00000 20.8 associated molecule with the SH3
domain of STAM
Transcribed locus, strongly similar to
NP_065850.1 associated molecule with
the SH3 domain of STAM (AMSH)
like protein; associated molecule with
the SH3 domain of STAM (AMSH) -
Family Protein [Homo sapiens]
Ssc.4425.1.S1_at #N/A 0.00022 19.28 #N/A Transcribed locus
Ssc.29867.1.A1_at NM_001001557 0.00000 19.09 growth differentiation factor 6 Transcribed locus
Ssc.27300.2.A1_a_at NM_001001557 0.00000 19.03 growth differentiation factor 6 Transcribed locus
Ssc.9991.1.S1_at NM_198966 0.00085 16.87 parathyroid hormone-like hormone parathyroid hormone-like hormone PTHLH
Ssc.7588.1.A1_at #N/A 0.00003 15.91 #N/A Transcribed locus
Ssc.23994.1.A1_at #N/A 0.00099 15.56 #N/A Transcribed locus
Ssc.7314.1.A1_at NM_000963 0.00045 14.81 prostaglandin-endoperoxide
synthase 2
prostaglandin G/H synthase-2 PGHS-2
199
Ssc.4004.1.A1_at NM_015180 0.00000 11.34 spectrin repeat containing; nuclear
envelope 2
Transcribed locus, moderately similar
to NP_055995.3 synaptic nuclei
expressed gene 2 isoform a; nesprin 2;
synaptic nuclei expressed gene 2;
nucleus and actin connecting element
[Homo sapiens]
Ssc.455.1.S1_at NM_001623 0.00023 10.87 allograft inflammatory factor 1 allograft inflammatory factor-1 AIF1
Ssc.12561.1.A1_at NM_005504 0.00003 10.29 branched chain aminotransferase 1;
cytosolic
Transcribed locus
Ssc.23271.1.S1_at #N/A 0.00013 8.77 #N/A Transcribed locus
Ssc.6969.1.A1_at NM_017440 0.00001 7.88 Mdm4; transformed 3T3 cell double
minute 1; p53 binding pr
Transcribed locus, strongly similar to
XP_509206.1 PREDICTED: similar to
nuclear protein double minute 1 [Pan
troglodytes]
Ssc.24509.1.A1_at NM_014211 0.00028 7.81 gamma-aminobutyric acid Transcribed locus
Ssc.18004.1.A1_at #N/A 0.00003 7.75 #N/A Transcribed locus
Ssc.27388.1.S1_at NM_020128 0.00008 7.71 Mdm4; transformed 3T3 cell double
minute 1; p53 binding pro
Transcribed locus, moderately similar
to NP_059136.1 nuclear protein double
minute 1 [Homo sapiens]
Ssc.16475.1.S1_at NM_003489 0.00002 7.55 nuclear receptor interacting protein
1
Transcribed locus
Ssc.27508.1.A1_at NM_015265 0.00071 7.46 SATB family member 2 Transcribed locus
Ssc.9586.2.S1_at NM_004657 0.00007 7.28 serum deprivation response Transcribed locus
Ssc.30064.1.A1_at #N/A 0.00000 7.21 #N/A Transcribed locus
Ssc.19413.1.A1_at NM_003107 0.00078 6.89 SRY Transcribed locus
Ssc.12565.1.A1_at NM_005504 0.00026 6.42 branched chain aminotransferase 1;
cytosolic
Transcribed locus, strongly similar to
NP_005495.2 branched chain
aminotransferase 1, cytosolic [Homo
sapiens]
Ssc.15335.1.S1_at #N/A 0.00010 6.14 #N/A Transcribed locus
Ssc.22876.1.S1_at NM_015864 0.00030 6.1 chromosome 6 open reading frame
32
Transcribed locus, strongly similar to
XP_518275.1 PREDICTED: similar to
chromosome 6 open reading frame 32
[Pan troglodytes]
200
Ssc.13665.1.A1_at NM_006089 0.00018 5.97 sex comb on midleg-like 2 Transcribed locus, strongly similar to
XP_528899.1 PREDICTED: sex comb
on midleg-like 2 [Pan troglodytes]
Ssc.19360.1.S1_at NM_020379 0.00001 5.94 mannosidase; alpha; class 1C;
member 1
Transcribed locus, strongly similar to
NP_065112.1 mannosidase, alpha,
class 1C, member 1; 1,2-alpha-
mannosidase IC; Mannosyl-
oligosaccharide 1,2-alpha-mannosidase
IC; Processing alpha-1,2-mannosidase
IC
Ssc.27738.1.S1_at NM_015265 0.00011 5.92 SATB family member 2 Transcribed locus
Ssc.21647.1.A1_at NM_018131 0.00000 5.9 chromosome 10 open reading frame
3
Transcribed locus
Ssc.7399.1.A1_at #N/A 0.00009 5.83 #N/A Transcribed locus
Ssc.27407.1.A1_at NM_003489 0.00006 5.81 nuclear receptor interacting protein
1
Transcribed locus
Ssc.11757.1.S1_at NM_001003688 0.00005 5.34 SMAD; mothers against DPP
homolog 1
mothers against decapentaplegic
homolog 1
MADH1
Ssc.29811.1.A1_at NM_147150 0.00058 5.32 PALM2-AKAP2 protein Transcribed locus
Ssc.23944.1.A1_at #N/A 0.00012 4.88 #N/A Transcribed locus
Ssc.14340.3.S1_at NM_004862 0.00033 4.81 lipopolysaccharide-induced TNF
factor
Transcribed locus, strongly similar to
XP_547124.1 PREDICTED: similar to
TBX1 protein [Canis familiaris]
Ssc.14126.1.A1_at #N/A 0.00025 4.8 #N/A Transcribed locus
Ssc.5165.1.S1_at #N/A 0.00010 4.72 #N/A Transcribed locus
Ssc.21328.1.S1_at NM_018050 0.00006 4.7 MANSC domain containing 1 Transcribed locus, weakly similar to
NP_060520.2 MANSC domain
containing 1 [Homo sapiens]
Ssc.13284.1.A1_at NM_001010927 0.00094 4.67 T-cell lymphoma invasion and
metastasis 2
Transcribed locus, strongly similar to
XP_541162.1 PREDICTED:
hypothetical protein XP_541162 [Canis
familiaris]
Ssc.17206.1.A1_at NM_133367 0.00073 4.67 progestin and adipoQ receptor
family member VIII
Transcribed locus
Ssc.9063.1.A1_at #N/A 0.00004 4.57 #N/A Transcribed locus
201
Ssc.25773.1.S1_at NM_133265 0.00014 4.41 angiomotin Transcribed locus
Ssc.26944.1.S1_at #N/A 0.00007 4.41 #N/A Transcribed locus
Ssc.4093.1.A1_at NM_000619 0.00033 4.26 interferon; gamma interferon gamma IFNG
Ssc.10328.1.A1_at NM_001010000 0.00020 4.21 Rho GTPase activating protein 28 Transcribed locus
Ssc.5016.1.A1_at #N/A 0.00001 4.2 #N/A Transcribed locus
Ssc.29855.1.A1_at NM_031942 0.00026 4.15 cell division cycle associated 7 Transcribed locus
Ssc.11197.1.S1_at NM_001540 0.00002 4.14 heat shock 27kDa protein 1 Heat shock 27kDa protein 1 Hsp27
Ssc.14400.1.A1_at NM_147156 0.00023 3.99 transmembrane protein 23 Transcribed locus
Ssc.10319.1.A1_at NM_023016 0.00021 3.95 chromosome 2 open reading frame
26
Transcribed locus
Ssc.20258.1.S1_at #N/A 0.00084 3.92 #N/A Transcribed locus
Ssc.6357.1.S1_at NM_002245 0.00048 3.86 potassium channel; subfamily K;
member 1
Transcribed locus, strongly similar to
NP_067720.1 potassium channel,
subfamily K, member 1 [Rattus
norvegicus]
Ssc.15740.1.S2_at NM_003376 0.00053 3.85 vascular endothelial growth factor vascular endothelial growth factor VEGFA
Ssc.383.1.S1_at NM_139212 0.00016 3.85 homeodomain-only protein odd homeobox 1 protein OB1
Ssc.14419.1.S1_at XM_376652 0.00019 3.78 distal-less homeo box 6 Transcribed locus
Ssc.15740.2.S1_a_at NM_003376 0.00015 3.68 vascular endothelial growth factor vascular endothelial growth factor VEGFA
Ssc.3853.1.S1_at NM_004816 0.00009 3.64 chromosome 9 open reading frame
61
Transcribed locus, strongly similar to
XP_520063.1 PREDICTED: similar to
chromosome 9 open reading frame 61;
Friedreich ataxia region gene X123
[Pan troglodytes]
Ssc.13805.1.S1_at NM_133265 0.00032 3.56 angiomotin Transcribed locus
Ssc.4900.2.S1_at NM_016441 0.00001 3.53 cysteine-rich motor neuron 1 Transcribed locus
Ssc.847.1.S1_at NM_006286 0.00003 3.49 transcription factor Dp-2 Transcribed locus, strongly similar to
XP_516790.1 PREDICTED: similar to
Transcription factor Dp-2 (E2F
dimerization partner 2) [Pan
troglodytes]
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Ssc.27454.3.S1_a_at NM_004044 0.00003 3.39 5-aminoimidazole-4-carboxamide
ribonucleotide formyltransf
Transcribed locus, strongly similar to
XP_545634.1 PREDICTED: similar to
5-aminoimidazole-4-carboxamide
ribonucleotide formyltransferase/IMP
cyclohydrolase [Canis familiaris]
Ssc.27454.2.S1_at NM_004044 0.00007 3.36 5-aminoimidazole-4-carboxamide
ribonucleotide formyltransf
Transcribed locus, strongly similar to
XP_545634.1 PREDICTED: similar to
5-aminoimidazole-4-carboxamide
ribonucleotide formyltransferase/IMP
cyclohydrolase [Canis familiaris]
Ssc.26446.2.S1_a_at NM_015143 0.00051 3.26 methionyl aminopeptidase 1 Transcribed locus, strongly similar to
NP_780433.1 methionyl
aminopeptidase 1 [Mus musculus]
Ssc.5605.1.A1_at NM_002222 0.00039 3.21 inositol 1;4;5-triphosphate receptor;
type 1
Transcribed locus
Ssc.18546.1.S1_at NM_016441 0.00008 3.1 cysteine-rich motor neuron 1 Transcribed locus, strongly similar to
XP_532931.1 PREDICTED:
hypothetical protein XP_532931 [Canis
familiaris]
Ssc.1696.1.A1_at NM_001004417 0.00013 3.07 formin-like 2 Transcribed locus, moderately similar
to NP_035841.1 formin-like 3 protein;
WW domain binding protein 3 [Mus
musculus]
Ssc.9321.1.S1_at NM_025078 0.00051 3.04 PQ loop repeat containing 1 Transcribed locus
Ssc.28645.1.A1_at NM_003045 0.00004 3.03 solute carrier family 7 cationic amino acid transporter-1 SLC7A1
Ssc.3088.1.S1_at #N/A 0.00052 3.03 #N/A Transcribed locus
Ssc.30743.1.S1_at NM_145753 0.00040 3 pleckstrin homology-like domain;
family B; member 2
Transcribed locus, strongly similar to
NP_700461.1 pleckstrin homology-like
domain, family B, member 2 [Mus
musculus]
Ssc.23921.1.S1_at #N/A 0.00011 2.99 #N/A Transcribed locus
Ssc.23922.1.A1_at NM_018169 0.00085 2.97 hypothetical protein FLJ10652 Transcribed locus, weakly similar to
XP_534845.1 PREDICTED: similar to
Bicaudal D homolog 1 isoform 1
[Canis familiaris]
Ssc.5039.2.S1_at NM_178568 0.00025 2.94 reticulon 4 receptor-like 1 Transcribed locus
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Ssc.4676.1.A1_at NM_018211 0.00049 2.86 hypothetical protein FLJ10770 Transcribed locus
Ssc.29842.1.A1_at #N/A 0.00075 2.85 #N/A Glycerol-3-phosphate dehydrogenase MGPD
Ssc.4214.1.A1_at #N/A 0.00027 2.85 #N/A Transcribed locus
Ssc.8027.1.A1_at NM_001018057 0.00009 2.82 dickkopf homolog 3 Transcribed locus, moderately similar
to XP_534060.1 PREDICTED: similar
to Dickkopf related protein-3 precursor
(Dkk-3) (Dickkopf-3) (hDkk-3)
(UNQ258/PRO295) [Canis familiaris]
Ssc.13553.1.A1_at #N/A 0.00015 2.81 #N/A Transcribed locus, moderately similar
to NP_112298.1 guanine nucleotide
binding protein, alpha q polypeptide
[Rattus norvegicus]
Ssc.2864.1.S1_at NM_006094 0.00014 2.76 deleted in liver cancer 1 Transcribed locus
Ssc.29596.1.A1_at #N/A 0.00000 2.75 #N/A Transcribed locus, strongly similar to
NP_659491.2 hypothetical protein
LOC146845 [Homo sapiens]
Ssc.1850.1.A1_at NM_022343 0.00092 2.73 chromosome 9 open reading frame
19
Clone Clu_25395.scr.msk.p1.Contig1,
mRNA sequence
Ssc.27520.1.A1_at XM_086186 0.00001 2.72 hypothetical protein FLJ13815 Transcribed locus, moderately similar
to XP_547305.1 PREDICTED: similar
to hypothetical protein FLJ13511
[Canis familiaris]
Ssc.25948.1.S1_at #N/A 0.00090 2.69 #N/A Transcribed locus
Ssc.22297.1.S1_at #N/A 0.00059 2.68 #N/A Transcribed locus
Ssc.6418.1.S1_at #N/A 0.00055 2.68 #N/A Transcribed locus, strongly similar to
XP_534557.1 PREDICTED: similar to
FDFT1 protein [Canis familiaris]
Ssc.27995.1.A1_at NM_013282 0.00005 2.67 ubiquitin-like; containing PHD and
RING finger domains; 1
Transcribed locus
Ssc.5039.1.A1_at NM_178568 0.00001 2.64 reticulon 4 receptor-like 1 Transcribed locus
Ssc.30400.1.A1_at #N/A 0.00087 2.63 #N/A Transcribed locus
Ssc.8528.1.A1_at #N/A 0.00001 2.63 #N/A Transcribed locus
Ssc.1849.1.A1_at #N/A 0.00004 2.61 #N/A Clone Clu_29461.scr.msk.p1.Contig2,
mRNA sequence
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Ssc.24421.1.S1_at NM_018169 0.00043 2.6 hypothetical protein FLJ10652 Transcribed locus, weakly similar to
XP_132966.3 RIKEN cDNA
2810474O19 [Mus musculus]
Ssc.6034.1.S1_at NM_033102 0.00000 2.58 prostate cancer associated protein 6 Transcribed locus, strongly similar to
NP_149093.1 prostein protein [Homo
sapiens]
Ssc.19005.1.A1_at NM_015009 0.00043 2.57 PDZ domain containing RING
finger 3
Transcribed locus, strongly similar to
XP_041363.10 PREDICTED: PDZ
domain containing RING finger 3
[Homo sapiens]
Ssc.7554.1.S1_at NM_013242 0.00001 2.56 gene trap locus 3 Clone Clu_6033.scr.msk.p1.Contig1,
mRNA sequence
Ssc.8774.2.A1_at NM_006745 0.00021 2.54 sterol-C4-methyl oxidase-like Sterol-C4-methyl oxidase-like protein SC4MOL
Ssc.21617.1.A1_at #N/A 0.00006 2.53 #N/A Transcribed locus
Ssc.17512.1.S1_at #N/A 0.00052 2.52 #N/A Transcribed locus
Ssc.14376.1.A1_at #N/A 0.00060 2.5 #N/A Transcribed locus
Ssc.7839.1.A1_at NM_012307 0.00004 2.49 erythrocyte membrane protein band
4.1-like 3
Transcribed locus
Ssc.24556.1.S1_at NM_025181 0.00000 2.49 solute carrier family 35; member F5 Transcribed locus, strongly similar to
NP_079457.2 solute carrier family 35,
member F5 [Homo sapiens]
Ssc.1116.1.S1_at NM_001304 0.00001 2.48 carboxypeptidase D Transcribed locus
Ssc.8084.1.S1_at NM_006094 0.00050 2.48 deleted in liver cancer 1 Transcribed locus, strongly similar to
XP_532822.1 PREDICTED:
hypothetical protein XP_532822 [Canis
familiaris]
Ssc.7881.1.A1_at NM_145753 0.00064 2.48 pleckstrin homology-like domain;
family B; member 2
Transcribed locus
Ssc.24556.2.S1_a_at NM_025181 0.00070 2.47 solute carrier family 35; member F5 Transcribed locus, strongly similar to
NP_079457.2 solute carrier family 35,
member F5 [Homo sapiens]
Ssc.19008.1.A1_at #N/A 0.00037 2.47 #N/A Transcribed locus
Ssc.5287.1.S1_at #N/A 0.00029 2.47 #N/A Transcribed locus
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Ssc.6670.2.S1_at NM_012319 0.00081 2.46 solute carrier family 39 Transcribed locus, strongly similar to
NP_631882.1 solute carrier family 39
(metal ion transporter), member 6;
endoplasmic reticulum membrane
protein [Mus musculus]
Ssc.21060.1.A1_at NM_014498 0.00015 2.46 golgi phosphoprotein 4 Transcribed locus, strongly similar to
XP_516862.1 PREDICTED: similar to
golgi phosphoprotein 4; type II Golgi
membrane protein; 130 kDa golgi-
localized phosphoprotein; cis Golgi-
localized calcium-binding protein [Pan
troglodytes]
Ssc.25282.1.S1_at NM_001018009 0.00058 2.45 SH3-domain binding protein 5 Transcribed locus
Ssc.25195.1.A1_at #N/A 0.00022 2.45 #N/A Transcribed locus
Ssc.23488.1.S1_at NM_000637 0.00003 2.44 glutathione reductase glutathione reductase GSR
Ssc.7517.1.A1_at NM_024680 0.00008 2.43 likely ortholog of mouse E2F
transcription factor 8
Transcribed locus, moderately similar
to XP_508325.1 PREDICTED: similar
to FLJ23311 protein [Pan troglodytes]
Ssc.16621.1.S1_at NM_004170 0.00042 2.42 solute carrier family 1 high-affinity glutamate transporter
EAAC1
SLC1A1
Ssc.4900.1.A1_at NM_016441 0.00006 2.42 cysteine-rich motor neuron 1 Transcribed locus
Ssc.24444.1.A1_at NM_004816 0.00082 2.41 chromosome 9 open reading frame
61
Transcribed locus, strongly similar to
XP_355152.2 similar to chromosome 9
open reading frame 61; Friedreich
ataxia region gene X123 [Mus
musculus]
Ssc.16259.1.S1_at NM_002069 0.00034 2.4 guanine nucleotide binding protein Gi-alpha-1 protein GNAI1
Ssc.21179.1.S1_at #N/A 0.00036 2.4 #N/A Transcribed locus
Ssc.25289.1.S1_at NM_001259 0.00085 2.39 cyclin-dependent kinase 6 Transcribed locus
Ssc.23207.1.S1_at NM_007212 0.00079 2.38 ring finger protein 2 Clone Clu_5595.scr.msk.p1.Contig1,
mRNA sequence
Ssc.11796.1.S1_at NM_031934 0.00075 2.37 RAB34; member RAS oncogene
family
Clone Clu_91425.scr.msk.p1.Contig1,
mRNA sequence
Ssc.1205.1.S1_at #N/A 0.00002 2.37 #N/A Transcribed locus
Ssc.16693.1.S1_at NM_012106 0.00077 2.36 ADP-ribosylation factor-like 2 Clone Clu_6027.scr.msk.p1.Contig1,
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binding protein mRNA sequence
Ssc.1084.1.S1_at NM_016472 0.00009 2.36 chromosome 14 open reading frame
129
Transcribed locus
Ssc.24344.1.S1_at NM_001379 0.00006 2.35 DNA
Ssc.26386.2.S1_a_at NM_016101 0.00049 2.35 comparative gene identification
transcript 37
PUA protein LOC5951
07
Ssc.11797.1.A1_at NM_145804 0.00012 2.34 ankyrin repeat and BTB Transcribed locus
Ssc.7771.1.A1_at XM_034274 0.00021 2.34 v-myb myeloblastosis viral
oncogene homolog
Transcribed locus
Ssc.12845.1.S1_at NM_001259 0.00056 2.33 cyclin-dependent kinase 6 Transcribed locus
Ssc.7066.1.S1_at NM_020774 0.00023 2.33 mindbomb homolog 1 Transcribed locus
Ssc.25963.1.A1_at #N/A 0.00045 2.33 #N/A Transcribed locus
Ssc.25198.1.A1_at NM_000274 0.00029 2.32 ornithine aminotransferase Transcribed locus, strongly similar to
XP_508094.1 PREDICTED: ornithine
aminotransferase [Pan troglodytes]
Ssc.24679.1.S1_at NM_020774 0.00027 2.32 mindbomb homolog 1 Transcribed locus
Ssc.2099.1.S1_at NM_138555 0.00033 2.32 kinesin family member 23 Transcribed locus, strongly similar to
XP_535528.1 PREDICTED: similar to
kinesin family member 23 isoform 1
[Canis familiaris]
Ssc.27249.1.S1_at NM_005221 0.00011 2.31 distal-less homeo box 5 Transcribed locus, strongly similar to
XP_539430.1 PREDICTED: similar to
Homeobox protein DLX-5 [Canis
familiaris]
Ssc.19326.1.A1_at NM_016343 0.00042 2.29 centromere protein F; 350400ka Transcribed locus, moderately similar
to NP_057427.2 centromere protein F
(350/400kD); centromere protein F
(350/400kD, mitosin); mitosin; CENP-
F kinetochore protein; AH antigen;
cell-cycle-dependent 350K nuclear
protein [Homo sapiens]
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Ssc.20740.1.S1_at #N/A 0.00090 2.28 #N/A Transcribed locus, weakly similar to
XP_548196.1 PREDICTED: similar to
Neurabin-II (Neural tissue-specific F-
actin binding protein II) (Protein
phosphatase 1 regulatory subunit 9B)
(Spinophilin) (p130) (PP1bp134)
[Canis familiaris]
Ssc.2056.1.S1_at NM_022343 0.00001 2.27 chromosome 9 open reading frame
19
Clone Clu_25395.scr.msk.p1.Contig1,
mRNA sequence
Ssc.25441.2.S1_at NM_018169 0.00052 2.25 hypothetical protein FLJ10652 Transcribed locus, moderately similar
to NP_060639.1 hypothetical protein
FLJ10652 [Homo sapiens]
Ssc.10906.1.A1_at #N/A 0.00011 2.23 #N/A Transcribed locus
Ssc.21326.1.S1_at #N/A 0.00017 2.23 #N/A Transcribed locus
Ssc.27454.1.S1_at NM_004044 0.00061 2.22 5-aminoimidazole-4-carboxamide
ribonucleotide formyltransf
Transcribed locus, strongly similar to
XP_545634.1 PREDICTED: similar to
5-aminoimidazole-4-carboxamide
ribonucleotide formyltransferase/IMP
cyclohydrolase [Canis familiaris]
Ssc.7554.2.S1_at NM_013242 0.00004 2.22 gene trap locus 3 Clone Clu_6033.scr.msk.p1.Contig1,
mRNA sequence
Ssc.5082.1.A1_at #N/A 0.00093 2.22 #N/A Transcribed locus, weakly similar to
XP_537924.1 PREDICTED:
hypothetical protein XP_537924 [Canis
familiaris]
Ssc.27311.1.S1_at #N/A 0.00032 2.21 #N/A Transcribed locus
Ssc.30686.1.S1_at #N/A 0.00020 2.21 #N/A Transcribed locus
Ssc.18038.1.A1_at NM_005204 0.00012 2.19 mitogen-activated protein kinase
kinase kinase 8
Transcribed locus, strongly similar to
NP_005195.2 mitogen-activated
protein kinase kinase kinase 8; Cancer
Osaka thyroid oncogene; cot (cancer
Osaka thyroid) oncogene; Ewing
sarcoma transformant; proto-oncogene
serine/threoine protein kinase; tumor
progression locus-2 [Homo sapiens]
Ssc.15592.1.S1_at NM_020190 0.00071 2.19 olfactomedin-like 3 Clone Clu_2389.scr.msk.p1.Contig3,
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mRNA sequence
Ssc.19350.1.S1_at NM_016545 0.00032 2.18 immediate early response 5 Transcribed locus, strongly similar to
NP_057629.1 immediate early response
5 [Homo sapiens]
Ssc.19150.1.S1_at NM_197966 0.00095 2.18 BH3 interacting domain death
agonist
BH3 interacting domain death agonist BID
Ssc.27533.1.A1_at NM_022473 0.00067 2.16 zinc finger protein 106 homolog Transcribed locus, strongly similar to
NP_071918.1 zinc finger protein 106
homolog; zinc finger protein 106
homolog (mouse) [Homo sapiens]
Ssc.25405.1.S1_at NM_145119 0.00007 2.16 praja 1 Transcribed locus
Ssc.15912.1.A1_at NM_000165 0.00043 2.15 gap junction protein; alpha 1;
43kDa
connexin 43 CX43
Ssc.26446.1.S1_at NM_015143 0.00048 2.14 methionyl aminopeptidase 1 Transcribed locus, strongly similar to
NP_780433.1 methionyl
aminopeptidase 1 [Mus musculus]
Ssc.5073.1.A1_at NM_004456 0.00004 2.12 enhancer of zeste homolog 2 Transcribed locus, strongly similar to
NP_031996.1 enhancer of zeste
homolog 1 [Mus musculus]
Ssc.19290.2.A1_at #N/A 0.00017 2.1 #N/A Transcribed locus
Ssc.11694.1.S1_at NM_002166 0.00077 2.07 inhibitor of DNA binding 2;
dominant negative helix-loop-h
Clone rcad07b_d12.y1.abd, mRNA
sequence
Ssc.19011.1.S1_at NM_003983 0.00009 2.07 solute carrier family 7 Transcribed locus
Ssc.6238.3.S1_at NM_016282 0.00017 2.07 adenylate kinase 3 Clone Clu_26689.scr.msk.p1.Contig1,
mRNA sequence
Ssc.27842.1.S1_at NM_017746 0.00003 2.07 testis expressed sequence 10 Transcribed locus, strongly similar to
XP_532012.1 PREDICTED: similar to
nbla10363 [Canis familiaris]
Ssc.31097.1.A1_at NM_020774 0.00000 2.07 mindbomb homolog 1 Transcribed locus
Ssc.8582.1.S1_at NM_031307 0.00000 2.06 pseudouridylate synthase 3 Transcribed locus, moderately similar
to XP_536533.1 PREDICTED: similar
to pseudouridylate synthase 3 [Canis
familiaris]
Ssc.7570.2.S1_at NM_004170 0.00006 2.05 solute carrier family 1 Transcribed locus
Ssc.21965.1.S1_at NM_138285 0.00001 2.05 nucleoporin 35kDa Clone Clu_5208.scr.msk.p1.Contig1,
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mRNA sequence
SscAffx.8.1.S1_s_at NM_002467 0.00064 2.03 v-myc myelocytomatosis viral
oncogene homolog
c-myc proto-oncogene MYC
Ssc.13743.1.S1_at NM_016472 0.00068 2.03 chromosome 14 open reading frame
129
Transcribed locus
Ssc.20404.1.S1_at NM_001618 0.00027 2.02 poly Transcribed locus, strongly similar to
XP_547506.1 PREDICTED: similar to
Poly [ADP-ribose] polymerase-1
(PARP-1) (ADPRT) (NAD(+) ADP-
ribosyltransferase-1) (Poly[ADP-
ribose] synthetase-1) [Canis familiaris]
Ssc.26271.2.S1_at NM_006824 0.00022 2.02 EBNA1 binding protein 2 Transcribed locus, strongly similar to
NP_006815.1 EBNA1 binding protein
2; nucleolar protein p40; homolog of
yeast EBNA1-binding protein; nuclear
FGF3 binding protein; EBNA1-binding
protein 2 [Homo sapiens]
Ssc.18850.1.S1_at NM_016548 0.00013 2.02 golgi phosphoprotein 2 Transcribed locus, strongly similar to
XP_533506.1 PREDICTED: similar to
golgi phosphoprotein 2 [Canis
familiaris]
Ssc.19249.2.S1_a_at NM_017832 0.00047 2.01 hypothetical protein FLJ20457 Transcribed locus, moderately similar
to XP_532026.1 PREDICTED: similar
to hypothetical protein FLJ20457
[Canis familiaris]
Ssc.26771.1.S1_at #N/A 0.00006 2.01 #N/A Transcribed locus
Ssc.8475.1.A1_at #N/A 0.00004 2.01 #N/A Transcribed locus
Ssc.21987.2.S1_at NM_001550 0.00098 2 interferon-related developmental
regulator 1
interferon-related developmental
regulator 1
IFRD1
Ssc.19318.1.S1_at #N/A 0.00038 2 #N/A Transcribed locus
Ssc.12430.3.S1_at NM_002744 0.00079 -2 protein kinase C; zeta Transcribed locus, strongly similar to
NP_002735.2 protein kinase C, zeta
[Homo sapiens]
210
Ssc.28182.1.A1_at NM_006301 0.00075 -2 mitogen-activated protein kinase
kinase kinase 12
Transcribed locus, weakly similar to
NP_006292.2 mitogen-activated
protein kinase kinase kinase 12; leucine
zipper protein kinase; zipper protein
kinase; protein kinase MUK; dual
leucine zipper kinase DLK [Homo
sapiens]
Ssc.1624.1.S1_at NM_006369 0.00007 -2 leucine rich repeat containing 41 Transcribed locus, strongly similar to
NP_006360.3 MUF1 protein; likely
ortholog of mouse MUF1; elongin BC-
interacting leucine-rich repeat protein
[Homo sapiens]
Ssc.20226.1.S1_at NM_015528 0.00003 -2 ring finger protein 167 Transcribed locus, strongly similar to
NP_056343.1 ring finger protein 167
[Homo sapiens]
Ssc.12114.1.S1_a_at NM_005186 0.00080 -2.01 calpain 1; micromolar calcium-activated neutral
protease 1 isoform B
CAPN1
Ssc.12402.1.A1_at #N/A 0.00003 -2.01 #N/A Transcribed locus
Ssc.21963.1.S1_at NM_004295 0.00011 -2.02 TNF receptor-associated factor 4 Transcribed locus, strongly similar to
NP_004286.2 TNF receptor-associated
factor 4 isoform 1; tumor necrosis
receptor-associated factor 4A;
malignant 62; cysteine-rich domain
associated with ring and TRAF domain
[Homo sapiens]
Ssc.1323.1.A1_at NM_005578 0.00089 -2.02 LIM domain containing preferred
translocation partner in l
Transcribed locus
Ssc.8501.2.A1_at NM_006407 0.00006 -2.02 ADP-ribosylation-like factor 6
interacting protein 5
PRA1 family protein-like protein
Ssc.29845.1.A1_at NM_022087 0.00048 -2.02 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgal
Transcribed locus, strongly similar to
XP_539924.1 PREDICTED: similar to
N-acetylgalactosaminyltransferase;
similar to Q10473 (PID:g1709559)
[Canis familiaris]
Ssc.8213.2.A1_at NM_024613 0.00097 -2.02 pleckstrin homology domain
containing; family F
Transcribed locus
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Ssc.25450.1.S1_at #N/A 0.00099 -2.02 #N/A Transcribed locus
Ssc.25748.1.S1_at NM_004504 0.00001 -2.03 HIV-1 Rev binding protein Transcribed locus
Ssc.27214.2.S1_at NM_004924 0.00018 -2.03 actinin; alpha 4 Transcribed locus, strongly similar to
NP_004915.2 actinin, alpha 4 [Homo
sapiens]
Ssc.21456.1.S1_at NM_014584 0.00016 -2.03 ERO1-like Transcribed locus, strongly similar to
NP_055399.1 ERO1-like; ERO1 (S.
cerevisiae)-like [Homo sapiens]
Ssc.11338.1.S1_a_at NM_016417 0.00004 -2.03 chromosome 14 open reading frame
87
Clone Clu_43784.scr.msk.p1.Contig1,
mRNA sequence
Ssc.10155.1.S1_at NM_017634 0.00012 -2.03 potassium channel tetramerisation
domain containing 9
Transcribed locus, strongly similar to
NP_060104.2 potassium channel
tetramerisation domain containing 9
[Homo sapiens]
Ssc.15594.2.S1_at #N/A 0.00007 -2.03 #N/A Clone rcut39_i19.y1.abd, mRNA
sequence
Ssc.13508.1.A1_at NM_016048 0.00034 -2.04 isochorismatase domain containing
1
Clone Clu_9851.scr.msk.p1.Contig2,
mRNA sequence
Ssc.18476.2.S1_a_at NM_033389 0.00087 -2.04 slingshot homolog 2 Transcribed locus
Ssc.7608.2.S1_at NM_018184 0.00013 -2.05 ADP-ribosylation factor-like 10C Clone Clu_1719.scr.msk.p1.Contig3,
mRNA sequence
Ssc.3574.1.A1_at NM_145687 0.00003 -2.05 mitogen-activated protein kinase
kinase kinase kinase 4
Transcribed locus
Ssc.27168.1.S1_at #N/A 0.00012 -2.05 #N/A Transcribed locus
Ssc.17250.1.S1_at NM_000320 0.00075 -2.07 quinoid dihydropteridine reductase quinoid dihydropteridine reductase QDPR
Ssc.5353.2.S1_at NM_016598 0.00003 -2.07 zinc finger; DHHC-type containing
3
Transcribed locus, strongly similar to
XP_533859.1 PREDICTED: similar to
ZDHHC3 protein [Canis familiaris]
Ssc.23539.1.S1_at NM_152911 0.00021 -2.07 polyamine oxidase Transcribed locus, weakly similar to
XP_542910.1 PREDICTED: similar to
polyamine oxidase isoform 1 [Canis
familiaris]
Ssc.8444.1.S1_at XM_371706 0.00010 -2.07 hypothetical protein KIAA1109 Transcribed locus, strongly similar to
XP_371706.3 [Homo sapiens]
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Ssc.11910.1.S1_at NM_001981 0.00013 -2.08 epidermal growth factor receptor
pathway substrate 15
Transcribed locus, strongly similar to
NP_001972.1 epidermal growth factor
receptor pathway substrate 15 [Homo
sapiens]
Ssc.1657.1.S1_at NM_005688 0.00033 -2.08 ATP-binding cassette; sub-family C Transcribed locus
Ssc.2466.1.S1_at NM_014045 0.00044 -2.08 low density lipoprotein receptor-
related protein 10
Transcribed locus, strongly similar to
XP_537364.1 PREDICTED: similar to
low density lipoprotein receptor-related
protein 10 [Canis familiaris]
Ssc.26275.1.S1_at NM_015600 0.00001 -2.08 chromosome 20 open reading frame
22
Transcribed locus, strongly similar to
NP_056415.1 chromosome 20 open
reading frame 22 [Homo sapiens]
Ssc.5793.2.S1_at NM_014698 0.00005 -2.09 KIAA0792 Transcribed locus, strongly similar to
XP_375848.2 PREDICTED:
KIAA0792 gene product [Homo
sapiens]
Ssc.9284.1.S1_at NM_020728 0.00047 -2.09 family with sequence similarity 62 Transcribed locus, strongly similar to
XP_519490.1 PREDICTED: similar to
KIAA1228 protein [Pan troglodytes]
Ssc.10990.1.A1_at #N/A 0.00027 -2.09 #N/A Transcribed locus
Ssc.15594.3.S1_at #N/A 0.00001 -2.09 #N/A Clone rcut39_i19.y1.abd, mRNA
sequence
Ssc.4957.1.S1_at #N/A 0.00007 -2.09 #N/A Transcribed locus
Ssc.18096.1.A1_at NM_198353 0.00031 -2.1 potassium channel tetramerisation
domain containing 8
Transcribed locus
Ssc.6618.1.A1_at XM_290546 0.00014 -2.1 KIAA0830 protein Transcribed locus
Ssc.12099.1.A1_at #N/A 0.00002 -2.11 #N/A Clone Clu_607.scr.msk.p1.Contig1,
mRNA sequence
Ssc.5580.1.S1_at #N/A 0.00069 -2.11 #N/A Transcribed locus
Ssc.8355.1.A1_at NM_018330 0.00013 -2.12 KIAA1598 Transcribed locus
Ssc.6193.1.A1_at NM_130781 0.00013 -2.12 RAB24; member RAS oncogene
family
Clone Clu_22104.scr.msk.p1.Contig2,
mRNA sequence
Ssc.19024.1.A1_at NM_139182 0.00024 -2.12 centaurin; delta 1 Transcribed locus
Ssc.17293.1.A1_at NM_020940 0.00050 -2.13 KIAA1600 Transcribed locus
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Ssc.12826.2.A1_a_at NM_138463 0.00098 -2.13 hypothetical protein BC014072 Transcribed locus, moderately similar
to XP_511362.1 PREDICTED: similar
to hypothetical protein BC014072 [Pan
troglodytes]
Ssc.5257.1.S1_at NM_006577 0.00087 -2.16 UDP-GlcNAc:betaGal beta-1;3-N-
acetylglucosaminyltransferas
Transcribed locus
Ssc.16537.1.S1_at NM_007229 0.00018 -2.17 protein kinase C and casein kinase
substrate in neurons 2
Transcribed locus, strongly similar to
XP_525616.1 PREDICTED: protein
kinase C and casein kinase substrate in
neurons 2 [Pan troglodytes]
Ssc.2760.1.A1_at NM_018841 0.00085 -2.17 guanine nucleotide binding protein Transcribed locus
Ssc.9420.1.A1_at NM_201281 0.00000 -2.17 myotubularin related protein 2 Transcribed locus, strongly similar to
NP_057240.3 myotubularin-related
protein 2 isoform 1 [Homo sapiens]
Ssc.22732.1.S1_at #N/A 0.00079 -2.17 #N/A Transcribed locus
Ssc.2413.1.S1_at NM_000336 0.00006 -2.18 sodium channel; nonvoltage-gated
1; beta
Transcribed locus, strongly similar to
NP_000327.1 sodium channel,
nonvoltage-gated 1, beta [Homo
sapiens]
Ssc.21999.1.S1_a_at NM_000694 0.00000 -2.18 aldehyde dehydrogenase 3 family;
member B1
Transcribed locus, moderately similar
to XP_129134.2 RIKEN cDNA
C130048D07 [Mus musculus]
Ssc.17453.1.S1_at NM_001684 0.00032 -2.19 ATPase; Ca++ transporting; plasma
membrane 4
Transcribed locus
Ssc.8213.1.A1_at NM_024613 0.00044 -2.19 pleckstrin homology domain
containing; family F
Transcribed locus
Ssc.6615.1.S1_at #N/A 0.00056 -2.19 #N/A Transcribed locus
Ssc.55.1.S1_at NM_005228 0.00023 -2.2 epidermal growth factor receptor epidermal growth factor receptor EGFR
Ssc.26898.1.A1_at #N/A 0.00005 -2.2 #N/A Transcribed locus
Ssc.27147.1.A1_at NM_177532 0.00074 -2.21 Ras association Transcribed locus, moderately similar
to NP_958834.1 Ras association
(RalGDS/AF-6) domain family 6
isoform b; putative RAS binding
protein [Homo sapiens]
Ssc.5001.2.A1_at #N/A 0.00078 -2.21 #N/A Transcribed locus
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Ssc.27521.1.S1_at NM_020324 0.00047 -2.23 ATP-binding cassette; sub-family D Transcribed locus, strongly similar to
NP_005041.1 ATP-binding cassette,
sub-family D, member 4 isoform 1;
peroxisomal membrane protein 1-like
[Homo sapiens]
Ssc.28434.1.A1_at NM_025219 0.00024 -2.23 DnaJ Transcribed locus, strongly similar to
NP_079495.1 DnaJ (Hsp40) homolog,
subfamily C, member 5; cysteine string
protein [Homo sapiens]
Ssc.25022.1.A1_at #N/A 0.00003 -2.23 #N/A Transcribed locus
Ssc.8002.1.A1_at #N/A 0.00084 -2.23 #N/A Transcribed locus
Ssc.21905.1.S1_at #N/A 0.00060 -2.25 #N/A Transcribed locus
Ssc.12634.1.S1_at NM_014320 0.00017 -2.26 heme binding protein 2 Clone Clu_24795.scr.msk.p1.Contig2,
mRNA sequence
Ssc.10917.1.A1_at NM_181354 0.00065 -2.26 oxidation resistance 1 Transcribed locus
Ssc.17918.1.A1_at #N/A 0.00002 -2.26 #N/A Transcribed locus
Ssc.18606.2.A1_at #N/A 0.00034 -2.26 #N/A Transcribed locus
Ssc.779.1.S1_at NM_004433 0.00019 -2.27 E74-like factor 3 Transcribed locus, strongly similar to
XP_547356.1 PREDICTED: similar to
E74-like factor 3 (ets domain
transcription factor, epithelial-specific )
[Canis familiaris]
Ssc.24739.1.A1_at #N/A 0.00024 -2.27 #N/A Transcribed locus
Ssc.14180.1.A1_at NM_015458 0.00009 -2.28 myotubularin related protein 9 Transcribed locus
Ssc.6738.1.S1_at NM_032622 0.00013 -2.28 ligand of numb-protein X Transcribed locus, strongly similar to
XP_532373.1 PREDICTED: similar to
ligand of numb-protein X 1 [Canis
familiaris]
Ssc.19359.2.S1_at #N/A 0.00001 -2.28 #N/A Transcribed locus
Ssc.8061.1.A1_at #N/A 0.00011 -2.28 #N/A Transcribed locus
Ssc.27912.1.S1_at NM_020747 0.00001 -2.29 zinc finger protein 608 Transcribed locus, strongly similar to
XP_114432.3 PREDICTED: zinc
finger protein 608 [Homo sapiens]
Ssc.13318.1.A1_at #N/A 0.00055 -2.29 #N/A Transcribed locus
Ssc.28427.1.A1_at #N/A 0.00020 -2.29 #N/A Transcribed locus
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Ssc.22078.1.A1_at NM_003561 0.00034 -2.3 phospholipase A2; group X Transcribed locus, moderately similar
to NP_003552.1 phospholipase A2,
group X [Homo sapiens]
Ssc.19622.1.A1_at NM_007183 0.00000 -2.3 plakophilin 3 Transcribed locus, moderately similar
to XP_420926.1 PREDICTED: similar
to plakophilin-3 [Gallus gallus]
Ssc.23305.1.S1_at NM_018342 0.00084 -2.3 hypothetical protein FLJ11155 Transcribed locus
Ssc.3578.1.S1_at NM_020533 0.00002 -2.3 mucolipin 1 Transcribed locus, strongly similar to
NP_065394.1 mucolipin 1; mucolipidin
[Homo sapiens]
Ssc.9792.1.S1_at NM_020940 0.00005 -2.3 KIAA1600 Voltage-dependent anion channel 2 VDAC2
Ssc.1957.1.A1_at NM_000259 0.00023 -2.31 myosin VA Transcribed locus, strongly similar to
XP_510412.1 PREDICTED: similar to
myosin I heavy chain isoform [Pan
troglodytes]
Ssc.9918.1.A1_at NM_004504 0.00007 -2.32 HIV-1 Rev binding protein Transcribed locus, strongly similar to
NP_034602.1 HIV-1 Rev binding
protein [Mus musculus]
Ssc.28933.1.S1_at #N/A 0.00035 -2.32 #N/A Transcribed locus
Ssc.5432.1.A1_at #N/A 0.00032 -2.32 #N/A Transcribed locus
Ssc.5458.1.S1_at NM_015913 0.00039 -2.33 thioredoxin domain containing 12 Transcribed locus, strongly similar to
NP_056997.1 endoplasmic reticulum
thioredoxin superfamily member, 18
kDa; thioredoxin-like protein p19
[Homo sapiens]
Ssc.30212.1.A1_at #N/A 0.00035 -2.33 #N/A Transcribed locus
Ssc.3980.1.A1_at NM_014936 0.00014 -2.34 ectonucleotide
pyrophosphatasephosphodiesterase
4
Transcribed locus
Ssc.14164.1.A1_at #N/A 0.00002 -2.34 #N/A Transcribed locus
Ssc.21915.3.A1_at #N/A 0.00044 -2.34 #N/A Transcribed locus
Ssc.5158.1.S1_at NM_024819 0.00033 -2.35 hypothetical protein FLJ22955 Transcribed locus
Ssc.9953.1.A1_at #N/A 0.00081 -2.36 #N/A Transcribed locus
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Ssc.15316.1.S1_at NM_001311 0.00004 -2.37 cysteine-rich protein 1 Transcribed locus, moderately similar
to XP_422218.1 PREDICTED: similar
to LIM only protein HLP [Gallus
gallus]
Ssc.6528.1.S1_at NM_006412 0.00041 -2.38 1-acylglycerol-3-phosphate O-
acyltransferase 2
Transcribed locus, moderately similar
to NP_006403.2 1-acylglycerol-3-
phosphate O-acyltransferase 2
(lysophosphatidic acid acyltransferase,
beta); lysophosphatidic acid
acyltransferase beta; Berardinelli-Seip
congenital lipodsytrophy [Homo
sapiens]
Ssc.1808.1.S1_at #N/A 0.00017 -2.38 #N/A Transcribed locus
Ssc.18404.1.A1_at #N/A 0.00004 -2.38 #N/A Transcribed locus
Ssc.9908.1.A1_at #N/A 0.00025 -2.38 #N/A Transcribed locus
Ssc.30785.1.S1_at NM_007063 0.00004 -2.39 TBC1 domain family; member 8 Transcribed locus, strongly similar to
NP_008994.1 TBC1 domain family,
member 8 (with GRAM domain);
vascular Rab-GAP/TBC-containing;
BUB2-like protein 1 [Homo sapiens]
Ssc.16485.1.S1_at NM_004252 0.00006 -2.4 solute carrier family 9 Transcribed locus, strongly similar to
XP_540418.1 PREDICTED: similar to
ERM-binding phosphoprotein [Canis
familiaris]
Ssc.29905.1.A1_at #N/A 0.00013 -2.4 #N/A Transcribed locus
Ssc.4233.1.S1_at NM_022776 0.00036 -2.42 oxysterol binding protein-like 11 Transcribed locus, strongly similar to
oxysterol-binding protein-like protein
11 [Canis familiaris]
Ssc.18085.1.A1_at #N/A 0.00002 -2.42 #N/A Transcribed locus
Ssc.19359.1.A1_at #N/A 0.00007 -2.42 #N/A Transcribed locus
Ssc.29821.1.A1_at #N/A 0.00041 -2.42 #N/A Transcribed locus
Ssc.1588.1.S1_at NM_017567 0.00034 -2.43 N-acetylglucosamine kinase Clone Clu_7114.scr.msk.p1.Contig2,
mRNA sequence
Ssc.5622.1.A1_at #N/A 0.00056 -2.44 #N/A Transcribed locus
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Ssc.2672.1.S1_at NM_012156 0.00008 -2.47 erythrocyte membrane protein band
4.1-like 1
Transcribed locus, strongly similar to
NP_067713.1 erythrocyte protein band
4.1-like 1 isoform L [Rattus
norvegicus]
Ssc.12650.1.A1_at NM_014616 0.00000 -2.47 ATPase; Class VI; type 11B Transcribed locus
Ssc.1600.3.S1_at NM_020734 0.00007 -2.47 KIAA1238 protein Transcribed locus, strongly similar to
XP_132812.2 RIKEN cDNA
4931417E21 [Mus musculus]
Ssc.24831.1.A1_at NM_133373 0.00002 -2.47 phospholipase C; delta 3 Transcribed locus, strongly similar to
XP_548052.1 PREDICTED: similar to
mKIAA1964 protein [Canis familiaris]
Ssc.25088.1.A1_at #N/A 0.00026 -2.47 #N/A Transcribed locus
Ssc.5314.1.S1_at NM_006149 0.00007 -2.48 lectin; galactoside-binding; soluble;
4
L-36 lactose binding protein LGALS4
Ssc.4671.1.A1_at #N/A 0.00093 -2.48 #N/A Transcribed locus
Ssc.6441.1.A1_at NM_016029 0.00016 -2.49 dehydrogenasereductase Clone Clu_25564.scr.msk.p1.Contig2,
mRNA sequence
Ssc.21192.3.S1_at NM_145687 0.00048 -2.49 mitogen-activated protein kinase
kinase kinase kinase 4
Transcribed locus, strongly similar to
XP_538452.1 PREDICTED: similar to
mitogen-activated protein kinase kinase
kinase kinase 4 isoform 2 [Canis
familiaris]
Ssc.1600.1.A1_a_at NM_020734 0.00027 -2.5 KIAA1238 protein Transcribed locus, strongly similar to
XP_132812.2 RIKEN cDNA
4931417E21 [Mus musculus]
Ssc.8895.1.S1_at NM_004568 0.00010 -2.51 serine Transcribed locus, moderately similar
to NP_035584.1 serine (or cysteine)
proteinase inhibitor, clade B, member
6b; serine protease inhibitor 12 [Mus
musculus]
Ssc.15250.1.S1_at #N/A 0.00009 -2.51 #N/A Transcribed locus, moderately similar
to XP_533195.1 PREDICTED: similar
to CD82 antigen (Inducible membrane
protein R2) (C33 antigen) (IA4) [Canis
familiaris]
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Ssc.10025.3.S1_at NM_005195 0.00046 -2.52 CCAATenhancer binding protein Transcribed locus, strongly similar to
XP_519748.1 PREDICTED:
hypothetical protein XP_519748 [Pan
troglodytes]
Ssc.16392.2.A1_at NM_199054 0.00089 -2.53 MAP kinase interacting
serinethreonine kinase 2
Transcribed locus
Ssc.1868.1.S1_at NM_000901 0.00017 -2.56 nuclear receptor subfamily 3; group
C; member 2
mineralocorticoid receptor NR3C2
Ssc.5179.1.A1_at NM_006549 0.00000 -2.56 calciumcalmodulin-dependent
protein kinase kinase 2; beta
Transcribed locus
Ssc.10327.1.A1_at #N/A 0.00014 -2.56 #N/A Transcribed locus
Ssc.6783.1.S1_at NM_012338 0.00033 -2.59 tetraspanin 12 Transcribed locus
Ssc.23310.1.S1_at NM_000434 0.00033 -2.6 sialidase 1 Transcribed locus, strongly similar to
XP_538838.1 PREDICTED: similar to
Sialidase 1 precursor (Lysosomal
sialidase) (N-acetyl-alpha-
neuraminidase 1) (Acetylneuraminyl
hydrolase) (G9 sialidase) [Canis
familiaris]
Ssc.12938.1.A1_at NM_004841 0.00002 -2.6 RAS protein activator like 2 Transcribed locus
Ssc.1746.1.A1_at NM_138782 0.00017 -2.6 FCH domain only 2 Transcribed locus, strongly similar to
NP_766179.1 hypothetical protein
5832424M12 [Mus musculus]
Ssc.8699.1.A1_at #N/A 0.00031 -2.6 #N/A Transcribed locus
Ssc.14533.1.S1_at NM_002910 0.00055 -2.61 renin binding protein N-acyl-D-glucosamine 2-epimerase RENBP
Ssc.15578.1.A1_at NM_018205 0.00001 -2.61 leucine rich repeat containing 20 Transcribed locus
Ssc.27746.1.S1_at NM_198925 0.00054 -2.61 sema domain; immunoglobulin
domain
Transcribed locus, strongly similar to
XP_545859.1 PREDICTED: similar to
Semaphorin 4B precursor [Canis
familiaris]
Ssc.11670.3.A1_at XM_496093 0.00021 -2.61 similar to PERP; TP53 apoptosis
effector; p53-i
Clone Clu_21503.scr.msk.p1.Contig1,
mRNA sequence
Ssc.24540.1.S1_at #N/A 0.00024 -2.62 #N/A Transcribed locus
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Ssc.18246.1.S1_at NM_004529 0.00015 -2.63 myeloidlymphoid or mixed-lineage
leukemia
Transcribed locus, strongly similar to
XP_538677.1 PREDICTED: similar to
Myeloid/lymphoid or mixed lineage-
leukemia translocation to 3 homolog
[Canis familiaris]
Ssc.1600.1.A1_at NM_020734 0.00043 -2.63 KIAA1238 protein Transcribed locus, strongly similar to
XP_132812.2 RIKEN cDNA
4931417E21 [Mus musculus]
Ssc.18893.1.A1_at #N/A 0.00085 -2.64 #N/A Transcribed locus, moderately similar
to NP_057479.1 butyrate-induced
transcript 1 [Homo sapiens]
Ssc.422.1.S1_at NM_000876 0.00008 -2.65 insulin-like growth factor 2 receptor Mannose-6-phosphate/insulin-like
growth factor II receptor (m6p/igf2r)
mRNA, 3'UTR
Ssc.24390.1.A1_at XM_370777 0.00015 -2.66 Similar to Lysophospholipase Transcribed locus, moderately similar
to XP_370777.3 PREDICTED: similar
to lysophospholipase [Homo sapiens]
Ssc.21187.1.S1_at #N/A 0.00013 -2.66 #N/A Transcribed locus
Ssc.29965.1.A1_at #N/A 0.00019 -2.67 #N/A Transcribed locus
Ssc.13637.1.A1_at NM_002737 0.00001 -2.7 protein kinase C; alpha Transcribed locus
Ssc.1285.1.S1_at #N/A 0.00004 -2.7 #N/A Transcribed locus
Ssc.25172.1.S1_at NM_000820 0.00016 -2.71 growth arrest-specific 6 Transcribed locus, strongly similar to
XP_542676.1 PREDICTED: similar to
Growth-arrest-specific protein 6
precursor (GAS-6) [Canis familiaris]
Ssc.1817.1.S1_at NM_020728 0.00069 -2.71 family with sequence similarity 62 Transcribed locus
Ssc.4529.1.S1_at NM_181776 0.00016 -2.71 solute carrier family 36 Transcribed locus, moderately similar
to XP_518043.1 PREDICTED: similar
to solute carrier family 36
(proton/amino acid symporter),
member 2; proton/amino acid
transporter 2; tramdorin [Pan
troglodytes]
Ssc.18860.1.S1_at #N/A 0.00034 -2.71 #N/A Transcribed locus
Ssc.6833.1.S1_at NM_001731 0.00001 -2.72 B-cell translocation gene 1 Transcribed locus
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Ssc.4739.1.S1_at NM_024959 0.00007 -2.73 solute carrier family 24 Transcribed locus, strongly similar to
NP_079235.2 solute carrier family 24
member 6; sodium/potassium/calcium
exchanger [Homo sapiens]
Ssc.29953.1.A1_at #N/A 0.00004 -2.74 #N/A Transcribed locus
Ssc.27835.1.S1_at NM_020132 0.00043 -2.75 1-acylglycerol-3-phosphate O-
acyltransferase 3
Transcribed locus, strongly similar to
XP_514932.1 PREDICTED: 1-
acylglycerol-3-phosphate O-
acyltransferase 3 [Pan troglodytes]
Ssc.12430.1.S1_at NM_002744 0.00013 -2.76 protein kinase C; zeta Transcribed locus, strongly similar to
NP_002735.2 protein kinase C, zeta
[Homo sapiens]
Ssc.8309.1.A1_at NM_016245 0.00002 -2.78 dehydrogenasereductase Transcribed locus
Ssc.3255.1.S1_at NM_024071 0.00008 -2.79 zinc finger; FYVE domain
containing 21
Transcribed locus, moderately similar
to NP_076976.1 zinc finger, FYVE
domain containing 21; hypothetical
protein MGC2550 [Homo sapiens]
Ssc.26084.1.S1_at NM_001001323 0.00096 -2.82 ATPase; Ca++ transporting; plasma
membrane 1
Plasma membrane calcium ATPase
isoform 1, (ATP2B1 gene)
Ssc.13485.1.A1_at #N/A 0.00041 -2.83 #N/A Transcribed locus
Ssc.26169.1.S1_at #N/A 0.00022 -2.83 #N/A Transcribed locus
Ssc.17458.1.S1_at #N/A 0.00004 -2.84 #N/A Transcribed locus, strongly similar to
XP_535481.1 PREDICTED: similar to
rabconnectin-3 [Canis familiaris]
Ssc.3770.1.A1_at #N/A 0.00022 -2.84 #N/A Transcribed locus
Ssc.1641.1.S1_at NM_004356 0.00010 -2.85 CD81 antigen Transcribed locus, strongly similar to
NP_004347.1 CD81 antigen; target of
antiproliferative antibody 1; 26 kDa
cell surface protein TAPA-1 [Homo
sapiens]
Ssc.6276.1.S1_at NM_020676 0.00072 -2.85 abhydrolase domain containing 6 Transcribed locus, strongly similar to
NP_065727.3 abhydrolase domain
containing 6; lipase protein [Homo
sapiens]
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Ssc.23758.2.A1_at NM_181785 0.00003 -2.85 hypothetical protein LOC283537 Transcribed locus, moderately similar
to XP_534517.1 PREDICTED:
hypothetical protein XP_534517 [Canis
familiaris]
Ssc.17760.1.S1_at NM_002886 0.00003 -2.86 RAP2B; member of RAS oncogene
family
Transcribed locus, strongly similar to
NP_082988.1 RAP2B, member of RAS
oncogene family [Mus musculus]
Ssc.94.1.A1_at NM_004999 0.00003 -2.88 myosin VI unconventional myosin MYO6
Ssc.4641.1.A1_at NM_017771 0.00003 -2.88 PX domain containing
serinethreonine kinase
Transcribed locus, strongly similar to
NP_060241.2 PX domain containing
serine/threonine kinase; PX
serine/threonine kinase [Homo sapiens]
Ssc.5085.1.A1_at NM_006290 0.00013 -2.89 tumor necrosis factor; alpha-
induced protein 3
Transcribed locus
Ssc.25222.1.S1_at NM_005817 0.00023 -2.9 mannose-6-phosphate receptor
binding protein 1
TIP47
Ssc.6699.1.A1_at NM_000252 0.00001 -2.91 myotubularin 1 Transcribed locus
Ssc.16392.2.A1_a_at NM_199054 0.00002 -2.91 MAP kinase interacting
serinethreonine kinase 2
Transcribed locus
Ssc.23139.1.S1_at NM_002886 0.00003 -2.94 RAP2B; member of RAS oncogene
family
Transcribed locus, strongly similar to
NP_082988.1 RAP2B, member of RAS
oncogene family [Mus musculus]
Ssc.24375.1.S1_at NM_024109 0.00024 -2.94 hypothetical protein MGC2654 Transcribed locus
Ssc.17674.1.A1_at #N/A 0.00042 -2.95 #N/A Transcribed locus
Ssc.26354.1.S1_at #N/A 0.00001 -2.95 #N/A Transcribed locus
Ssc.1623.1.S1_at NM_004415 0.00028 -2.97 desmoplakin Transcribed locus, weakly similar to
NP_004406.1 desmoplakin;
desmoplakin (DPI, DPII) [Homo
sapiens]
Ssc.7985.1.S1_at NM_001682 0.00094 -3 ATPase; Ca++ transporting; plasma
membrane 1
plasma membrane Ca2+ pump
(PMCA1b)
ATP2B1
Ssc.5879.4.S1_a_at NM_172171 0.00096 -3 calciumcalmodulin-dependent
protein kinase
calcium/calmodulin-dependent protein
kinase II gamma
CAMK2G
Ssc.14047.2.A1_at #N/A 0.00063 -3.03 #N/A Transcribed locus
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Ssc.24460.1.A1_at #N/A 0.00020 -3.03 #N/A Transcribed locus
Ssc.11362.2.S1_at NM_004879 0.00072 -3.05 etoposide induced 2.4 mRNA Transcribed locus, strongly similar to
XP_522242.1 PREDICTED: similar to
EI24 protein [Pan troglodytes]
Ssc.7292.1.S1_at #N/A 0.00054 -3.05 #N/A Transcribed locus
Ssc.8373.1.A1_at #N/A 0.00025 -3.08 #N/A Transcribed locus
Ssc.26824.1.A1_at NM_004686 0.00016 -3.09 myotubularin related protein 7 Transcribed locus, strongly similar to
NP_062306.1 myotubularin related
protein 7 [Mus musculus]
Ssc.2795.2.S1_at NM_004059 0.00030 -3.13 cysteine conjugate-beta lyase;
cytoplasmic
Transcribed locus, moderately similar
to NP_765992.2 cysteine conjugate-
beta lyase; cytoplasmic (glutamine
transaminase K, kyneurenine
aminotransferase) [Mus musculus]
Ssc.16937.1.A1_at NM_021202 0.00003 -3.14 tumor protein p53 inducible nuclear
protein 2
Transcribed locus
Ssc.19455.2.S1_at NM_001003794 0.00015 -3.15 monoglyceride lipase Transcribed locus, strongly similar to
NP_009214.1 monoglyceride lipase
isoform 1; lysophospholipase-like
[Homo sapiens]
Ssc.24039.1.S1_at #N/A 0.00021 -3.15 #N/A Transcribed locus
Ssc.2142.1.S1_at NM_080881 0.00001 -3.2 drebrin 1 Transcribed locus, strongly similar to
XP_546204.1 PREDICTED: similar to
drebrin E [Canis familiaris]
Ssc.16334.1.S2_at NM_138578 0.00029 -3.2 BCL2-like 1 anti-apoptotic Bcl-xL BCL2L1
Ssc.2925.1.S1_at NM_017797 0.00003 -3.21 BTB Transcribed locus, strongly similar to
NP_060267.2 BTB (POZ) domain
containing 2 [Homo sapiens]
Ssc.30264.1.A1_at #N/A 0.00010 -3.22 #N/A Transcribed locus
Ssc.26450.1.A1_at NM_173570 0.00050 -3.24 zinc finger; DHHC-type containing
23
Transcribed locus
Ssc.6163.1.A1_at NM_005239 0.00044 -3.25 v-ets erythroblastosis virus E26
oncogene homolog 2
Transcribed locus
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Ssc.10534.3.A1_a_at NM_006506 0.00003 -3.27 RAS p21 protein activator 2 Transcribed locus, strongly similar to
NP_006497.2 RAS p21 protein
activator 2; GTPase-activating protein
of RAS [Homo sapiens]
Ssc.2142.2.S1_at NM_080881 0.00005 -3.27 drebrin 1 Transcribed locus, strongly similar to
XP_546204.1 PREDICTED: similar to
drebrin E [Canis familiaris]
Ssc.10002.1.A1_at #N/A 0.00055 -3.27 #N/A Transcribed locus
Ssc.15252.1.S1_at NM_201533 0.00014 -3.28 diacylglycerol kinase; zeta 104kDa Transcribed locus, strongly similar to
NP_963290.1 diacylglycerol kinase,
zeta 104kDa isoform 1; diacylglycerol
kinase, zeta (104kD) [Homo sapiens]
Ssc.2795.1.S1_at NM_004059 0.00075 -3.35 cysteine conjugate-beta lyase;
cytoplasmic
Transcribed locus, moderately similar
to NP_765992.2 cysteine conjugate-
beta lyase; cytoplasmic (glutamine
transaminase K, kyneurenine
aminotransferase) [Mus musculus]
Ssc.1028.1.S1_at NM_032312 0.00043 -3.36 hypothetical protein MGC11061 Clone Clu_12742.scr.msk.p1.Contig1,
mRNA sequence
Ssc.18773.1.A1_at #N/A 0.00011 -3.36 #N/A Clone rski0137_l13.y1.abd, mRNA
sequence
Ssc.943.1.S1_at NM_198538 0.00017 -3.38 suprabasin Transcribed locus, moderately similar
to NP_940940.1 HLAR698 [Homo
sapiens]
Ssc.19164.1.A1_at #N/A 0.00002 -3.38 #N/A Transcribed locus
Ssc.21290.1.S1_at NM_014779 0.00041 -3.4 TSC22 domain family; member 2 Transcribed locus
Ssc.2070.1.S1_at NM_012156 0.00000 -3.41 erythrocyte membrane protein band
4.1-like 1
Transcribed locus
Ssc.24938.1.S1_at NM_001004431 0.00006 -3.42 meteorin; glial cell differentiation
regulator-like
Transcribed locus, moderately similar
to XP_209073.2 PREDICTED:
hypothetical protein XP_209073
[Homo sapiens]
Ssc.29966.1.A1_s_at #N/A 0.00000 -3.42 #N/A Transcribed locus, strongly similar to
XP_539924.1 PREDICTED: similar to
N-acetylgalactosaminyltransferase;
similar to Q10473 (PID:g1709559)
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[Canis familiaris]
Ssc.16120.1.S1_at NM_005536 0.00018 -3.43 inositol myo-inositol monophosphatase IMPA1
Ssc.22221.1.S1_a_at NM_000167 0.00040 -3.46 glycerol kinase Transcribed locus, moderately similar
to XP_225769.2 PREDICTED:
glucokinase activity, related sequence 1
[Rattus norvegicus]
Ssc.9286.1.A1_at #N/A 0.00047 -3.46 #N/A Transcribed locus
Ssc.3442.1.S1_at #N/A 0.00007 -3.49 #N/A Transcribed locus
Ssc.21227.1.S1_at NM_080881 0.00000 -3.55 drebrin 1 Transcribed locus, strongly similar to
XP_546204.1 PREDICTED: similar to
drebrin E [Canis familiaris]
Ssc.25396.1.A1_at #N/A 0.00006 -3.59 #N/A Transcribed locus
Ssc.7469.1.S1_at NM_022087 0.00003 -3.62 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgal
Transcribed locus, strongly similar to
XP_539924.1 PREDICTED: similar to
N-acetylgalactosaminyltransferase;
similar to Q10473 (PID:g1709559)
[Canis familiaris]
Ssc.6323.1.S1_at NM_001122 0.00030 -3.63 adipose differentiation-related
protein
adipose differentiation-related protein ADRP
Ssc.1126.1.A1_at NM_006714 0.00000 -3.64 sphingomyelin phosphodiesterase;
acid-like 3A
Transcribed locus, moderately similar
to NP_006705.1 acid
sphingomyelinase-like
phosphodiesterase 3A; acid
sphingomyelinase-like
phosphodiesterase; 0610010C24Rik
[Homo sapiens]
Ssc.23746.1.S1_at NM_015385 0.00019 -3.66 sorbin and SH3 domain containing
1
Transcribed locus, strongly similar to
XP_484807.1 sorbin and SH3 domain
containing 1 [Mus musculus]
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Ssc.27550.1.S1_at NM_003358 0.00000 -3.69 UDP-glucose ceramide
glucosyltransferase
Transcribed locus, strongly similar to
XP_538788.1 PREDICTED: similar to
Ceramide glucosyltransferase
(Glucosylceramide synthase) (GCS)
(UDP-glucose:N-acylsphingosine D-
glucosyltransferase) (UDP-glucose
ceramide glucosyltransferase) (GLCT-
1) [Canis familiaris]
Ssc.24718.1.S1_at NM_005536 0.00003 -3.69 inositol Transcribed locus
Ssc.12176.1.S1_at NM_022036 0.00011 -3.74 G protein-coupled receptor; family
C; group 5; member C
Transcribed locus, strongly similar to
NP_071319.2 G protein-coupled
receptor family C, group 5, member C
isoform a; retinoic acid responsive gene
protein; orphan G-protein coupled
receptor [Homo sapiens]
Ssc.6425.1.A1_at #N/A 0.00012 -3.74 #N/A Transcribed locus, moderately similar
to NP_005679.1 ATP-binding cassette,
sub-family C, member 5; canalicular
multispecific organic anion transporter
C [Homo sapiens]
Ssc.26303.1.A1_at #N/A 0.00050 -3.78 #N/A Transcribed locus
Ssc.5000.1.A1_at #N/A 0.00000 -3.83 #N/A Transcribed locus, moderately similar
to NP_004439.1 v-erb-b2 erythroblastic
leukemia viral oncogene homolog 2,
neuro/glioblastoma derived oncogene
homolog; Avian erythroblastic
leukemia viral (v-erb-b2) oncogene
homolog 2; v-erb-b2 avian
erythroblastic leukemia viral oncogene
homolog 2 (neuro/glioblastoma derived
oncogene homolog) [Homo sapiens]
Ssc.13891.1.A1_at NM_152869 0.00031 -3.84 regucalcin Transcribed locus, strongly similar to
XP_538011.1 PREDICTED: similar to
regucalcin [Canis familiaris]
Ssc.31172.3.S1_at NM_001006946 0.00005 -3.86 syndecan 1 Transcribed locus
Ssc.24128.1.A1_at #N/A 0.00005 -3.86 #N/A Transcribed locus
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Ssc.2179.1.S1_at NM_024980 0.00000 -3.87 G protein-coupled receptor 157 Transcribed locus, moderately similar
to NP_796340.1 RIKEN cDNA
F730108M23 gene [Mus musculus]
Ssc.10307.1.A1_at #N/A 0.00006 -3.88 #N/A Transcribed locus
Ssc.14211.1.A1_at #N/A 0.00011 -3.93 #N/A Transcribed locus
Ssc.19175.2.S1_at #N/A 0.00008 -3.95 #N/A Transcribed locus
Ssc.28415.1.S1_at NM_031308 0.00010 -4.06 epiplakin 1 Transcribed locus, strongly similar to
XP_372063.2 PREDICTED: similar to
epiplakin [Homo sapiens]
Ssc.25149.1.S1_at #N/A 0.00002 -4.06 #N/A Transcribed locus, moderately similar
to XP_540332.1 PREDICTED: similar
to membrane-associated guanylate
kinase-related 3 [Canis familiaris]
Ssc.27241.1.S1_at NM_170692 0.00007 -4.1 RAS protein activator like 2 Transcribed locus, strongly similar to
XP_537177.1 PREDICTED: similar to
Ras GTPase-activating protein nGAP
(RAS protein activator like 1) [Canis
familiaris]
Ssc.23264.1.A1_at #N/A 0.00009 -4.13 #N/A Transcribed locus, moderately similar
to XP_537446.1 PREDICTED: similar
to KIAA1344 protein [Canis familiaris]
Ssc.25412.1.A1_at #N/A 0.00043 -4.14 #N/A Transcribed locus
Ssc.25189.1.S1_a_at NM_020784 0.00038 -4.15 KIAA1344 Transcribed locus, strongly similar to
XP_051699.4 PREDICTED:
KIAA1344 [Homo sapiens]
Ssc.28921.1.S1_at #N/A 0.00003 -4.23 #N/A Transcribed locus
Ssc.21382.1.A1_at NM_004419 0.00004 -4.28 dual specificity phosphatase 5 Transcribed locus
Ssc.30194.1.A1_at NM_207015 0.00051 -4.38 N-acetylated alpha-linked acidic
dipeptidase 2
Transcribed locus, moderately similar
to NP_996898.1 N-acetylated alpha-
linked acidic dipeptidase 2 [Homo
sapiens]
Ssc.13473.1.A1_at #N/A 0.00071 -4.4 #N/A Transcribed locus
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Ssc.2176.1.A1_at NM_203372 0.00004 -4.42 acyl-CoA synthetase long-chain
family member 3
Transcribed locus, strongly similar to
NP_004448.2 acyl-CoA synthetase
long-chain family member 3;
lignoceroyl-CoA synthase; fatty-acid-
Coenzyme A ligase, long-chain 3
[Homo sapiens]
Ssc.29231.1.A1_at #N/A 0.00011 -4.44 #N/A Transcribed locus
Ssc.31172.1.S1_at NM_001006946 0.00000 -4.46 syndecan 1 Transcribed locus
Ssc.22476.1.A1_at XM_373594 0.00008 -4.49 hypothetical LOC387992 Transcribed locus
Ssc.2492.2.S1_at NM_001001669 0.00000 -4.5 FLJ41603 protein Transcribed locus
Ssc.24593.1.A1_at #N/A 0.00074 -4.57 #N/A Transcribed locus
Ssc.5887.1.A1_at #N/A 0.00096 -4.57 #N/A Transcribed locus, strongly similar to
NP_938018.1 solute carrier family 37
(glycerol-3-phosphate transporter),
member 2 [Homo sapiens]
Ssc.428.23.A1_at #N/A 0.00026 -4.58 #N/A T-cell receptor alpha chain mRNA C-
region, 3' end of cds
Ssc.25134.1.A1_at NM_020784 0.00018 -4.62 KIAA1344 Transcribed locus, moderately similar
to XP_051699.4 PREDICTED:
KIAA1344 [Homo sapiens]
Ssc.12176.3.S1_at NM_018653 0.00003 -4.72 G protein-coupled receptor; family
C; group 5; member C
Transcribed locus, strongly similar to
NP_071319.2 G protein-coupled
receptor family C, group 5, member C
isoform a; retinoic acid responsive gene
protein; orphan G-protein coupled
receptor [Homo sapiens]
Ssc.4204.1.S1_at NM_004130 0.00046 -4.76 glycogenin Transcribed locus, strongly similar to
NP_004121.2 glycogenin [Homo
sapiens]
Ssc.2746.1.A1_at #N/A 0.00025 -4.78 #N/A Transcribed locus
Ssc.28059.1.A1_at XM_498662 0.00017 -4.84 hypothetical gene supported by
AK092922; AL8319
Transcribed locus
Ssc.1093.3.S1_at NM_012193 0.00026 -4.88 frizzled homolog 4 Transcribed locus
Ssc.25230.1.S1_at NM_012193 0.00011 -4.88 frizzled homolog 4 Transcribed locus
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Ssc.25155.1.S1_at NM_018390 0.00033 -4.89 phosphatidylinositol-specific
phospholipase C; X domain con
Transcribed locus, moderately similar
to NP_060860.1 hypothetical protein
FLJ11323 [Homo sapiens]
Ssc.2197.1.S1_at NM_018004 0.00053 -5.17 transmembrane protein 45A Transcribed locus, moderately similar
to XP_535720.1 PREDICTED:
hypothetical protein XP_535720 [Canis
familiaris]
Ssc.26693.1.S1_at NM_002639 0.00003 -5.2 serine Transcribed locus, strongly similar to
XP_533382.1 PREDICTED:
hypothetical protein XP_533382 [Canis
familiaris]
Ssc.26816.1.S1_at NM_145176 0.00000 -5.37 solute carrier family 2 Transcribed locus, moderately similar
to NP_660159.1 solute carrier family 2
(facilitated glucose transporter),
member 12 [Homo sapiens]
Ssc.4105.1.S1_at #N/A 0.00000 -5.42 #N/A Transcribed locus
Ssc.19539.2.S1_at NM_018941 0.00076 -5.46 ceroid-lipofuscinosis; neuronal 8 Transcribed locus, moderately similar
to NP_036130.1 ceroid-lipofuscinosis,
neuronal 8; motor neuron degeneration
[Mus musculus]
Ssc.16963.1.S1_at NM_004776 0.00000 -5.52 UDP-Gal:betaGlcNAc beta 1;4-
galactosyltransferase; polype
Transcribed locus, strongly similar to
XP_512417.1 PREDICTED: glutaryl-
Coenzyme A dehydrogenase [Pan
troglodytes]
Ssc.27052.1.A1_at #N/A 0.00000 -5.71 #N/A Transcribed locus
Ssc.27177.1.S1_at NM_006095 0.00003 -5.88 ATPase; aminophospholipid
transporter
Transcribed locus, strongly similar to
NP_006086.1 ATPase,
aminophospholipid transporter (APLT),
class I, type 8A, member 1; ATPase II;
aminophospholipid translocase [Homo
sapiens]
Ssc.2963.1.S1_at #N/A 0.00008 -5.89 #N/A Transcribed locus
Ssc.16333.1.S1_at NM_000927 0.00002 -6.05 ATP-binding cassette; sub-family B ATP-binding cassette, sub-family B
(MDR/TAP), member 1
ABCB1
Ssc.3832.1.S1_at NM_004925 0.00001 -6.14 aquaporin 3 Transcribed locus, similar to Aqp3
[Canis familiaris]
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Ssc.24978.2.S1_at #N/A 0.00058 -6.16 #N/A Transcribed locus
Ssc.30871.1.A1_at NM_033285 0.00052 -6.27 tumor protein p53 inducible nuclear
protein 1
Transcribed locus
Ssc.4272.1.A1_at #N/A 0.00085 -6.4 #N/A Transcribed locus
Ssc.4076.1.S1_at NM_015225 0.00036 -6.41 KIAA0367 Transcribed locus
Ssc.3785.1.S1_a_at XM_379250 0.00031 -6.53 hypothetical LOC401115 Transcribed locus
Ssc.19482.1.A1_at #N/A 0.00011 -6.61 #N/A Transcribed locus
Ssc.5848.1.S1_at NM_004776 0.00002 -6.69 UDP-Gal:betaGlcNAc beta 1;4-
galactosyltransferase; polype
Transcribed locus, strongly similar to
NP_004767.1 UDP-Gal:betaGlcNAc
beta 1,4- galactosyltransferase 5; beta-
1,4-GalT IV; beta4-GalT IV [Homo
sapiens]
Ssc.19442.1.A1_at #N/A 0.00006 -6.77 #N/A Transcribed locus
Ssc.12727.1.A1_at #N/A 0.00000 -6.8 #N/A Transcribed locus
Ssc.5848.2.S1_a_at NM_004776 0.00003 -6.94 UDP-Gal:betaGlcNAc beta 1;4-
galactosyltransferase; polype
Transcribed locus, strongly similar to
NP_004767.1 UDP-Gal:betaGlcNAc
beta 1,4- galactosyltransferase 5; beta-
1,4-GalT IV; beta4-GalT IV [Homo
sapiens]
Ssc.21383.1.A1_at NM_178500 0.00024 -6.94 phosphatase; orphan 1 Transcribed locus, strongly similar to
XP_511946.1 PREDICTED:
hypothetical protein XP_511946 [Pan
troglodytes]
Ssc.27177.2.S1_at #N/A 0.00006 -7.32 #N/A Transcribed locus, strongly similar to
NP_006086.1 ATPase,
aminophospholipid transporter (APLT),
class I, type 8A, member 1; ATPase II;
aminophospholipid translocase [Homo
sapiens]
Ssc.16236.1.S1_at NM_001935 0.00001 -7.58 dipeptidylpeptidase 4 dipeptidyl peptidase IV DPPIV
Ssc.27292.1.S1_at #N/A 0.00099 -7.72 #N/A Transcribed locus
Ssc.29750.1.A1_at NM_033285 0.00018 -7.79 tumor protein p53 inducible nuclear
protein 1
Transcribed locus
Ssc.5434.1.A1_at NM_033274 0.00037 -7.98 a disintegrin and metalloproteinase
domain 19
Transcribed locus
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Ssc.3012.1.S1_at NM_181597 0.00013 -8.64 uridine phosphorylase 1 Transcribed locus
Ssc.6055.1.A1_at NM_181785 0.00001 -8.86 hypothetical protein LOC283537 Transcribed locus, moderately similar
to XP_534517.1 PREDICTED:
hypothetical protein XP_534517 [Canis
familiaris]
Ssc.27433.1.S1_at NM_000359 0.00019 -9.01 transglutaminase 1 Transcribed locus, strongly similar to
NP_001003079.1 transglutaminase 1
[Canis familiaris]
Ssc.12727.2.A1_at #N/A 0.00002 -9.01 #N/A Transcribed locus
Ssc.2492.1.A1_at #N/A 0.00010 -9.2 #N/A Transcribed locus
Ssc.27182.1.S1_at NM_017682 0.00000 -9.61 vitelliform macular dystrophy 2-like
1
Transcribed locus, moderately similar
to XP_512414.1 PREDICTED: similar
to Bestrophin 2 (Vitelliform macular
dystrophy 2-like protein 1) [Pan
troglodytes]
Ssc.64.1.S1_at NM_004827 0.00000 -10.26 ATP-binding cassette; sub-family G brain multidrug resistance protein BMDP
Ssc.12802.1.A1_at #N/A 0.00000 -10.52 #N/A Transcribed locus
Ssc.29246.1.A1_at NM_199461 0.00049 -10.66 nanos homolog 1 Transcribed locus
Ssc.17364.1.S1_at NM_015444 0.00063 -11.8 Ras-induced senescence 1 Transcribed locus
Ssc.29840.1.A1_at #N/A 0.00044 -11.81 #N/A Transcribed locus
Ssc.27372.1.S1_at #N/A 0.00000 -12.59 #N/A Transcribed locus
Ssc.1534.1.A1_at NM_015385 0.00001 -12.71 sorbin and SH3 domain containing
1
Transcribed locus
Ssc.24311.1.S1_at #N/A 0.00083 -16.29 #N/A Transcribed locus, weakly similar to
NP_112603.1 placental-like alkaline
phosphatase preproprotein; testicular
and thymus alkaline phosphatase;
Nagao isozyme; germ cell alkaline
phosphatase [Homo sapiens]
Ssc.26185.1.S1_at #N/A 0.00047 -17.27 #N/A Transcribed locus
Ssc.24503.1.S1_at XM_496688 0.00006 -18.39 hypothetical protein BC012029 Transcribed locus
Ssc.10403.1.S1_at NM_012101 0.00004 -19.37 tripartite motif-containing 29 Transcribed locus, similar to tripartite
motif protein TRIM29 isoform beta
[Canis familiaris]
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Ssc.6056.1.S1_at NM_181797 0.00049 -19.65 potassium voltage-gated channel;
KQT-like subfamily; membe
Transcribed locus
Ssc.27264.1.S1_at NM_024861 0.00001 -21.19 hypothetical protein FLJ22671 Transcribed locus, moderately similar
to hypothetical protein FLJ22671
[Homo sapiens]
Ssc.29858.1.A1_at NM_000927 0.00000 -25.81 ATP-binding cassette; sub-family B Transcribed locus
Ssc.8594.1.A1_at NM_013314 0.00002 -28.75 B-cell linker Transcribed locus, strongly similar to
NP_037446.1 B-cell linker; B cell
linker protein [Homo sapiens]
Ssc.7243.1.A1_at NM_199168 0.00023 -44.53 chemokine Transcribed locus
Ssc.19431.1.S1_at NM_005021 0.00002 -63 ectonucleotide
pyrophosphatasephosphodiesterase
3
Transcribed locus, moderately similar
to NP_005012.1 ectonucleotide
pyrophosphatase/phosphodiesterase 3;
phosphodiesterase-I beta; gp130RB13-
6; phosphodiesterase I/nucleotide
pyrophosphatase 3 [Homo sapiens]
aThe Affymetrix ID is specific to a porcine sequence for which a specific probe set was designed to interrogate.
bGenBank Accession number assigned for those genes, as associated with the Affymetrix ID, having homology to annotated human
genes.
cThe probability for statistical differences was determined using unpaired t-tests via dChip described in Chapter 3.
dOnly those genes significantly different and with a fold change equal or greater than 2.0 were included.
eThis annotation refers to the targets whose interrogated sequence had significant homology to an annotated human sequence.
fThis annotation was assigned by Affymetrix.
gAcronyms for genes have been assigned by Affymetrix.
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Table A.2. Differentially expressed genes during the transition from Day 12 to Day 14 filamentous conceptuses.
Probe Set IDa
GenBank
Accesion
Numberb
P
Valuec
Fold
Changed
Putative Identity Following
Annotation Based on Homology
to Known GenBank Identitiese
Gene Title Assigned By Affymetrix
Annotationf
Gene
Symbolg
Ssc.19394.1.A1_at #N/A 0.00023 38.75 #N/A Transcribed locus, strongly similar to
NP_653308.1 prominin 2; prominin-
related protein [Homo sapiens]
Ssc.4815.1.A1_at #N/A 0.00008 37.15 #N/A Transcribed locus
Ssc.15316.2.S1_at NM_001311 0.00020 36.87 cysteine-rich protein 1 Transcribed locus, moderately similar
to XP_422218.1 PREDICTED: similar
to LIM only protein HLP [Gallus
gallus]
Ssc.20438.1.S1_at NM_000959 0.00074 19.36 prostaglandin F receptor Transcribed locus
Ssc.4984.1.S1_at NM_004887 0.00075 19.07 chemokine chemokine CXCL14
Ssc.2197.1.S1_at NM_018004 0.00044 13.72 transmembrane protein 45A Transcribed locus, moderately similar
to XP_535720.1 PREDICTED:
hypothetical protein XP_535720 [Canis
familiaris]
Ssc.18707.1.A1_at #N/A 0.00045 13.47 #N/A Transcribed locus, strongly similar to
NP_003610.1 neurotrypsin precursor;
brain-specific serine protease 3; leydin
[Homo sapiens]
Ssc.20578.1.S1_at #N/A 0.00074 11.99 #N/A Transcribed locus
Ssc.10942.1.S1_at NM_053013 0.00009 11.18 enolase 3 Transcribed locus, strongly similar to
XP_484728.1 similar to Eno1 protein
[Mus musculus]
Ssc.5165.1.S1_at #N/A 0.00010 9.03 #N/A Transcribed locus
Ssc.11131.1.S1_at NM_003380 0.00086 8.48 vimentin Transcribed locus, strongly similar to
XP_535175.1 PREDICTED: similar to
vimentin [Canis familiaris]
Ssc.29483.1.A1_at #N/A 0.00059 7.69 #N/A Transcribed locus
Ssc.6057.1.A1_at NM_015550 0.00021 7.52 oxysterol binding protein-like 3 Transcribed locus
Ssc.29437.1.S1_at #N/A 0.00034 6.9 #N/A Transcribed locus
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Ssc.19579.2.S1_at #N/A 0.00096 6.52 #N/A Transcribed locus, strongly similar to
nuclear receptor subfamily 2, group F,
member 2 [Pan troglodytes]
Ssc.1544.1.S1_at NM_000257 0.00082 5.96 myosin; heavy polypeptide 7;
cardiac muscle; beta
beta-myosin heavy chain MYH7
Ssc.22082.1.A1_at #N/A 0.00038 5.63 #N/A Transcribed locus, strongly similar to
NP_066566.3 disabled homolog 1;
disabled (Drosophila) homolog 1
[Homo sapiens]
Ssc.24345.1.S1_at NM_015556 0.00020 5.52 signal-induced proliferation-
associated 1 like 1
Transcribed locus, strongly similar to
NP_056371.1 signal-induced
proliferation-associated 1 like 1; signal-
induced proliferation-associated 1-like
1 [Homo sapiens]
Ssc.8479.1.A1_at NM_005410 0.00016 5.28 selenoprotein P; plasma; 1 Transcribed locus, weakly similar to
NP_005401.2 selenoprotein P precursor
[Homo sapiens]
Ssc.16989.1.A1_at NM_001753 0.00011 5.09 caveolin 1; caveolae protein;
22kDa
Transcribed locus
Ssc.15695.1.S1_at NM_006744 0.00030 5.04 retinol binding protein 4; plasma retinol-binding protein RBP4
Ssc.2824.1.S1_at NM_198234 0.00096 4.43 ribonuclease; RNase A family; 1 Clone Clu_87699.scr.msk.p1.Contig1,
mRNA sequence
Ssc.5737.1.S1_at NM_078467 0.00027 4.36 cyclin-dependent kinase inhibitor
1A
Transcribed locus, moderately similar
to XP_532125.1 PREDICTED: similar
to p21/WAF1 [Canis familiaris]
Ssc.8373.1.A1_at #N/A 0.00007 4.31 #N/A Transcribed locus
Ssc.7588.1.A1_at #N/A 0.00022 4.25 #N/A Transcribed locus
Ssc.18578.1.S1_at NM_175842 0.00083 3.95 spermine oxidase Transcribed locus, strongly similar to
XP_514493.1 PREDICTED: similar to
polyamine oxidase isoform 1;
polyamine oxidase; chromosome 20
open reading frame 16; flavin-
containing spermine oxidase; putative
cyclin G1 interacting protein; flavin
containing amine oxidase [Pan
troglodytes]
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Ssc.18014.1.A1_at NM_052954 0.00077 3.92 cysteine and tyrosine-rich 1 Transcribed locus
Ssc.18030.1.A1_at #N/A 0.00072 3.89 #N/A Transcribed locus
Ssc.9286.1.A1_at #N/A 0.00053 3.88 #N/A Transcribed locus
Ssc.20258.1.S1_at #N/A 0.00068 3.77 #N/A Transcribed locus
Ssc.26224.1.S1_at NM_199171 0.00056 3.69 transmembrane; prostate androgen
induced RNA
Transcribed locus, strongly similar to
transmembrane prostate androgen-
induced protein isoform a [Homo
sapiens]
Ssc.17518.1.S1_at NM_000674 0.00008 3.61 adenosine A1 receptor Transcribed locus, strongly similar to
NP_000665.1 adenosine A1 receptor
[Homo sapiens]
Ssc.5683.1.S1_a_at NM_022371 0.00077 3.55 torsin family 3; member A Transcribed locus, strongly similar to
XP_547446.1 PREDICTED: similar to
ADIR1 [Canis familiaris]
Ssc.4914.1.A1_at NM_032181 0.00064 3.47 hypothetical protein FLJ13391 Transcribed locus, strongly similar to
XP_525794.1 PREDICTED: similar to
hypothetical protein FLJ13391 [Pan
troglodytes]
Ssc.4266.1.S1_at #N/A 0.00079 3.45 #N/A Transcribed locus
Ssc.23077.1.A1_at #N/A 0.00016 3.43 #N/A Transcribed locus
Ssc.18996.2.A1_a_at NM_003963 0.00052 3.38 transmembrane 4 L six family
member 5
Transcribed locus, moderately similar
to NP_003954.2 transmembrane 4
superfamily member 5; tetraspan
transmembrane protein L6H [Homo
sapiens]
Ssc.21848.1.S1_at NM_014292 0.00000 3.35 chromobox homolog 6 Transcribed locus
Ssc.26253.1.S1_at #N/A 0.00091 3.33 #N/A Transcribed locus
Ssc.1308.1.S1_at NM_002081 0.00048 3.29 glypican 1 Transcribed locus, moderately similar
to NP_002072.1 glypican 1 precursor
[Homo sapiens]
Ssc.8609.1.A1_at NM_014456 0.00006 3.29 programmed cell death 4 Transcribed locus, strongly similar to
XP_535012.1 PREDICTED: similar to
programmed cell death 4 isoform 1
[Canis familiaris]
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Ssc.19323.1.S1_at NM_138389 0.00001 3.29 hypothetical protein BC001096 Transcribed locus, strongly similar to
NP_612398.1 hypothetical protein
BC001096 [Homo sapiens]
Ssc.18540.1.S1_at #N/A 0.00005 3.23 #N/A Transcribed locus, strongly similar to
NP_005838.3 solute carrier family 23
(nucleobase transporters), member 1
isoform a; sodium-dependent vitamin C
transporter-1; yolk sac permease-like
molecule 3; solute carrier family 23
(nucleobase transporters), member 2;
Na(+)/L-ascorbic acid transporter 1
[Homo sapiens]
Ssc.25410.1.S1_at #N/A 0.00028 3.16 #N/A Transcribed locus
Ssc.3016.1.S1_at #N/A 0.00018 3.15 #N/A Transcribed locus
Ssc.21617.1.A1_at #N/A 0.00003 3.14 #N/A Transcribed locus
Ssc.9504.1.A1_at #N/A 0.00035 3.14 #N/A Transcribed locus
Ssc.6988.1.A1_at NM_138766 0.00048 3.03 peptidylglycine alpha-amidating
monooxygenase
Transcribed locus, strongly similar to
NP_037132.2 peptidylglycine alpha-
amidating monooxygenase [Rattus
norvegicus]
Ssc.4676.1.A1_at NM_018211 0.00030 3.02 hypothetical protein FLJ10770 Transcribed locus
Ssc.19579.3.S1_at NM_021005 0.00097 3.01 nuclear receptor subfamily 2;
group F; member 2
Transcribed locus, strongly similar to
nuclear receptor subfamily 2, group F,
member 2 [Pan troglodytes]
Ssc.25051.1.S1_at NM_016950 0.00091 2.96 sparcosteonectin; cwcv and kazal-
like domains proteoglycan
Transcribed locus, moderately similar
to NP_058646.1 testican 3 [Homo
sapiens]
Ssc.27354.1.S1_at NM_139244 0.00009 2.96 syntaxin binding protein 5 Transcribed locus, strongly similar to
XP_533442.1 PREDICTED:
hypothetical protein XP_533442 [Canis
familiaris]
Ssc.28006.1.A1_at NM_152526 0.00007 2.95 amyotrophic lateral sclerosis 2 Transcribed locus, moderately similar
to NP_995585.1 amyotrophic lateral
sclerosis 2 (juvenile), partitioning-
defective 3-like [Homo sapiens]
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Ssc.5580.1.S1_at #N/A 0.00024 2.93 #N/A Transcribed locus
Ssc.12842.1.S1_at NM_001753 0.00049 2.92 caveolin 1; caveolae protein;
22kDa
Caveolin 1 CAV1
Ssc.16346.1.S1_at NM_022972 0.00062 2.92 fibroblast growth factor receptor 2 fibroblast growth factor receptor FGFR2
Ssc.23169.1.S1_at NM_002856 0.00097 2.91 poliovirus receptor-related 2 Transcribed locus, moderately similar
to NP_002847.1 poliovirus receptor-
related 2 (herpesvirus entry mediator
B); nectin 2; poliovirus receptor-like 2;
herpesvirus entry mediator B
(poliovirus receptor-related 2);
herpesvirus entry protein B; poliovirus
receptor related 2 [Homo sapiens]
Ssc.25002.1.S1_at NM_031283 0.00099 2.91 transcription factor 7-like 1 Transcribed locus, strongly similar to
NP_112573.1 HMG-box transcription
factor TCF-3 [Homo sapiens]
Ssc.19873.1.S1_at NM_194071 0.00006 2.91 cAMP responsive element binding
protein 3-like 2
Transcribed locus
Ssc.18900.1.A1_at #N/A 0.00048 2.91 #N/A Transcribed locus
Ssc.6382.1.A1_at NM_024607 0.00007 2.86 protein phosphatase 1; regulatory Transcribed locus
Ssc.20353.1.S1_at #N/A 0.00009 2.84 #N/A Transcribed locus
Ssc.3021.1.A1_at #N/A 0.00001 2.82 #N/A Transcribed locus
Ssc.12412.1.A1_at NM_022044 0.00029 2.81 stromal cell-derived factor 2-like 1 Transcribed locus, strongly similar to
NP_071327.1 stromal cell-derived
factor 2-like 1; AP000553.C22.4;
OTTHUMT00000075032 [Homo
sapiens]
Ssc.26363.1.S1_at NM_012262 0.00000 2.78 heparan sulfate 2-O-
sulfotransferase 1
Transcribed locus, strongly similar to
NP_036394.1 heparan sulfate 2-O-
sulfotransferase 1 [Homo sapiens]
Ssc.17312.1.A1_at XM_373497 0.00080 2.78 hypothetical LOC387763 Transcribed locus, strongly similar to
NP_001003058.1 CMP-sialic acid
transporter [Canis familiaris]
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Ssc.29043.2.A1_at NM_205860 0.00097 2.77 nuclear receptor subfamily 5;
group A; member 2
Transcribed locus, strongly similar to
NP_995582.1 nuclear receptor
subfamily 5, group A, member 2
isoform 1; CYP7A promoter-binding
factor; fetoprotein-alpha 1 (AFP)
transcription factor; b1-binding factor,
hepatocyte transcription factor which
activates enhancer II of hepatitis B
virus; liver receptor homolog 1 [Homo
sapiens]
Ssc.13380.1.A1_at #N/A 0.00032 2.76 #N/A Transcribed locus
Ssc.23905.1.A1_at #N/A 0.00097 2.75 #N/A Transcribed locus
Ssc.9588.1.A1_at #N/A 0.00048 2.75 #N/A Transcribed locus
Ssc.19212.1.S1_at NM_000387 0.00042 2.73 solute carrier family 25 Clone Clu_23714.scr.msk.p1.Contig3,
mRNA sequence
Ssc.30989.1.A1_at XM_035299 0.00081 2.73 zinc finger; SWIM domain
containing 6
Transcribed locus
Ssc.19873.1.S1_a_at NM_194071 0.00004 2.69 cAMP responsive element binding
protein 3-like 2
Transcribed locus
Ssc.2642.1.S1_at NM_003312 0.00096 2.67 thiosulfate sulfurtransferase Transcribed locus, strongly similar to
XP_515109.1 PREDICTED: similar to
TST [Pan troglodytes]
Ssc.29435.1.A1_at NM_003483 0.00086 2.67 high mobility group AT-hook 2 Transcribed locus
Ssc.9391.1.A1_at NM_014734 0.00037 2.67 KIAA0247 Transcribed locus
Ssc.18375.1.A1_at NM_006378 0.00056 2.65 sema domain; immunoglobulin
domain
Transcribed locus
Ssc.19579.1.A1_at NM_021005 0.00028 2.65 nuclear receptor subfamily 2;
group F; member 2
Transcribed locus, strongly similar to
XP_523164.1 PREDICTED: similar to
nuclear receptor subfamily 2, group F,
member 2 [Pan troglodytes]
Ssc.31053.1.A1_at NM_004487 0.00012 2.63 golgi autoantigen; golgin
subfamily b; macrogolgin
Transcribed locus, moderately similar
to XP_516685.1 PREDICTED: golgi
autoantigen, golgin subfamily b,
macrogolgin (with transmembrane
signal), 1 [Pan troglodytes]
Ssc.14376.1.A1_at #N/A 0.00047 2.63 #N/A Transcribed locus
238
Ssc.22563.1.S1_at NM_006581 0.00013 2.62 fucosyltransferase 9 Transcribed locus, strongly similar to
NP_001005380.1 alpha-1,3-
fucosyltransferase 9 [Canis familiaris]
Ssc.21188.1.S1_at NM_021195 0.00048 2.62 claudin 6 Transcribed locus, strongly similar to
NP_067018.1 claudin 6 [Homo
sapiens]
Ssc.16982.1.S1_at NM_014061 0.00033 2.61 melanoma antigen family H; 1 Transcribed locus, strongly similar to
NP_076277.1 melanoma antigen,
family H, 1 [Mus musculus]
Ssc.24304.2.A1_at NM_182801 0.00091 2.6 hypothetical protein FLJ39155 Transcribed locus
Ssc.27592.2.S1_at NM_003956 0.00045 2.58 cholesterol 25-hydroxylase Transcribed locus, moderately similar
to XP_220063.2 PREDICTED: similar
to Cholesterol 25-hydroxylase [Rattus
norvegicus]
Ssc.31000.1.A1_at XM_294353 0.00038 2.58 similar to RIKEN cDNA
6332401O19 gene
Transcribed locus, strongly similar to
RIKEN cDNA 6332401O19 gene
[Homo sapiens]
Ssc.24540.1.S1_at #N/A 0.00020 2.58 #N/A Transcribed locus
Ssc.7145.1.A1_at #N/A 0.00014 2.58 #N/A Transcribed locus, moderately similar
to XP_509017.1 PREDICTED: similar
to splicing factor, arginine/serine-rich
2, interacting protein; SC35-interacting
protein 1 [Pan troglodytes]
Ssc.772.1.S1_at NM_014316 0.00071 2.56 calcium regulated heat stable
protein 1; 24kDa
Clone Clu_112017.scr.msk.p1.Contig2,
mRNA sequence
Ssc.12628.1.A1_at NM_207015 0.00018 2.54 N-acetylated alpha-linked acidic
dipeptidase 2
Transcribed locus, weakly similar to
XP_355456.2 similar to N-acetylated
alpha-linked acidic dipeptidase 2 [Mus
musculus]
Ssc.1896.2.A1_a_at NM_000156 0.00081 2.5 guanidinoacetate N-
methyltransferase
Transcribed locus, strongly similar to
NP_000147.1 guanidinoacetate N-
methyltransferase isoform a [Homo
sapiens]
Ssc.8950.1.A1_at #N/A 0.00001 2.49 #N/A Transcribed locus
Ssc.55.1.S1_at NM_005228 0.00002 2.47 epidermal growth factor receptor epidermal growth factor receptor EGFR
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Ssc.19075.1.A1_at NM_022739 0.00050 2.47 SMAD specific E3 ubiquitin
protein ligase 2
Transcribed locus, strongly similar to
NP_073576.1 SMAD specific E3
ubiquitin protein ligase 2; E3 ubiquitin
ligase SMURF2 [Homo sapiens]
Ssc.19620.1.S1_at NM_199262 0.00046 2.47 Sp6 transcription factor Transcribed locus
Ssc.26215.1.S1_at NM_019896 0.00005 2.43 polymerase Transcribed locus, strongly similar to
XP_540212.1 PREDICTED:
hypothetical protein XP_540212 [Canis
familiaris]
Ssc.16312.1.S1_at NM_006825 0.00003 2.42 cytoskeleton-associated protein 4 Unidentified hepatic protein mRNA
Ssc.11659.1.A1_at #N/A 0.00065 2.38 #N/A Transcribed locus
Ssc.19459.1.A1_at #N/A 0.00005 2.38 #N/A Transcribed locus
Ssc.3832.1.S1_at NM_004925 0.00082 2.34 aquaporin 3 Transcribed locus, strongly similar to
XP_531973.1 PREDICTED: similar to
Aqp3 protein [Canis familiaris]
Ssc.24330.1.S1_at NM_004820 0.00019 2.31 cytochrome P450; family 7;
subfamily B; polypeptide 1
Transcribed locus, moderately similar
to XP_544102.1 PREDICTED: similar
to oxysterol 7alpha-hydroxylase [Canis
familiaris]
Ssc.21408.1.S1_at NM_006260 0.00051 2.31 DnaJ Transcribed locus, weakly similar to
XP_359458.1 hypothetical protein
MG05319.4 [Magnaporthe grisea 70-
15]
Ssc.3409.1.A1_at NM_213662 0.00020 2.31 signal transducer and activator of
transcription 3
Transcribed locus, strongly similar to
NP_003141.2 signal transducer and
activator of transcription 3 isoform 2;
acute-phase response factor; DNA-
binding protein APRF [Homo sapiens]
Ssc.10777.1.A1_at #N/A 0.00029 2.31 #N/A Transcribed locus
Ssc.11502.1.A1_at #N/A 0.00002 2.31 #N/A Transcribed locus
Ssc.8427.1.A1_at NM_018999 0.00096 2.29 KIAA1128 Transcribed locus
Ssc.12430.1.S1_at NM_002744 0.00047 2.28 protein kinase C; zeta Transcribed locus, strongly similar to
NP_002735.2 protein kinase C, zeta
[Homo sapiens]
Ssc.9936.1.A1_at NM_001002860 0.00001 2.26 BTB Transcribed locus
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Ssc.7304.2.A1_at NM_005544 0.00003 2.26 insulin receptor substrate 1 Transcribed locus, strongly similar to
NP_005535.1 insulin receptor substrate
1 [Homo sapiens]
Ssc.1986.1.S1_at NM_080591 0.00024 2.26 prostaglandin-endoperoxide
synthase 1
Transcribed locus, moderately similar
to NP_000953.2 prostaglandin-
endoperoxide synthase 1 isoform 1
precursor; prostaglandin G/H synthase
and cyclooxygenase [Homo sapiens]
Ssc.16540.1.S1_at NM_002827 0.00051 2.25 protein tyrosine phosphatase; non-
receptor type 1
Transcribed locus
Ssc.27912.1.S1_at NM_020747 0.00097 2.25 zinc finger protein 608 Transcribed locus, strongly similar to
XP_114432.3 PREDICTED: zinc
finger protein 608 [Homo sapiens]
Ssc.24138.1.A1_at #N/A 0.00035 2.25 #N/A Transcribed locus
Ssc.29710.1.A1_at #N/A 0.00037 2.25 #N/A Transcribed locus
Ssc.24233.1.S1_at NM_015170 0.00028 2.24 sulfatase 1 Transcribed locus, strongly similar to
NP_055985.1 sulfatase 1; sulfatase FP
[Homo sapiens]
Ssc.13553.1.A1_at #N/A 0.00043 2.24 #N/A Transcribed locus, moderately similar
to NP_112298.1 guanine nucleotide
binding protein, alpha q polypeptide
[Rattus norvegicus]
Ssc.5226.1.S1_at NM_015252 0.00061 2.23 EH domain binding protein 1 Transcribed locus, strongly similar to
XP_515506.1 PREDICTED:
hypothetical protein XP_515506 [Pan
troglodytes]
Ssc.11401.1.A1_a_at NM_007110 0.00037 2.22 telomerase-associated protein 1 Transcribed locus, moderately similar
to NP_009041.2 telomerase-associated
protein 1; telomerase protein
component 1 [Homo sapiens]
Ssc.22444.2.A1_at #N/A 0.00013 2.22 #N/A Transcribed locus
Ssc.5966.1.A1_at NM_024324 0.00046 2.2 hypothetical protein MGC11256 Transcribed locus, moderately similar
to hypothetical protein MGC11256;
cystein-rich with EGF-like domains 2
[Homo sapiens]
Ssc.17280.2.A1_at #N/A 0.00059 2.19 #N/A Transcribed locus
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Ssc.2688.1.S1_at NM_182924 0.00027 2.17 MICAL-like 2 Transcribed locus, moderately similar
to NP_078999.1 MICAL-like 2 isoform
2 [Homo sapiens]
Ssc.18306.1.A1_at #N/A 0.00089 2.17 #N/A Transcribed locus
Ssc.4740.2.A1_at #N/A 0.00050 2.17 #N/A Transcribed locus
Ssc.14521.1.S1_at NM_153326 0.00095 2.16 aldo-keto reductase family 1;
member A1
aldehyde reductase ALR1
Ssc.14277.1.A1_at #N/A 0.00030 2.16 #N/A Transcribed locus
Ssc.3670.1.S1_a_at NM_022356 0.00024 2.15 leucine proline-enriched
proteoglycan
Transcribed locus, strongly similar to
NP_446119.1 leprecan 1 [Rattus
norvegicus]
Ssc.19892.1.A1_at NM_024408 0.00042 2.15 Notch homolog 2 Transcribed locus
Ssc.6352.1.S1_at NM_000581 0.00098 2.14 glutathione peroxidase 1 cytosolic glutathione peroxidase GPX1
Ssc.4228.1.S1_at NM_015537 0.00076 2.13 nasal embryonic LHRH factor Transcribed locus, strongly similar to
NP_056352.3 nasal embryonic LHRH
factor; nasal embryonic luteinizing
hormone-releasing hormone factor
[Homo sapiens]
Ssc.19416.1.A1_at #N/A 0.00040 2.13 #N/A Transcribed locus
Ssc.21595.1.S1_at #N/A 0.00059 2.11 #N/A Alpha-stimulatory subunit of GTP-
binding protein
PORGSA1
Ssc.24596.1.S1_at #N/A 0.00023 2.1 #N/A Transcribed locus
Ssc.24608.1.S1_at #N/A 0.00013 2.09 #N/A Transcribed locus
Ssc.27249.1.S1_at NM_005221 0.00022 2.08 distal-less homeo box 5 Transcribed locus, strongly similar to
XP_539430.1 PREDICTED: similar to
Homeobox protein DLX-5 [Canis
familiaris]
Ssc.25182.1.A1_at #N/A 0.00030 2.08 #N/A Transcribed locus
Ssc.16689.1.S1_at NM_003980 0.00003 2.07 microtubule-associated protein 7 Transcribed locus, moderately similar
to XP_533419.1 PREDICTED:
hypothetical protein XP_533419 [Canis
familiaris]
Ssc.10775.1.A1_at #N/A 0.00009 2.07 #N/A Transcribed locus
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Ssc.26025.1.S1_at NM_017641 0.00069 2.06 kinesin family member 21A Transcribed locus, strongly similar to
XP_534839.1 PREDICTED: similar to
Kinesin family member 21A (Kinesin-
like protein KIF2) (NY-REN-62
antigen) [Canis familiaris]
Ssc.14336.1.A1_at #N/A 0.00092 2.06 #N/A Transcribed locus
Ssc.30240.1.A1_at #N/A 0.00031 2.06 #N/A Transcribed locus
Ssc.31070.1.S1_at NM_012201 0.00058 2.05 golgi apparatus protein 1 Transcribed locus, strongly similar to
NP_033175.1 golgi apparatus protein
1; selectin, endothelial cell, ligand
[Mus musculus]
Ssc.2187.1.S1_at NM_015267 0.00051 2.05 cut-like 2 Transcribed locus
Ssc.6511.1.A1_at #N/A 0.00082 2.05 #N/A Transcribed locus
Ssc.19873.2.S1_at NM_194071 0.00081 2.04 cAMP responsive element binding
protein 3-like 2
Transcribed locus
Ssc.27182.1.S1_at NM_017682 0.00068 2.03 vitelliform macular dystrophy 2-
like 1
Transcribed locus, moderately similar
to XP_512414.1 PREDICTED: similar
to Bestrophin 2 (Vitelliform macular
dystrophy 2-like protein 1) [Pan
troglodytes]
Ssc.4084.1.S1_at XM_371474 0.00098 2.03 plexin B2 Transcribed locus
Ssc.31006.2.A1_at #N/A 0.00055 2.03 #N/A Transcribed locus, strongly similar to
XP_508612.1 PREDICTED: similar to
PTPRF interacting protein alpha 1
isoform a; LAR-interacting protein 1
[Pan troglodytes]
Ssc.26941.1.S1_at #N/A 0.00058 2.02 #N/A Transcribed locus
Ssc.17572.1.S1_at NM_032840 0.00044 2.01 hypothetical protein FLJ14800 Transcribed locus
Ssc.30295.1.A1_at #N/A 0.00058 2.01 #N/A Transcribed locus
Ssc.3043.1.S1_at NM_152999 0.00065 2 six transmembrane epithelial
antigen of the prostate 2
Transcribed locus
Ssc.5362.1.S1_at NM_014397 0.00094 -2.02 NIMA Transcribed locus
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Ssc.20740.1.S1_at #N/A 0.00032 -2.02 #N/A Transcribed locus, weakly similar to
XP_548196.1 PREDICTED: similar to
Neurabin-II (Neural tissue-specific F-
actin binding protein II) (Protein
phosphatase 1 regulatory subunit 9B)
(Spinophilin) (p130) (PP1bp134)
[Canis familiaris]
Ssc.2768.2.S1_at NM_000437 0.00082 -2.03 platelet-activating factor
acetylhydrolase 2; 40kDa
Transcribed locus, moderately similar
to XP_535348.1 PREDICTED: similar
to platelet-activating factor
acetylhydrolase 2 [Canis familiaris]
Ssc.27871.2.S1_at NM_139274 0.00011 -2.03 acetyl-Coenzyme A synthetase 2 Clone Clu_5971.scr.msk.p1.Contig1,
mRNA sequence
Ssc.18495.2.S1_at #N/A 0.00084 -2.03 #N/A Transcribed locus
Ssc.19213.1.S1_at NM_173553 0.00082 -2.04 hypothetical protein FLJ25801 Transcribed locus, moderately similar
to XP_540017.1 PREDICTED: similar
to hypothetical protein FLJ25801
[Canis familiaris]
Ssc.19150.1.S1_s_at NM_197966 0.00078 -2.06 BH3 interacting domain death
agonist
BH3 interacting domain death agonist BID
Ssc.8305.1.A1_at #N/A 0.00075 -2.08 #N/A Transcribed locus
Ssc.24630.1.A1_at NM_016045 0.00060 -2.09 chromosome 20 open reading
frame 45
Clone Clu_13954.scr.msk.p1.Contig1,
mRNA sequence
Ssc.3802.1.S1_at NM_139207 0.00098 -2.1 nucleosome assembly protein 1-
like 1
Transcribed locus, weakly similar to
NP_004528.1 nucleosome assembly
protein 1-like 1; HSP22-like protein
interacting protein; NAP-1 related
protein [Homo sapiens]
Ssc.4863.1.S1_at NM_003798 0.00066 -2.12 catenin Transcribed locus, strongly similar to
NP_003789.1 catenin (cadherin-
associated protein), alpha-like 1; alpha-
catulin [Homo sapiens]
Ssc.22083.1.S1_at NM_005746 0.00070 -2.12 pre-B-cell colony enhancing factor
1
Pre-B-cell colony enhancing factor 1
transcript variant 1 (PBEF1)
Ssc.24556.2.S1_a_at NM_025181 0.00076 -2.13 solute carrier family 35; member
F5
Transcribed locus, strongly similar to
NP_079457.2 solute carrier family 35,
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member F5 [Homo sapiens]
Ssc.3666.1.A1_at #N/A 0.00035 -2.13 #N/A Transcribed locus
Ssc.13793.2.S1_at NM_006479 0.00037 -2.15 RAD51 associated protein 1 Transcribed locus, moderately similar
to NP_006470.1 RAD51-interacting
protein [Homo sapiens]
Ssc.6618.1.A1_at XM_290546 0.00023 -2.15 KIAA0830 protein Transcribed locus
Ssc.24870.1.S1_at NM_005100 0.00058 -2.17 A kinase Transcribed locus, moderately similar
to XP_533451.1 PREDICTED:
hypothetical protein XP_533451 [Canis
familiaris]
Ssc.7106.1.S1_at NM_001801 0.00006 -2.18 cysteine dioxygenase; type I Clone Clu_1053.scr.msk.p1.Contig1,
mRNA sequence
Ssc.26446.1.S1_at NM_015143 0.00075 -2.18 methionyl aminopeptidase 1 Transcribed locus, strongly similar to
NP_780433.1 methionyl
aminopeptidase 1 [Mus musculus]
Ssc.1429.1.A1_at NM_004537 0.00041 -2.21 nucleosome assembly protein 1-
like 1
Clone Clu_594.scr.msk.p1.Contig8,
mRNA sequence
Ssc.11450.1.S1_at NM_001288 0.00014 -2.22 chloride intracellular channel 1 chloride intracellular channel 1 CLIC1
Ssc.24403.1.S1_at NM_002040 0.00096 -2.22 GA binding protein transcription
factor; alpha subunit 60k
Transcribed locus, strongly similar to
NP_002031.2 GA binding protein
transcription factor, alpha subunit
(60kD); GA-binding protein
transcription factor, alpha subunit
(60kD); human nuclear respiratory
factor-2 subunit alpha [Homo sapiens]
Ssc.2963.1.S1_at #N/A 0.00073 -2.22 #N/A Transcribed locus
Ssc.23953.1.S1_at NM_022484 0.00098 -2.23 hypothetical protein FLJ13576 Transcribed locus
Ssc.6940.1.A1_at NM_022337 0.00096 -2.25 RAB38; member RAS oncogene
family
Transcribed locus, strongly similar to
XP_542265.1 PREDICTED: similar to
RAB38 [Canis familiaris]
Ssc.8577.1.A1_at NM_152265 0.00031 -2.26 basic transcription factor 3-like 4 Transcribed locus
Ssc.11714.2.A1_at #N/A 0.00064 -2.3 #N/A Transcribed locus, strongly similar to
hypothetical protein dJ122O8.2 [Homo
sapiens]
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Ssc.16722.2.S1_at NM_152391 0.00061 -2.31 chromosome 2 open reading frame
22
Transcribed locus, moderately similar
to NP_689604.1 hypothetical protein
MGC33602 [Homo sapiens]
Ssc.17965.1.S1_at NM_153347 0.00025 -2.31 hypothetical protein FLJ90119 Transcribed locus, strongly similar to
XP_521860.1 PREDICTED: similar to
hypothetical protein FLJ90119 [Pan
troglodytes]
Ssc.8027.1.A1_at NM_001018057 0.00094 -2.33 dickkopf homolog 3 Transcribed locus, moderately similar
to Dickkopf related protein-3 precursor
(Dkk-3) (Dickkopf-3) (hDkk-3)
(UNQ258/PRO295) [Canis familiaris]
Ssc.3452.1.A1_at NM_182540 0.00002 -2.34 DEADH Transcribed locus
Ssc.15740.2.S1_a_at NM_003376 0.00052 -2.38 vascular endothelial growth factor vascular endothelial growth factor VEGFA
Ssc.21922.1.S1_at NM_021630 0.00019 -2.43 PDZ and LIM domain 2 Transcribed locus, strongly similar to
NP_067643.2 PDZ and LIM domain 2
isoform 2; mystique [Homo sapiens]
Ssc.21101.1.S1_at NM_000688 0.00029 -2.47 aminolevulinate; delta-; synthase 1 Transcribed locus, strongly similar to
NP_000679.1 aminolevulinate, delta,
synthase 1 [Homo sapiens]
Ssc.24795.1.A1_at #N/A 0.00010 -2.47 #N/A Transcribed locus, strongly similar to
NP_079184.1 hypothetical protein
FLJ12973 [Homo sapiens]
Ssc.29247.1.A1_at #N/A 0.00010 -2.51 #N/A Transcribed locus
Ssc.19150.1.S1_at NM_197966 0.00035 -2.55 BH3 interacting domain death
agonist
BH3 interacting domain death agonist BID
Ssc.26621.1.S1_at NM_153694 0.00040 -2.56 synaptonemal complex protein 3 Transcribed locus, moderately similar
to NP_710161.1 synaptonemal
complex protein 3 [Homo sapiens]
Ssc.10263.1.A1_at NM_152903 0.00034 -2.59 kelch repeat and BTB Transcribed locus
Ssc.10226.1.A2_at NM_004040 0.00079 -2.63 ras homolog gene family; member
B
Transcribed locus, strongly similar to
NP_786886.1 ras homolog gene family,
member C; Aplysia RAS-related
homolog 9 (oncogene RHO H9); RAS
homolog gene family, member C
(oncogene RHO H9)
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Ssc.22261.1.S1_at NM_017686 0.00027 -2.64 ganglioside induced differentiation
associated protein 2
Transcribed locus, strongly similar to
ganglioside induced differentiation
associated protein 2 [Homo sapiens]
Ssc.1058.1.S1_at NM_007285 0.00087 -2.65 GABA Clone Clu_4417.scr.msk.p1.Contig2,
mRNA sequence
Ssc.1432.1.A1_at NM_000413 0.00008 -2.66 hydroxysteroid Transcribed locus, moderately similar
to NP_000404.1 hydroxysteroid (17-
beta) dehydrogenase 1; Estradiol 17-
beta-dehydrogenase-1 [Homo sapiens]
Ssc.23809.2.S1_at #N/A 0.00063 -2.67 #N/A Transcribed locus
Ssc.2165.2.S1_a_at NM_006142 0.00038 -2.7 stratifin Transcribed locus, strongly similar to
XP_544477.1 PREDICTED: similar to
stratifin [Canis familiaris]
Ssc.24968.2.S1_at NM_014062 0.00019 -2.7 nin one binding protein Transcribed locus, strongly similar to
XP_546853.1 PREDICTED: similar to
nin one binding protein [Canis
familiaris]
Ssc.5389.2.S1_at NM_005530 0.00055 -2.71 isocitrate dehydrogenase 3 Clone Clu_241.scr.msk.p1.Contig4,
mRNA sequence
Ssc.24970.2.S1_at NM_032839 0.00066 -2.73 disrupted in renal carcinoma 2 Transcribed locus, strongly similar to
NP_116228.1 disrupted in renal
carcinoma 2; Renal cell carcinoma 4
[Homo sapiens]
Ssc.24430.1.S1_at NM_033274 0.00057 -2.75 a disintegrin and
metalloproteinase domain 19
Transcribed locus
Ssc.383.1.S1_at NM_139212 0.00068 -2.81 homeodomain-only protein odd homeobox 1 protein OB1
Ssc.3088.1.S1_at #N/A 0.00067 -2.83 #N/A Transcribed locus
Ssc.8213.2.A1_at NM_024613 0.00068 -2.9 pleckstrin homology domain
containing; family F
Transcribed locus
Ssc.21248.1.S1_at NM_022047 0.00007 -3.03 differentially expressed in FDCP 6
homolog
Transcribed locus, strongly similar to
XP_518424.1 PREDICTED: similar to
differentially expressed in FDCP 6
homolog; IRF4-binding protein [Pan
troglodytes]
Ssc.4891.1.A1_at NM_032717 0.00020 -3.04 hypothetical protein MGC11324 Transcribed locus, moderately similar
to NP_061213.2 putative
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lysophosphatidic acid acyltransferase
[Mus musculus]
Ssc.25577.1.S1_at #N/A 0.00012 -3.39 #N/A Transcribed locus
Ssc.24921.3.S1_a_at NM_199166 0.00080 -3.67 aminolevulinate; delta-; synthase 1 Transcribed locus, moderately similar
to NP_000679.1 aminolevulinate, delta,
synthase 1 [Homo sapiens]
Ssc.3442.1.S1_at #N/A 0.00029 -3.73 #N/A Transcribed locus
Ssc.7602.1.A1_at #N/A 0.00001 -3.77 #N/A Transcribed locus
Ssc.9392.2.S1_at #N/A 0.00054 -3.95 #N/A Transcribed locus
Ssc.5404.1.S1_at NM_019556 0.00015 -4.05 motile sperm domain containing 1 Transcribed locus
Ssc.9392.3.A1_at #N/A 0.00069 -4.26 #N/A Transcribed locus
Ssc.25037.2.S1_at NM_016300 0.00058 -4.33 cyclic AMP-regulated
phosphoprotein; 21 kD
Transcribed locus, strongly similar to
XP_526169.1 PREDICTED: similar to
cyclic AMP-regulated phosphoprotein,
21 kD isoform 1 [Pan troglodytes]
Ssc.7568.1.A1_at XM_378780 0.00009 -4.35 hypothetical protein LOC126536 Transcribed locus
Ssc.20489.1.S1_at NM_002391 0.00046 -4.52 midkine Clone rese36c_i5.y1.abd, mRNA
sequence
Ssc.27614.1.S1_at NM_013402 0.00014 -4.73 fatty acid desaturase 1 delta-5 fatty acid desaturase FADS1
Ssc.1595.1.S1_a_at #N/A 0.00047 -5.04 #N/A Transcribed locus
Ssc.23963.1.S1_at NM_014059 0.00030 -5.16 response gene to complement 32 Clone rmed06c_i24.y1.abd, mRNA
sequence
Ssc.26868.1.S1_at NM_002863 0.00016 -5.19 phosphorylase; glycogen; liver Transcribed locus, moderately similar
to XP_537443.1 PREDICTED: similar
to liver glycogen phosphorylase [Canis
familiaris]
Ssc.1303.1.S1_at NM_030666 0.00048 -5.58 serine Transcribed locus, weakly similar to
XP_541071.1 PREDICTED:
hypothetical protein XP_541071 [Canis
familiaris]
Ssc.1013.1.A1_at NM_145792 0.00084 -5.75 microsomal glutathione S-
transferase 1
glutathione S-transferase MGST1
Ssc.18343.1.A1_at NM_001006625 0.00009 -5.98 lung type-I cell membrane-
associated glycoprotein
Transcribed locus
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Ssc.6940.1.A1_s_at NM_022337 0.00007 -6.75 RAB38; member RAS oncogene
family
Transcribed locus, strongly similar to
XP_542265.1 PREDICTED: similar to
RAB38 [Canis familiaris]
Ssc.115.1.S1_s_at NM_002133 0.00040 -6.9 heme oxygenase heme oxygenase HMOX1
Ssc.881.1.S1_at NM_145202 0.00026 -8.02 proline-rich acidic protein 1 Transcribed locus, weakly similar to
proline-rich acidic protein 1; uterine-
specific proline-rich acidic protein
[Homo sapiens]
Ssc.14484.1.A1_at NM_031226 0.00077 -10.64 cytochrome P450; family 19;
subfamily A; polypeptide 1
cytochrome P450 19A1 CYP19A1
Ssc.27256.1.S1_at NM_000405 0.00010 -12.76 GM2 ganglioside activator Transcribed locus, moderately similar
to NP_000396.2 GM2 ganglioside
activator precursor; cerebroside sulfate
activator protein; sphingolipid activator
protein 3; GM2 ganglioside activator
protein [Homo sapiens]
Ssc.2825.1.S1_at #N/A 0.00051 -12.92 #N/A Transcribed locus, moderately similar
to XP_538963.1 PREDICTED: similar
to Glutathione S-transferase 8 (GST 8-
8) (Chain 8) (GST class-alpha) [Canis
familiaris]
Ssc.279.1.S2_at NM_000349 0.00021 -63.67 steroidogenic acute regulator steroidogenic acute regulatory protein STAR
Ssc.26876.1.A1_at #N/A 0.00031 -66.94 #N/A Transcribed locus
aThe Affymetrix ID is specific to a porcine sequence for which a specific probe set was designed to interrogate.
bGenBank Accession number assigned for those genes, as associated with the Affymetrix ID, having homology to annotated human
genes.
cThe probability for statistical differences was determined using unpaired t-tests via dChip described in Chapter 3.
dOnly those genes significantly different and with a fold change equal or greater than 2.0 were included.
eThis annotation refers to the targets whose interrogated sequence had significant homology to an annotated human sequence.
fThis annotation was assigned by Affymetrix.
gAcronyms for genes have been assigned by Affymetrix.
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Table A.3 Genes grouped within a k-means cluster in association with their putative identity.
Expression Comparisonc
K-Means
Clustera Affymetrix IDb
S vs.
T
S vs.
D12F
S vs.
D14F
NM Accession
Numberd NM Annotatione
Ssc.28006.1.A1_at 1.4 2.5 7.4 NM_152526 amyotrophic lateral sclerosis 2Cluster 1
Ssc.26224.1.S1_at 1.6 2.1 7.7 NM_199171 transmembrane; prostate androgen induced RNA
Ssc.27041.1.A1_at 1.2 2.2 7.7 NM_153013 hypothetical protein FLJ30596
Ssc.8965.1.A1_at 1.7 3.0 7.8 NM_001430 endothelial PAS domain protein 1
Ssc.14465.1.A1_at 1.5 2.4 7.8 NM_018976 solute carrier family 38; member 2
Ssc.2047.1.S1_at -1.1 2.5 8.0 NM_014923 fibronectin type III domain containing 3A
Ssc.21617.1.A1_at 1.3 2.5 8.0 #N/A #N/A
Ssc.16989.1.A1_at 1.2 1.6 8.0 NM_001753 caveolin 1; caveolae protein; 22kDa
Ssc.8676.1.S1_at -1.3 3.2 8.1 NM_021005 nuclear receptor subfamily 2; group F; member 2
Ssc.4511.1.S1_at 1.6 3.1 8.1 NM_004753 dehydrogenasereductase
Ssc.17283.1.A1_at 1.1 3.2 8.3 #N/A #N/A
Ssc.2143.1.S1_at -1.2 1.7 8.4 #N/A #N/A
Ssc.29483.1.A1_at -1.1 1.1 8.5 #N/A #N/A
Ssc.4266.1.S1_at 1.8 2.5 8.6 #N/A #N/A
Ssc.18996.1.S1_at -1.0 2.4 8.6 NM_003963 transmembrane 4 L six family member 5
Ssc.4676.1.A1_at -1.0 2.9 8.6 NM_018211 hypothetical protein FLJ10770
Ssc.7242.1.A1_at 1.1 1.9 8.7 NM_014393 staufen; RNA binding protein; homolog 2
Ssc.13439.1.A1_at -1.0 1.2 8.7 #N/A #N/A
Ssc.6906.1.A1_at 1.2 3.6 8.9 NM_014923 fibronectin type III domain containing 3A
Ssc.3373.1.A1_at -1.2 1.9 9.0 #N/A #N/A
Ssc.21113.2.S1_at 1.2 1.6 9.1 #N/A #N/A
Ssc.9517.1.A1_at -1.6 2.8 9.1 NM_000441 solute carrier family 26; member 4
Ssc.3920.1.S1_at 1.8 2.6 9.1 NM_020182 transmembrane; prostate androgen induced RNA
Ssc.9154.1.A1_at -1.8 1.4 9.5 NM_004466 glypican 5
Ssc.1544.1.S1_at 1.1 1.6 9.6 NM_000257 myosin; heavy polypeptide 7; cardiac muscle; beta
Ssc.10942.1.S1_at -1.3 -1.1 9.8 NM_053013 enolase 3
Ssc.24345.1.S1_at 1.2 1.8 10.0 NM_015556 signal-induced proliferation-associated 1 like 1
Ssc.29437.1.S1_at 1.2 1.5 10.0 #N/A #N/A
n = 28 1.2 2.2 8.6
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Ssc.28336.1.A1_at -1.2 2.0 5.1 NM_001018009 SH3-domain binding protein 5Cluster 2
Ssc.6869.1.A1_at -1.2 -1.2 5.1 #N/A #N/A
Ssc.16027.1.S1_at 1.3 1.9 5.2 NM_003256 tissue inhibitor of metalloproteinase 4
Ssc.17283.2.S1_at 1.1 2.1 5.2 #N/A #N/A
Ssc.30657.1.S1_at 1.4 2.5 5.2 NM_173854 solute carrier family 41; member 1
Ssc.4914.1.A1_at 1.0 1.5 5.3 NM_032181 hypothetical protein FLJ13391
Ssc.21848.1.S1_at 1.1 1.6 5.3 NM_014292 chromobox homolog 6
Ssc.3967.1.A1_at 1.1 1.6 5.4 NM_001497 UDP-Gal:betaGlcNAc beta 1;4- galactosyltransferase;
Ssc.10801.1.A1_at -1.1 1.8 5.4 NM_173552 hypothetical protein MGC33365
Ssc.29473.1.A1_at -1.0 2.3 5.4 #N/A #N/A
Ssc.15886.1.S1_at 1.2 2.8 5.4 NM_032991 caspase 3; apoptosis-related cysteine protease
Ssc.18224.1.S1_at 1.1 2.8 5.4 #N/A #N/A
Ssc.30550.1.A1_at 1.1 -1.0 5.5 #N/A #N/A
Ssc.11555.1.S1_at 1.2 2.5 5.5 NM_015544 DKFZP564K1964 protein
Ssc.2697.1.S1_at -1.1 1.5 5.5 #N/A #N/A
Ssc.22248.1.A1_at 1.0 1.7 5.6 #N/A #N/A
Ssc.10731.1.A1_at -1.0 1.0 5.6 NM_002581 pregnancy-associated plasma protein A; pappalysin 1
Ssc.19579.3.S1_at -1.1 1.9 5.7 NM_021005 nuclear receptor subfamily 2; group F; member 2
Ssc.22082.1.A1_at -1.2 1.1 5.9 #N/A #N/A
Ssc.1702.1.S1_at -1.7 2.3 5.9 NM_145290 G protein-coupled receptor 125
Ssc.8516.1.A1_at 1.2 1.9 6.0 NM_145740 glutathione S-transferase A1
Ssc.889.1.A1_a_at 1.3 1.5 6.0 NM_002614 PDZ domain containing 1
Ssc.1276.1.S1_at 1.1 2.7 6.0 NM_002165 inhibitor of DNA binding 1; dominant negative helix-loop-h
Ssc.18996.2.A1_a_at -1.0 1.8 6.0 NM_003963 transmembrane 4 L six family member 5
Ssc.8479.1.A1_at 1.2 1.2 6.2 NM_005410 selenoprotein P; plasma; 1
Ssc.13553.1.A1_at -1.2 2.8 6.3 #N/A #N/A
Ssc.3549.1.S1_at 1.7 3.2 6.4 NM_001430 endothelial PAS domain protein 1
Ssc.15648.1.S1_at 1.4 3.1 6.4 XM_043653 brain expressed X-linked-like 1
Ssc.12102.1.A1_at 1.2 2.5 6.5 NM_014668 GREB1 protein
Ssc.11187.1.S1_at 1.1 3.0 6.5 NM_000201 intercellular adhesion molecule 1
Ssc.1882.1.S1_at -1.5 1.7 6.5 NM_000141 fibroblast growth factor receptor 2
Ssc.14376.1.A1_at -1.2 2.5 6.6 #N/A #N/A
Ssc.11374.1.S1_at -1.1 2.8 6.6 NM_015696 glutathione peroxidase 7
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Ssc.1866.1.S1_at 1.1 2.0 6.7 NM_032876 jub; ajuba homologCluster 2
cont. Ssc.30465.1.A1_at 1.1 2.5 6.9 #N/A #N/A
Ssc.5260.1.A1_at 1.3 2.1 7.0 #N/A #N/A
n = 36 1.1 2.0 5.9
Ssc.15335.1.S1_at 2.0 6.1 6.3 #N/A #N/ACluster 3
Ssc.14419.1.S1_at -1.0 3.8 6.6 XM_376652 distal-less homeo box 6
Ssc.8562.3.A1_at 2.6 3.9 6.6 NM_001901 connective tissue growth factor
Ssc.1407.1.A1_at 1.6 5.8 6.7 NM_007203 PALM2-AKAP2 protein
Ssc.3853.1.S1_at 1.3 3.6 6.7 NM_004816 chromosome 9 open reading frame 61
Ssc.13665.1.A1_at -1.3 6.0 6.7 NM_006089 sex comb on midleg-like 2
Ssc.26944.1.S1_at 1.5 4.4 7.0 #N/A #N/A
Ssc.21647.1.A1_at 1.1 5.9 7.4 NM_018131 chromosome 10 open reading frame 3
Ssc.1407.2.S1_at 1.5 5.7 7.4 NM_007203 PALM2-AKAP2 protein
Ssc.30789.1.A1_at 1.5 3.8 7.4 #N/A #N/A
Ssc.9537.1.S1_at -1.1 4.7 7.6 NM_012342 BMP and activin membrane-bound inhibitor homolog
Ssc.7944.1.A1_at -1.2 4.2 8.0 #N/A #N/A
Ssc.24190.1.S1_at 1.5 4.8 8.5 NM_003865 homeo box
Ssc.14126.1.A1_at 2.0 4.8 8.6 #N/A #N/A
Ssc.2976.1.S1_at 1.2 5.1 8.6 NM_004821 heart and neural crest derivatives expressed 1
Ssc.23944.1.A1_at 1.0 4.9 8.8 #N/A #N/A
Ssc.29811.1.A1_at 1.5 5.3 9.0 NM_147150 PALM2-AKAP2 protein
Ssc.27404.1.S1_at 1.7 4.5 9.1 NM_004405 distal-less homeo box 2
Ssc.11757.1.S1_at 1.1 5.3 9.6 NM_001003688 SMAD; mothers against DPP homolog 1
n = 19 1.4 4.9 7.7
Ssc.21175.1.S1_at 2.6 2.6 -6.9 NM_001017372 solute carrier family 27Cluster 4
Ssc.1013.1.A1_at 2.1 2.3 -2.5 NM_145792 microsomal glutathione S-transferase 1
Ssc.115.1.S1_s_at 1.2 3.2 -2.2 NM_002133 heme oxygenase
Ssc.27614.1.S1_at 1.8 3.2 -1.5 NM_013402 fatty acid desaturase 1
Ssc.1595.1.S1_a_at 1.8 3.6 -1.4 #N/A #N/A
Ssc.26446.2.S1_a_at 1.1 3.3 -1.0 NM_015143 methionyl aminopeptidase 1
Ssc.3088.1.S1_at 1.1 3.0 1.1 #N/A #N/A
Ssc.27454.3.S1_a_at -1.3 3.4 1.1 NM_004044 5-aminoimidazole-4-carboxamide ribonucleotide formyltransf
Ssc.27454.2.S1_at -1.2 3.4 1.1 NM_004044 5-aminoimidazole-4-carboxamide ribonucleotide formyltransf
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Ssc.8027.1.A1_at 1.3 2.8 1.2 NM_001018057 dickkopf homolog 3Cluster 4
cont. Ssc.21922.1.S1_at 2.9 3.2 1.3 NM_021630 PDZ and LIM domain 2
Ssc.383.1.S1_at 1.2 3.9 1.4 NM_139212 homeodomain-only protein
Ssc.17206.1.A1_at 1.7 4.7 1.4 NM_133367 progestin and adipoQ receptor family member VIII
Ssc.15740.2.S1_a_at 1.0 3.7 1.6 NM_003376 vascular endothelial growth factor
Ssc.15740.1.S2_at -1.1 3.9 1.8 NM_003376 vascular endothelial growth factor
Ssc.10319.1.A1_at 1.3 4.0 2.2 NM_023016 chromosome 2 open reading frame 26
Ssc.22043.1.S1_at -1.4 4.3 2.4 NM_001546 inhibitor of DNA binding 4; dominant negative helix-loop-h
n = 17 1.4 3.4 1.2
Ssc.279.1.S2_at 1.7 1.2 -54.0 NM_000349 steroidogenic acute regulatorCluster 5
Ssc.27593.1.S1_at 2.3 -6.9 -46.0 NM_003239 transforming growth factor; beta 3
Ssc.279.1.S1_at 2.0 1.4 -37.1 NM_000349 steroidogenic acute regulator
Ssc.6138.1.S1_at 2.5 -6.3 -10.8 #N/A #N/A
Ssc.22559.1.S1_at 2.3 -2.2 -10.5 #N/A #N/A
Ssc.4415.1.S1_at 2.2 -3.7 -5.7 NM_000697 arachidonate 12-lipoxygenase
Ssc.3102.1.S1_at 2.0 1.2 -5.6 NM_012152 endothelial differentiation; lysophosphatidic acid G-protei
Ssc.5396.1.S1_at 2.9 1.7 -4.6 NM_198392 transcription factor 21
Ssc.15588.1.S2_at 3.1 -3.2 -4.4 NM_000598 insulin-like growth factor binding protein 3
Ssc.20017.2.S1_at 1.8 -1.4 -4.3 NM_005964 myosin; heavy polypeptide 10; non-muscle
Ssc.14085.1.A1_at 1.9 -1.6 -4.0 #N/A #N/A
Ssc.5471.1.A1_at 1.9 -4.0 -3.9 #N/A #N/A
Ssc.7157.1.A1_at 2.1 -1.1 -3.4 NM_000519 hemoglobin; delta
Ssc.26781.1.A1_at 1.9 -2.5 -3.4 #N/A #N/A
Ssc.4580.1.A1_at 1.9 -1.3 -2.9 NM_152277 dendritic cell-derived ubiquitin-like protein
Ssc.12356.1.A1_at 2.1 -1.0 -2.2 NM_024315 chromosome 7 open reading frame 23
Ssc.7403.1.A1_at 2.1 -1.2 -1.8 #N/A #N/A
Ssc.27288.1.S1_at 2.3 1.1 -1.8 NM_033505 selenoprotein I
Ssc.28471.2.S1_at 2.2 1.1 -1.7 NM_001894 casein kinase 1; epsilon
Ssc.14204.3.S1_at 2.9 -1.2 -1.7 #N/A #N/A
Ssc.14204.1.A1_at 2.7 -1.3 -1.4 #N/A #N/A
Ssc.4127.2.A1_at 2.1 -1.1 -1.3 NM_005168 Rho family GTPase 3
Ssc.4127.1.A1_at 2.4 1.3 -1.3 NM_005168 Rho family GTPase 3
Ssc.16202.1.S1_at 2.7 -1.6 -1.3 #N/A #N/A
253
Cluster 5 Ssc.9607.1.A1_at 2.9 -2.3 -1.2 NM_203417 Down syndrome critical region gene 1
cont. Ssc.3189.1.A1_at 2.1 -2.5 1.1 NM_004414 Down syndrome critical region gene 1
n = 26 2.3 -1.3 -2.5
Ssc.3673.1.S1_at 1.4 -5.3 -125.9 NM_003049 solute carrier family 10Cluster 6
Ssc.26876.1.A1_at 1.1 -1.8 -120.0 #N/A #N/A
Ssc.14095.1.A1_at 1.6 -6.2 -28.6 #N/A #N/A
Ssc.14484.3.A1_a_at 1.5 -1.4 -27.7 NM_031226 cytochrome P450; family 19; subfamily A; polypeptide 1
Ssc.14541.1.S1_s_at 1.4 -1.5 -25.5 NM_031226 cytochrome P450; family 19; subfamily A; polypeptide 1
Ssc.27433.1.S1_at 1.5 -9.0 -20.0 NM_000359 transglutaminase 1
Ssc.14484.1.A1_at 1.2 -1.6 -16.8 NM_031226 cytochrome P450; family 19; subfamily A; polypeptide 1
Ssc.7751.1.A1_at 1.5 -7.2 -16.7 #N/A #N/A
Ssc.2282.1.A1_at 1.4 -4.3 -14.3 NM_016357 epithelial protein lost in neoplasm beta
Ssc.6940.1.A1_s_at 1.2 -2.0 -13.2 NM_022337 RAB38; member RAS oncogene family
Ssc.6055.1.A1_at 1.4 -8.9 -10.5 NM_181785 hypothetical protein LOC283537
Ssc.5404.1.S1_at 1.1 -2.4 -9.6 NM_019556 motile sperm domain containing 1
Ssc.27480.1.S1_at 1.4 -1.7 -9.3 NM_003212 teratocarcinoma-derived growth factor 1
Ssc.14484.3.S1_at 1.5 -1.3 -9.2 NM_031226 cytochrome P450; family 19; subfamily A; polypeptide 1
Ssc.6219.1.A1_at 1.4 -2.5 -8.5 #N/A #N/A
Ssc.7565.2.S1_at 1.6 -3.0 -8.2 #N/A #N/A
Ssc.14422.2.S1_at 1.6 -4.0 -8.2 NM_016206 vestigial-like 3
Ssc.4272.1.A1_at 1.4 -6.4 -8.1 #N/A #N/A
Ssc.14422.1.A1_at 1.5 -3.9 -7.8 #N/A #N/A
Ssc.1310.1.S1_at 1.2 -1.9 -7.2 NM_004878 prostaglandin E synthase
Ssc.18343.1.A1_at 1.1 -1.2 -6.9 NM_001006625 lung type-I cell membrane-associated glycoprotein
Ssc.26868.1.S1_at -1.0 -1.3 -6.9 NM_002863 phosphorylase; glycogen; liver
Ssc.2237.1.A1_at 1.3 -3.1 -6.9 NM_016206 vestigial-like 3
Ssc.24136.1.A1_at 1.8 -4.8 -6.4 #N/A #N/A
Ssc.7470.1.S1_at 1.2 -1.7 -6.4 NM_003212 teratocarcinoma-derived growth factor 1
Ssc.14533.1.S1_at 1.2 -2.6 -6.4 NM_002910 renin binding protein
Ssc.7565.1.A1_at 1.3 -3.6 -6.2 NM_016206 vestigial-like 3
Ssc.20489.1.S1_at 1.2 -1.4 -6.2 NM_002391 midkine
Ssc.7116.1.A1_at 1.5 -4.6 -6.2 NM_016489 5-nucleotidase; cytosolic III
Ssc.8213.2.A1_at 1.2 -2.0 -5.9 NM_024613 pleckstrin homology domain containing; family F
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Cluster 6 Ssc.6276.2.S1_at 1.5 -2.8 -5.7 NM_020676 abhydrolase domain containing 6
cont. Ssc.6276.1.S1_at 1.3 -2.9 -5.5 NM_020676 abhydrolase domain containing 6
Ssc.9740.1.A1_at 1.7 -2.6 -5.4 #N/A #N/A
Ssc.14114.1.A1_at 1.5 -2.6 -5.4 NM_002858 ATP-binding cassette; sub-family D
Ssc.24018.1.S1_at 1.3 -1.4 -5.3 #N/A #N/A
Ssc.2165.2.S1_a_at 1.3 -1.9 -5.2 NM_006142 stratifin
Ssc.1477.1.A1_at 1.2 -2.8 -5.2 #N/A #N/A
Ssc.6654.1.A1_at 1.5 -4.9 -5.0 #N/A #N/A
Ssc.4891.1.A1_at 1.5 -1.6 -5.0 NM_032717 hypothetical protein MGC11324
Ssc.14470.1.S1_at 1.6 -1.4 -4.9 NM_002444 moesin
Ssc.26809.1.A1_at 1.7 -3.2 -4.8 NM_021020 leucine zipper; putative tumor suppressor 1
Ssc.231.1.S2_at 1.3 -1.4 -4.7 NM_004109 ferredoxin 1
Ssc.21917.3.S1_at 1.3 -1.8 -4.7 NM_017882 ceroid-lipofuscinosis; neuronal 6; late infantile; variant
Ssc.529.1.S1_at 1.0 -1.4 -4.7 NM_006432 Niemann-Pick disease; type C2
Ssc.28162.1.A1_at 1.2 -2.2 -4.7 NM_018841 guanine nucleotide binding protein
Ssc.7602.1.A1_at 1.5 -1.2 -4.6 #N/A #N/A
Ssc.11816.1.A1_at 1.4 -2.2 -4.6 NM_002858 ATP-binding cassette; sub-family D
Ssc.18377.3.S1_a_at 1.3 -1.7 -4.5 NM_002560 purinergic receptor P2X; ligand-gated ion channel; 4
Ssc.9739.1.A1_at 1.5 -2.7 -4.5 #N/A #N/A
Ssc.13587.1.A1_at 1.4 -2.0 -4.5 NM_001149 ankyrin 3; node of Ranvier
Ssc.13587.2.S1_at 1.4 -2.6 -4.4 NM_001149 ankyrin 3; node of Ranvier
Ssc.21016.1.S1_at 1.2 -2.1 -4.4 NM_002906 radixin
Ssc.12832.1.A1_at 1.4 -2.5 -4.4 NM_052873 MGC16028 similar to RIKEN cDNA 1700019E19 gene
Ssc.1028.1.S1_at 1.3 -3.4 -4.4 NM_032312 hypothetical protein MGC11061
Ssc.19659.2.S1_at 1.5 1.2 -4.3 NM_005768 putative protein similar to nessy
Ssc.18377.3.S1_at 1.3 -1.5 -4.3 NM_002560 purinergic receptor P2X; ligand-gated ion channel; 4
Ssc.9392.3.A1_at 1.6 -1.0 -4.3 #N/A #N/A
Ssc.22399.1.A1_at 1.3 -4.0 -4.2 #N/A #N/A
Ssc.1817.1.S1_at 1.3 -2.7 -4.2 NM_020728 family with sequence similarity 62
Ssc.31120.1.A1_at 1.4 -1.9 -4.1 NM_003743 nuclear receptor coactivator 1
Ssc.1434.1.A1_at 1.1 -1.8 -4.1 NM_013974 dimethylarginine dimethylaminohydrolase 2
Ssc.29106.1.S1_at 1.3 -1.7 -4.1 #N/A #N/A
Ssc.6940.1.A1_at 1.1 -1.8 -4.1 NM_022337 RAB38; member RAS oncogene family
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Cluster 6 Ssc.17427.1.S1_at 1.3 -1.7 -4.0 NM_006317 brain abundant; membrane attached signal protein 1
cont. Ssc.6812.1.A1_at 1.1 -1.9 -4.0 #N/A #N/A
Ssc.5941.2.S1_at 1.3 -1.4 -4.0 NM_001102 actinin; alpha 1
Ssc.6163.1.A1_at 1.6 -3.3 -4.0 NM_005239 v-ets erythroblastosis virus E26 oncogene homolog 2
Ssc.20489.1.S1_s_at 1.1 -1.3 -4.0 NM_002391 midkine
Ssc.9392.2.S1_at 1.6 -1.0 -4.0 #N/A #N/A
Ssc.6163.2.S1_at 1.7 -2.8 -3.9 NM_005239 v-ets erythroblastosis virus E26 oncogene homolog 2
Ssc.11528.1.A1_at 1.5 -2.9 -3.9 NM_014622 loss of heterozygosity; 11; chromosomal region 2; gene A
Ssc.1414.1.A1_at 1.5 -2.3 -3.9 NM_147223 nuclear receptor coactivator 1
Ssc.18377.1.S1_at 1.3 -1.7 -3.9 NM_175567 purinergic receptor P2X; ligand-gated ion channel; 4
Ssc.21917.1.S1_a_at 1.3 -1.8 -3.9 #N/A #N/A
Ssc.3079.1.S1_at 1.4 -3.0 -3.9 NM_012396 pleckstrin homology-like domain; family A; member 3
Ssc.26816.1.S1_at 1.5 -5.4 -3.9 NM_145176 solute carrier family 2
Ssc.19688.1.S1_at 1.3 -2.8 -3.8 NM_000079 cholinergic receptor; nicotinic; alpha polypeptide 1
Ssc.24970.2.S1_at 1.2 -1.4 -3.8 NM_032839 disrupted in renal carcinoma 2
Ssc.22120.1.S1_a_at 1.2 -2.2 -3.8 NM_001017927 hypothetical protein LOC130355
Ssc.21382.1.A1_at 1.2 -4.3 -3.7 NM_004419 dual specificity phosphatase 5
Ssc.29852.1.A1_at 1.2 -1.9 -3.7 #N/A #N/A
Ssc.11450.1.S1_at 1.0 -1.7 -3.7 NM_001288 chloride intracellular channel 1
Ssc.6365.1.A1_at 1.8 -2.1 -3.6 NM_033071 spectrin repeat containing; nuclear envelope 1
Ssc.25037.2.S1_at -1.2 1.2 -3.6 NM_016300 cyclic AMP-regulated phosphoprotein; 21 kD
Ssc.27588.1.S1_at 1.2 -2.9 -3.6 NM_014861 KIAA0703 gene product
Ssc.18612.1.S1_at 1.1 -1.4 -3.6 #N/A #N/A
Ssc.25059.1.A1_at 1.2 -1.8 -3.6 NM_019850 neuronal guanine nucleotide exchange factor
Ssc.4739.1.S1_at 1.2 -2.7 -3.6 NM_024959 solute carrier family 24
Ssc.5620.1.A1_at 1.3 -2.9 -3.6 NM_005749 transducer of ERBB2; 1
Ssc.14257.1.A1_at 1.2 -2.3 -3.6 NM_005749 transducer of ERBB2; 1
Ssc.8700.1.A1_at 1.2 -1.7 -3.5 NM_005968 heterogeneous nuclear ribonucleoprotein M
Ssc.1414.2.S1_at 1.4 -1.7 -3.5 NM_003743 nuclear receptor coactivator 1
Ssc.11816.2.A1_a_at 1.3 -2.3 -3.5 NM_002858 ATP-binding cassette; sub-family D
Ssc.1432.1.A1_at 1.1 -1.3 -3.4 NM_000413 hydroxysteroid
Ssc.9918.1.A1_at 1.2 -2.3 -3.4 NM_004504 HIV-1 Rev binding protein
Ssc.30951.1.A1_at 1.1 -1.7 -3.4 NM_006350 follistatin
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Cluster 6 Ssc.24817.1.A1_at 1.4 -2.3 -3.4 #N/A #N/A
cont. Ssc.13729.1.A1_at 1.1 -1.8 -3.4 #N/A #N/A
Ssc.5554.1.S1_at 1.3 -1.1 -3.4 NM_030579 outer mitochondrial membrane cytochrome b5
Ssc.17250.1.S1_at 1.1 -2.1 -3.3 NM_000320 quinoid dihydropteridine reductase
Ssc.11577.1.A1_at 1.3 -1.4 -3.3 #N/A #N/A
Ssc.22641.3.S1_at 1.1 -1.5 -3.3 NM_003708 retinol dehydrogenase 16
Ssc.9538.1.S1_at 1.1 -1.7 -3.2 NM_173475 hypothetical protein MGC48972
Ssc.19602.2.S1_at 1.0 -1.7 -3.2 NM_000086 ceroid-lipofuscinosis; neuronal 3; juvenile
Ssc.31120.2.S1_at 1.4 -1.7 -3.2 NM_147223 nuclear receptor coactivator 1
Ssc.21770.1.A1_at 1.4 -1.8 -3.2 NM_013304 zinc finger; DHHC-type containing 1
Ssc.1199.1.A1_at 1.1 -2.2 -3.2 NM_000414 hydroxysteroid
Ssc.10226.1.A3_at 1.3 -1.2 -3.2 NM_004040 ras homolog gene family; member B
Ssc.6916.1.S1_at 1.4 -1.9 -3.2 NM_031206 LAS1-like
Ssc.14162.1.A1_at 1.4 -3.1 -3.2 #N/A #N/A
Ssc.10274.1.A1_at 1.1 -1.9 -3.2 #N/A #N/A
Ssc.1414.1.A1_a_at 1.3 -1.9 -3.1 NM_147223 nuclear receptor coactivator 1
Ssc.18511.1.S1_at 1.3 -1.8 -3.1 NM_152359 carnitine palmitoyltransferase 1C
Ssc.10226.1.A2_at 1.2 -1.2 -3.1 NM_004040 ras homolog gene family; member B
Ssc.17400.1.S1_at 1.4 -2.1 -3.1 NM_033071 spectrin repeat containing; nuclear envelope 1
Ssc.12400.1.S1_at 1.4 -1.9 -3.1 NM_014580 solute carrier family 2;
Ssc.26621.1.S1_at 1.1 -1.2 -3.1 NM_153694 synaptonemal complex protein 3
Ssc.14480.1.S1_at 1.3 1.1 -3.1 NM_001221 calciumcalmodulin-dependent protein kinase
Ssc.18456.2.S1_at 1.6 -2.5 -3.0 NM_005239 v-ets erythroblastosis virus E26 oncogene homolog 2
Ssc.9284.1.S1_at 1.2 -2.1 -3.0 NM_020728 family with sequence similarity 62
Ssc.25577.1.S1_at -1.2 1.1 -3.0 #N/A #N/A
Ssc.3666.1.A1_at 1.0 -1.4 -3.0 #N/A #N/A
Ssc.235.1.S1_a_at 1.5 -1.9 -3.0 NM_001750 calpastatin
Ssc.13644.1.A1_at 1.1 -1.5 -3.0 #N/A #N/A
Ssc.5362.2.S1_at 1.6 -1.2 -3.0 NM_014397 NIMA
Ssc.18377.2.S1_at 1.2 -1.9 -2.9 NM_002560 purinergic receptor P2X; ligand-gated ion channel; 4
Ssc.6078.1.A1_at 1.1 -1.8 -2.9 #N/A #N/A
Ssc.3452.1.A1_at 1.0 -1.2 -2.9 NM_182540 DEADH
Ssc.5362.1.S1_at 1.5 -1.4 -2.9 NM_014397 NIMA
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Cluster 6 Ssc.23809.2.S1_at 1.3 -1.1 -2.9 #N/A #N/A
cont. Ssc.19175.2.S1_at 1.4 -4.0 -2.9 #N/A #N/A
Ssc.16726.1.A1_at 1.2 -2.5 -2.9 #N/A #N/A
Ssc.11790.1.S1_at 1.4 -1.6 -2.9 NM_006224 phosphatidylinositol transfer protein; alpha
Ssc.14470.1.S2_at 1.3 -1.5 -2.9 NM_002444 moesin
Ssc.24222.1.A1_at 1.1 -1.6 -2.9 NM_198240 restin
Ssc.12826.2.A1_a_at 1.2 -2.1 -2.8 NM_138463 hypothetical protein BC014072
Ssc.10263.1.A1_at -1.2 -1.1 -2.8 NM_152903 kelch repeat and BTB
Ssc.2768.1.S1_at 1.3 -1.7 -2.8 #N/A #N/A
Ssc.3584.2.S1_at 1.1 -1.4 -2.8 NM_001943 desmoglein 2
Ssc.16934.1.S1_at 1.1 -2.0 -2.8 NM_024417 ferredoxin reductase
Ssc.12448.1.S1_at 1.2 -2.0 -2.8 #N/A #N/A
Ssc.1367.1.A1_at 1.3 -1.5 -2.8 NM_003114 sperm associated antigen 1
Ssc.18475.3.A1_at 1.4 -1.2 -2.8 NM_152331 peroxisomal acyl-CoA thioesterase 2B
Ssc.6425.2.S1_at 1.4 -1.5 -2.8 NM_001023587 ATP-binding cassette; sub-family C
Ssc.11911.1.A1_at 1.4 -1.5 -2.8 NM_145284 similar to hypothetical protein MGC17347
Ssc.16722.2.S1_at 1.5 -1.2 -2.8 NM_152391 chromosome 2 open reading frame 22
Ssc.18718.1.A1_at 1.2 -1.9 -2.8 #N/A #N/A
Ssc.24968.2.S1_at 1.4 -1.0 -2.7 NM_014062 nin one binding protein
Ssc.27241.1.S1_at 1.2 -4.1 -2.7 NM_170692 RAS protein activator like 2
Ssc.4858.1.S1_at 1.6 -2.4 -2.7 NM_001012515 ferrochelatase
Ssc.19297.1.S1_at 1.3 -1.6 -2.7 NM_000391 tripeptidyl peptidase I
Ssc.30898.1.S1_at 1.1 -1.6 -2.7 NM_198240 restin
Ssc.23758.2.A1_at 1.4 -2.9 -2.7 NM_181785 hypothetical protein LOC283537
Ssc.3584.3.S1_at 1.0 -1.5 -2.7 NM_001943 desmoglein 2
Ssc.2491.1.S1_at 1.2 -2.4 -2.7 NM_172169 calciumcalmodulin-dependent protein kinase
Ssc.16934.2.S1_at 1.3 -1.4 -2.7 NM_024417 ferredoxin reductase
Ssc.235.2.S1_at 1.5 -2.4 -2.7 NM_001750 calpastatin
Ssc.4747.1.S1_at -1.0 -1.7 -2.7 NM_013409 follistatin
Ssc.231.1.S1_at 1.1 -1.1 -2.7 NM_004109 ferredoxin 1
Ssc.11096.1.S1_at 1.1 -1.4 -2.7 NM_000436 3-oxoacid CoA transferase 1
Ssc.27871.2.S1_at 1.2 -1.3 -2.7 NM_139274 acetyl-Coenzyme A synthetase 2
Ssc.1657.1.S1_at 1.2 -2.1 -2.7 NM_005688 ATP-binding cassette; sub-family C
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Cluster 6 Ssc.29845.1.A1_at 1.1 -2.0 -2.7 NM_022087 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgal
cont. Ssc.17250.1.S1_a_at 1.1 -1.7 -2.7 NM_000320 quinoid dihydropteridine reductase
Ssc.12474.1.A1_at 1.1 -2.0 -2.7 #N/A #N/A
Ssc.20355.1.S1_at 1.3 -2.2 -2.6 NM_015178 Rho-related BTB domain containing 2
Ssc.11404.1.A1_at 1.1 -2.1 -2.6 NM_000332 ataxin 1
Ssc.460.1.S1_at 1.3 -1.4 -2.6 NM_012094 peroxiredoxin 5
Ssc.11770.1.S1_at 1.1 -1.7 -2.6 NM_203352 PDZ and LIM domain 7
Ssc.8845.1.S1_at 1.2 -1.1 -2.6 NM_001423 epithelial membrane protein 1
Ssc.23919.1.S1_at 1.2 -1.6 -2.6 #N/A #N/A
Ssc.2627.2.S1_at 1.1 -1.5 -2.6 NM_002353 tumor-associated calcium signal transducer 2
Ssc.13485.1.A1_at 1.3 -2.8 -2.6 #N/A #N/A
Ssc.6345.1.S1_at 1.0 -1.5 -2.6 NM_024657 zinc finger; CW type with coiled-coil domain 2
Ssc.8776.1.S1_at 1.5 1.0 -2.6 NM_000781 cytochrome P450; family 11; subfamily A; polypeptide 1
Ssc.2768.3.S1_at 1.3 -1.3 -2.5 NM_000437 platelet-activating factor acetylhydrolase 2; 40kDa
Ssc.773.2.S1_a_at 1.0 -1.7 -2.5 NM_080593 histone 1; H2bk
Ssc.4046.2.S1_at 1.1 -1.4 -2.5 NM_004341 carbamoyl-phosphate synthetase 2; aspartate transcarbamyla
Ssc.7435.1.A1_at 1.2 -1.5 -2.5 NM_020474 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgal
Ssc.22526.1.A1_at 1.3 -2.9 -2.5 #N/A #N/A
Ssc.7024.1.A1_at 1.1 -2.0 -2.5 #N/A #N/A
Ssc.16831.1.S1_at 1.1 -1.9 -2.5 NM_032285 hypothetical protein MGC3207
Ssc.27871.1.S1_at 1.1 -1.7 -2.5 NM_018677 acetyl-Coenzyme A synthetase 2
Ssc.17461.1.A1_a_at -1.0 -1.1 -2.5 NM_004411 dynein; cytoplasmic; intermediate polypeptide 1
Ssc.1527.2.A1_at 1.4 -1.1 -2.5 NM_005415 solute carrier family 20
Ssc.6425.3.A1_at 1.3 -1.9 -2.5 NM_001023587 ATP-binding cassette; sub-family C
Ssc.1876.1.S1_at 1.4 1.0 -2.5 NM_005964 myosin; heavy polypeptide 10; non-muscle
Ssc.7289.1.A1_at 1.2 -1.6 -2.5 NM_001008392 CTD
Ssc.828.1.S1_at 1.3 -1.4 -2.5 NM_022911 solute carrier family 26; member 6
Ssc.3897.1.S1_at 1.4 -1.4 -2.5 NM_138501 glycoprotein; synaptic 2
Ssc.11790.3.A1_a_at 1.2 -1.8 -2.5 NM_006224 phosphatidylinositol transfer protein; alpha
Ssc.1018.1.S1_at 1.1 -1.5 -2.5 NM_001752 catalase
Ssc.2768.2.S1_at 1.3 -1.2 -2.5 NM_000437 platelet-activating factor acetylhydrolase 2; 40kDa
Ssc.26612.1.S1_a_at 1.4 -1.2 -2.5 NM_153344 chromosome 6 open reading frame 141
Ssc.16722.1.S1_at 1.1 -1.6 -2.4 NM_152391 chromosome 2 open reading frame 22
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Cluster 6 Ssc.19807.1.S1_at 1.3 -1.5 -2.4 NM_014646 lipin 2
cont. Ssc.7329.1.A1_at 1.1 -2.0 -2.4 #N/A #N/A
Ssc.12013.1.A1_at 1.7 -1.7 -2.4 #N/A #N/A
Ssc.30436.1.A1_at -1.0 -1.0 -2.4 NM_199136 hypothetical protein MGC72075
Ssc.6236.1.S1_at 1.0 -1.9 -2.4 #N/A #N/A
Ssc.24886.1.S1_at 1.4 -1.7 -2.4 NM_001676 ATPase; H+K+ transporting; nongastric; alpha polypeptide
Ssc.9834.2.S1_at 1.0 -1.5 -2.4 #N/A #N/A
Ssc.12209.1.A1_at 1.2 -1.3 -2.4 NM_002610 pyruvate dehydrogenase kinase; isoenzyme 1
Ssc.27365.1.S1_at 1.1 -1.0 -2.4 NM_014961 rap2 interacting protein x
Ssc.30592.1.S1_at 1.2 -1.5 -2.4 NM_005605 protein phosphatase 3
Ssc.15469.1.A1_at 1.2 -2.1 -2.4 NM_016395 butyrate-induced transcript 1
Ssc.13934.1.A1_at 1.1 -1.6 -2.4 NM_002670 plastin 1
Ssc.25032.1.S1_at -1.0 -1.6 -2.4 NM_182728 solute carrier family 7
Ssc.22923.1.S1_at 1.0 -1.4 -2.4 NM_015687 filamin A interacting protein 1
Ssc.9918.2.A1_at 1.2 -1.4 -2.4 NM_004504 HIV-1 Rev binding protein
Ssc.21778.1.S1_at 1.2 -2.6 -2.4 NM_144580 chromosome 1 open reading frame 85
Ssc.3848.1.S1_at 1.1 -1.7 -2.4 NM_015944 CGI-14 protein
Ssc.28680.1.S1_at 1.2 -1.6 -2.4 NM_002821 PTK7 protein tyrosine kinase 7
Ssc.2807.2.A1_at 1.1 -1.4 -2.4 NM_001343 disabled homolog 2; mitogen-responsive phosphoprotein
Ssc.11338.1.S1_a_at 1.1 -2.0 -2.4 NM_016417 chromosome 14 open reading frame 87
Ssc.11969.1.A1_at 1.3 -1.3 -2.4 NM_005766 FERM; RhoGEF
Ssc.26786.1.S1_at 1.7 -1.2 -2.4 #N/A #N/A
Ssc.16377.2.A1_at 1.3 1.2 -2.4 NM_145740 glutathione S-transferase A1
Ssc.834.1.S1_at 1.1 -2.1 -2.3 NM_002668 proteolipid protein 2
Ssc.2966.3.S1_a_at 1.3 1.0 -2.3 NM_138452 dehydrogenasereductase
Ssc.11715.1.A1_at 1.1 -1.8 -2.3 NM_013349 SCIRP10-related protein
Ssc.16873.1.S1_at 1.0 -1.7 -2.3 NM_019045 WD repeat domain 44
Ssc.8161.2.A1_at 1.0 -1.5 -2.3 NM_001981 epidermal growth factor receptor pathway substrate 15
Ssc.8245.1.A1_at 1.1 -1.3 -2.3 #N/A #N/A
Ssc.3802.1.S1_at 1.2 -1.1 -2.3 NM_139207 nucleosome assembly protein 1-like 1
Ssc.824.1.S1_at 1.4 -3.3 -2.3 NM_006147 interferon regulatory factor 6
Ssc.1686.1.S1_at -1.0 -1.2 -2.3 NM_001760 cyclin D3
Ssc.4469.1.A1_at 1.3 -2.6 -2.3 NM_005197 checkpoint suppressor 1
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Cluster 6 Ssc.5607.2.S1_at 1.0 -1.8 -2.3 NM_003748 aldehyde dehydrogenase 4 family; member A1
cont. Ssc.30822.1.A1_at 1.5 -1.2 -2.3 NM_004096 eukaryotic translation initiation factor 4E binding protei
Ssc.17281.1.A1_at -1.0 -1.3 -2.3 NM_033535 F-box and leucine-rich repeat protein 5
Ssc.31184.1.S1_at 1.3 -1.1 -2.3 NM_015982 germ cell specific Y-box binding protein
Ssc.21456.1.S1_at 1.1 -2.0 -2.3 NM_014584 ERO1-like
Ssc.1844.1.S1_at 1.3 -2.0 -2.3 NM_003995 natriuretic peptide receptor Bguanylate cyclase B
Ssc.20653.1.S1_at 1.1 -2.0 -2.3 NM_002447 macrophage stimulating 1 receptor
Ssc.10716.1.A1_at 1.2 -1.7 -2.3 NM_017988 SCY1-like 2
Ssc.8858.1.S1_at 1.2 -1.7 -2.3 NM_145284 similar to hypothetical protein MGC17347
Ssc.12596.2.S1_at 1.1 -1.4 -2.3 #N/A #N/A
Ssc.23179.1.A1_at 1.3 -2.2 -2.3 NM_005539 inositol polyphosphate-5-phosphatase; 40kDa
Ssc.17815.1.S1_at 1.2 -1.8 -2.3 NM_002306 lectin; galactoside-binding; soluble; 3
Ssc.10771.1.A1_at 1.7 -1.6 -2.3 #N/A #N/A
Ssc.1588.1.S1_at 1.1 -2.4 -2.3 NM_017567 N-acetylglucosamine kinase
Ssc.2949.1.S1_at 1.2 -1.8 -2.3 NM_024667 hypothetical protein FLJ12750
Ssc.4254.1.S1_at 1.1 -1.7 -2.3 #N/A #N/A
Ssc.16953.1.S1_at 1.2 -1.6 -2.3 NM_175744 ras homolog gene family; member C
Ssc.27529.1.A1_at 1.3 -1.4 -2.3 NM_001017972 hect domain and RLD 4
Ssc.26155.1.A1_at 1.4 -2.0 -2.3 NM_032283 zinc finger; DHHC-type containing 18
Ssc.7257.1.S1_at 1.1 -2.0 -2.2 #N/A #N/A
Ssc.30922.1.A1_at 1.3 -2.0 -2.2 NM_020468 sorting nexin 14
Ssc.21889.2.A1_at 1.3 -1.5 -2.2 NM_018238 multiple substrate lipid kinase
Ssc.28567.1.A1_at 1.2 -1.5 -2.2 #N/A #N/A
Ssc.2297.1.A1_at 1.1 -1.7 -2.2 #N/A #N/A
Ssc.15720.1.A1_at 1.1 -1.5 -2.2 NM_018235 CNDP dipeptidase 2
Ssc.22622.1.S1_at 1.2 -1.8 -2.2 NM_003971 sperm associated antigen 9
Ssc.1372.1.A1_at -1.1 -1.4 -2.2 NM_014900 COBL-like 1
Ssc.12198.1.A1_at 1.1 -1.3 -2.2 NM_148923 cytochrome b-5
Ssc.30663.1.A1_at 1.1 1.1 -2.2 NM_015275 KIAA1033
Ssc.22454.1.S1_at 1.5 -1.9 -2.2 #N/A #N/A
Ssc.11822.1.A1_at 1.2 -1.2 -2.2 NM_014220 transmembrane 4 L six family member 1
Ssc.977.1.A1_at 1.2 -1.2 -2.2 NM_134264 WD repeat and SOCS box-containing 1
Ssc.24788.1.S1_at 1.3 -1.8 -2.2 #N/A #N/A
261
Cluster 6 Ssc.5968.2.S1_at 1.3 -1.7 -2.2 #N/A #N/A
cont. Ssc.1228.1.S1_at 1.0 -1.6 -2.2 NM_002356 myristoylated alanine-rich protein kinase C substrate
Ssc.13508.2.S1_at -1.1 -1.3 -2.2 NM_016048 isochorismatase domain containing 1
Ssc.25835.1.S1_at -1.0 -1.6 -2.2 #N/A #N/A
Ssc.24928.1.S1_at 1.0 -1.6 -2.2 #N/A #N/A
Ssc.5968.3.A1_at 1.5 -1.4 -2.2 NM_003901 sphingosine-1-phosphate lyase 1
Ssc.24226.1.A1_at 1.3 -1.3 -2.2 #N/A #N/A
Ssc.20238.2.S1_a_at 1.1 -1.8 -2.2 NM_005471 glucosamine-6-phosphate deaminase 1
Ssc.4046.1.S1_at 1.1 -1.7 -2.2 NM_004341 carbamoyl-phosphate synthetase 2; aspartate transcarbamyla
Ssc.22674.1.S1_at 1.1 -1.5 -2.2 NM_139246 chromosome 9 open reading frame 97
Ssc.1015.1.S1_at 1.1 -1.4 -2.2 NM_001154 annexin A5
Ssc.4175.1.A1_at 1.7 -1.3 -2.1 NM_033505 selenoprotein I
Ssc.3749.2.S1_at -1.1 -1.3 -2.1 XM_051264 thioredoxin reductase 3
Ssc.30665.1.S1_at 1.0 -1.2 -2.1 NM_152400 hypothetical protein FLJ39370
Ssc.24182.1.S1_at 1.2 -2.0 -2.1 NM_022918 hypothetical protein FLJ22104
Ssc.26726.1.S1_a_at 1.2 -1.6 -2.1 NM_012320 lysophospholipase 3
Ssc.21889.1.S1_at 1.2 -1.5 -2.1 NM_018238 multiple substrate lipid kinase
Ssc.28330.1.S1_at -1.1 -1.3 -2.1 NM_006148 LIM and SH3 protein 1
Ssc.10721.1.A1_at 1.4 -1.1 -2.1 #N/A #N/A
Ssc.11071.2.S1_a_at 1.4 -1.3 -2.1 NM_014000 vinculin
Ssc.20017.3.A1_at 1.5 -1.1 -2.1 NM_005964 myosin; heavy polypeptide 10; non-muscle
Ssc.13874.2.A1_s_at 1.3 1.0 -2.1 NM_001100 actin; alpha 1; skeletal muscle
Ssc.4129.2.S1_a_at -1.0 -1.6 -2.1 NM_198799 breast carcinoma amplified sequence 4
Ssc.21890.1.S1_at 1.3 -1.1 -2.1 NM_198240 restin
Ssc.2066.1.S1_at 1.1 1.0 -2.1 NM_016066 glutaredoxin 2
Ssc.26661.1.S1_at 1.3 -2.0 -2.1 #N/A #N/A
Ssc.16363.1.S1_at 1.1 -1.8 -2.1 NM_014547 tropomodulin 3
Ssc.16363.1.S2_at 1.1 -1.5 -2.1 NM_014547 tropomodulin 3
Ssc.19224.1.S1_at 1.4 -1.4 -2.1 #N/A #N/A
Ssc.1735.1.S1_at 1.0 -1.1 -2.1 NM_001995 acyl-CoA synthetase long-chain family member 1
Ssc.900.1.A1_at 1.1 -1.7 -2.1 NM_016462 transmembrane protein 14C
Ssc.24086.1.A1_at 1.1 -1.3 -2.1 NM_001008493 enabled homolog
Ssc.30827.2.S1_at 1.3 -1.2 -2.1 NM_015173 TBC1
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Cluster 6 Ssc.30540.1.A1_at 1.1 -1.2 -2.1 NM_005188 Cas-Br-M
cont. Ssc.25026.1.A1_at 1.0 -1.7 -2.1 #N/A #N/A
Ssc.19602.1.A1_at 1.0 -1.7 -2.1 NM_000086 ceroid-lipofuscinosis; neuronal 3; juvenile
Ssc.11499.1.A1_at 1.3 -1.3 -2.1 #N/A #N/A
Ssc.24976.1.S1_at 1.2 -2.5 -2.0 NM_005197 checkpoint suppressor 1
Ssc.14134.1.S1_at 1.1 -1.6 -2.0 NM_020474 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgal
Ssc.3218.1.S1_at 1.0 -1.4 -2.0 NM_003684 MAP kinase interacting serinethreonine kinase 1
Ssc.24039.1.S1_at 1.2 -3.2 -2.0 #N/A #N/A
Ssc.6742.1.A1_at 1.0 -1.3 -2.0 NM_001007100 sterol carrier protein 2
Ssc.19213.1.S1_at -1.2 1.0 -2.0 NM_173553 hypothetical protein FLJ25801
Ssc.6193.1.A1_at 1.2 -2.1 -2.0 NM_130781 RAB24; member RAS oncogene family
Ssc.23345.1.S1_at 1.2 -1.8 -2.0 NM_001004720 NCK adaptor protein 2
Ssc.12885.1.A1_at 1.2 -1.4 -2.0 NM_004096 eukaryotic translation initiation factor 4E binding protei
Ssc.4989.1.A1_at 1.1 -2.0 -2.0 NM_001902 cystathionase
Ssc.6451.1.S1_at 1.1 -1.9 -2.0 #N/A #N/A
Ssc.5870.3.S1_at 1.1 -1.2 -2.0 #N/A #N/A
Ssc.6383.1.A1_at 1.1 -1.1 -2.0 #N/A #N/A
Ssc.27429.1.A1_at 1.2 -2.4 -2.0 NM_182485 cytoplasmic polyadenylation element binding protein 2
Ssc.11006.1.S1_at 1.4 -2.3 -2.0 NM_013322 sorting nexin 10
Ssc.17453.1.S1_at 1.2 -2.2 -2.0 NM_001684 ATPase; Ca++ transporting; plasma membrane 4
Ssc.26309.1.A1_at 1.2 -2.5 -1.9 NM_005197 checkpoint suppressor 1
Ssc.11746.1.A1_at 1.4 -2.7 -1.9 NM_032947 putative small membrane protein NID67
Ssc.25205.1.S1_at 1.4 -2.0 -1.9 #N/A #N/A
Ssc.14139.1.A1_at 1.6 -2.4 -1.8 NM_006117 peroxisomal D3;D2-enoyl-CoA isomerase
Ssc.4274.1.S1_at 1.2 -2.0 -1.8 #N/A #N/A
Ssc.7292.1.S1_at 1.4 -3.1 -1.8 #N/A #N/A
Ssc.29905.1.A1_at 1.2 -2.4 -1.8 #N/A #N/A
Ssc.10232.1.A1_at 1.5 -11.6 -1.8 NM_013262 myosin regulatory light chain interacting protein
Ssc.8038.1.A1_at 1.4 -2.0 -1.7 NM_030627 cytoplasmic polyadenylation element binding protein 4
Ssc.10608.1.S1_at 1.5 -2.2 -1.4 NM_030627 cytoplasmic polyadenylation element binding protein 4
n = 324 1.2 -1.7 -2.8
Ssc.3770.1.A1_at 1.1 -2.8 -2.0 #N/A #N/ACluster 7
Ssc.18860.1.S1_at 1.1 -2.7 -1.9 #N/A #N/A
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Cluster 7 Ssc.5001.2.A1_at 1.0 -2.2 -1.9 #N/A #N/A
cont. Ssc.28434.1.A1_at 1.1 -2.2 -1.9 NM_025219 DnaJ
Ssc.3649.1.A1_at 1.1 -2.5 -1.9 #N/A #N/A
Ssc.28182.1.A1_at -1.1 -2.0 -1.8 NM_006301 mitogen-activated protein kinase kinase kinase 12
Ssc.5622.1.A1_at -1.1 -2.4 -1.8 #N/A #N/A
Ssc.7608.2.S1_at -1.1 -2.1 -1.8 NM_018184 ADP-ribosylation factor-like 10C
Ssc.13318.1.A1_at -1.1 -2.3 -1.8 #N/A #N/A
Ssc.14047.2.A1_at -1.1 -3.0 -1.8 #N/A #N/A
Ssc.18606.1.A1_at -1.1 -2.1 -1.8 #N/A #N/A
Ssc.28044.1.A1_at -1.1 -3.0 -1.7 #N/A #N/A
Ssc.8444.1.S1_at -1.0 -2.1 -1.7 XM_371706 hypothetical protein KIAA1109
Ssc.16537.1.S1_at 1.2 -2.2 -1.7 NM_007229 protein kinase C and casein kinase substrate in neurons 2
Ssc.25172.1.S1_at -1.1 -2.7 -1.7 NM_000820 growth arrest-specific 6
Ssc.11815.1.A1_s_at -1.1 -2.3 -1.7 NM_000426 laminin; alpha 2
Ssc.8002.1.A1_at -1.4 -2.2 -1.7 #N/A #N/A
Ssc.19359.2.S1_at -1.1 -2.3 -1.6 #N/A #N/A
Ssc.21290.1.S1_at -1.3 -3.4 -1.6 NM_014779 TSC22 domain family; member 2
Ssc.3574.1.A1_at 1.1 -2.1 -1.6 NM_145687 mitogen-activated protein kinase kinase kinase kinase 4
Ssc.28933.1.S1_at 1.1 -2.3 -1.6 #N/A #N/A
Ssc.23305.1.S1_at -1.3 -2.3 -1.6 NM_018342 hypothetical protein FLJ11155
Ssc.19621.1.A1_at 1.1 -2.1 -1.6 NM_006844 ilvB
Ssc.3980.1.A1_at -1.4 -2.3 -1.6 NM_014936 ectonucleotide pyrophosphatasephosphodiesterase 4
Ssc.5458.1.S1_at -1.2 -2.3 -1.6 NM_015913 thioredoxin domain containing 12
Ssc.21963.1.S1_at -1.1 -2.0 -1.6 NM_004295 TNF receptor-associated factor 4
Ssc.18528.2.A1_at 1.1 -2.1 -1.6 NM_022736 major facilitator superfamily domain containing 1
Ssc.19359.1.A1_at -1.1 -2.4 -1.6 #N/A #N/A
Ssc.21905.1.S1_at -1.4 -2.3 -1.6 #N/A #N/A
Ssc.24739.1.A1_at -1.6 -2.3 -1.6 #N/A #N/A
Ssc.27521.1.S1_at -1.1 -2.2 -1.6 NM_020324 ATP-binding cassette; sub-family D
Ssc.10990.1.A1_at -1.0 -2.1 -1.6 #N/A #N/A
Ssc.27168.1.S1_at -1.1 -2.1 -1.6 #N/A #N/A
Ssc.9792.1.S1_at -1.0 -2.3 -1.5 NM_020940 KIAA1600
Ssc.24634.1.A1_at -1.0 -2.2 -1.5 #N/A #N/A
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Cluster 7 Ssc.10155.1.S1_at -1.1 -2.0 -1.5 NM_017634 potassium channel tetramerisation domain containing 9
cont. Ssc.1323.1.A1_at 1.1 -2.0 -1.5 NM_005578 LIM domain containing preferred translocation partner in l
Ssc.30212.1.A1_at 1.0 -2.3 -1.5 #N/A #N/A
Ssc.18476.2.S1_a_at -1.2 -2.0 -1.5 NM_033389 slingshot homolog 2
Ssc.22078.1.A1_at -1.0 -2.3 -1.4 NM_003561 phospholipase A2; group X
Ssc.8699.1.A1_at -1.2 -2.6 -1.4 #N/A #N/A
Ssc.20226.1.S1_at -1.2 -2.0 -1.4 NM_015528 ring finger protein 167
Ssc.1624.1.S1_at -1.0 -2.0 -1.4 NM_006369 leucine rich repeat containing 41
Ssc.6738.1.S1_at 1.3 -2.3 -1.4 NM_032622 ligand of numb-protein X
Ssc.15594.3.S1_at 1.2 -2.1 -1.4 #N/A #N/A
Ssc.10327.1.A1_at 1.0 -2.6 -1.4 #N/A #N/A
Ssc.28427.1.A1_at -1.1 -2.3 -1.4 #N/A #N/A
Ssc.2413.1.S1_at -1.0 -2.2 -1.4 NM_000336 sodium channel; nonvoltage-gated 1; beta
Ssc.15594.2.S1_at -1.1 -2.0 -1.4 #N/A #N/A
Ssc.12114.1.S1_a_at 1.1 -2.0 -1.4 NM_005186 calpain 1;
Ssc.14211.1.A1_at -1.0 -3.9 -1.4 #N/A #N/A
Ssc.5563.1.S1_at -1.1 -2.7 -1.4 NM_002899 retinol binding protein 1; cellular
Ssc.12430.3.S1_at -1.0 -2.0 -1.3 NM_002744 protein kinase C; zeta
Ssc.19311.1.A1_at 1.2 -2.0 -1.3 NM_015995 Kruppel-like factor 13
Ssc.5432.1.A1_at -1.1 -2.3 -1.3 #N/A #N/A
Ssc.26898.1.A1_at -1.4 -2.2 -1.3 #N/A #N/A
Ssc.25222.1.S1_at 1.3 -2.9 -1.3 NM_005817 mannose-6-phosphate receptor binding protein 1
Ssc.2140.1.S1_at 1.1 -2.5 -1.3 NM_173176 PTK2B protein tyrosine kinase 2 beta
Ssc.27214.2.S1_at -1.2 -2.0 -1.3 NM_004924 actinin; alpha 4
Ssc.10608.2.A1_at 1.5 -2.1 -1.3 NM_030627 cytoplasmic polyadenylation element binding protein 4
Ssc.24460.1.A1_at -1.1 -3.0 -1.3 #N/A #N/A
Ssc.1808.1.S1_at -1.2 -2.4 -1.3 #N/A #N/A
Ssc.27746.1.S1_at -1.0 -2.6 -1.3 NM_198925 sema domain; immunoglobulin domain
Ssc.3196.1.S1_at 1.1 -2.1 -1.3 NM_000521 hexosaminidase B
Ssc.12430.1.S1_at 1.1 -2.8 -1.2 NM_002744 protein kinase C; zeta
Ssc.4529.1.S1_at 1.1 -2.7 -1.2 NM_181776 solute carrier family 36
Ssc.25022.1.A1_at -1.3 -2.2 -1.2 #N/A #N/A
Ssc.2466.1.S1_at 1.2 -2.1 -1.2 NM_014045 low density lipoprotein receptor-related protein 10
265
Cluster 7 Ssc.6951.1.A1_at 1.3 -4.2 -1.2 #N/A #N/A
cont. Ssc.27147.1.A1_at 1.1 -2.2 -1.2 NM_177532 Ras association
Ssc.1339.1.A1_at -1.1 -2.2 -1.1 NM_139045 SWISNF related; matrix associated; actin dependent regulator
Ssc.30194.1.A1_at -1.1 -4.4 -1.1 NM_207015 N-acetylated alpha-linked acidic dipeptidase 2
Ssc.10025.3.S1_at 1.1 -2.5 -1.1 NM_005195 CCAATenhancer binding protein
Ssc.779.1.S1_at -1.4 -2.3 -1.1 NM_004433 E74-like factor 3
Ssc.21178.1.S1_at -1.8 -2.1 -1.1 #N/A #N/A
Ssc.24540.1.S1_at 1.0 -2.6 -1.0 #N/A #N/A
Ssc.27912.1.S1_at 1.1 -2.3 -1.0 NM_020747 zinc finger protein 608
Ssc.772.1.S1_at -1.1 -2.5 1.0 NM_014316 calcium regulated heat stable protein 1; 24kDa
Ssc.2824.1.S1_at 1.2 -4.1 1.1 NM_198234 ribonuclease; RNase A family; 1
Ssc.9286.1.A1_at -1.1 -3.5 1.1 #N/A #N/A
Ssc.55.1.S1_at 1.1 -2.2 1.1 NM_005228 epidermal growth factor receptor
Ssc.10917.1.A1_at -1.2 -2.3 1.2 NM_181354 oxidation resistance 1
Ssc.25088.1.A1_at 1.2 -2.5 1.2 #N/A #N/A
Ssc.18085.1.A1_at -1.1 -2.4 1.3 #N/A #N/A
Ssc.5580.1.S1_at 1.0 -2.1 1.4 #N/A #N/A
Ssc.8373.1.A1_at 1.3 -3.1 1.4 #N/A #N/A
Ssc.5118.1.S1_at 1.7 -2.0 1.5 NM_005603 ATPase; Class I; type 8B; member 1
Ssc.1977.1.S1_at 1.2 -2.6 1.7 NM_006096 N-myc downstream regulated gene 1
n = 88 -1.0 -2.4 -1.3
Ssc.4142.1.S1_at 1.1 59.2 118.2 NM_181644 hypothetical protein DKFZp761N1114Cluster 8
Ssc.22459.1.A1_at 1.1 15.5 160.3 #N/A #N/A
Ssc.7484.1.S1_at -1.4 45.0 254.7 #N/A #N/A
n = 3 -1.0 39.9 177.7
Ssc.1583.1.A1_at 1.1 4.4 3.1 NM_001624 absent in melanoma 1Cluster 9
Ssc.14340.3.S1_at 1.5 4.8 3.1 NM_004862 lipopolysaccharide-induced TNF factor
Ssc.14400.1.A1_at 1.5 4.0 3.2 NM_147156 transmembrane protein 23
Ssc.29855.1.A1_at 1.5 4.2 3.3 NM_031942 cell division cycle associated 7
Ssc.5016.1.A1_at 1.2 4.2 3.5 #N/A #N/A
Ssc.9063.1.A1_at 1.2 4.6 3.9 #N/A #N/A
Ssc.27431.1.A1_at 1.1 5.1 4.0 NM_005504 branched chain aminotransferase 1; cytosolic
Ssc.246.1.S1_at 1.1 5.1 4.4 NM_001677 ATPase; Na+K+ transporting; beta 1 polypeptide
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Cluster 9 Ssc.13805.1.S1_at 1.1 3.6 4.5 NM_133265 angiomotin
cont. Ssc.25773.1.S1_at 1.1 4.4 4.7 NM_133265 angiomotin
Ssc.6357.1.S1_at 1.2 3.9 4.8 NM_002245 potassium channel; subfamily K; member 1
Ssc.4093.1.A1_at -1.0 4.3 4.8 NM_000619 interferon; gamma
Ssc.11197.1.S1_at 1.2 4.1 4.8 NM_001540 heat shock 27kDa protein 1
Ssc.310.1.S1_at -1.1 3.9 4.9 NM_004963 guanylate cyclase 2C
Ssc.847.1.S1_at 1.0 3.5 5.3 NM_006286 transcription factor Dp-2
Ssc.12491.1.A1_at -1.3 3.7 5.3 NM_024015 homeo box B4
Ssc.196.1.S1_at 1.7 3.7 5.5 NM_000930 plasminogen activator; tissue
Ssc.1407.3.S1_at 1.4 5.4 5.6 NM_007203 PALM2-AKAP2 protein
Ssc.21328.1.S1_at -1.2 4.7 6.0 NM_018050 MANSC domain containing 1
n = 19 1.2 4.3 4.5
Ssc.11255.1.A1_at -1.0 -9.9 -167.1 NM_001009185 acyl-CoA synthetase long-chain family member 6Cluster 10
Ssc.19431.1.S1_at -1.4 -63.0 -110.5 NM_005021 ectonucleotide pyrophosphatasephosphodiesterase 3
Ssc.24311.1.S1_at -1.5 -16.3 -40.5 #N/A #N/A
Ssc.881.1.S1_at -1.1 -4.6 -37.0 NM_145202 proline-rich acidic protein 1
Ssc.24984.1.S1_at -1.0 -8.1 -34.1 #N/A #N/A
Ssc.27256.1.S1_at 1.1 -2.6 -33.6 NM_000405 GM2 ganglioside activator
Ssc.2825.1.S1_at -1.0 -2.6 -33.4 #N/A #N/A
Ssc.15060.1.S1_at 1.2 -3.4 -28.3 NM_000102 cytochrome P450; family 17; subfamily A; polypeptide 1
Ssc.1534.1.A1_at -1.6 -12.7 -28.2 NM_015385 sorbin and SH3 domain containing 1
Ssc.27264.1.S1_at -1.1 -21.2 -27.8 NM_024861 hypothetical protein FLJ22671
Ssc.26185.1.S1_at -1.7 -17.3 -26.7 #N/A #N/A
Ssc.7243.1.A1_at 1.2 -44.5 -26.5 NM_199168 chemokine
Ssc.10403.1.S1_at -1.3 -19.4 -25.3 NM_012101 tripartite motif-containing 29
Ssc.1733.1.A1_at 1.2 -5.6 -22.8 NM_002220 inositol 1;4;5-trisphosphate 3-kinase A
Ssc.19166.1.S1_s_at -1.7 -9.3 -22.7 NM_005170 achaete-scute complex-like 2
Ssc.24430.1.S1_at 1.0 -7.8 -21.5 NM_033274 a disintegrin and metalloproteinase domain 19
Ssc.24372.1.S1_at -2.2 -4.9 -19.9 NM_147161 thioesterase; adipose associated
Ssc.6056.1.S1_at -2.0 -19.7 -18.2 NM_181797 potassium voltage-gated channel; KQT-like subfamily
Ssc.8594.1.A1_at -2.0 -28.8 -17.3 NM_013314 B-cell linker
Ssc.29840.1.A1_at -2.0 -11.8 -17.3 #N/A #N/A
Ssc.1303.1.S1_at 1.1 -3.0 -16.7 NM_030666 serine
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Cluster 10 Ssc.24503.1.S1_at -1.3 -18.4 -16.5 XM_496688 hypothetical protein BC012029
cont. Ssc.3785.1.S1_a_at -1.3 -6.5 -14.8 XM_379250 hypothetical LOC401115
Ssc.2963.1.S1_at -1.7 -5.9 -13.1 #N/A #N/A
Ssc.3442.1.S1_at -1.1 -3.5 -13.0 #N/A #N/A
Ssc.4076.1.S1_at -1.9 -6.4 -12.3 NM_015225 KIAA0367
Ssc.2492.1.A1_at 1.0 -9.2 -12.0 #N/A #N/A
Ssc.17364.1.S1_at -1.2 -11.8 -12.0 NM_015444 Ras-induced senescence 1
Ssc.3012.1.S1_at -2.7 -8.6 -11.9 NM_181597 uridine phosphorylase 1
Ssc.23963.1.S1_at -1.5 -2.3 -11.9 NM_014059 response gene to complement 32
Ssc.2158.1.A1_at -1.3 -3.7 -11.7 NM_004529 myeloidlymphoid or mixed-lineage leukemia
Ssc.2746.1.A1_at -1.0 -4.8 -11.4 #N/A #N/A
Ssc.5607.1.S1_at 1.1 -3.2 -11.2 NM_003748 aldehyde dehydrogenase 4 family; member A1
Ssc.5434.1.A1_at 1.1 -8.0 -10.9 NM_033274 a disintegrin and metalloproteinase domain 19
Ssc.26690.1.A1_at -1.1 -2.7 -10.8 XM_090294 hypothetical protein FLJ38508
Ssc.2887.1.S1_at 1.1 -5.5 -10.7 NM_000941 P450
Ssc.17965.1.S1_at -2.0 -4.6 -10.6 NM_153347 hypothetical protein FLJ90119
Ssc.19539.2.S1_at -2.3 -5.5 -10.3 NM_018941 ceroid-lipofuscinosis; neuronal 8
Ssc.28059.1.A1_at 1.2 -4.8 -9.9 XM_498662 hypothetical gene supported by AK092922; AL8319
Ssc.9114.1.S1_at 1.1 -5.2 -9.8 NM_024636 tumor necrosis factor; alpha-induced protein 9
Ssc.27372.1.S1_at -1.1 -12.6 -8.7 #N/A #N/A
Ssc.21826.1.S1_at -1.1 -1.9 -8.5 NM_001632 alkaline phosphatase; placental
Ssc.4105.1.S1_at 1.1 -5.4 -8.2 #N/A #N/A
Ssc.64.1.S1_at -1.3 -10.3 -7.8 NM_004827 ATP-binding cassette; sub-family G
Ssc.943.1.S1_at 1.0 -3.4 -7.8 NM_198538 suprabasin
Ssc.19539.1.A1_at -2.4 -5.4 -7.7 #N/A #N/A
Ssc.27183.1.S1_at -1.1 -3.7 -7.5 NM_002068 guanine nucleotide binding protein
Ssc.12727.2.A1_at 1.2 -9.0 -7.1 #N/A #N/A
Ssc.3699.1.S1_at -1.0 -2.0 -7.0 NM_178140 PDZ domain containing 3
Ssc.12727.1.A1_at 1.1 -6.8 -6.7 #N/A #N/A
Ssc.12802.1.A1_at -1.0 -10.5 -6.7 #N/A #N/A
Ssc.24768.1.S1_at -2.0 -3.4 -6.3 NM_152729 5-nucleotidase; cytosolic II-like 1
Ssc.4204.1.S1_at -1.4 -4.8 -6.1 NM_004130 glycogenin
Ssc.24593.1.A1_at -1.1 -4.6 -6.1 #N/A #N/A
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Cluster 10 Ssc.9553.1.A1_s_at -1.3 -2.1 -6.1 NM_014059 response gene to complement 32
cont. Ssc.16120.1.S1_at -1.2 -3.4 -6.1 NM_005536 inositol
Ssc.25189.1.S1_a_at 1.1 -4.2 -6.0 NM_020784 KIAA1344
Ssc.16236.1.S1_at -1.9 -7.6 -6.0 NM_001935 dipeptidylpeptidase 4
Ssc.16250.1.S2_at 1.0 -4.4 -6.0 NM_173841 interleukin 1 receptor antagonist
Ssc.26693.1.S1_at -1.1 -5.2 -5.9 NM_002639 serine
Ssc.25134.1.A1_at -1.0 -4.6 -5.9 NM_020784 KIAA1344
Ssc.21383.1.A1_at -1.9 -6.9 -5.9 NM_178500 phosphatase; orphan 1
Ssc.5848.2.S1_a_at -1.3 -6.9 -5.8 NM_004776 UDP-Gal:betaGlcNAc beta 1;4- galactosyltransferase; polype
Ssc.25155.1.S1_at -1.2 -4.9 -5.7 NM_018390 phosphatidylinositol-specific phospholipase C; X domain con
Ssc.28921.1.S1_at -1.2 -4.2 -5.6 #N/A #N/A
Ssc.13611.1.A1_at -2.3 -3.4 -5.6 NM_152729 5-nucleotidase; cytosolic II-like 1
Ssc.27947.1.S1_at -1.3 -2.9 -5.6 NM_013401 RAB3A interacting protein
Ssc.16725.1.S1_at -1.1 -2.5 -5.6 NM_033375 myosin IC
Ssc.7469.1.S1_at -1.0 -3.6 -5.6 NM_022087 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgal
Ssc.19455.1.S1_at 1.1 -2.9 -5.6 #N/A #N/A
Ssc.16334.1.S2_at -1.0 -3.2 -5.5 NM_138578 BCL2-like 1
Ssc.984.1.S1_at -1.0 -1.8 -5.4 NM_002778 prosaposin
Ssc.15252.1.S1_at 1.0 -3.3 -5.4 NM_201533 diacylglycerol kinase; zeta 104kDa
Ssc.1950.1.A1_at -1.3 -3.8 -5.3 #N/A #N/A
Ssc.2285.1.S1_at 1.1 -2.9 -5.3 NM_020424 hypothetical protein A-211C6.1
Ssc.12680.1.A1_at -1.1 -2.1 -5.3 NM_015541 leucine-rich repeats and immunoglobulin-like domains 1
Ssc.12176.1.S1_at 1.1 -3.7 -5.3 NM_022036 G protein-coupled receptor; family C; group 5; member C
Ssc.1093.3.S1_at 1.1 -4.9 -5.2 NM_012193 frizzled homolog 4
Ssc.29966.1.A1_s_at -1.0 -3.4 -5.2 #N/A #N/A
Ssc.2674.1.S1_at 1.2 -4.0 -5.2 #N/A #N/A
Ssc.18111.1.A1_at -1.8 -3.8 -5.1 #N/A #N/A
Ssc.19063.1.S1_at -1.3 -2.5 -5.0 #N/A #N/A
Ssc.12176.3.S1_at 1.1 -4.7 -5.0 NM_018653 G protein-coupled receptor; family C; group 5; member C
Ssc.15926.1.S1_at -1.0 -2.8 -5.0 NM_001285 chloride channel; calcium activated; family member 1
Ssc.19164.1.A1_at -1.4 -3.4 -5.0 #N/A #N/A
Ssc.2142.2.S1_at -1.3 -3.3 -5.0 NM_080881 drebrin 1
Ssc.26303.1.A1_at -1.3 -3.8 -4.9 #N/A #N/A
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Cluster 10 Ssc.28415.1.S1_at -1.2 -4.1 -4.9 NM_031308 epiplakin 1
cont. Ssc.2492.2.S1_at 1.1 -4.5 -4.9 NM_001001669 FLJ41603 protein
Ssc.29858.1.A1_at -1.7 -25.8 -4.9 NM_000927 ATP-binding cassette; sub-family B
Ssc.1093.2.A1_at 1.1 -5.9 -4.8 NM_012193 frizzled homolog 4
Ssc.19455.2.S1_at 1.1 -3.2 -4.8 NM_001003794 monoglyceride lipase
Ssc.773.1.S1_at 1.0 -2.4 -4.8 NM_080593 histone 1; H2bk
Ssc.7593.1.S1_at -1.2 -2.0 -4.8 #N/A #N/A
Ssc.25230.1.S1_at 1.2 -4.9 -4.8 NM_012193 frizzled homolog 4
Ssc.24718.1.S1_at -1.2 -3.7 -4.7 NM_005536 inositol
Ssc.27182.1.S1_at -1.4 -9.6 -4.7 NM_017682 vitelliform macular dystrophy 2-like 1
Ssc.21227.1.S1_at -1.3 -3.6 -4.7 NM_080881 drebrin 1
Ssc.13637.1.A1_at 1.1 -2.7 -4.7 NM_002737 protein kinase C; alpha
Ssc.29246.1.A1_at -1.9 -10.7 -4.6 NM_199461 nanos homolog 1
Ssc.13473.1.A1_at 1.1 -4.4 -4.6 #N/A #N/A
Ssc.23264.1.A1_at -1.0 -4.1 -4.5 #N/A #N/A
Ssc.6618.1.A1_at -1.1 -2.1 -4.5 XM_290546 KIAA0830 protein
Ssc.18773.1.A1_at 1.0 -3.4 -4.4 #N/A #N/A
Ssc.2142.1.S1_at -1.3 -3.2 -4.4 NM_080881 drebrin 1
Ssc.27550.1.S1_at 1.0 -3.7 -4.4 NM_003358 UDP-glucose ceramide glucosyltransferase
Ssc.28458.1.A1_at -1.1 -1.5 -4.4 #N/A #N/A
Ssc.5848.1.S1_at -1.3 -6.7 -4.3 NM_004776 UDP-Gal:betaGlcNAc beta 1;4- galactosyltransferase; polype
Ssc.3610.1.A1_at -1.1 -3.3 -4.3 #N/A #N/A
Ssc.26450.1.A1_at -1.4 -3.2 -4.3 NM_173570 zinc finger; DHHC-type containing 23
Ssc.24414.1.S1_at -1.1 -2.8 -4.3 NM_004879 etoposide induced 2.4 mRNA
Ssc.7568.1.A1_at -1.6 1.0 -4.3 XM_378780 hypothetical protein LOC126536
Ssc.6323.1.S1_at -1.3 -3.6 -4.3 NM_001122 adipose differentiation-related protein
Ssc.422.1.S1_at -1.2 -2.7 -4.3 NM_000876 insulin-like growth factor 2 receptor
Ssc.17674.1.A1_at 1.1 -3.0 -4.3 #N/A #N/A
Ssc.19482.1.A1_at -1.1 -6.6 -4.2 #N/A #N/A
Ssc.16963.1.S1_at -1.2 -5.5 -4.2 NM_004776 UDP-Gal:betaGlcNAc beta 1;4- galactosyltransferase; polype
Ssc.23746.1.S1_at -1.2 -3.7 -4.2 NM_015385 sorbin and SH3 domain containing 1
Ssc.11362.2.S1_at -1.2 -3.1 -4.2 NM_004879 etoposide induced 2.4 mRNA
Ssc.26354.1.S1_at -1.2 -3.0 -4.2 #N/A #N/A
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Cluster 10 Ssc.27369.1.A1_at 1.1 -2.5 -4.2 NM_024422 desmocollin 2
cont. Ssc.25149.1.S1_at -1.3 -4.1 -4.1 #N/A #N/A
Ssc.12402.1.A1_at -1.2 -2.0 -4.1 #N/A #N/A
Ssc.29231.1.A1_at 1.2 -4.4 -4.1 #N/A #N/A
Ssc.9594.1.A1_at -1.4 -1.7 -4.1 NM_015440 methylenetetrahydrofolate dehydrogenase
Ssc.29081.1.S1_at 1.2 -3.7 -4.1 #N/A #N/A
Ssc.1376.1.S1_at -1.0 -3.6 -4.1 NM_020432 putative homeodomain transcription factor 2
Ssc.22476.1.A1_at -1.1 -4.5 -4.1 XM_373594 hypothetical LOC387992
Ssc.1641.1.S1_at -1.1 -2.9 -4.1 NM_004356 CD81 antigen
Ssc.19602.3.S1_at -1.0 -1.7 -4.1 NM_000086 ceroid-lipofuscinosis; neuronal 3; juvenile
Ssc.30264.1.A1_at -1.1 -3.2 -4.0 #N/A #N/A
Ssc.26824.1.A1_at -1.1 -3.1 -4.0 NM_004686 myotubularin related protein 7
Ssc.25158.2.A1_at -1.1 -2.2 -4.0 NM_022725 Fanconi anemia; complementation group F
Ssc.15818.1.S1_at -1.3 -2.7 -4.0 NM_000876 insulin-like growth factor 2 receptor
Ssc.4155.1.S1_at -1.3 -2.1 -3.9 NM_003566 early endosome antigen 1; 162kD
Ssc.24938.1.S1_at -1.2 -3.4 -3.9 NM_001004431 meteorin; glial cell differentiation regulator-like
Ssc.8213.1.A1_at 1.0 -2.2 -3.9 NM_024613 pleckstrin homology domain containing; family F
Ssc.1533.1.S1_at -1.3 -2.0 -3.9 NM_000271 Niemann-Pick disease; type C1
Ssc.19442.1.A1_at 1.1 -6.8 -3.8 #N/A #N/A
Ssc.18132.1.A1_at -1.2 -1.9 -3.8 NM_138571 histidine triad nucleotide binding protein 3
Ssc.27177.2.S1_at -1.3 -7.3 -3.8 #N/A #N/A
Ssc.27177.1.S1_at -1.0 -5.9 -3.8 NM_006095 ATPase; aminophospholipid transporter
Ssc.23758.1.S1_at 1.1 -2.5 -3.8 #N/A #N/A
Ssc.18246.1.S1_at -1.2 -2.6 -3.8 NM_004529 myeloidlymphoid or mixed-lineage leukemia
Ssc.16727.1.A1_at -1.0 -2.1 -3.7 NM_000398 diaphorase
Ssc.2176.1.A1_at 1.2 -4.4 -3.7 NM_203372 acyl-CoA synthetase long-chain family member 3
Ssc.8451.1.A1_at -1.5 -2.0 -3.7 NM_182765 HECT domain containing 2
Ssc.10002.1.A1_at -1.2 -3.3 -3.7 #N/A #N/A
Ssc.23139.1.S1_at -1.1 -2.9 -3.7 NM_002886 RAP2B; member of RAS oncogene family
Ssc.16068.1.S1_at -1.1 -4.9 -3.6 NM_001004452 olfactory receptor; family 1; subfamily J; member 4
Ssc.24102.1.S1_at 1.0 -1.9 -3.6 NM_004504 HIV-1 Rev binding protein
Ssc.25748.1.S1_at -1.0 -2.0 -3.6 NM_004504 HIV-1 Rev binding protein
Ssc.8566.1.A1_at 1.2 -3.8 -3.6 #N/A #N/A
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Cluster 10 Ssc.29424.1.A1_at -1.5 -1.8 -3.6 NM_019012 pleckstrin homology domain containing; family A member 5
cont. Ssc.94.1.A1_at -1.0 -2.9 -3.6 NM_004999 myosin VI
Ssc.2589.1.S1_at -1.5 -5.9 -3.5 NM_000363 troponin I; cardiac
Ssc.1600.3.S1_at 1.0 -2.5 -3.5 NM_020734 KIAA1238 protein
Ssc.10624.1.S1_at -1.0 -2.0 -3.5 NM_014033 DKFZP586A0522 protein
Ssc.29837.1.A1_at -1.1 -1.7 -3.5 #N/A #N/A
Ssc.2925.2.S1_a_at 1.1 -4.2 -3.5 NM_017797 BTB
Ssc.10082.1.A1_at -1.3 -2.1 -3.4 NM_024312 MGC4170 protein
Ssc.23539.1.S1_at -1.2 -2.1 -3.4 NM_152911 polyamine oxidase
Ssc.1764.1.A1_at 1.0 -2.2 -3.4 NM_002906 radixin
Ssc.18261.1.S1_at -1.2 -2.3 -3.4 NM_024430 proline-serine-threonine phosphatase interacting protein 2
Ssc.10534.3.A1_a_at -1.2 -3.3 -3.4 NM_006506 RAS p21 protein activator 2
Ssc.83.1.S1_at -1.2 -2.6 -3.4 NM_001977 glutamyl aminopeptidase
Ssc.25450.1.S1_at -1.1 -2.0 -3.4 #N/A #N/A
Ssc.5793.1.S1_at -1.6 -3.1 -3.3 #N/A #N/A
Ssc.2760.1.A1_at 1.1 -2.2 -3.3 NM_018841 guanine nucleotide binding protein
Ssc.19553.1.A1_at -1.4 -3.6 -3.3 NM_206862 transforming; acidic coiled-coil containing protein 2
Ssc.14425.1.A1_at -1.0 -2.0 -3.3 NM_020921 ninein
Ssc.17377.1.S1_a_at -1.1 -1.8 -3.3 #N/A #N/A
Ssc.6342.1.S1_at -1.5 -1.6 -3.3 NM_153613 PLSC domain containing protein
Ssc.10534.2.S1_at -1.1 -2.1 -3.3 NM_006506 RAS p21 protein activator 2
Ssc.6699.1.A1_at -1.3 -2.9 -3.3 NM_000252 myotubularin 1
Ssc.29750.1.A1_at 1.2 -7.8 -3.2 NM_033285 tumor protein p53 inducible nuclear protein 1
Ssc.30871.1.A1_at 1.2 -6.3 -3.2 NM_033285 tumor protein p53 inducible nuclear protein 1
Ssc.24375.1.S1_at -1.1 -2.9 -3.2 NM_024109 hypothetical protein MGC2654
Ssc.1868.1.S1_at 1.1 -2.6 -3.2 NM_000901 nuclear receptor subfamily 3; group C; member 2
Ssc.24978.2.S1_at -1.4 -6.2 -3.2 #N/A #N/A
Ssc.30316.1.A1_at -1.2 -1.9 -3.2 NM_001007794 cholineethanolamine phosphotransferase 1
Ssc.12650.1.A1_at 1.1 -2.5 -3.2 NM_014616 ATPase; Class VI; type 11B
Ssc.27573.1.S1_at -1.3 -1.3 -3.1 NM_001001132 intersectin 1
Ssc.19478.1.S1_at -1.3 -1.6 -3.1 #N/A #N/A
Ssc.2795.2.S1_at -1.4 -3.1 -3.1 NM_004059 cysteine conjugate-beta lyase; cytoplasmic
Ssc.26084.1.S1_at -1.2 -2.8 -3.1 NM_001001323 ATPase; Ca++ transporting; plasma membrane 1
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Cluster 10 Ssc.27137.1.A1_at -1.2 -2.0 -3.1 #N/A #N/A
cont. Ssc.13508.1.A1_at -1.3 -2.0 -3.0 NM_016048 isochorismatase domain containing 1
Ssc.24396.1.S1_at 1.1 -2.7 -3.0 NM_014216 inositol 1;3;4-triphosphate 56 kinase
Ssc.1525.1.S1_at 1.0 -1.8 -3.0 NM_032219 hypothetical protein FLJ22269
Ssc.4641.1.A1_at -1.4 -2.9 -3.0 NM_017771 PX domain containing serinethreonine kinase
Ssc.12099.1.A1_at -1.0 -2.1 -3.0 #N/A #N/A
Ssc.16937.1.A1_at -1.1 -3.1 -3.0 NM_021202 tumor protein p53 inducible nuclear protein 2
Ssc.21033.2.S1_at -1.0 -1.7 -3.0 NM_006319 CDP-diacylglycerol--inositol 3-phosphatidyltransferase
Ssc.428.12.A1_at 1.0 -2.0 -3.0 #N/A #N/A
Ssc.17458.1.S1_at -1.1 -2.8 -3.0 #N/A #N/A
Ssc.428.23.A1_at -1.1 -4.6 -3.0 #N/A #N/A
Ssc.6342.1.S1_a_at -1.6 -1.2 -3.0 NM_153613 PLSC domain containing protein
Ssc.1623.1.S1_at -1.1 -3.0 -2.9 NM_004415 desmoplakin
Ssc.21192.3.S1_at 1.1 -2.5 -2.9 NM_145687 mitogen-activated protein kinase kinase kinase kinase 4
Ssc.11670.3.A1_at 1.0 -2.6 -2.9 XM_496093 similar to PERP; TP53 apoptosis effector; p53-i
Ssc.9719.1.S1_at -1.4 -1.5 -2.9 NM_018330 KIAA1598
Ssc.8355.1.A1_at -1.4 -2.1 -2.9 NM_018330 KIAA1598
Ssc.3578.1.S1_at -1.0 -2.3 -2.9 NM_020533 mucolipin 1
Ssc.22089.1.A1_at -1.0 -1.9 -2.9 #N/A #N/A
Ssc.18404.1.A1_at -1.1 -2.4 -2.9 #N/A #N/A
Ssc.27052.1.A1_at -1.3 -5.7 -2.9 #N/A #N/A
Ssc.2925.3.S1_a_at 1.1 -3.9 -2.9 #N/A #N/A
Ssc.5314.1.S1_at -1.2 -2.5 -2.8 NM_006149 lectin; galactoside-binding; soluble; 4
Ssc.16485.1.S1_at -1.3 -2.4 -2.8 NM_004252 solute carrier family 9
Ssc.9334.1.S1_at -1.1 -1.4 -2.8 NM_144563 ribose 5-phosphate isomerase A
Ssc.7034.2.S1_at -1.1 -2.6 -2.8 NM_016297 prenylcysteine oxidase 1
Ssc.16333.1.S1_at -1.5 -6.1 -2.8 NM_000927 ATP-binding cassette; sub-family B
Ssc.24795.1.A1_at -1.4 -1.1 -2.8 #N/A #N/A
Ssc.4671.1.A1_at -1.2 -2.5 -2.8 #N/A #N/A
Ssc.14180.1.A1_at 1.0 -2.3 -2.8 NM_015458 myotubularin related protein 9
Ssc.54.1.A1_at -1.0 -2.1 -2.8 NM_001769 CD9 antigen
Ssc.6677.1.S1_at -1.2 -1.7 -2.8 NM_003379 villin 2
Ssc.6441.1.A1_at -1.1 -2.5 -2.7 NM_016029 dehydrogenasereductase
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Cluster 10 Ssc.15515.1.A1_at -1.0 -2.0 -2.7 #N/A #N/A
cont. Ssc.19041.2.S1_at -1.1 -1.7 -2.7 NM_005689 ATP-binding cassette; sub-family B
Ssc.15578.1.A1_at 1.1 -2.6 -2.7 NM_018205 leucine rich repeat containing 20
Ssc.8501.1.S1_at -1.1 -1.6 -2.7 NM_006407 ADP-ribosylation-like factor 6 interacting protein 5
Ssc.26169.1.S1_at -1.2 -2.8 -2.7 #N/A #N/A
Ssc.1957.1.A1_at -1.1 -2.3 -2.7 NM_000259 myosin VA
Ssc.8501.2.A1_at -1.2 -2.0 -2.7 NM_006407 ADP-ribosylation-like factor 6 interacting protein 5
Ssc.14173.1.S1_at -1.1 -5.5 -2.7 #N/A #N/A
Ssc.6783.1.S1_at 1.1 -2.6 -2.7 NM_012338 tetraspanin 12
Ssc.2672.1.S1_at -1.3 -2.5 -2.7 NM_012156 erythrocyte membrane protein band 4.1-like 1
Ssc.26275.1.S1_at -1.2 -2.1 -2.7 NM_015600 chromosome 20 open reading frame 22
Ssc.18208.1.S1_at -1.3 -2.1 -2.7 #N/A #N/A
Ssc.2070.1.S1_at -1.1 -3.4 -2.6 NM_012156 erythrocyte membrane protein band 4.1-like 1
Ssc.17760.1.S1_at -1.2 -2.9 -2.6 NM_002886 RAP2B; member of RAS oncogene family
Ssc.3832.1.S1_at -1.5 -6.1 -2.6 NM_004925 aquaporin 3
Ssc.1732.1.S1_at -1.2 -1.8 -2.6 NM_006407 ADP-ribosylation-like factor 6 interacting protein 5
Ssc.1285.1.S1_at -1.1 -2.7 -2.6 #N/A #N/A
Ssc.15621.1.A1_at 1.0 -2.4 -2.6 #N/A #N/A
Ssc.3255.1.S1_at -1.1 -2.8 -2.6 NM_024071 zinc finger; FYVE domain containing 21
Ssc.24390.1.A1_at -1.4 -2.7 -2.6 XM_370777 Similar to Lysophospholipase
Ssc.1126.1.A1_at 1.0 -3.6 -2.6 NM_006714 sphingomyelin phosphodiesterase; acid-like 3A
Ssc.7985.1.S1_at -1.4 -3.0 -2.6 NM_001682 ATPase; Ca++ transporting; plasma membrane 1
Ssc.30785.1.S1_at -1.1 -2.4 -2.6 NM_007063 TBC1 domain family; member 8
Ssc.24403.1.S1_at -1.3 -1.2 -2.6 NM_002040 GA binding protein transcription factor; alpha subunit 60k
Ssc.7084.1.A1_at -1.8 -2.3 -2.6 #N/A #N/A
Ssc.19229.3.A1_at -1.1 -2.0 -2.6 NM_014857 RAB GTPase activating protein 1-like
Ssc.4833.1.S1_at -1.0 -2.2 -2.6 NM_002881 v-ral simian leukemia viral oncogene homolog B
Ssc.5887.1.A1_at 1.0 -4.6 -2.6 #N/A #N/A
Ssc.8612.1.A1_at -1.1 -2.0 -2.5 #N/A #N/A
Ssc.2925.1.S1_at -1.0 -3.2 -2.5 NM_017797 BTB
Ssc.30491.1.A1_at -1.1 -1.9 -2.5 NM_004483 glycine cleavage system protein H
Ssc.11670.1.A1_at 1.0 -2.0 -2.5 NM_022121 PERP; TP53 apoptosis effector
Ssc.7818.1.A1_at -1.0 -1.8 -2.5 NM_012089 ATP-binding cassette; sub-family B
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Cluster 10 Ssc.541.1.S1_at -1.3 -1.9 -2.5 NM_033553 guanylate cyclase activator 2A
cont. Ssc.27292.1.S1_at -1.5 -7.7 -2.5 #N/A #N/A
Ssc.7238.1.A1_at -1.1 -1.9 -2.5 #N/A #N/A
Ssc.22275.1.S1_at -1.3 -1.7 -2.5 NM_003580 neutral sphingomyelinase
Ssc.5879.4.S1_a_at 1.0 -3.0 -2.5 NM_172171 calciumcalmodulin-dependent protein kinase
Ssc.12693.1.S1_at -1.0 -2.0 -2.5 NM_198402 protein tyrosine phosphatase-like
Ssc.29965.1.A1_at -1.2 -2.7 -2.5 #N/A #N/A
Ssc.23310.1.S1_at -1.1 -2.6 -2.5 NM_000434 sialidase 1
Ssc.24831.1.A1_at -1.1 -2.5 -2.5 NM_133373 phospholipase C; delta 3
Ssc.21915.3.A1_at -1.2 -2.3 -2.5 #N/A #N/A
Ssc.3278.1.A1_at -1.1 -1.8 -2.5 NM_012406 PR domain containing 4
Ssc.4289.1.S1_at -1.3 -1.3 -2.5 #N/A #N/A
Ssc.2795.1.S1_at -1.4 -3.4 -2.4 NM_004059 cysteine conjugate-beta lyase; cytoplasmic
Ssc.8317.1.A1_at -1.1 -2.3 -2.4 NM_019009 toll interacting protein
Ssc.6792.1.A1_at -1.6 -1.9 -2.4 NM_001166 baculoviral IAP repeat-containing 2
Ssc.25412.1.A1_at -1.0 -4.1 -2.4 #N/A #N/A
Ssc.4957.1.S1_at 1.0 -2.1 -2.4 #N/A #N/A
Ssc.26491.1.A1_at -1.2 -1.4 -2.4 NM_006795 EH-domain containing 1
Ssc.9420.1.A1_at -1.1 -2.2 -2.4 NM_201281 myotubularin related protein 2
Ssc.16669.1.S1_at -1.0 -1.7 -2.4 #N/A #N/A
Ssc.25396.1.A1_at -1.3 -3.6 -2.4 #N/A #N/A
Ssc.16392.2.A1_a_at -1.3 -2.9 -2.4 NM_199054 MAP kinase interacting serinethreonine kinase 2
Ssc.5085.1.A1_at -1.1 -2.9 -2.4 NM_006290 tumor necrosis factor; alpha-induced protein 3
Ssc.16392.2.A1_at -1.2 -2.5 -2.4 NM_199054 MAP kinase interacting serinethreonine kinase 2
Ssc.29821.1.A1_at 1.0 -2.4 -2.4 #N/A #N/A
Ssc.2306.1.S1_at -1.0 -2.0 -2.4 NM_015987 heme binding protein 1
Ssc.6425.1.A1_at 1.1 -3.7 -2.3 #N/A #N/A
Ssc.14164.1.A1_at -1.4 -2.3 -2.3 #N/A #N/A
Ssc.16888.1.S1_at -1.1 -1.6 -2.3 NM_005558 ladinin 1
Ssc.1600.1.A1_at -1.3 -2.6 -2.3 NM_020734 KIAA1238 protein
Ssc.6615.1.S1_at -1.4 -2.2 -2.3 #N/A #N/A
Ssc.19024.1.A1_at 1.0 -2.1 -2.3 NM_139182 centaurin; delta 1
Ssc.24128.1.A1_at 1.1 -3.9 -2.3 #N/A #N/A
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Cluster 10 Ssc.7034.1.A1_at -1.2 -2.0 -2.3 NM_016297 prenylcysteine oxidase 1
cont. Ssc.2947.1.S1_at -1.1 -1.7 -2.3 NM_001006665 ribosomal protein S6 kinase; 90kDa; polypeptide 1
Ssc.15594.1.S1_at -1.0 -3.3 -2.3 NM_021149 coactosin-like 1
Ssc.5763.1.A1_at -1.1 -1.9 -2.3 NM_032936 chromosome 7 open reading frame 35
Ssc.7460.1.A1_at -1.5 -1.9 -2.3 NM_006469 influenza virus NS1A binding protein
Ssc.16147.1.S1_at -1.0 -1.8 -2.3 NM_001232 calsequestrin 2
Ssc.19622.1.A1_at -1.3 -2.3 -2.3 NM_007183 plakophilin 3
Ssc.8895.1.S1_at -1.2 -2.5 -2.3 NM_004568 serine
Ssc.4233.1.S1_at -1.5 -2.4 -2.3 NM_022776 oxysterol binding protein-like 11
Ssc.5755.1.S1_at -1.0 -1.6 -2.3 NM_173823 DnaJ
Ssc.21187.1.S1_at -1.0 -2.7 -2.3 #N/A #N/A
Ssc.16496.1.S1_at -1.2 -1.9 -2.3 #N/A #N/A
Ssc.4553.1.S1_at -1.2 -1.5 -2.2 NM_033412 mitochondrial carrier triple repeat 1
Ssc.23953.1.S1_at -1.4 -1.0 -2.2 NM_022484 hypothetical protein FLJ13576
Ssc.30708.1.S1_at -1.2 -1.8 -2.2 NM_006254 protein kinase C; delta
Ssc.26027.1.A1_at -1.2 -1.7 -2.2 #N/A #N/A
Ssc.2064.1.A1_at 1.1 -2.5 -2.2 XM_290615 hypothetical protein DKFZp762F0713
Ssc.12634.1.S1_at -1.0 -2.3 -2.2 NM_014320 heme binding protein 2
Ssc.21275.2.S1_at -1.2 -1.8 -2.2 NM_004703 rabaptin; RAB GTPase binding effector protein 1
Ssc.5179.1.A1_at 1.1 -2.6 -2.2 NM_006549 calciumcalmodulin-dependent protein kinase kinase 2; beta
Ssc.22221.1.S1_a_at -1.5 -3.5 -2.2 NM_000167 glycerol kinase
Ssc.12633.1.S1_at -1.1 -1.8 -2.2 #N/A #N/A
Ssc.68.1.A1_at -1.1 -1.5 -2.2 NM_003850 succinate-CoA ligase; ADP-forming; beta subunit
Ssc.2179.1.S1_at 1.2 -3.9 -2.2 NM_024980 G protein-coupled receptor 157
Ssc.12938.1.A1_at 1.1 -2.6 -2.2 NM_004841 RAS protein activator like 2
Ssc.5793.2.S1_at -1.3 -2.1 -2.2 NM_014698 KIAA0792
Ssc.5000.1.A1_at -1.2 -3.8 -2.2 #N/A #N/A
Ssc.5353.2.S1_at -1.1 -2.1 -2.2 NM_016598 zinc finger; DHHC-type containing 3
Ssc.12282.1.S1_at -1.2 -2.0 -2.2 NM_006243 protein phosphatase 2; regulatory subunit B
Ssc.21275.1.A1_at -1.2 -1.7 -2.2 NM_004703 rabaptin; RAB GTPase binding effector protein 1
Ssc.24766.1.S1_at -1.1 -1.8 -2.2 #N/A #N/A
Ssc.3623.2.A1_at -1.5 -1.5 -2.1 NM_001166 baculoviral IAP repeat-containing 2
Ssc.23132.1.A1_at -1.1 -1.9 -2.1 NM_198039 nudix
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Cluster 10 Ssc.25008.1.S1_at -1.3 -1.9 -2.1 #N/A #N/A
cont. Ssc.22083.1.S1_at -1.5 -1.0 -2.1 NM_005746 pre-B-cell colony enhancing factor 1
Ssc.1746.1.A1_at -1.1 -2.6 -2.1 NM_138782 FCH domain only 2
Ssc.31172.3.S1_at 1.1 -3.9 -2.1 NM_001006946 syndecan 1
Ssc.15316.1.S1_at -1.2 -2.4 -2.1 NM_001311 cysteine-rich protein 1
Ssc.4206.1.A1_at -1.1 -2.3 -2.1 #N/A #N/A
Ssc.5353.1.S1_at -1.1 -1.9 -2.1 NM_016598 zinc finger; DHHC-type containing 3
Ssc.6441.2.S1_at -1.0 -1.8 -2.1 NM_016029 dehydrogenasereductase
Ssc.24193.1.S1_at -1.1 -1.6 -2.1 NM_024719 growth hormone regulated TBC protein 1
Ssc.10991.1.A1_at -1.1 -1.5 -2.1 NM_021160 HLA-B associated transcript 5
Ssc.1600.1.A1_a_at -1.2 -2.5 -2.1 NM_020734 KIAA1238 protein
Ssc.23539.2.S1_at -1.1 -1.6 -2.1 NM_207125 polyamine oxidase
Ssc.5158.1.S1_at -1.1 -2.4 -2.1 NM_024819 hypothetical protein FLJ22955
Ssc.11910.1.S1_at 1.0 -2.1 -2.1 NM_001981 epidermal growth factor receptor pathway substrate 15
Ssc.18208.2.S1_at -1.2 -1.6 -2.1 NM_031436 aldo-keto reductase family 1; member C-like 2
Ssc.15250.1.S1_at -1.1 -2.5 -2.1 #N/A #N/A
Ssc.21033.1.S1_at -1.1 -2.0 -2.1 #N/A #N/A
Ssc.6771.1.S1_a_at -1.0 -1.8 -2.1 NM_003130 sorcin
Ssc.18606.2.A1_at -1.1 -2.3 -2.1 #N/A #N/A
Ssc.27258.1.A1_at -1.0 -2.0 -2.1 NM_004415 desmoplakin
Ssc.17318.1.S1_at -1.1 -1.5 -2.1 NM_003379 villin 2
Ssc.26747.1.A1_at -1.3 -1.9 -2.1 XR_000216 cysteine-rich hydrophobic domain 1
Ssc.17293.1.A1_at -1.1 -2.1 -2.1 NM_020940 KIAA1600
Ssc.11077.1.S1_at -1.1 -1.9 -2.0 NM_003003 SEC14-like 1
Ssc.18756.1.S1_at -1.2 -1.2 -2.0 NM_018650 MAPmicrotubule affinity-regulating kinase 1
Ssc.17918.1.A1_at -1.1 -2.3 -2.0 #N/A #N/A
Ssc.10366.1.A1_at -1.3 -1.7 -2.0 #N/A #N/A
Ssc.6833.1.S1_at -1.1 -2.7 -2.0 NM_001731 B-cell translocation gene 1; anti-proliferative
Ssc.22945.1.S1_at -1.2 -1.9 -2.0 NM_000036 adenosine monophosphate deaminase 1
Ssc.13891.1.A1_at -1.5 -3.8 -2.0 NM_152869 regucalcin
Ssc.3941.1.S1_at -1.2 -2.2 -2.0 #N/A #N/A
Ssc.27835.1.S1_at -1.1 -2.8 -1.9 NM_020132 1-acylglycerol-3-phosphate O-acyltransferase 3
Ssc.9953.1.A1_at -1.5 -2.4 -1.9 #N/A #N/A
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Cluster 10 Ssc.22732.1.S1_at -1.1 -2.2 -1.9 #N/A #N/A
cont. Ssc.31172.1.S1_at 1.0 -4.5 -1.9 NM_001006946 syndecan 1
Ssc.20926.1.S1_at -1.1 -2.1 -1.9 NM_005271 glutamate dehydrogenase 1
Ssc.29953.1.A1_at -1.0 -2.7 -1.9 #N/A #N/A
Ssc.9908.1.A1_at -1.2 -2.4 -1.9 #N/A #N/A
Ssc.8309.1.A1_at -1.1 -2.8 -1.9 NM_016245 dehydrogenasereductase
Ssc.6528.1.S1_at -1.2 -2.4 -1.9 NM_006412 1-acylglycerol-3-phosphate O-acyltransferase 2
Ssc.18096.1.A1_at -1.5 -2.1 -1.8 NM_198353 potassium channel tetramerisation domain containing 8
Ssc.8061.1.A1_at -1.2 -2.3 -1.8 #N/A #N/A
Ssc.5257.1.S1_at -1.5 -2.2 -1.8 NM_006577 UDP-GlcNAc:betaGal beta-1;3-N-acetylglucosaminyltransferas
Ssc.21999.1.S1_a_at -1.4 -2.2 -1.8 NM_000694 aldehyde dehydrogenase 3 family; member B1
Ssc.18893.1.A1_at -1.4 -2.6 -1.7 #N/A #N/A
Ssc.10307.1.A1_at -1.5 -3.9 -1.7 #N/A #N/A
n = 364 -1.1 -2.7 -3.3
Ssc.18619.1.A1_at -1.0 1.3 2.9 NM_021183 RAP2C; member of RAS oncogene familyCluster 11
Ssc.1987.1.S1_at -1.1 1.1 3.0 NM_004740 TGFB1-induced anti-apoptotic factor 1
Ssc.19323.1.S1_at 1.2 -1.1 3.0 NM_138389 hypothetical protein BC001096
Ssc.15674.1.A1_at -1.2 1.6 3.0 XM_497242 similar to Cathepsin L; preproprotein
Ssc.2897.1.S1_at 1.1 1.4 3.0 NM_170662 Cas-Br-M
Ssc.6923.1.A1_at 1.5 1.4 3.0 #N/A #N/A
Ssc.27592.2.S1_at 1.1 1.2 3.0 NM_003956 cholesterol 25-hydroxylase
Ssc.19212.1.S1_at -1.0 1.1 3.0 NM_000387 solute carrier family 25
Ssc.6666.1.A1_at 1.2 1.6 3.0 NM_014575 schwannomin interacting protein 1
Ssc.18578.1.S1_at -1.3 -1.3 3.1 NM_175842 spermine oxidase
Ssc.18900.1.A1_at 1.1 1.1 3.1 #N/A #N/A
Ssc.7697.1.A1_at 1.3 1.8 3.1 #N/A #N/A
Ssc.9279.1.A1_at -1.0 1.1 3.1 #N/A #N/A
Ssc.1798.1.S1_at 1.2 1.4 3.1 NM_003088 fascin homolog 1; actin-bundling protein
Ssc.2567.2.A1_at -1.1 1.7 3.2 #N/A #N/A
Ssc.8427.1.A1_at 1.1 1.4 3.2 NM_018999 KIAA1128
Ssc.30667.1.S1_at -1.3 1.1 3.2 #N/A #N/A
Ssc.11251.1.A1_at 1.0 1.1 3.2 #N/A #N/A
Ssc.24543.1.S1_at 1.2 1.9 3.2 #N/A #N/A
278
Cluster 11 Ssc.7021.1.A1_at 1.2 1.5 3.3 NM_001431 erythrocyte membrane protein band 4.1-like 2
cont. Ssc.3321.1.A1_at 1.2 1.8 3.3 NM_001017423 aldehyde dehydrogenase 18 family; member A1
Ssc.9391.1.A1_at 1.0 1.2 3.3 NM_014734 KIAA0247
Ssc.12578.1.A1_at 1.6 -1.1 3.3 NM_000618 insulin-like growth factor 1
Ssc.12842.1.S1_at 1.0 1.1 3.3 NM_001753 caveolin 1; caveolae protein; 22kDa
Ssc.18540.1.S1_at 1.0 1.0 3.3 #N/A #N/A
Ssc.26253.1.S1_at -1.2 1.0 3.4 #N/A #N/A
Ssc.27142.1.A1_at -2.9 -1.7 3.4 #N/A #N/A
Ssc.10859.1.S1_at -1.1 1.3 3.4 #N/A #N/A
Ssc.2642.1.S1_at 1.1 1.3 3.4 NM_003312 thiosulfate sulfurtransferase
Ssc.1447.1.A1_at 1.1 1.9 3.4 #N/A #N/A
Ssc.3021.1.A1_at 1.5 1.2 3.4 #N/A #N/A
Ssc.5574.1.S1_at 1.2 1.6 3.4 #N/A #N/A
Ssc.5683.1.S1_a_at -1.2 -1.0 3.4 NM_022371 torsin family 3; member A
Ssc.26771.1.S1_at 1.0 2.0 3.5 #N/A #N/A
Ssc.19873.1.S1_at 1.1 1.2 3.5 NM_194071 cAMP responsive element binding protein 3-like 2
Ssc.30989.1.A1_at 1.0 1.3 3.5 XM_035299 zinc finger; SWIM domain containing 6
Ssc.21666.1.S1_at 1.3 1.9 3.5 NM_032562 phospholipase A2; group XIIB
Ssc.3016.1.S1_at -1.3 1.1 3.5 #N/A #N/A
Ssc.5330.1.A1_at -1.0 2.0 3.5 #N/A #N/A
Ssc.24880.2.S1_at 1.1 1.9 3.5 NM_005385 natural killer-tumor recognition sequence
Ssc.25121.1.S1_at 1.0 1.2 3.5 #N/A #N/A
Ssc.23823.1.A1_at -1.2 1.5 3.5 NM_005994 T-box 2
Ssc.18030.1.A1_at -1.0 -1.1 3.5 #N/A #N/A
Ssc.22444.1.A1_at 1.1 1.6 3.5 #N/A #N/A
Ssc.11177.1.S1_at 1.2 1.6 3.5 #N/A #N/A
Ssc.6394.1.S1_at 1.0 1.5 3.6 NM_198968 DAZ interacting protein 1
Ssc.2301.1.S1_at -1.3 1.5 3.6 NM_031283 transcription factor 7-like 1
Ssc.14914.1.A1_at 1.1 1.2 3.6 NM_002166 inhibitor of DNA binding 2; dominant negative helix-loop-h
Ssc.9617.1.A1_at 1.5 1.8 3.6 NM_006718 pleiomorphic adenoma gene-like 1
Ssc.3409.1.A1_at 1.3 1.6 3.6 NM_213662 signal transducer and activator of transcription 3
Ssc.29038.1.A1_at -1.1 1.4 3.6 NM_018388 muscleblind-like 3
Ssc.7149.3.S1_at -1.0 1.5 3.6 NM_144607 hypothetical protein FLJ32499
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Cluster 11 Ssc.24152.1.A1_at -1.2 1.2 3.7 NM_005585 SMAD; mothers against DPP homolog 6
cont. Ssc.24304.2.A1_at 1.3 1.4 3.7 NM_182801 hypothetical protein FLJ39155
Ssc.31000.1.A1_at -1.2 1.4 3.7 XM_294353 similar to RIKEN cDNA 6332401O19 gene
Ssc.183.1.S1_at 1.1 1.9 3.7 NM_004832 glutathione S-transferase omega 1
Ssc.6352.1.S1_at 1.2 1.7 3.7 NM_000581 glutathione peroxidase 1
Ssc.2131.1.S1_at 1.3 1.6 3.7 NM_031920 ARG99 protein
Ssc.2845.1.S1_at 1.0 1.8 3.7 NM_014994 mouse mitogen-activated protein kinase binding protein 1-l
Ssc.5737.1.S1_at 1.7 -1.2 3.8 NM_078467 cyclin-dependent kinase inhibitor 1A
Ssc.30029.1.A1_at -1.2 1.3 3.8 #N/A #N/A
Ssc.29435.1.A1_at 1.3 1.4 3.8 NM_003483 high mobility group AT-hook 2
Ssc.19620.1.S1_at 1.2 1.5 3.8 NM_199262 Sp6 transcription factor
Ssc.2203.1.A1_at -1.1 1.7 3.8 #N/A #N/A
Ssc.27310.1.S1_at 1.2 1.1 3.8 NM_207361 FRAS1 related extracellular matrix protein 2
Ssc.26237.1.A1_at -1.2 -1.1 3.9 NM_006522 wingless-type MMTV integration site family; member 6
Ssc.18618.1.A1_at -1.1 -1.0 3.9 #N/A #N/A
Ssc.1351.1.S1_at -1.1 1.3 3.9 NM_006612 kinesin family member 1C
Ssc.29043.2.A1_at 1.2 1.4 4.0 NM_205860 nuclear receptor subfamily 5; group A; member 2
n = 69 1.1 1.4 3.4
Ssc.4984.1.S1_at -1.0 1.9 36.7 NM_004887 chemokineCluster 12
Ssc.18707.1.A1_at 1.1 2.9 38.7 #N/A #N/A
Ssc.8859.1.A1_at -1.1 4.9 42.2 #N/A #N/A
Ssc.5165.1.S1_at 1.1 4.7 42.6 #N/A #N/A
Ssc.24584.1.S1_at 1.4 4.8 43.9 #N/A #N/A
Ssc.8803.1.A1_at -1.1 5.9 44.2 NM_016542 Mst3 and SOK1-related kinase
Ssc.15316.2.S1_at 1.0 1.2 44.7 NM_001311 cysteine-rich protein 1
Ssc.10389.1.A1_at -1.0 6.1 49.3 #N/A #N/A
Ssc.4815.1.A1_at 1.1 1.4 50.9 #N/A #N/A
Ssc.19394.1.A1_at 1.0 1.3 51.9 #N/A #N/A
Ssc.8859.1.A1_s_at -1.1 6.3 54.7 #N/A #N/A
n = 11 1.0 3.8 45.4
Ssc.17283.3.S1_at 1.0 2.9 10.3 #N/A #N/ACluster 13
Ssc.23766.1.S1_at 1.3 2.3 10.5 NM_015288 PHD finger protein 15
Ssc.19579.2.S1_at -1.2 1.7 11.1 #N/A #N/A
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Cluster 13 Ssc.19587.1.A1_at 1.4 2.4 11.4 NM_205860 nuclear receptor subfamily 5; group A; member 2
cont. Ssc.10328.1.A1_at 1.1 4.2 11.4 NM_001010000 Rho GTPase activating protein 28
Ssc.24731.1.A1_at 1.1 4.6 12.0 NM_032246 ring finger and KH domain containing 3
Ssc.23501.1.S1_s_at 1.4 2.2 12.1 #N/A #N/A
Ssc.15695.1.S1_at 1.8 2.4 12.2 NM_006744 retinol binding protein 4; plasma
Ssc.11131.1.S1_at 1.0 1.5 12.4 NM_003380 vimentin
Ssc.14258.1.S1_at 1.5 4.7 12.6 NM_000484 amyloid beta
Ssc.21113.1.A1_at 1.2 1.8 12.7 #N/A #N/A
Ssc.20728.1.S1_at 1.5 3.0 12.8 NM_005141 fibrinogen; B beta polypeptide
Ssc.13284.1.A1_at 1.6 4.7 13.1 NM_001010927 T-cell lymphoma invasion and metastasis 2
n = 13 1.3 3.0 11.9
Ssc.23271.1.S1_at 1.7 8.8 2.1 #N/A #N/ACluster 14
Ssc.16475.1.S1_at -1.0 7.6 3.2 NM_003489 nuclear receptor interacting protein 1
Ssc.19413.1.A1_at 1.4 6.9 3.6 NM_003107 SRY
Ssc.1583.2.S1_at 1.1 6.9 4.0 NM_001624 absent in melanoma 1
Ssc.22876.1.S1_at 1.9 6.1 4.2 NM_015864 chromosome 6 open reading frame 32
Ssc.27407.1.A1_at 1.1 5.8 4.2 NM_003489 nuclear receptor interacting protein 1
Ssc.12565.1.A1_at 1.3 6.4 4.3 NM_005504 branched chain aminotransferase 1; cytosolic
Ssc.18004.1.A1_at 1.8 7.8 4.5 #N/A #N/A
Ssc.9586.2.S1_at 2.0 7.3 4.6 NM_004657 serum deprivation response
Ssc.19360.1.S1_at -1.3 5.9 4.8 NM_020379 mannosidase; alpha; class 1C; member 1
n = 10 1.4 6.9 4.0
Ssc.7598.1.A1_at 1.3 9.2 22.1 NM_003711 phosphatidic acid phosphatase type 2ACluster 15
Ssc.7399.1.A1_at 1.4 5.8 23.0 #N/A #N/A
Ssc.265.1.S3_at 1.1 7.6 24.2 NM_000230 leptin
Ssc.27522.1.S1_at 1.3 4.0 26.0 NM_015550 oxysterol binding protein-like 3
Ssc.3668.1.A1_at -1.1 1.8 26.9 NM_005382 neurofilament 3
Ssc.7486.1.A1_at 1.6 11.7 30.6 NM_000783 cytochrome P450; family 26; subfamily A; polypeptide 1
Ssc.5545.1.S1_at -1.1 3.4 30.9 #N/A #N/A
Ssc.6070.1.A1_at 1.5 5.1 34.7 NM_015550 oxysterol binding protein-like 3
n = 8 1.3 6.1 27.3
Ssc.29187.1.A1_at 1.5 24.2 49.1 NM_000165 gap junction protein; alpha 1; 43kDaCluster 16
Ssc.942.1.S1_at 1.3 24.6 51.3 NM_000165 gap junction protein; alpha 1; 43kDa
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Cluster 16 Ssc.7484.3.S1_at -1.6 14.7 59.8 #N/A #N/A
cont. Ssc.21874.1.S1_at 1.5 4.2 65.6 NM_015550 oxysterol binding protein-like 3
Ssc.7588.1.A1_at 1.3 15.9 67.6 #N/A #N/A
Ssc.28944.1.S1_at 1.1 3.6 71.6 #N/A #N/A
Ssc.22563.1.S1_at 2.1 27.8 72.7 NM_006581 fucosyltransferase 9
Ssc.10188.1.A1_at 1.1 9.3 73.9 #N/A #N/A
Ssc.4193.1.S1_at -1.1 52.4 75.9 #N/A #N/A
n = 9 1.3 19.6 65.3
Ssc.29168.1.A1_at 1.2 2.0 2.0 NM_024420 phospholipase A2; group IVACluster 17
Ssc.2877.1.A1_at -1.0 1.7 2.0 #N/A #N/A
Ssc.1340.1.A1_at 1.5 1.9 2.0 #N/A #N/A
Ssc.29108.1.S1_at 1.2 1.7 2.1 NM_022845 core-binding factor; beta subunit
Ssc.27561.2.S1_at -1.1 1.9 2.1 NM_032636 differential display and activated by p53
Ssc.4414.1.S1_at 1.0 1.7 2.1 NM_002657 pleiomorphic adenoma gene-like 2
Ssc.1053.1.S1_at 1.6 1.8 2.1 NM_007361 nidogen 2
Ssc.6034.2.S1_a_at 1.0 1.9 2.1 NM_033102 prostate cancer associated protein 6
Ssc.19508.1.S1_at 1.1 1.6 2.1 #N/A #N/A
Ssc.19208.2.S1_at 1.3 1.6 2.1 NM_000457 hepatocyte nuclear factor 4; alpha
Ssc.5073.1.A1_at 1.0 2.1 2.1 NM_004456 enhancer of zeste homolog 2
Ssc.7712.1.A1_at 1.2 1.6 2.2 #N/A #N/A
Ssc.15228.1.A1_at 1.3 1.5 2.2 NM_016824 adducin 3
Ssc.26216.2.A1_at 1.3 1.7 2.2 NM_003745 suppressor of cytokine signaling 1
Ssc.30916.1.A1_at 1.2 1.6 2.2 NM_181847 amphoterin induced gene 2
Ssc.1333.1.A1_at -1.0 1.9 2.2 NM_001009882 zinc finger; CCHC domain containing 11
Ssc.4306.1.A1_at 1.3 1.5 2.2 NM_022566 mesoderm development candidate 1
Ssc.17405.2.A1_at 1.0 1.6 2.2 NM_002537 ornithine decarboxylase antizyme 2
Ssc.4044.1.A1_at -1.2 1.8 2.2 #N/A #N/A
Ssc.1725.1.S1_at 1.2 1.9 2.2 NM_003705 solute carrier family 25
Ssc.19801.1.S1_at 1.3 1.7 2.2 NM_033495 kelch-like 13
Ssc.21326.1.S1_at 1.2 2.2 2.2 #N/A #N/A
Ssc.2441.2.A1_at 1.0 1.6 2.2 NM_000341 solute carrier family 3
Ssc.14340.1.S1_at 1.3 1.9 2.2 NM_004862 lipopolysaccharide-induced TNF factor
Ssc.1702.2.S1_at -1.1 1.6 2.2 NM_145290 G protein-coupled receptor 125
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Cluster 17 Ssc.10300.1.S1_at 1.3 1.9 2.3 NM_033495 kelch-like 13
cont. Ssc.31097.1.A1_at 1.1 2.1 2.3 NM_020774 mindbomb homolog 1
Ssc.19282.1.S1_at 1.2 1.6 2.3 NM_198530 transmembrane anchor protein 1
Ssc.9299.1.S1_at 1.4 1.5 2.3 NM_030751 transcription factor 8
Ssc.21928.1.A1_at 1.0 1.7 2.3 NM_001010853 aminoacylase 1-like 2
Ssc.384.2.S1_at 1.0 2.0 2.3 NM_002056 glutamine-fructose-6-phosphate transaminase 1
Ssc.20404.1.S1_at 1.1 2.0 2.3 NM_001618 poly
Ssc.5157.1.S1_at 1.4 1.7 2.3 NM_022003 FXYD domain containing ion transport regulator 6
Ssc.26660.1.A1_at 1.1 1.9 2.3 NM_175848 DNA
Ssc.1097.1.A1_at 1.2 1.8 2.4 #N/A #N/A
Ssc.7567.1.S1_at 1.2 2.0 2.4 NM_020774 mindbomb homolog 1
Ssc.24254.1.S1_at -1.2 1.6 2.4 NM_138423 H63 breast cancer expressed gene
Ssc.20239.1.A1_at 1.1 1.6 2.4 #N/A #N/A
Ssc.7351.1.S1_at -1.5 1.7 2.4 NM_014962 BTB
Ssc.7481.1.A1_at 1.2 1.4 2.4 NM_020200 phosphoribosyl transferase domain containing 1
Ssc.16609.1.S1_at -1.1 1.7 2.4 NM_000232 sarcoglycan; beta
Ssc.25221.1.A1_at 1.2 1.7 2.4 NM_033331 CDC14 cell division cycle 14 homolog B
Ssc.1084.1.S1_at 1.1 2.4 2.4 NM_016472 chromosome 14 open reading frame 129
Ssc.8552.3.S1_a_at 1.1 1.5 2.4 NM_182974 glycosyltransferase 6 domain containing 1
Ssc.23933.1.A1_at 1.1 1.5 2.4 #N/A #N/A
Ssc.8905.1.A1_at -1.1 1.8 2.4 NM_014335 CREBBPEP300 inhibitor 1
Ssc.5455.1.S1_at 1.1 2.0 2.5 NM_001360 7-dehydrocholesterol reductase
Ssc.4578.2.S1_at 1.2 1.5 2.5 NM_003567 breast cancer anti-estrogen resistance 3
Ssc.3990.1.S1_at -1.1 1.9 2.5 #N/A #N/A
Ssc.9037.1.A1_at 1.1 2.1 2.5 #N/A #N/A
Ssc.25570.1.S1_at -1.1 1.5 2.5 NM_024896 KIAA1815
Ssc.6736.1.S1_at -1.2 1.8 2.5 NM_002449 msh homeo box homolog 2
Ssc.15912.1.A1_at 1.2 2.2 2.5 NM_000165 gap junction protein; alpha 1; 43kDa
Ssc.10906.1.A1_at 1.1 2.2 2.5 #N/A #N/A
Ssc.24616.1.S1_a_at 1.7 1.8 2.5 NM_022128 ribokinase
Ssc.25535.1.S1_at 1.2 1.5 2.5 #N/A #N/A
Ssc.1267.1.S1_at -1.1 1.5 2.5 NM_015554 glucuronyl C5-epimerase
Ssc.112.1.S1_at 1.0 1.8 2.5 NM_002192 inhibin; beta A
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Cluster 17 Ssc.4159.1.A1_at -1.1 1.8 2.5 NM_002069 guanine nucleotide binding protein
cont. Ssc.16704.1.S1_at 1.3 1.9 2.6 NM_006283 transforming; acidic coiled-coil containing protein 1
Ssc.21860.2.S1_at -1.1 1.9 2.6 NM_002823 prothymosin; alpha
Ssc.5735.2.S1_at 1.0 1.4 2.6 NM_022908 hypothetical protein FLJ12442
Ssc.8407.1.A1_at -1.1 2.1 2.6 NM_138423 H63 breast cancer expressed gene
Ssc.12668.1.A1_at 1.3 1.4 2.6 NM_173561 unc-5 homolog C
Ssc.16996.1.S1_at 1.2 1.4 2.6 NM_006640 septin 9
Ssc.897.1.S1_at 1.5 2.1 2.6 NM_006307 sushi-repeat-containing protein; X-linked
Ssc.13844.1.A1_at 1.1 2.0 2.6 NM_032186 zinc finger protein 644
Ssc.29146.1.A1_at -1.2 1.5 2.7 #N/A #N/A
Ssc.2147.1.A1_at 1.0 1.5 2.7 #N/A #N/A
Ssc.2012.1.A1_at 1.2 2.1 2.7 #N/A #N/A
Ssc.15592.1.S1_at 1.0 2.2 2.7 NM_020190 olfactomedin-like 3
Ssc.9914.1.A1_at -1.0 1.9 2.7 NM_001823 creatine kinase; brain
Ssc.11844.1.A1_at 1.2 1.6 2.7 #N/A #N/A
Ssc.12316.1.S1_at 1.1 1.6 2.7 NM_182565 hypothetical protein MGC29814
Ssc.17824.1.A1_at 1.0 1.8 2.7 #N/A #N/A
Ssc.25405.1.S1_at 1.3 2.2 2.7 NM_145119 praja 1
Ssc.21154.1.A1_at 1.3 1.7 2.7 NM_005443 3-phosphoadenosine 5-phosphosulfate synthase 1
Ssc.11694.1.S1_at 1.1 2.1 2.8 NM_002166 inhibitor of DNA binding 2; dominant negative helix-loop-h
Ssc.24804.1.S1_at 1.1 1.6 2.8 #N/A #N/A
Ssc.955.1.S1_at 1.2 1.4 2.8 NM_000769 cytochrome P450; family 2; subfamily C; polypeptide 19
Ssc.19798.2.A1_at 1.2 1.7 2.8 #N/A #N/A
Ssc.6376.1.A1_at -1.1 2.0 2.8 #N/A #N/A
Ssc.7429.1.A1_at -1.0 1.5 2.8 #N/A #N/A
Ssc.27015.1.A1_at 1.0 1.5 2.8 #N/A #N/A
Ssc.24083.1.A1_at 1.2 1.5 2.8 NM_017523 XIAP associated factor-1
Ssc.3128.1.A1_at 1.6 1.4 2.8 #N/A #N/A
Ssc.30377.1.A1_at 1.4 1.9 2.9 NM_015271 tripartite motif-containing 2
Ssc.7712.2.S1_at 1.2 1.8 2.9 NM_006283 transforming; acidic coiled-coil containing protein 1
Ssc.29090.1.A1_at 1.5 1.7 2.9 NM_015278 SAM and SH3 domain containing 1
Ssc.12789.1.A1_at 1.2 1.6 2.9 #N/A #N/A
Ssc.5832.1.S1_at -1.1 1.6 2.9 NM_004973 Jumonji; AT rich interactive domain 2
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Cluster 17 Ssc.5663.2.S1_at 1.5 2.0 2.9 #N/A #N/A
cont. Ssc.7266.1.A1_at -1.1 1.9 2.9 NM_006475 periostin; osteoblast specific factor
Ssc.24911.1.S1_at -1.0 2.0 2.9 NM_018964 solute carrier family 37
Ssc.26296.1.S1_at 1.1 1.7 2.9 NM_012288 translocation associated membrane protein 2
Ssc.6789.1.A1_at 1.2 1.7 2.9 NM_003690 protein kinase; interferon-inducible double stranded RNA d
Ssc.24304.1.S1_at 1.3 1.5 3.0 NM_152403 hypothetical protein FLJ39155
Ssc.19208.1.S1_at 1.3 1.7 3.0 #N/A #N/A
Ssc.3921.1.S1_at 1.2 1.9 3.0 NM_001430 endothelial PAS domain protein 1
Ssc.21972.1.A1_at 1.3 2.0 3.1 #N/A #N/A
n = 100 1.1 1.8 2.5
Ssc.27995.1.A1_at -1.1 2.7 2.4 NM_013282 ubiquitin-like; containing PHD and RING finger domains; 1Cluster 18
Ssc.17512.1.S1_at 1.3 2.5 2.6 #N/A #N/A
Ssc.1696.1.A1_at 1.4 3.1 2.6 NM_001004417 formin-like 2
Ssc.5287.1.S1_at 1.3 2.5 2.6 #N/A #N/A
Ssc.5039.1.A1_at 1.3 2.6 2.7 NM_178568 reticulon 4 receptor-like 1
Ssc.30743.1.S1_at 1.5 3.0 2.7 NM_145753 pleckstrin homology-like domain; family B; member 2
Ssc.4900.2.S1_at 1.2 3.5 2.7 NM_016441 cysteine-rich motor neuron 1
Ssc.16259.1.S1_at 1.1 2.4 2.8 NM_002069 guanine nucleotide binding protein
Ssc.1849.1.A1_at 1.2 2.6 2.8 #N/A #N/A
Ssc.22297.1.S1_at -1.1 2.7 2.8 #N/A #N/A
Ssc.12340.1.A1_at 2.5 2.2 2.8 #N/A #N/A
Ssc.5039.2.S1_at 1.3 2.9 2.8 NM_178568 reticulon 4 receptor-like 1
Ssc.1638.1.S1_at -1.4 2.3 2.9 NM_002167 inhibitor of DNA binding 3; dominant negative helix-loop-h
Ssc.6034.1.S1_at -1.0 2.6 2.9 NM_033102 prostate cancer associated protein 6
Ssc.8929.1.S1_at 1.3 2.2 2.9 NM_153333 transcription elongation factor A
Ssc.23085.2.S1_at 1.1 3.1 3.0 NM_032637 S-phase kinase-associated protein 2
Ssc.23085.1.S1_at 1.1 2.4 3.0 #N/A #N/A
Ssc.9321.1.S1_at -1.3 3.0 3.0 NM_025078 PQ loop repeat containing 1
Ssc.18546.1.S1_at 1.3 3.1 3.1 NM_016441 cysteine-rich motor neuron 1
Ssc.7210.1.A1_at 1.4 2.3 3.1 NM_015271 tripartite motif-containing 2
Ssc.1969.1.A1_at -1.2 3.2 3.1 NM_006022 TSC22 domain family; member 1
Ssc.7881.1.A1_at 1.4 2.5 3.2 NM_145753 pleckstrin homology-like domain; family B; member 2
Ssc.4214.1.A1_at 1.2 2.9 3.2 #N/A #N/A
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Cluster 18 Ssc.29264.1.A1_at 1.4 3.1 3.2 #N/A #N/A
cont. Ssc.26957.1.S1_at 1.1 2.1 3.3 NM_004172 solute carrier family 1
Ssc.11796.1.S1_at 1.0 2.4 3.3 NM_031934 RAB34; member RAS oncogene family
Ssc.24444.1.A1_at 1.1 2.4 3.3 NM_004816 chromosome 9 open reading frame 61
Ssc.19008.1.A1_at 1.1 2.5 3.3 #N/A #N/A
Ssc.27045.1.A1_at 1.2 3.0 3.3 NM_004508 isopentenyl-diphosphate delta isomerase
Ssc.13537.1.A1_at 1.3 2.2 3.4 NM_005399 protein kinase; AMP-activated; beta 2 non-catalytic subuni
Ssc.5605.1.A1_at -1.3 3.2 3.4 NM_002222 inositol 1;4;5-triphosphate receptor; type 1
Ssc.6474.1.S1_at -1.1 2.7 3.4 NM_000637 glutathione reductase
Ssc.25282.1.S1_at -1.1 2.5 3.5 NM_001018009 SH3-domain binding protein 5
Ssc.8528.1.A1_at 1.1 2.6 3.7 #N/A #N/A
Ssc.12429.1.S1_at -1.1 2.7 3.7 NM_032790 hypothetical protein FLJ14466
Ssc.28645.1.A1_at 1.2 3.0 3.8 NM_003045 solute carrier family 7
Ssc.4503.1.A1_at -1.2 2.8 3.8 #N/A #N/A
Ssc.26270.1.S1_at -1.6 3.3 3.8 NM_147189 hypothetical protein MGC39325
Ssc.2864.1.S1_at 1.1 2.8 3.9 NM_006094 deleted in liver cancer 1
Ssc.7312.1.A1_at 1.7 3.1 4.0 #N/A #N/A
n = 40 1.2 2.7 3.1
Ssc.13529.1.A1_at -2.0 1.2 2.0 #N/A #N/ACluster 19
Ssc.3889.1.S1_at -1.1 1.2 2.0 #N/A #N/A
Ssc.7149.2.A1_at -1.0 1.3 2.0 NM_144607 hypothetical protein FLJ32499
Ssc.23095.1.A1_at 1.0 1.3 2.0 #N/A #N/A
Ssc.12654.2.A1_at -1.0 1.4 2.0 #N/A #N/A
Ssc.3043.1.S1_at 1.1 1.0 2.0 NM_152999 six transmembrane epithelial antigen of the prostate 2
Ssc.11518.1.A1_at -1.2 1.1 2.0 #N/A #N/A
Ssc.894.1.A1_at -1.0 1.5 2.0 #N/A #N/A
Ssc.4692.1.A1_at 1.0 1.2 2.0 #N/A #N/A
Ssc.15840.1.S1_a_at -1.1 1.3 2.0 NM_022969 fibroblast growth factor receptor 2
Ssc.8623.1.A1_at 1.1 1.2 2.1 NM_006364 Sec23 homolog A
Ssc.19161.1.A1_at -1.3 1.2 2.1 #N/A #N/A
Ssc.27462.1.A1_at 1.1 1.1 2.1 NM_015691 KIAA1280 protein
Ssc.22055.1.A1_at -1.0 -1.0 2.1 NM_022763 fibronectin type III domain containing 3B
Ssc.17490.1.S1_at 1.3 1.1 2.1 #N/A #N/A
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Cluster 19 Ssc.9714.1.S1_at 1.1 1.1 2.1 NM_006769 LIM domain only 4
cont. Ssc.28930.1.S1_at -1.2 1.2 2.1 #N/A #N/A
Ssc.27539.1.A1_at -1.0 1.3 2.1 NM_173519 hypothetical protein MGC34646
Ssc.19763.1.S1_at 1.1 1.4 2.1 #N/A #N/A
Ssc.21559.1.S1_at -1.5 1.1 2.1 NM_017664 ankyrin repeat domain 10
Ssc.28935.1.S1_at -1.0 1.3 2.1 NM_182896 ADP-ribosylation factor-like 2-like 1
Ssc.3570.1.S1_at 1.0 1.3 2.1 #N/A #N/A
Ssc.13640.1.A1_at -1.0 1.4 2.1 #N/A #N/A
Ssc.3548.1.S1_at 1.4 -1.9 2.1 #N/A #N/A
Ssc.18472.1.S1_at 1.1 1.3 2.1 #N/A #N/A
Ssc.1943.1.S1_at 1.1 1.1 2.1 #N/A #N/A
Ssc.3799.3.A1_a_at -1.1 1.3 2.1 NM_001008710 RNA binding protein with multiple splicing
Ssc.15875.1.S1_at -1.0 1.5 2.1 NM_021069 ArgAbl-interacting protein ArgBP2
Ssc.10317.1.A1_at -1.1 1.5 2.1 NM_024089 KDEL
Ssc.18674.1.A1_at -1.2 1.2 2.1 NM_004497 forkhead box A3
Ssc.16380.1.A1_at -1.2 1.2 2.1 #N/A #N/A
Ssc.17347.1.S1_at 1.1 1.1 2.1 NM_022172 pyruvate carboxylase
Ssc.15917.1.S1_at -1.1 1.3 2.1 NM_000546 tumor protein p53
Ssc.27134.1.A1_at -1.1 1.1 2.1 #N/A #N/A
Ssc.2869.1.S1_at -1.1 1.5 2.1 NM_017911 chromosome 22 open reading frame 8
Ssc.4021.1.S1_at 1.0 1.2 2.2 NM_006411 1-acylglycerol-3-phosphate O-acyltransferase 1
Ssc.16982.1.S1_at -1.5 -1.2 2.2 NM_014061 melanoma antigen family H; 1
Ssc.4950.1.S1_at -1.1 1.3 2.2 #N/A #N/A
Ssc.8576.1.A1_at 1.1 1.5 2.2 NM_018847 kelch-like 9
Ssc.3670.1.S1_a_at 1.2 1.0 2.2 NM_022356 leucine proline-enriched proteoglycan
Ssc.29043.3.S1_at -1.0 1.2 2.2 NM_003822 nuclear receptor subfamily 5; group A; member 2
Ssc.20161.1.S1_at -1.2 1.5 2.2 XM_059037 WT1-interacting protein
Ssc.27799.1.S1_at -1.3 1.2 2.2 NM_004093 ephrin-B2
Ssc.24239.1.S1_at 1.3 1.2 2.2 NM_031453 chromosome 10 open reading frame 45
Ssc.23540.3.S1_at 1.1 1.1 2.2 #N/A #N/A
Ssc.19798.1.S1_at 1.1 1.5 2.2 NM_152261 hypothetical protein MGC17943
Ssc.19462.1.S1_at -1.0 1.1 2.2 NM_005587 MADS box transcription enhancer factor 2; polypeptide A
Ssc.28226.1.S1_at 1.0 1.4 2.2 #N/A #N/A
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Cluster 19 Ssc.5966.1.A1_at -1.5 1.0 2.2 NM_024324 hypothetical protein MGC11256
cont. Ssc.23073.1.A1_at 1.1 1.1 2.2 NM_015691 KIAA1280 protein
Ssc.13397.1.S1_at 1.1 1.2 2.2 NM_004311 ADP-ribosylation factor-like 3
Ssc.6333.1.A1_at -1.0 1.2 2.2 #N/A #N/A
Ssc.23658.1.S1_at 1.0 1.2 2.2 NM_016459 proapoptotic caspase adaptor protein
Ssc.24596.1.S1_at 1.3 1.1 2.2 #N/A #N/A
Ssc.19363.1.S1_at -1.1 1.3 2.2 NM_032493 adaptor-related protein complex 1; mu 1 subunit
Ssc.9504.1.A1_at -1.1 -1.4 2.3 #N/A #N/A
Ssc.1896.2.A1_a_at 1.1 -1.1 2.3 NM_000156 guanidinoacetate N-methyltransferase
Ssc.18253.1.S1_at -1.3 1.3 2.3 #N/A #N/A
Ssc.27354.1.S1_at -1.3 -1.3 2.3 NM_139244 syntaxin binding protein 5
Ssc.12524.1.S1_at 1.1 1.3 2.3 NM_016579 CD320 antigen
Ssc.30788.1.S1_at -1.1 1.5 2.3 #N/A #N/A
Ssc.21857.1.S1_at -1.0 1.2 2.3 NM_001001555 growth factor receptor-bound protein 10
Ssc.3799.1.S1_a_at -1.1 1.4 2.3 NM_001008712 RNA binding protein with multiple splicing
Ssc.6570.1.S1_at -1.1 1.4 2.3 NM_000031 aminolevulinate; delta-; dehydratase
Ssc.272.1.S1_a_at 1.7 1.1 2.3 NM_000574 decay accelerating factor for complement
Ssc.17824.2.A1_at -1.0 1.5 2.3 #N/A #N/A
Ssc.25051.1.S1_at 1.5 -1.3 2.3 NM_016950 sparcosteonectin; cwcv and kazal-like domains proteoglycan
Ssc.26363.1.S1_at -1.2 -1.2 2.3 NM_012262 heparan sulfate 2-O-sulfotransferase 1
Ssc.13380.1.A1_at -1.1 -1.2 2.3 #N/A #N/A
Ssc.29936.1.A1_at -1.0 1.4 2.3 #N/A #N/A
Ssc.9874.1.S1_at 1.1 1.4 2.3 NM_014764 DAZ associated protein 2
Ssc.11794.1.A1_at -1.2 -1.1 2.3 #N/A #N/A
Ssc.18072.1.A1_at 1.7 1.3 2.3 #N/A #N/A
Ssc.26813.1.S1_at -1.4 -1.2 2.3 NM_201614 IKK interacting protein
Ssc.20242.1.A1_at 1.0 1.0 2.3 NM_020119 zinc finger CCCH-type; antiviral 1
Ssc.12946.1.A1_at -1.1 -1.8 2.4 #N/A #N/A
Ssc.23169.1.S1_at 1.0 -1.2 2.4 NM_002856 poliovirus receptor-related 2
Ssc.16676.1.A1_at -1.0 1.5 2.4 NM_173469 hypothetical protein LOC92912
Ssc.1986.1.S1_at 1.0 1.1 2.4 NM_080591 prostaglandin-endoperoxide synthase 1
Ssc.15357.1.S1_at 1.2 1.3 2.4 NM_005813 protein kinase D3
Ssc.21700.1.A1_at 1.1 1.3 2.4 #N/A #N/A
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Cluster 19 Ssc.19511.1.A1_a_at -1.0 1.4 2.4 #N/A #N/A
cont. Ssc.27556.1.S1_at 1.1 1.3 2.4 NM_017709 family with sequence similarity 46; member C
Ssc.24233.1.S1_at 1.1 1.1 2.4 NM_015170 sulfatase 1
Ssc.3714.1.S1_a_at 1.0 1.2 2.4 NM_032621 brain expressed X-linked 2
Ssc.19591.1.S1_at 1.3 1.3 2.4 NM_000166 gap junction protein; beta 1; 32kDa
Ssc.12654.1.A1_at -1.1 1.4 2.4 #N/A #N/A
Ssc.7274.1.A1_at 1.1 1.2 2.4 NM_002759 eukaryotic translation initiation factor 2-alpha kinase 2
Ssc.1308.1.S1_at -1.3 -1.4 2.4 NM_002081 glypican 1
Ssc.17312.1.A1_at 1.0 -1.2 2.4 XM_373497 hypothetical LOC387763
Ssc.16540.1.S1_at 1.2 1.1 2.4 NM_002827 protein tyrosine phosphatase; non-receptor type 1
Ssc.18306.1.A1_at -1.0 1.1 2.4 #N/A #N/A
Ssc.10777.1.A1_at -1.3 1.1 2.4 #N/A #N/A
Ssc.3588.1.S1_at 1.1 1.3 2.4 NM_002080 glutamic-oxaloacetic transaminase 2; mitochondrial
Ssc.4578.1.A1_at 1.3 1.3 2.4 NM_003567 breast cancer anti-estrogen resistance 3
Ssc.23905.1.A1_at 1.2 -1.1 2.4 #N/A #N/A
Ssc.22444.2.A1_at -1.1 1.1 2.5 #N/A #N/A
Ssc.12129.1.A1_at 1.0 1.3 2.5 NM_016824 adducin 3
Ssc.22555.1.A1_at 1.0 1.4 2.5 #N/A #N/A
Ssc.11839.1.S1_at 1.2 1.2 2.5 NM_021224 zinc finger protein 462
Ssc.18610.1.A1_at -1.2 1.5 2.5 #N/A #N/A
Ssc.4228.1.S1_at -1.1 1.2 2.5 NM_015537 nasal embryonic LHRH factor
Ssc.29813.1.A1_at 1.1 1.3 2.5 NM_003822 nuclear receptor subfamily 5; group A; member 2
Ssc.29710.1.A1_at -1.2 1.1 2.5 #N/A #N/A
Ssc.3128.2.S1_at 1.4 1.3 2.5 #N/A #N/A
Ssc.5226.1.S1_at -1.0 1.1 2.6 NM_015252 EH domain binding protein 1
Ssc.18619.2.A1_at -1.1 1.2 2.6 NM_021183 RAP2C; member of RAS oncogene family
Ssc.6988.1.A1_at 1.2 -1.2 2.6 NM_138766 peptidylglycine alpha-amidating monooxygenase
Ssc.2147.2.A1_at -1.0 1.2 2.6 #N/A #N/A
Ssc.24330.1.S1_at 1.3 1.1 2.6 NM_004820 cytochrome P450; family 7; subfamily B; polypeptide 1
Ssc.9588.1.A1_at -1.2 -1.1 2.6 #N/A #N/A
Ssc.25410.1.S1_at 1.0 -1.2 2.6 #N/A #N/A
Ssc.6430.1.A1_at 1.2 1.1 2.6 #N/A #N/A
Ssc.20419.1.S1_at 1.2 1.2 2.6 #N/A #N/A
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Cluster 19 Ssc.19892.1.A1_at 1.3 1.2 2.6 NM_024408 Notch homolog 2
cont. Ssc.7434.1.S1_at -1.2 1.3 2.6 NM_005851 CDK2-associated protein 2
Ssc.1631.1.S1_at -1.2 1.1 2.7 NM_002957 retinoid X receptor; alpha
Ssc.2861.1.A1_at 1.1 1.3 2.7 NM_006010 arginine-rich; mutated in early stage tumors
Ssc.2197.1.S1_at -3.0 -5.2 2.7 NM_018004 transmembrane protein 45A
Ssc.1789.1.S1_at -1.5 1.2 2.7 #N/A #N/A
Ssc.19873.2.S1_at 1.2 1.3 2.7 NM_194071 cAMP responsive element binding protein 3-like 2
Ssc.22530.1.S1_at 1.2 1.0 2.7 #N/A #N/A
Ssc.7610.1.S1_at 1.0 1.4 2.7 NM_014764 DAZ associated protein 2
Ssc.21188.1.S1_at 1.1 1.0 2.7 NM_021195 claudin 6
Ssc.265.1.S2_at -1.1 1.1 2.7 NM_000230 leptin
Ssc.16312.1.S1_at -1.0 1.1 2.8 NM_006825 cytoskeleton-associated protein 4
Ssc.19873.1.S1_a_at 1.1 1.0 2.8 NM_194071 cAMP responsive element binding protein 3-like 2
Ssc.3479.1.A1_at -1.2 1.3 2.8 #N/A #N/A
Ssc.27248.1.S1_at -1.1 1.4 2.8 NM_022373 hypothetical protein FLJ22313
Ssc.19075.1.A1_at 1.1 1.2 2.8 NM_022739 SMAD specific E3 ubiquitin protein ligase 2
Ssc.18014.1.A1_at -1.2 -1.4 2.8 NM_052954 cysteine and tyrosine-rich 1
Ssc.27361.1.A1_at -1.9 1.2 2.9 #N/A #N/A
Ssc.18190.1.A1_at 1.2 -1.2 2.9 NM_182920 a disintegrin-like and metalloprotease
n = 133 1.0 1.2 2.3
Ssc.4255.1.S1_at 1.2 2.2 3.8 #N/A #N/ACluster 20
Ssc.9434.1.A1_at 1.1 2.1 3.8 #N/A #N/A
Ssc.1205.1.S1_at -1.0 2.4 3.8 #N/A #N/A
Ssc.5663.1.S1_at 1.5 1.9 3.9 NM_004385 chondroitin sulfate proteoglycan 2
Ssc.7938.1.A1_at 1.3 1.8 4.0 #N/A #N/A
Ssc.19544.1.A1_at 1.2 1.9 4.0 #N/A #N/A
Ssc.24138.1.A1_at 1.1 1.8 4.0 #N/A #N/A
Ssc.1745.1.A1_at 1.0 2.3 4.0 #N/A #N/A
Ssc.5243.1.A1_at 1.2 2.4 4.0 NM_000264 patched homolog
Ssc.9511.1.A1_at 1.2 1.6 4.0 NM_016073 hepatoma-derived growth factor; related protein 3
Ssc.18375.1.A1_at -1.4 1.6 4.1 NM_006378 sema domain; immunoglobulin domain
Ssc.26651.1.S1_at 1.3 1.8 4.1 NM_016593 cytochrome P450; family 39; subfamily A; polypeptide 1
Ssc.13476.1.A1_at -1.1 2.1 4.1 XM_496907 paternally expressed 10
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Cluster 20 Ssc.8084.1.S1_at 1.1 2.5 4.1 NM_006094 deleted in liver cancer 1
cont. Ssc.24669.1.A1_at -1.1 1.8 4.1 NM_194317 hypothetical protein MGC52057
Ssc.16987.1.A1_at 1.2 2.1 4.2 #N/A #N/A
Ssc.16453.1.S1_at -1.1 1.7 4.2 NM_030576 hypothetical protein MGC10986
Ssc.27110.1.A1_at 2.2 2.2 4.2 #N/A #N/A
Ssc.28646.1.A1_at 1.1 2.6 4.2 #N/A #N/A
Ssc.12017.1.A1_at -1.4 2.0 4.2 NM_001010990 homocysteine-inducible; endoplasmic reticulum stress-in
Ssc.9273.1.A1_at 1.1 2.3 4.3 #N/A #N/A
Ssc.29596.1.A1_at 1.3 2.8 4.3 #N/A #N/A
Ssc.3129.1.A1_at -1.1 2.0 4.3 NM_004242 high mobility group nucleosomal binding domain 3
Ssc.21595.1.S1_at 1.3 2.1 4.3 #N/A #N/A
Ssc.2131.2.A1_at 1.4 1.7 4.3 #N/A #N/A
Ssc.1125.1.A1_at 1.9 1.5 4.4 NM_000362 tissue inhibitor of metalloproteinase 3
Ssc.9483.1.A1_s_at -1.1 1.4 4.4 NM_032523 oxysterol binding protein-like 6
Ssc.17518.1.S1_at -1.0 1.2 4.4 NM_000674 adenosine A1 receptor
Ssc.17140.1.A1_at 1.2 3.0 4.4 NM_003778 UDP-Gal:betaGlcNAc beta 1;4- galactosyltransferase; polype
Ssc.23921.1.S1_at 1.4 3.0 4.5 #N/A #N/A
Ssc.25198.1.A1_at 1.1 2.3 4.5 NM_000274 ornithine aminotransferase
Ssc.20890.1.S1_at 1.2 1.7 4.5 NM_205860 nuclear receptor subfamily 5; group A; member 2
Ssc.29275.1.A1_at 1.3 2.1 4.5 #N/A #N/A
Ssc.30400.1.A1_at 1.0 2.6 4.6 #N/A #N/A
Ssc.9522.1.A1_at 1.1 2.0 4.6 #N/A #N/A
Ssc.13553.2.S1_at 1.1 3.1 4.7 NM_004297 guanine nucleotide binding protein
Ssc.19005.1.A1_at 1.1 2.6 4.7 NM_015009 PDZ domain containing RING finger 3
Ssc.19579.1.A1_at -1.0 1.8 4.7 NM_021005 nuclear receptor subfamily 2; group F; member 2
Ssc.13531.1.A1_at 1.3 1.8 4.7 #N/A #N/A
Ssc.22504.1.S1_at -1.1 1.5 4.8 NM_003619 protease; serine; 12
Ssc.27249.1.S1_at -1.3 2.3 4.8 NM_005221 distal-less homeo box 5
Ssc.7408.1.A1_at 1.5 2.5 4.9 #N/A #N/A
Ssc.25002.1.S1_at -1.7 1.7 4.9 NM_031283 transcription factor 7-like 1
Ssc.4791.1.S1_at -1.3 1.9 4.9 #N/A #N/A
Ssc.20841.1.S1_at 1.1 1.1 5.0 NM_198291 v-src sarcoma
Ssc.16346.1.S1_at -1.4 1.7 5.0 NM_022972 fibroblast growth factor receptor 2
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Cluster 20 Ssc.8609.1.A1_at 1.5 1.5 5.0 NM_014456 programmed cell death 4
n = 47 1.1 2.0 4.4
Ssc.7314.1.A1_at 3.4 14.8 2.6 NM_000963 prostaglandin-endoperoxide synthase 2Cluster 21
Ssc.23994.1.A1_at 2.9 15.6 5.0 #N/A #N/A
Ssc.12561.1.A1_at 1.9 10.3 6.3 NM_005504 branched chain aminotransferase 1; cytosolic
n = 3 2.7 13.6 4.6
Ssc.17615.1.S1_at 1.3 8.9 8.7 NM_001677 ATPase; Na+K+ transporting; beta 1 polypeptideCluster 22
Ssc.7721.1.A1_at 1.6 8.4 8.8 NM_005032 plastin 3
Ssc.30064.1.A1_at -1.1 7.2 9.4 #N/A #N/A
Ssc.27388.1.S1_at 1.1 7.7 9.7 NM_020128 Mdm4; transformed 3T3 cell double minute 1; p53 binding pro
Ssc.6969.1.A1_at 1.0 7.9 11.8 NM_017440 Mdm4; transformed 3T3 cell double minute 1; p53 binding pr
Ssc.455.1.S1_at 2.0 10.9 12.6 NM_001623 allograft inflammatory factor 1
Ssc.27508.1.A1_at -1.3 7.5 12.8 NM_015265 SATB family member 2
Ssc.4004.1.A1_at -1.0 11.3 12.9 NM_015180 spectrin repeat containing; nuclear envelope 2
Ssc.24509.1.A1_at 1.5 7.8 13.6 NM_014211 gamma-aminobutyric acid
n = 9 1.3 8.6 11.1
Ssc.20438.1.S1_at 1.1 -1.4 14.1 NM_000959 prostaglandin F receptorCluster 23
Ssc.22354.1.A1_at 1.3 1.6 14.5 NM_018664 Jun dimerization protein p21SNFT
Ssc.20258.1.S1_at 1.1 3.9 14.8 #N/A #N/A
Ssc.23077.1.A1_at 1.8 4.4 15.0 #N/A #N/A
Ssc.20578.1.S1_at -1.0 1.3 15.0 #N/A #N/A
Ssc.16886.1.A1_at 1.4 5.4 15.7 NM_003115 UDP-N-acteylglucosamine pyrophosphorylase 1
Ssc.8698.1.S1_at 1.3 3.5 15.8 NM_033664 cadherin 11; type 2; OB-cadherin
Ssc.2444.2.A1_a_at 1.8 2.1 15.8 NM_000227 laminin; alpha 3
Ssc.15906.1.S1_at -1.3 1.8 15.9 #N/A #N/A
Ssc.27738.1.S1_at -1.4 5.9 16.0 NM_015265 SATB family member 2
Ssc.27592.1.S1_at 1.1 2.0 18.2 NM_003956 cholesterol 25-hydroxylase
Ssc.6057.1.A1_at 1.3 2.6 19.4 NM_015550 oxysterol binding protein-like 3
Ssc.18844.1.S1_at 1.0 1.3 19.5 NM_032510 par-6 partitioning defective 6 homolog gamma
Ssc.7175.1.S1_at 1.4 3.6 19.6 NM_014375 fetuin B
n = 14 1.2 2.9 16.4
Ssc.21987.2.S1_at 1.3 2.0 -1.3 NM_001550 interferon-related developmental regulator 1Cluster 24
Ssc.19150.1.S1_at 1.0 2.2 -1.2 NM_197966 BH3 interacting domain death agonist
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Cluster 24 Ssc.26386.2.S1_a_at 1.1 2.4 -1.1 NM_016101 comparative gene identification transcript 37
cont. Ssc.26446.1.S1_at -1.1 2.1 -1.0 NM_015143 methionyl aminopeptidase 1
Ssc.20740.1.S1_at 1.3 2.3 1.1 #N/A #N/A
Ssc.29842.1.A1_at -1.1 2.9 1.1 #N/A #N/A
Ssc.26271.2.S1_at 1.1 2.0 1.2 NM_006824 EBNA1 binding protein 2
Ssc.24556.2.S1_a_at 1.0 2.5 1.2 NM_025181 solute carrier family 35; member F5
Ssc.27533.1.A1_at -1.1 2.2 1.2 NM_022473 zinc finger protein 106 homolog
Ssc.26568.1.A1_s_at -1.4 2.2 1.2 NM_033671 cyclin B3
Ssc.27311.1.S1_at -1.1 2.2 1.2 #N/A #N/A
Ssc.27454.1.S1_at -1.2 2.2 1.2 NM_004044 5-aminoimidazole-4-carboxamide ribonucleotide formyltransf
Ssc.8582.1.S1_at 1.1 2.1 1.2 NM_031307 pseudouridylate synthase 3
Ssc.27543.1.S1_at 1.5 2.4 1.2 NM_145693 lipin 1
Ssc.19326.1.A1_at -1.2 2.3 1.2 NM_016343 centromere protein F; 350400ka
Ssc.21179.1.S1_at 1.8 2.4 1.3 #N/A #N/A
Ssc.13743.1.S1_at 1.2 2.0 1.3 NM_016472 chromosome 14 open reading frame 129
Ssc.21965.1.S1_at 1.1 2.1 1.3 NM_138285 nucleoporin 35kDa
Ssc.7111.1.A1_at -1.3 2.2 1.3 NM_001034 ribonucleotide reductase M2 polypeptide
Ssc.19249.2.S1_a_at -1.0 2.0 1.4 NM_017832 hypothetical protein FLJ20457
Ssc.6238.3.S1_at 1.2 2.1 1.4 NM_016282 adenylate kinase 3
Ssc.5082.1.A1_at 1.1 2.2 1.4 #N/A #N/A
Ssc.8475.1.A1_at 1.0 2.0 1.4 #N/A #N/A
Ssc.25289.1.S1_at 1.9 2.4 1.4 NM_001259 cyclin-dependent kinase 6
Ssc.18038.1.A1_at 1.0 2.2 1.5 NM_005204 mitogen-activated protein kinase kinase kinase 8
Ssc.19318.1.S1_at -1.0 2.0 1.5 #N/A #N/A
Ssc.26407.1.S1_at -1.4 2.0 1.5 NM_020886 ubiquitin specific protease 28
Ssc.15219.1.S1_at -1.1 2.4 1.5 NM_012248 selenophosphate synthetase 2
Ssc.24344.1.S1_at -1.0 2.4 1.5 NM_001379 DNA
SscAffx.8.1.S1_s_at -1.0 2.0 1.5 NM_002467 v-myc myelocytomatosis viral oncogene homolog
Ssc.7839.1.A1_at 1.2 2.5 1.5 NM_012307 erythrocyte membrane protein band 4.1-like 3
Ssc.25963.1.A1_at 1.2 2.3 1.5 #N/A #N/A
Ssc.8774.2.A1_at 1.2 2.5 1.6 NM_006745 sterol-C4-methyl oxidase-like
Ssc.24344.1.S1_a_at -1.1 2.2 1.6 NM_001379 DNA
Ssc.12845.1.S1_at 1.7 2.3 1.6 NM_001259 cyclin-dependent kinase 6
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Cluster 24 Ssc.25195.1.A1_at 1.2 2.5 1.6 #N/A #N/A
cont. Ssc.27520.1.A1_at 1.1 2.7 1.6 XM_086186 hypothetical protein FLJ13815
Ssc.7554.2.S1_at -1.0 2.2 1.6 NM_013242 gene trap locus 3
Ssc.7517.1.A1_at -1.0 2.4 1.6 NM_024680 likely ortholog of mouse E2F transcription factor 8
Ssc.5087.1.A1_at 1.0 2.1 1.6 #N/A #N/A
Ssc.24556.1.S1_at -1.1 2.5 1.6 NM_025181 solute carrier family 35; member F5
Ssc.16693.1.S1_at -1.1 2.4 1.7 NM_012106 ADP-ribosylation factor-like 2 binding protein
Ssc.10623.2.S1_at 1.0 2.2 1.7 #N/A #N/A
Ssc.16621.1.S1_at 1.5 2.4 1.7 NM_004170 solute carrier family 1
Ssc.24679.1.S1_at 1.3 2.3 1.7 NM_020774 mindbomb homolog 1
Ssc.7771.1.A1_at -1.1 2.3 1.7 XM_034274 v-myb myeloblastosis viral oncogene homolog
Ssc.12786.1.A1_at 1.0 2.6 1.7 NM_003864 sin3-associated polypeptide; 30kDa
Ssc.19290.2.A1_at 1.2 2.1 1.7 #N/A #N/A
Ssc.14506.1.S1_at -1.3 2.1 1.7 NM_001067 topoisomerase
Ssc.30686.1.S1_at -1.0 2.2 1.7 #N/A #N/A
Ssc.23207.1.S1_at 1.1 2.4 1.7 NM_007212 ring finger protein 2
Ssc.7554.1.S1_at 1.1 2.6 1.7 NM_013242 gene trap locus 3
Ssc.240.1.S1_at 1.2 2.7 1.7 NM_001147 angiopoietin 2
Ssc.24852.1.A1_at 1.4 2.1 1.7 NM_018482 development and differentiation enhancing factor 1
Ssc.4900.1.A1_at 1.2 2.4 1.8 NM_016441 cysteine-rich motor neuron 1
Ssc.23922.1.A1_at -1.0 3.0 1.8 NM_018169 hypothetical protein FLJ10652
Ssc.19011.1.S1_at 1.1 2.1 1.8 NM_003983 solute carrier family 7
Ssc.2099.1.S1_at -1.3 2.3 1.8 NM_138555 kinesin family member 23
Ssc.2056.1.S1_at 1.3 2.3 1.9 NM_022343 chromosome 9 open reading frame 19
Ssc.15905.1.S1_at 1.2 2.0 1.9 NM_005811 growth differentiation factor 11
Ssc.24421.1.S1_at -1.1 2.6 1.9 NM_018169 hypothetical protein FLJ10652
Ssc.18850.1.S1_at 1.3 2.0 1.9 NM_016548 golgi phosphoprotein 2
Ssc.28763.1.A1_at -1.1 2.5 1.9 NM_080743 serine-arginine repressor protein
Ssc.25441.2.S1_at -1.1 2.3 1.9 NM_018169 hypothetical protein FLJ10652
Ssc.25948.1.S1_at 1.0 2.7 1.9 #N/A #N/A
Ssc.7570.2.S1_at 1.4 2.1 1.9 NM_004170 solute carrier family 1
Ssc.11797.1.A1_at 1.1 2.3 1.9 NM_145804 ankyrin repeat and BTB
Ssc.27842.1.S1_at -1.0 2.1 1.9 NM_017746 testis expressed sequence 10
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Cluster 24 Ssc.7066.1.S1_at 1.2 2.3 2.0 NM_020774 mindbomb homolog 1
cont. Ssc.1116.1.S1_at 1.1 2.5 2.0 NM_001304 carboxypeptidase D
Ssc.6670.2.S1_at -1.1 2.5 2.0 NM_012319 solute carrier family 39
Ssc.21060.1.A1_at 1.1 2.5 2.1 NM_014498 golgi phosphoprotein 4
Ssc.19350.1.S1_at 1.3 2.2 2.1 NM_016545 immediate early response 5
Ssc.23488.1.S1_at -1.1 2.4 2.1 NM_000637 glutathione reductase
Ssc.6418.1.S1_at 1.4 2.7 2.1 #N/A #N/A
Ssc.1850.1.A1_at 1.3 2.7 2.2 NM_022343 chromosome 9 open reading frame 19
n = 76 1.1 2.3 1.6
Ssc.7106.1.S1_at 2.7 25.4 11.7 NM_001801 cysteine dioxygenase; type ICluster 25
Ssc.9781.1.S1_at 1.5 17.8 14.4 NM_000602 serine
Ssc.9288.1.A1_at 1.7 20.8 17.6 NM_020799 associated molecule with the SH3 domain of STAM
Ssc.9991.1.S1_at 1.2 16.9 20.3 NM_198966 parathyroid hormone-like hormone
Ssc.27300.2.A1_a_at 1.4 19.0 21.5 NM_001001557 growth differentiation factor 6
Ssc.4425.1.S1_at 1.3 19.3 24.3 #N/A #N/A
Ssc.29867.1.A1_at 1.6 19.1 25.5 NM_001001557 growth differentiation factor 6
n = 7 1.6 19.8 19.3
aThis column indicates the 25 clusters generated by the k-means algorithm.
bEach gene within a cluster has a specific, non-redundant AffyID that was assigned to a sequence interrogated by a specific probe
set.
cThe fold difference in gene expression is presented for each gene with the relative amount reported in comparison to the expression
level of spherical conceptuses. S = spherical; T = tubular; D12F = Day 12 filamentous; and D14F = Day 14 filamentous.
dThis column represents the human accession number for each gene that had significant homology to human genes that have been
annotated and reported in GenBank.
eThe annotation, as determined by the homology of the porcine sequence similarity to that reported and annotated for the human
genome.
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Appendix II
Methodology for In Situ Hybridization
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Tissue Fixation
1. Uterine tissue should be excised and immediately processed. In general, a section
of the uterine horn (not greater than 1.0 cm) is placed in 40 ml of freshly 4%
paraformaldehyde (w/v) in phosphate buffered saline (PBS). It is important to
keep a very high fixative volume to tissue ratio.
2. The section of uterine horn in a fixative should be gently agitated on a rocker or
orbital shaker for 24h @ RT.
3. After 24 h, the fixative shall be drained out, and replaced with 40 ml of 70%
EtOH (v/v in H20) and gently agitated overnight at RT.
4. After 24 h, the 70% EtOH should be replaced with fresh 70% EtOH, and tissue
permanently stored at RT.
Solution preparations
4% Paraformaldehyde
1. Heat 2/3 final volume to 60 C in fume hood with stir bar.
2. Add granulated paraformaldhyde slowly, add 1 to 2 drops of 1N
NaOH (this will help clear solution )
3. When solution is clear, remove from heat
4. Add 1X PBS to make final desired volume
5. After solution is cool, adjust pH to 7.2
10X PBS (1 Liter)
80g NaCl
2g KCl
14.4g Na2HPO4 or (11.5g Na2HPO4 . 7 H20)
2.4g KH2PO4
Add components to 800 mL of ddH20, adjust pH to 7.6, bring to 1000 mL
final volume.
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Tissue Sectioning
1. Trim blocks so that they are about 1cm square on the block surface. This is easier
to handle in long strips (Ribbons)
a. Face Blocks to get tissue (Cut at 20 µM) embedded in paraplast
b. After facing blocks turn the block face down on ice (freeze H20 in a flat
dish). Place 5-6 blocks on the ice at a time.
c. Use 37oC water (with small amount of gelatin dissolved) to expand
sections in the ribbons.
d. Use positively charged slides to hold sections to slide.
Linearization of Plasmids for in vitro Transcription (IVT)
1. Digest 20 µg of DNA with appropriate restriction enzyme for >2h at appropriate
temperature.
DNA 20 µg
10X REB 20 µl
Enzyme 10 µl
Water to 200 µl
2. Extract once with an equal volume of PCI (Phenol:Chloroform:Isoamly alcohol)
and once again with chloroform
3. Precipitate DNA with 3 vol 100% EtOH, 1/10 vol 3M NaOAc and 5  of
Dextrane T500 (10mg/ml)
4. Place at -80 C for 15 min, then spin down for 10 min at MAX speed @ RT
5. Remove EtOH, and wash pellet with 150 µl of 70% EtOH
6. Remove all 70% EtOH and resuspend pellet in 40  of Rnase-free water. The
DNA is at approximately 0.5 µg/µl
Note: About which enzyme to use with the promoter.
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Preparation of Probe
1. Set up probe synthesis reaction (enough for about 10 slides) in a 1.5 mL tube. Use
RNAse free tubes and pipet tips.
Order Solution 10 Slides 20 Slides 40 Slides
1 Water (Ambion DEPC) 4.0 µL 8.0 16.00
2 5X Transfer Buffer (Vortex) 2.5 µL 5.0 10.0
3 100 mM DTT 1.25 2.50 5.0
4 2.5 mM rACG 1.25 2.50 5.0
5 DNA (10mg/ml) 1.0 µ 2.00 4.0
6 Rnasin (Keep Cold) 0.5 µL 1.00 2.0
7 UTP (35S)-40 mCi/mL 1.25 2.50 5.0
8 Either T7, SP6 or T3 Poly 0.75 1.50 3.0
Remember you need to know directions of the insert from the plasmid (T7 or
SP6) to get antisense or sense gene (Sense is Control!).
2. Vortex tube, Quick spin and then incubate for 2 h at 37 C in heat block
3. Prepare CENTRI-SEP column (Princeton Separations, Inc-CAT# CS-90)
-Need two columns for 4X reaction. The column can only handle 100 uL of fluid.
Need to rehydrate the column at least 1 h before the probe reaction is added to the
column.
a) Add 80 uL Ambion water to the column
b) Invert and gently vortex
c) Sit upright for at least 30 min –leave bottom cap on (don’t start flow yet).
4. After 2 h incubation add 3uL RQ1-DNAse I (Promega) and 0.5 uL RNasin to tubes.
If 4X reaction (40 slides) double the volume-6uL RQ-1-DNase, 1.0 uL RNasin.
Vortex, centrifuge briefly and incubate for 15 min at 37oC.
5. After incubation add 20 mL yeast tRNA (10mg/ml) and 40 uL (1-2 X reaction)
-Phenol:Chlorofrom:Isoamyl alcohol (Ratio 25:24:1; light sensitive, store at –4oC).
-For 3-4X Rxn 40 mL yeast tRNA and 80 uL PCI. Vortex well. When pipetting
from PCI, make sure to get lower layer where phenol is bottom layer, and water is on
top.
**Water Saturated Phenol is for RNA, Tris buffered phenol is for DNA**
a) Centrifuge at full speed on a microcentrifuge (27,000 x g) for 5 min
b) Remove top layer with a pipet (filtered) and place in a new bullet tube (Don’t
get bottom layer)
6. Add a volume of chloroform to match PCI
1X=40uL
3X=80uL
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a. Vortex and spin at full speed for 5 min
-Complete SEP column preparation: Take top and bottom cap off. Place
in tube and use finger to push (top pressure) a drop from the bottom to
start flow. After spinning tubes with probe, SEP columns in centrifuged
and position the column so the notch on the rim faces out (top of rotor).
Centrifuge at 750 x g for 2 min. Use column immediately- do not let it
dry out.
b. Add PCI:CI purified probe to Centrisep column (place in middle of matrix and
don’t touch matrix with pipet tip).
c. Centrifuge column for at 750 x g for 2 min. then discard the column. Purified
probe is the flow through remaining in the tube.
7. Precipitate with 60 uL 3M NaOAc (pH 5), 1 uL yeast tRNA, 5uL Dextran T500
(10mg/ml) and 300uL EtOH for 1-2X reactions. Double for 3-4X reactions.
8. Spin bullet tubes at maximum speed for 10 min Pour off liquid in radioactive waste.
9. Wash pellets with 70% EtOH
10. Wash pellets in 50 uL (1X-2X) or 100 uL (3X-4X) of 100 mM DTT. Can use pipet to
break-up pellet.
11. Count in -counter (1-2 uL).
Calculation for probe Hybridization
Antisense -20 slides: 5 X 106 cpm/slide
20 slides X 70 uL hybridization soln/slide=1400 uL (may add for 1-2 more slides) +
Volume of probe (Need 5 million cpm/slide)
Final solution should be 10% DTT (100 mM DTT) so, divide the amount of hybridization
solution + amount of probe and divide the sum by 9 to determine amount of 1M DTT to
add.
Need only 1-2 slides for sense Probe.
Vortex, quick spin and incubate at 70 C for 10 min to denature probe.
Summary
cRNA probes (5 X 106 cpm/slide) with hybridization Solution containing 100 mM DTT
at 70 C for 10 min. then place in 55oC incubator before until applied to slide.
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Preparation of Slides
1. Xylene (CitrSolve CAT# 22-143975) CitriSolve will have a layer on the bottom,
so be careful not to pour in the tanks. Make sure tank solvent is clean between
runs. Treat for 5 min and agitate every 1-2 min “Critical” repeat 2X. Check to
make sure the paraplast is cleared from slides.
2. 100%EtOH fro 1 min -2X (agitate slides through procedure)
3. 95% EtOH 1 min-2X
4. 70% EtOH 3 min- 1X
5. PBS for 5 min-2X
6. Fresh 4% paraformaldhyde (PAF) 20 min-1X
- Dissolve 4g PAF/100ml of PBS-Need 400-500mL
To Make: Fill beaker with ddH20 to about 60% of final volume (Do Not
Heat Water). Add PAF (20g/500mL) and about 1.25g NaOH
pellets/500 mL. Stir on stir plate in hood until it goes into
solution~10 min, then add enough 10X PBS to make final
concentration 1X. pH to 7.2 with 12N NaOH “slowly” and bring
to volume with ddH20
7. PBS for 5 min-2X
8. Proteinase K for 7.5 min-1X
For 500mL:
25 mL 1M Tris (pH 8.0)
5 mL 0.5 M EDTA
1 mL Proteinase K (10mg/mL) stock kept in freezer
Q.S. with ddH2O
9. 4% PAF for 15 min 1X(Can reuse the PAF from first wash in step 6)-Dispose
PAF in waste bottle
10. ddH2O for 1 min-1X
11. PBS for 5 min-2X
12. 70% EtOH for 3 min-1X
13. 95% EtOH for 1 min-2X
14. 100% EtOH for 1 min-2X
15. Air dry slides at RT (10 min) on paper towels in tray. While drying slides start
denaturation of probe.
Probe Hybridizations
1. Following the denaturation of the probe (70 C), add the Hyb soln to the middle of
the slide. Set pipetman at 75 µL, but when adding don’t blowout last fluid to
avoid air bubbles.
2. Put on coverslip
a. Touch middle soln with coverslip and drawback to edge. Slowly drop
cover slip on slide!
3. Place a layer of 3MM paper in a pyrex baking dish that has been wetted with 250
mL of 50% Formamide / 5X SSC
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a. Formamide is stored in freezer as stock! Must thaw out before use. Once
thawed keep in the cooler.
4. Cover pyrex dish with plastic wrap and seal. Place in an incubator at 55 C for at
least 16 h
5. Make 50% formaldehyde /2X SSC/50 mM BME-*Leave BME out until just
before use the next day [make sure BME is not old]
a. Make 1 liter =500 mL formaldehyde /100 mL 20X SSC=h20 to 1000mL
(add 3.5 mL BME next day)
b. Make 5X SSC/10 mM BME-*Leave BME out until just before use next
day. 500 mL=125 mL 20X SSC+H20 to 500 mL (add 350 uL BME Next
Day)
c. Place soln in incubator at 55 C for next day use!!!
6. Add BME to solutions the next day
a. 50% Formaldhyde/2X SSC/50 mM BME (3.56 mL/liter)
b. 5X SSC/10 mM BME (350 uL/500 mL) keep in incubator at 55 C
c. Place the 50% formaldehyde /2X SSC/50 mM BME in 65 C water bath or
incubator. Use glass slide holders.
7. Gently remove coverslips by sliding down into radioactive waste container (use
empty NaCl container). If coverslip sticks to slide, dip in buffer and slide off.
Place slides in rack with 55 C 5X SSC/10 mM BME.
a. Place in 55 C incubator for 30 min-agitate every 10 min
8. Dump out baking dish (In isotope sink). Wash with 10% Count-off (rinse bottle)
then rinse with DDH20. Dry table and rinse large double taped pipets
9. Dump first hybridization wash into radioactive liquid waste [35S]. Add 50%
Formaldhyde/2X SSC/50 mM BME and place in 65 C incubator or water bath for
20 min
10. Dump second wash of hybridization in radioactive liquid waste. Add TEN (0.5M
NaCl/10mM Tris(pH 8)/5mM EDTA) for 10 min at RT
a. 10X TEN (1 Liter)
b. 292.2g NaCL
c. 10 mL 1M TrisCL (pH 8)
d. 10 mL 0.5 M EDTA
11. 1X TEN 10 min 37 C. Repeat twice.
12. 1X TEN with RNase A (10ug/mL) -500 mL (0.5 mL Rnase stock 10mg/ml) in the
freezer). Incubate 37 C for 30 min.
13. 1X TEN 15 Min at 37 C
14. 50 % Formamide/2X SSC/50 mM BME at 65oC for 20 min.
15. 2X SSC at RT for 15 min
16. 0.1X SSC RT for 12 min
17. 70% EtOH/0.3 M Ammonium Actetate at RT for 5 min. Repeat once.
18. 95% EtOH/0.3 M Ammonium Acetate for RT for 1min.
19. 100% EtOH at RT for 1 min. Repeat once.
20. Air dry and expose to Kodak Biomax Film overnight. Develop next day to
estimate length needed to develop slides.
a. Place slides in order in film case-tape down corners to keep from moving
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b. Use Kodak BioMax MR film-packaged in single sheets. Make sure
emulsion side down (Non-shiny side)-notched should be in upper left
corner. Expose at least 16 hours.
Autoradiography
1. Thaw Kodak NTB2 emulsion vials at 42 C in a light tight container (wrapped in
foil).
-Emulsion is aliquoted in vials (5mL) stored in a box covered in a foil
pack in a black plastic bag in the refrigerator. MUST BE LIGHT
TIGHT!!!
-Take strips of foil to wrap two vials in dark room. Don’t use safe light,
just wrap in total darkness. As an alternative, use orange safe light.
Make sure the vials are completely wrapped in foil and the lids are on
tight.
-The slide dipper takes two vials to fill it. This is enough to cover 50-60
slides
-Make up the slide boxes to holes slides following covering with
emulsion. Place a slide about 3-4 notches from the top of the box. Take
two kimwipes and cross them. Place some dridrite in the middle and roll
up to place above the slide box. Put paper towel cut to the bottom of the
box. Wrap up dridrite in paper towels to place in the bread box when
slides have been dipped.
2. Need to bring 50 ml conical tube with 10 mL ddH20 placed in 42 C water bath
with vials (Make sure light is on). Can get by with as soon as it reaches
TEMP./FOR 20 SLIDES. In the dark room with the orange filter, gently mix the
emulsion with ddh20 in the conical tube. No air bubbles (rotate tube side to side).
Emulsion is 1:1 with water.
3. Fill slide dipper that has been placed in the 42 C H2O bath.
4. Dip each slide to the bottom of the slide dipper. Wipe off excess, polish back to
remove film from edge.
5. After dipping , place towels in light tight box. Leave lids off during this time.
Allow to dry for 6 to 8 hours. Rotate slides 3-6 hours.
6. After 3-6 hours drying go to dark room and place lids on slide boxes. Wrap in
foil, store at 4C for number of days or weeks based on exposure to X-ray film.
7. To develop allow slides to reach RT
8. Kodak D-19 developer (78.3g / 500 mL) for 4 min-1x
9. ddH2O- 0.5 min-1X 
10. Fixer for 5 min-1X 
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Fixer (Kodak Rapid Fixer with Hardener):
171 mL water
59.5 mL Solution A (Fixer)
6.5 mL Solution B (Hardener)
11. Water for 5 min
12. Hematoxylin (diluted with ddH2O 1:3) for 30 seconds
13. Water for 30 sec
14. Water for 5 min. Repeat until hematoxylin quits leaching into water.
15. 70 EtOH-3 min
16. 95 EtOH-1 min 2X
17. 100 EtOH-1 min 2X
18. Xylene for 3 min 3X
19. Permount and coverslip
Other In Situ Hybridization Solutions:
5X SSC/10 mM BME (500mL)
125 mL 20X SSC
350 µl BME
q.s. ddH2O
50% Formamide/2X SSC/50 mM BME (800 mL)
400 mL Formamide
80 mL 20X SSC
2.72 mL BME
q.s. ddH2O
20X SSC (1 liter)
175.4 g NaCl
88.2 g Sodium citrate
Dissolve in 800 mL ddH2O, adjust pH to 7.0 with a few drops of 10N NaOH. Bring to volume
with ddH2O and filter sterilize. DEPC treat and autoclave.
10X TEN (1 Liter)
292.2g NaCL (5M)
10 mL 1M TrisCL (pH 8) – (100 mM)
10 mL 0.5 M EDTA – (50 mM)
50X Denhardt’s (500 mL)
5 g Ficoll 400
5 g Polyvinylpyrrolidone
5 g BSA (Pentax Fraction V)
500 mL Water
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Hybridization Solution (100 mL)
50 mL Formamide – (50%)
6 mL 5M NaCL – (0.3 M)
2 mL 1M Tris-HCl pH 8.0 - (20mM)
1 mL 0.5 M EDTA pH 8.0 – (5mM)
1 mL 1M Sodium Phosphate pH 8.0 – (10 mM)
2 mL 50X Denhardt’s (1X)
10 g Dextran Sulfate (10%)
5 mL of 10 mg/mL Stock Yeast tRNA (0.5 mg/mL)
q.s. H2O to 20 mL
Store Frozen in -20C
Before use add 1M DTT to a final concentration of 100 mM DTT for probes during
hybridization.
VITA
Jason Wayne Ross
Candidate for the Degree of
Doctor of Philosophy
Thesis:CONCEPTUS AND UTERINE FACTORS CONTRIBUTING TO THE
ESTABLISHMENT OF PREGNANCY IN PIGS
Major Field: Animal Reproduction
Minor Field: Biochemistry
Biographical:
Personal Information: Born in Grinnell, IA on October 10, 1977, the son of
Wayne and Marla Ross
Education: Graduated from Iowa City West High School, Iowa City, Iowa in
May of 1996. Earned Bachelor of Science degree from Iowa State University,
Ames, Iowa in December 2000. Earned a Master of Science Degree at Oklahoma
State University, Stillwater, Oklahoma in May 2003. Completed the requirements
for Doctor of Philosophy degree at Oklahoma State University, Stillwater,
Oklahoma, in December, 2006.
Experience: Graduate Research Assistant, Oklahoma State University, 2001-2006.
Professional Organizations: Society for the Study of Reproduction, Sigma Xi
Scientific Research Society, Animal Science Graduate Student Association.
